#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Sexual trauma history is associated with reduced orbitofrontal network strength in substance-dependent women
#Text=Aim
#Text=Substance use disorders (SUDs) are highly comorbid with post-traumatic stress disorder (PTSD).
1-1	0-6	Sexual	_	
1-2	7-13	trauma	_	
1-3	14-21	history	_	
1-4	22-24	is	_	
1-5	25-35	associated	_	
1-6	36-40	with	_	
1-7	41-48	reduced	_	
1-8	49-62	orbitofrontal	_	
1-9	63-70	network	_	
1-10	71-79	strength	_	
1-11	80-82	in	_	
1-12	83-102	substance-dependent	_	
1-13	103-108	women	_	
1-14	109-112	Aim	_	
1-15	113-122	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-16	123-126	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-17	127-136	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-18	137-138	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-19	138-142	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-20	142-143	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-21	144-147	are	_	
1-22	148-154	highly	_	
1-23	155-163	comorbid	_	
1-24	164-168	with	_	
1-25	169-183	post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-26	184-190	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-27	191-199	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-28	200-201	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-29	201-205	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-30	205-206	)	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-31	206-207	.	_	

#Text=PTSD-SUD comorbidity is associated with greater functional impairments and relapse risk.
2-1	208-216	PTSD-SUD	_	
2-2	217-228	comorbidity	_	
2-3	229-231	is	_	
2-4	232-242	associated	_	
2-5	243-247	with	_	
2-6	248-255	greater	_	
2-7	256-266	functional	_	
2-8	267-278	impairments	_	
2-9	279-282	and	_	
2-10	283-290	relapse	_	
2-11	291-295	risk	_	
2-12	295-296	.	_	

#Text=Women with SUDs experience markedly higher rates of trauma and PTSD compared to men with SUDs, particularly due to sexual and domestic abuse.
3-1	297-302	Women	_	
3-2	303-307	with	_	
3-3	308-312	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
3-4	313-323	experience	_	
3-5	324-332	markedly	_	
3-6	333-339	higher	_	
3-7	340-345	rates	_	
3-8	346-348	of	_	
3-9	349-355	trauma	_	
3-10	356-359	and	_	
3-11	360-364	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
3-12	365-373	compared	_	
3-13	374-376	to	_	
3-14	377-380	men	_	
3-15	381-385	with	_	
3-16	386-390	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
3-17	390-391	,	_	
3-18	392-404	particularly	_	
3-19	405-408	due	_	
3-20	409-411	to	_	
3-21	412-418	sexual	_	
3-22	419-422	and	_	
3-23	423-431	domestic	_	
3-24	432-437	abuse	_	
3-25	437-438	.	_	

#Text=Despite the strong association between trauma exposure and SUDs, the neurobiological correlates are understudied, particularly among females with SUDs.
4-1	439-446	Despite	_	
4-2	447-450	the	_	
4-3	451-457	strong	_	
4-4	458-469	association	_	
4-5	470-477	between	_	
4-6	478-484	trauma	_	
4-7	485-493	exposure	_	
4-8	494-497	and	_	
4-9	498-502	SUDs	_	
4-10	502-503	,	_	
4-11	504-507	the	_	
4-12	508-523	neurobiological	_	
4-13	524-534	correlates	_	
4-14	535-538	are	_	
4-15	539-551	understudied	_	
4-16	551-552	,	_	
4-17	553-565	particularly	_	
4-18	566-571	among	_	
4-19	572-579	females	_	
4-20	580-584	with	_	
4-21	585-589	SUDs	_	
4-22	589-590	.	_	

#Text=However, there is indication of abnormal somatic and interoceptive processing in women with PTSD.
5-1	591-598	However	_	
5-2	598-599	,	_	
5-3	600-605	there	_	
5-4	606-608	is	_	
5-5	609-619	indication	_	
5-6	620-622	of	_	
5-7	623-631	abnormal	_	
5-8	632-639	somatic	_	
5-9	640-643	and	_	
5-10	644-657	interoceptive	_	
5-11	658-668	processing	_	
5-12	669-671	in	_	
5-13	672-677	women	_	
5-14	678-682	with	_	
5-15	683-687	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
5-16	687-688	.	_	

#Text=The present study examines interoception-linked differences in intrinsic brain networks in a group of women with SUDs and varying histories of trauma exposure, some of whom have a current PTSD diagnosis.
6-1	689-692	The	_	
6-2	693-700	present	_	
6-3	701-706	study	_	
6-4	707-715	examines	_	
6-5	716-736	interoception-linked	_	
6-6	737-748	differences	_	
6-7	749-751	in	_	
6-8	752-761	intrinsic	_	
6-9	762-767	brain	_	
6-10	768-776	networks	_	
6-11	777-779	in	_	
6-12	780-781	a	_	
6-13	782-787	group	_	
6-14	788-790	of	_	
6-15	791-796	women	_	
6-16	797-801	with	_	
6-17	802-806	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
6-18	807-810	and	_	
6-19	811-818	varying	_	
6-20	819-828	histories	_	
6-21	829-831	of	_	
6-22	832-838	trauma	_	
6-23	839-847	exposure	_	
6-24	847-848	,	_	
6-25	849-853	some	_	
6-26	854-856	of	_	
6-27	857-861	whom	_	
6-28	862-866	have	_	
6-29	867-868	a	_	
6-30	869-876	current	_	
6-31	877-881	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
6-32	882-891	diagnosis	_	
6-33	891-892	.	_	

#Text=Methods
#Text=Pre-intervention data were analyzed from a subset (N = 43) of women in SUD residential treatment recruited for a mindfulness-based intervention efficacy clinical trial.
7-1	893-900	Methods	_	
7-2	901-917	Pre-intervention	_	
7-3	918-922	data	_	
7-4	923-927	were	_	
7-5	928-936	analyzed	_	
7-6	937-941	from	_	
7-7	942-943	a	_	
7-8	944-950	subset	_	
7-9	951-952	(	_	
7-10	952-953	N	_	
7-11	953-954	 	_	
7-12	954-955	=	_	
7-13	955-956	 	_	
7-14	956-958	43	_	
7-15	958-959	)	_	
7-16	960-962	of	_	
7-17	963-968	women	_	
7-18	969-971	in	_	
7-19	972-975	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
7-20	976-987	residential	_	
7-21	988-997	treatment	_	
7-22	998-1007	recruited	_	
7-23	1008-1011	for	_	
7-24	1012-1013	a	_	
7-25	1014-1031	mindfulness-based	_	
7-26	1032-1044	intervention	_	
7-27	1045-1053	efficacy	_	
7-28	1054-1062	clinical	_	
7-29	1063-1068	trial	_	
7-30	1068-1069	.	_	

#Text=Participants diagnosed with PTSD (n = 14) or not (n = 29) performed a task which involved attending to the somatic and visceral sensations of the breathing cycle (interoception) while undergoing a functional MRI (fMRI) scan.
8-1	1070-1082	Participants	_	
8-2	1083-1092	diagnosed	_	
8-3	1093-1097	with	_	
8-4	1098-1102	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
8-5	1103-1104	(	_	
8-6	1104-1105	n	_	
8-7	1105-1106	 	_	
8-8	1106-1107	=	_	
8-9	1107-1108	 	_	
8-10	1108-1110	14	_	
8-11	1110-1111	)	_	
8-12	1112-1114	or	_	
8-13	1115-1118	not	_	
8-14	1119-1120	(	_	
8-15	1120-1121	n	_	
8-16	1121-1122	 	_	
8-17	1122-1123	=	_	
8-18	1123-1124	 	_	
8-19	1124-1126	29	_	
8-20	1126-1127	)	_	
8-21	1128-1137	performed	_	
8-22	1138-1139	a	_	
8-23	1140-1144	task	_	
8-24	1145-1150	which	_	
8-25	1151-1159	involved	_	
8-26	1160-1169	attending	_	
8-27	1170-1172	to	_	
8-28	1173-1176	the	_	
8-29	1177-1184	somatic	_	
8-30	1185-1188	and	_	
8-31	1189-1197	visceral	_	
8-32	1198-1208	sensations	_	
8-33	1209-1211	of	_	
8-34	1212-1215	the	_	
8-35	1216-1225	breathing	_	
8-36	1226-1231	cycle	_	
8-37	1232-1233	(	_	
8-38	1233-1246	interoception	_	
8-39	1246-1247	)	_	
8-40	1248-1253	while	_	
8-41	1254-1264	undergoing	_	
8-42	1265-1266	a	_	
8-43	1267-1277	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
8-44	1278-1281	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
8-45	1282-1283	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
8-46	1283-1287	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
8-47	1287-1288	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
8-48	1289-1293	scan	_	
8-49	1293-1294	.	_	

#Text=FMRI analysis employed independent components analysis and dual regression.
9-1	1295-1299	FMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
9-2	1300-1308	analysis	_	
9-3	1309-1317	employed	_	
9-4	1318-1329	independent	_	
9-5	1330-1340	components	_	
9-6	1341-1349	analysis	_	
9-7	1350-1353	and	_	
9-8	1354-1358	dual	_	
9-9	1359-1369	regression	_	
9-10	1369-1370	.	_	

#Text=First, we assessed differences in functional connectivity of interoception-modulated functional networks among those with and without PTSD.
10-1	1371-1376	First	_	
10-2	1376-1377	,	_	
10-3	1378-1380	we	_	
10-4	1381-1389	assessed	_	
10-5	1390-1401	differences	_	
10-6	1402-1404	in	_	
10-7	1405-1415	functional	_	
10-8	1416-1428	connectivity	_	
10-9	1429-1431	of	_	
10-10	1432-1455	interoception-modulated	_	
10-11	1456-1466	functional	_	
10-12	1467-1475	networks	_	
10-13	1476-1481	among	_	
10-14	1482-1487	those	_	
10-15	1488-1492	with	_	
10-16	1493-1496	and	_	
10-17	1497-1504	without	_	
10-18	1505-1509	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
10-19	1509-1510	.	_	

#Text=Second, we tested associations between network strength and lifetime sexual violence exposure across all participants on networks that showed significant group differences.
11-1	1511-1517	Second	_	
11-2	1517-1518	,	_	
11-3	1519-1521	we	_	
11-4	1522-1528	tested	_	
11-5	1529-1541	associations	_	
11-6	1542-1549	between	_	
11-7	1550-1557	network	_	
11-8	1558-1566	strength	_	
11-9	1567-1570	and	_	
11-10	1571-1579	lifetime	_	
11-11	1580-1586	sexual	_	
11-12	1587-1595	violence	_	
11-13	1596-1604	exposure	_	
11-14	1605-1611	across	_	
11-15	1612-1615	all	_	
11-16	1616-1628	participants	_	
11-17	1629-1631	on	_	
11-18	1632-1640	networks	_	
11-19	1641-1645	that	_	
11-20	1646-1652	showed	_	
11-21	1653-1664	significant	_	
11-22	1665-1670	group	_	
11-23	1671-1682	differences	_	
11-24	1682-1683	.	_	

#Text=Results
#Text=PTSD diagnosis was associated with reduced functional connectivity of an orbitofrontal network with the precuneus, mid-posterior insula, lateral prefrontal cortex and angular gyrus.
12-1	1684-1691	Results	_	
12-2	1692-1696	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
12-3	1697-1706	diagnosis	_	
12-4	1707-1710	was	_	
12-5	1711-1721	associated	_	
12-6	1722-1726	with	_	
12-7	1727-1734	reduced	_	
12-8	1735-1745	functional	_	
12-9	1746-1758	connectivity	_	
12-10	1759-1761	of	_	
12-11	1762-1764	an	_	
12-12	1765-1778	orbitofrontal	_	
12-13	1779-1786	network	_	
12-14	1787-1791	with	_	
12-15	1792-1795	the	_	
12-16	1796-1805	precuneus	_	
12-17	1805-1806	,	_	
12-18	1807-1820	mid-posterior	_	
12-19	1821-1827	insula	_	
12-20	1827-1828	,	_	
12-21	1829-1836	lateral	_	
12-22	1837-1847	prefrontal	_	
12-23	1848-1854	cortex	_	
12-24	1855-1858	and	_	
12-25	1859-1866	angular	_	
12-26	1867-1872	gyrus	_	
12-27	1872-1873	.	_	

#Text=OFC network strength was inversely associated with sexual violence exposure over-and-above the contribution of PTSD status alone.
13-1	1874-1877	OFC	_	
13-2	1878-1885	network	_	
13-3	1886-1894	strength	_	
13-4	1895-1898	was	_	
13-5	1899-1908	inversely	_	
13-6	1909-1919	associated	_	
13-7	1920-1924	with	_	
13-8	1925-1931	sexual	_	
13-9	1932-1940	violence	_	
13-10	1941-1949	exposure	_	
13-11	1950-1964	over-and-above	_	
13-12	1965-1968	the	_	
13-13	1969-1981	contribution	_	
13-14	1982-1984	of	_	
13-15	1985-1989	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
13-16	1990-1996	status	_	
13-17	1997-2002	alone	_	
13-18	2002-2003	.	_	

#Text=Conclusions
#Text=Our findings provide a novel network-level account of brain activity associated with PTSD among women with SUDs, which may inform treatment response in this subpopulation.
14-1	2004-2015	Conclusions	_	
14-2	2016-2019	Our	_	
14-3	2020-2028	findings	_	
14-4	2029-2036	provide	_	
14-5	2037-2038	a	_	
14-6	2039-2044	novel	_	
14-7	2045-2058	network-level	_	
14-8	2059-2066	account	_	
14-9	2067-2069	of	_	
14-10	2070-2075	brain	_	
14-11	2076-2084	activity	_	
14-12	2085-2095	associated	_	
14-13	2096-2100	with	_	
14-14	2101-2105	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
14-15	2106-2111	among	_	
14-16	2112-2117	women	_	
14-17	2118-2122	with	_	
14-18	2123-2127	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
14-19	2127-2128	,	_	
14-20	2129-2134	which	_	
14-21	2135-2138	may	_	
14-22	2139-2145	inform	_	
14-23	2146-2155	treatment	_	
14-24	2156-2164	response	_	
14-25	2165-2167	in	_	
14-26	2168-2172	this	_	
14-27	2173-2186	subpopulation	_	
14-28	2186-2187	.	_	

#Text=Highlights
#Text=FMRI correlates of interoceptive attention in women with substance use disorder (SUD) and post-traumatic stress (PTSD)
#Text=Task-based data analyzed using independent components analysis and dual regression
#Text=Reduced orbitofrontal network connectivity with insula and frontoparietal regions in SUD_PTSD comorbidity compared to SUD
#Text=Functional networks associated with exteroception did not distinguish PTSD-SUD from SUD-only
#Text=Severity of sexual trauma exposure is inversely associated with orbitofrontal network strength beyond PTSD status
#Text=Introduction
#Text=Interoceptive awareness is compromised in SUD, and is a functional resource for recovery
#Text=Interoception describes the process by which the nervous system transduces, integrates, and interprets visceral and somatic sensory signals.
15-1	2188-2198	Highlights	_	
15-2	2199-2203	FMRI	_	
15-3	2204-2214	correlates	_	
15-4	2215-2217	of	_	
15-5	2218-2231	interoceptive	_	
15-6	2232-2241	attention	_	
15-7	2242-2244	in	_	
15-8	2245-2250	women	_	
15-9	2251-2255	with	_	
15-10	2256-2265	substance	_	
15-11	2266-2269	use	_	
15-12	2270-2278	disorder	_	
15-13	2279-2280	(	_	
15-14	2280-2283	SUD	_	
15-15	2283-2284	)	_	
15-16	2285-2288	and	_	
15-17	2289-2303	post-traumatic	_	
15-18	2304-2310	stress	_	
15-19	2311-2312	(	_	
15-20	2312-2316	PTSD	_	
15-21	2316-2317	)	_	
15-22	2318-2328	Task-based	_	
15-23	2329-2333	data	_	
15-24	2334-2342	analyzed	_	
15-25	2343-2348	using	_	
15-26	2349-2360	independent	_	
15-27	2361-2371	components	_	
15-28	2372-2380	analysis	_	
15-29	2381-2384	and	_	
15-30	2385-2389	dual	_	
15-31	2390-2400	regression	_	
15-32	2401-2408	Reduced	_	
15-33	2409-2422	orbitofrontal	_	
15-34	2423-2430	network	_	
15-35	2431-2443	connectivity	_	
15-36	2444-2448	with	_	
15-37	2449-2455	insula	_	
15-38	2456-2459	and	_	
15-39	2460-2474	frontoparietal	_	
15-40	2475-2482	regions	_	
15-41	2483-2485	in	_	
15-42	2486-2494	SUD_PTSD	_	
15-43	2495-2506	comorbidity	_	
15-44	2507-2515	compared	_	
15-45	2516-2518	to	_	
15-46	2519-2522	SUD	_	
15-47	2523-2533	Functional	_	
15-48	2534-2542	networks	_	
15-49	2543-2553	associated	_	
15-50	2554-2558	with	_	
15-51	2559-2572	exteroception	_	
15-52	2573-2576	did	_	
15-53	2577-2580	not	_	
15-54	2581-2592	distinguish	_	
15-55	2593-2601	PTSD-SUD	_	
15-56	2602-2606	from	_	
15-57	2607-2615	SUD-only	_	
15-58	2616-2624	Severity	_	
15-59	2625-2627	of	_	
15-60	2628-2634	sexual	_	
15-61	2635-2641	trauma	_	
15-62	2642-2650	exposure	_	
15-63	2651-2653	is	_	
15-64	2654-2663	inversely	_	
15-65	2664-2674	associated	_	
15-66	2675-2679	with	_	
15-67	2680-2693	orbitofrontal	_	
15-68	2694-2701	network	_	
15-69	2702-2710	strength	_	
15-70	2711-2717	beyond	_	
15-71	2718-2722	PTSD	_	
15-72	2723-2729	status	_	
15-73	2730-2742	Introduction	_	
15-74	2743-2756	Interoceptive	_	
15-75	2757-2766	awareness	_	
15-76	2767-2769	is	_	
15-77	2770-2781	compromised	_	
15-78	2782-2784	in	_	
15-79	2785-2788	SUD	_	
15-80	2788-2789	,	_	
15-81	2790-2793	and	_	
15-82	2794-2796	is	_	
15-83	2797-2798	a	_	
15-84	2799-2809	functional	_	
15-85	2810-2818	resource	_	
15-86	2819-2822	for	_	
15-87	2823-2831	recovery	_	
15-88	2832-2845	Interoception	_	
15-89	2846-2855	describes	_	
15-90	2856-2859	the	_	
15-91	2860-2867	process	_	
15-92	2868-2870	by	_	
15-93	2871-2876	which	_	
15-94	2877-2880	the	_	
15-95	2881-2888	nervous	_	
15-96	2889-2895	system	_	
15-97	2896-2906	transduces	_	
15-98	2906-2907	,	_	
15-99	2908-2918	integrates	_	
15-100	2918-2919	,	_	
15-101	2920-2923	and	_	
15-102	2924-2934	interprets	_	
15-103	2935-2943	visceral	_	
15-104	2944-2947	and	_	
15-105	2948-2955	somatic	_	
15-106	2956-2963	sensory	_	
15-107	2964-2971	signals	_	
15-108	2971-2972	.	_	

#Text=These signals provide temporally dynamic maps of the body's homeostatic and physiological milieu at both conscious and unconscious levels of awareness which convey information critical for adaptive behaviors.
16-1	2973-2978	These	_	
16-2	2979-2986	signals	_	
16-3	2987-2994	provide	_	
16-4	2995-3005	temporally	_	
16-5	3006-3013	dynamic	_	
16-6	3014-3018	maps	_	
16-7	3019-3021	of	_	
16-8	3022-3025	the	_	
16-9	3026-3032	body's	_	
16-10	3033-3044	homeostatic	_	
16-11	3045-3048	and	_	
16-12	3049-3062	physiological	_	
16-13	3063-3069	milieu	_	
16-14	3070-3072	at	_	
16-15	3073-3077	both	_	
16-16	3078-3087	conscious	_	
16-17	3088-3091	and	_	
16-18	3092-3103	unconscious	_	
16-19	3104-3110	levels	_	
16-20	3111-3113	of	_	
16-21	3114-3123	awareness	_	
16-22	3124-3129	which	_	
16-23	3130-3136	convey	_	
16-24	3137-3148	information	_	
16-25	3149-3157	critical	_	
16-26	3158-3161	for	_	
16-27	3162-3170	adaptive	_	
16-28	3171-3180	behaviors	_	
16-29	3180-3181	.	_	

#Text=The various sources of interoceptive information (e.g., cardiovascular, respiratory, gastrointestinal, immunological, etc.) are conveyed to the Central Nervous System (CNS), where they become integrated in somatosensory and viscerosensory representation.
17-1	3182-3185	The	_	
17-2	3186-3193	various	_	
17-3	3194-3201	sources	_	
17-4	3202-3204	of	_	
17-5	3205-3218	interoceptive	_	
17-6	3219-3230	information	_	
17-7	3231-3232	(	_	
17-8	3232-3235	e.g	_	
17-9	3235-3236	.	_	
17-10	3236-3237	,	_	
17-11	3238-3252	cardiovascular	_	
17-12	3252-3253	,	_	
17-13	3254-3265	respiratory	_	
17-14	3265-3266	,	_	
17-15	3267-3283	gastrointestinal	_	
17-16	3283-3284	,	_	
17-17	3285-3298	immunological	_	
17-18	3298-3299	,	_	
17-19	3300-3303	etc	_	
17-20	3303-3304	.	_	
17-21	3304-3305	)	_	
17-22	3306-3309	are	_	
17-23	3310-3318	conveyed	_	
17-24	3319-3321	to	_	
17-25	3322-3325	the	_	
17-26	3326-3333	Central	_	
17-27	3334-3341	Nervous	_	
17-28	3342-3348	System	_	
17-29	3349-3350	(	_	
17-30	3350-3353	CNS	_	
17-31	3353-3354	)	_	
17-32	3354-3355	,	_	
17-33	3356-3361	where	_	
17-34	3362-3366	they	_	
17-35	3367-3373	become	_	
17-36	3374-3384	integrated	_	
17-37	3385-3387	in	_	
17-38	3388-3401	somatosensory	_	
17-39	3402-3405	and	_	
17-40	3406-3420	viscerosensory	_	
17-41	3421-3435	representation	_	
17-42	3435-3436	.	_	

#Text=The primary neurofunctional pathways associated with interoception include the c-fiber and spinothalamic afferents, vagal afferent fibers, and specific brainstem and thalamic nuclei, which project to the insula.
18-1	3437-3440	The	_	
18-2	3441-3448	primary	_	
18-3	3449-3464	neurofunctional	_	
18-4	3465-3473	pathways	_	
18-5	3474-3484	associated	_	
18-6	3485-3489	with	_	
18-7	3490-3503	interoception	_	
18-8	3504-3511	include	_	
18-9	3512-3515	the	_	
18-10	3516-3523	c-fiber	_	
18-11	3524-3527	and	_	
18-12	3528-3541	spinothalamic	_	
18-13	3542-3551	afferents	_	
18-14	3551-3552	,	_	
18-15	3553-3558	vagal	_	
18-16	3559-3567	afferent	_	
18-17	3568-3574	fibers	_	
18-18	3574-3575	,	_	
18-19	3576-3579	and	_	
18-20	3580-3588	specific	_	
18-21	3589-3598	brainstem	_	
18-22	3599-3602	and	_	
18-23	3603-3611	thalamic	_	
18-24	3612-3618	nuclei	_	
18-25	3618-3619	,	_	
18-26	3620-3625	which	_	
18-27	3626-3633	project	_	
18-28	3634-3636	to	_	
18-29	3637-3640	the	_	
18-30	3641-3647	insula	_	
18-31	3647-3648	.	_	

#Text=The influence of top-down control is evident from the up-regulation of activity linked to interoceptive signal processing in CNS (e.g., especially sectors of the insula) when attention is explicitly directed at bodily sensations and down-regulation when attention is directed away from bodily sensations.
19-1	3649-3652	The	_	
19-2	3653-3662	influence	_	
19-3	3663-3665	of	_	
19-4	3666-3674	top-down	_	
19-5	3675-3682	control	_	
19-6	3683-3685	is	_	
19-7	3686-3693	evident	_	
19-8	3694-3698	from	_	
19-9	3699-3702	the	_	
19-10	3703-3716	up-regulation	_	
19-11	3717-3719	of	_	
19-12	3720-3728	activity	_	
19-13	3729-3735	linked	_	
19-14	3736-3738	to	_	
19-15	3739-3752	interoceptive	_	
19-16	3753-3759	signal	_	
19-17	3760-3770	processing	_	
19-18	3771-3773	in	_	
19-19	3774-3777	CNS	_	
19-20	3778-3779	(	_	
19-21	3779-3782	e.g	_	
19-22	3782-3783	.	_	
19-23	3783-3784	,	_	
19-24	3785-3795	especially	_	
19-25	3796-3803	sectors	_	
19-26	3804-3806	of	_	
19-27	3807-3810	the	_	
19-28	3811-3817	insula	_	
19-29	3817-3818	)	_	
19-30	3819-3823	when	_	
19-31	3824-3833	attention	_	
19-32	3834-3836	is	_	
19-33	3837-3847	explicitly	_	
19-34	3848-3856	directed	_	
19-35	3857-3859	at	_	
19-36	3860-3866	bodily	_	
19-37	3867-3877	sensations	_	
19-38	3878-3881	and	_	
19-39	3882-3897	down-regulation	_	
19-40	3898-3902	when	_	
19-41	3903-3912	attention	_	
19-42	3913-3915	is	_	
19-43	3916-3924	directed	_	
19-44	3925-3929	away	_	
19-45	3930-3934	from	_	
19-46	3935-3941	bodily	_	
19-47	3942-3952	sensations	_	
19-48	3952-3953	.	_	

#Text=There is presently growing interest in the role of interoception and (interoceptive dysfunction) in psychopathology (for a summary see the Biological Psychiatry consensus statement from the 2016 Interoception Summit).
20-1	3954-3959	There	_	
20-2	3960-3962	is	_	
20-3	3963-3972	presently	_	
20-4	3973-3980	growing	_	
20-5	3981-3989	interest	_	
20-6	3990-3992	in	_	
20-7	3993-3996	the	_	
20-8	3997-4001	role	_	
20-9	4002-4004	of	_	
20-10	4005-4018	interoception	_	
20-11	4019-4022	and	_	
20-12	4023-4024	(	_	
20-13	4024-4037	interoceptive	_	
20-14	4038-4049	dysfunction	_	
20-15	4049-4050	)	_	
20-16	4051-4053	in	_	
20-17	4054-4069	psychopathology	_	
20-18	4070-4071	(	_	
20-19	4071-4074	for	_	
20-20	4075-4076	a	_	
20-21	4077-4084	summary	_	
20-22	4085-4088	see	_	
20-23	4089-4092	the	_	
20-24	4093-4103	Biological	_	
20-25	4104-4114	Psychiatry	_	
20-26	4115-4124	consensus	_	
20-27	4125-4134	statement	_	
20-28	4135-4139	from	_	
20-29	4140-4143	the	_	
20-30	4144-4148	2016	_	
20-31	4149-4162	Interoception	_	
20-32	4163-4169	Summit	_	
20-33	4169-4170	)	_	
20-34	4170-4171	.	_	

#Text=Interoception may be an important factor in substance use disorder (SUD), and in recovery from addiction.
21-1	4172-4185	Interoception	_	
21-2	4186-4189	may	_	
21-3	4190-4192	be	_	
21-4	4193-4195	an	_	
21-5	4196-4205	important	_	
21-6	4206-4212	factor	_	
21-7	4213-4215	in	_	
21-8	4216-4225	substance	_	
21-9	4226-4229	use	_	
21-10	4230-4238	disorder	_	
21-11	4239-4240	(	_	
21-12	4240-4243	SUD	_	
21-13	4243-4244	)	_	
21-14	4244-4245	,	_	
21-15	4246-4249	and	_	
21-16	4250-4252	in	_	
21-17	4253-4261	recovery	_	
21-18	4262-4266	from	_	
21-19	4267-4276	addiction	_	
21-20	4276-4277	.	_	

#Text=For instance, psychoactive drugs stimulate bodily sensations (e.g., via autonomic system stimulation) and these sensations may become part of the feelings sought by frequent users.
22-1	4278-4281	For	_	
22-2	4282-4290	instance	_	
22-3	4290-4291	,	_	
22-4	4292-4304	psychoactive	_	
22-5	4305-4310	drugs	_	
22-6	4311-4320	stimulate	_	
22-7	4321-4327	bodily	_	
22-8	4328-4338	sensations	_	
22-9	4339-4340	(	_	
22-10	4340-4343	e.g	_	
22-11	4343-4344	.	_	
22-12	4344-4345	,	_	
22-13	4346-4349	via	_	
22-14	4350-4359	autonomic	_	
22-15	4360-4366	system	_	
22-16	4367-4378	stimulation	_	
22-17	4378-4379	)	_	
22-18	4380-4383	and	_	
22-19	4384-4389	these	_	
22-20	4390-4400	sensations	_	
22-21	4401-4404	may	_	
22-22	4405-4411	become	_	
22-23	4412-4416	part	_	
22-24	4417-4419	of	_	
22-25	4420-4423	the	_	
22-26	4424-4432	feelings	_	
22-27	4433-4439	sought	_	
22-28	4440-4442	by	_	
22-29	4443-4451	frequent	_	
22-30	4452-4457	users	_	
22-31	4457-4458	.	_	

#Text=Similarly, withdrawal is marked by aversive interoceptive signals (e.g., aching and nausea) which can drive motivation to use.
23-1	4459-4468	Similarly	_	
23-2	4468-4469	,	_	
23-3	4470-4480	withdrawal	_	
23-4	4481-4483	is	_	
23-5	4484-4490	marked	_	
23-6	4491-4493	by	_	
23-7	4494-4502	aversive	_	
23-8	4503-4516	interoceptive	_	
23-9	4517-4524	signals	_	
23-10	4525-4526	(	_	
23-11	4526-4529	e.g	_	
23-12	4529-4530	.	_	
23-13	4530-4531	,	_	
23-14	4532-4538	aching	_	
23-15	4539-4542	and	_	
23-16	4543-4549	nausea	_	
23-17	4549-4550	)	_	
23-18	4551-4556	which	_	
23-19	4557-4560	can	_	
23-20	4561-4566	drive	_	
23-21	4567-4577	motivation	_	
23-22	4578-4580	to	_	
23-23	4581-4584	use	_	
23-24	4584-4585	.	_	

#Text=Interoceptive signals contribute to drug craving and to mood states which can also be triggers for drug use.
24-1	4586-4599	Interoceptive	_	
24-2	4600-4607	signals	_	
24-3	4608-4618	contribute	_	
24-4	4619-4621	to	_	
24-5	4622-4626	drug	_	
24-6	4627-4634	craving	_	
24-7	4635-4638	and	_	
24-8	4639-4641	to	_	
24-9	4642-4646	mood	_	
24-10	4647-4653	states	_	
24-11	4654-4659	which	_	
24-12	4660-4663	can	_	
24-13	4664-4668	also	_	
24-14	4669-4671	be	_	
24-15	4672-4680	triggers	_	
24-16	4681-4684	for	_	
24-17	4685-4689	drug	_	
24-18	4690-4693	use	_	
24-19	4693-4694	.	_	

#Text=A chronic use history with a particular drug may alter the response to interoceptive signals, particularly when those signals are directly linked to the rewarding drug.
25-1	4695-4696	A	_	
25-2	4697-4704	chronic	_	
25-3	4705-4708	use	_	
25-4	4709-4716	history	_	
25-5	4717-4721	with	_	
25-6	4722-4723	a	_	
25-7	4724-4734	particular	_	
25-8	4735-4739	drug	_	
25-9	4740-4743	may	_	
25-10	4744-4749	alter	_	
25-11	4750-4753	the	_	
25-12	4754-4762	response	_	
25-13	4763-4765	to	_	
25-14	4766-4779	interoceptive	_	
25-15	4780-4787	signals	_	
25-16	4787-4788	,	_	
25-17	4789-4801	particularly	_	
25-18	4802-4806	when	_	
25-19	4807-4812	those	_	
25-20	4813-4820	signals	_	
25-21	4821-4824	are	_	
25-22	4825-4833	directly	_	
25-23	4834-4840	linked	_	
25-24	4841-4843	to	_	
25-25	4844-4847	the	_	
25-26	4848-4857	rewarding	_	
25-27	4858-4862	drug	_	
25-28	4862-4863	.	_	

#Text=For example, sympathetic arousal accompanying danger may normally provoke caution, but may provoke approach behavior in a cocaine-dependent individual, since the interoceptive signals of sympathetic activation are similar to those accompanying acute cocaine intake.
26-1	4864-4867	For	_	
26-2	4868-4875	example	_	
26-3	4875-4876	,	_	
26-4	4877-4888	sympathetic	_	
26-5	4889-4896	arousal	_	
26-6	4897-4909	accompanying	_	
26-7	4910-4916	danger	_	
26-8	4917-4920	may	_	
26-9	4921-4929	normally	_	
26-10	4930-4937	provoke	_	
26-11	4938-4945	caution	_	
26-12	4945-4946	,	_	
26-13	4947-4950	but	_	
26-14	4951-4954	may	_	
26-15	4955-4962	provoke	_	
26-16	4963-4971	approach	_	
26-17	4972-4980	behavior	_	
26-18	4981-4983	in	_	
26-19	4984-4985	a	_	
26-20	4986-5003	cocaine-dependent	_	
26-21	5004-5014	individual	_	
26-22	5014-5015	,	_	
26-23	5016-5021	since	_	
26-24	5022-5025	the	_	
26-25	5026-5039	interoceptive	_	
26-26	5040-5047	signals	_	
26-27	5048-5050	of	_	
26-28	5051-5062	sympathetic	_	
26-29	5063-5073	activation	_	
26-30	5074-5077	are	_	
26-31	5078-5085	similar	_	
26-32	5086-5088	to	_	
26-33	5089-5094	those	_	
26-34	5095-5107	accompanying	_	
26-35	5108-5113	acute	_	
26-36	5114-5121	cocaine	_	
26-37	5122-5128	intake	_	
26-38	5128-5129	.	_	

#Text=In addition, impairment (or neglect) of interoceptive information could diminish the capacity for insight regarding problem drug use.
27-1	5130-5132	In	_	
27-2	5133-5141	addition	_	
27-3	5141-5142	,	_	
27-4	5143-5153	impairment	_	
27-5	5154-5155	(	_	
27-6	5155-5157	or	_	
27-7	5158-5165	neglect	_	
27-8	5165-5166	)	_	
27-9	5167-5169	of	_	
27-10	5170-5183	interoceptive	_	
27-11	5184-5195	information	_	
27-12	5196-5201	could	_	
27-13	5202-5210	diminish	_	
27-14	5211-5214	the	_	
27-15	5215-5223	capacity	_	
27-16	5224-5227	for	_	
27-17	5228-5235	insight	_	
27-18	5236-5245	regarding	_	
27-19	5246-5253	problem	_	
27-20	5254-5258	drug	_	
27-21	5259-5262	use	_	
27-22	5262-5263	.	_	

#Text=Interestingly, alexithymia, the inability to recognize one's own emotional states, is associated with interoceptive deficits and is frequently comorbid with SUD.
28-1	5264-5277	Interestingly	_	
28-2	5277-5278	,	_	
28-3	5279-5290	alexithymia	_	
28-4	5290-5291	,	_	
28-5	5292-5295	the	_	
28-6	5296-5305	inability	_	
28-7	5306-5308	to	_	
28-8	5309-5318	recognize	_	
28-9	5319-5324	one's	_	
28-10	5325-5328	own	_	
28-11	5329-5338	emotional	_	
28-12	5339-5345	states	_	
28-13	5345-5346	,	_	
28-14	5347-5349	is	_	
28-15	5350-5360	associated	_	
28-16	5361-5365	with	_	
28-17	5366-5379	interoceptive	_	
28-18	5380-5388	deficits	_	
28-19	5389-5392	and	_	
28-20	5393-5395	is	_	
28-21	5396-5406	frequently	_	
28-22	5407-5415	comorbid	_	
28-23	5416-5420	with	_	
28-24	5421-5424	SUD	_	
28-25	5424-5425	.	_	

#Text=Alexithymia also predicts poorer long-term outcomes in treatment for SUD, suggesting the possibility that the interoceptive signals informing emotional awareness might be important resources for addiction recovery.
29-1	5426-5437	Alexithymia	_	
29-2	5438-5442	also	_	
29-3	5443-5451	predicts	_	
29-4	5452-5458	poorer	_	
29-5	5459-5468	long-term	_	
29-6	5469-5477	outcomes	_	
29-7	5478-5480	in	_	
29-8	5481-5490	treatment	_	
29-9	5491-5494	for	_	
29-10	5495-5498	SUD	_	
29-11	5498-5499	,	_	
29-12	5500-5510	suggesting	_	
29-13	5511-5514	the	_	
29-14	5515-5526	possibility	_	
29-15	5527-5531	that	_	
29-16	5532-5535	the	_	
29-17	5536-5549	interoceptive	_	
29-18	5550-5557	signals	_	
29-19	5558-5567	informing	_	
29-20	5568-5577	emotional	_	
29-21	5578-5587	awareness	_	
29-22	5588-5593	might	_	
29-23	5594-5596	be	_	
29-24	5597-5606	important	_	
29-25	5607-5616	resources	_	
29-26	5617-5620	for	_	
29-27	5621-5630	addiction	_	
29-28	5631-5639	recovery	_	
29-29	5639-5640	.	_	

#Text=Indeed several models of addiction treatment, including Cognitive Behavioral Therapy (CBT) and mindfulness-based interventions explicitly work with clients to help them better recognize their own bodily sensations.
30-1	5641-5647	Indeed	_	
30-2	5648-5655	several	_	
30-3	5656-5662	models	_	
30-4	5663-5665	of	_	
30-5	5666-5675	addiction	_	
30-6	5676-5685	treatment	_	
30-7	5685-5686	,	_	
30-8	5687-5696	including	_	
30-9	5697-5706	Cognitive	_	
30-10	5707-5717	Behavioral	_	
30-11	5718-5725	Therapy	_	
30-12	5726-5727	(	_	
30-13	5727-5730	CBT	_	
30-14	5730-5731	)	_	
30-15	5732-5735	and	_	
30-16	5736-5753	mindfulness-based	_	
30-17	5754-5767	interventions	_	
30-18	5768-5778	explicitly	_	
30-19	5779-5783	work	_	
30-20	5784-5788	with	_	
30-21	5789-5796	clients	_	
30-22	5797-5799	to	_	
30-23	5800-5804	help	_	
30-24	5805-5809	them	_	
30-25	5810-5816	better	_	
30-26	5817-5826	recognize	_	
30-27	5827-5832	their	_	
30-28	5833-5836	own	_	
30-29	5837-5843	bodily	_	
30-30	5844-5854	sensations	_	
30-31	5854-5855	.	_	

#Text=For example, in CBT, clients are taught to work to monitor their body for sensations of craving and to, “pay attention to all the somatic and affective signals and try to put them into words.
31-1	5856-5859	For	_	
31-2	5860-5867	example	_	
31-3	5867-5868	,	_	
31-4	5869-5871	in	_	
31-5	5872-5875	CBT	_	
31-6	5875-5876	,	_	
31-7	5877-5884	clients	_	
31-8	5885-5888	are	_	
31-9	5889-5895	taught	_	
31-10	5896-5898	to	_	
31-11	5899-5903	work	_	
31-12	5904-5906	to	_	
31-13	5907-5914	monitor	_	
31-14	5915-5920	their	_	
31-15	5921-5925	body	_	
31-16	5926-5929	for	_	
31-17	5930-5940	sensations	_	
31-18	5941-5943	of	_	
31-19	5944-5951	craving	_	
31-20	5952-5955	and	_	
31-21	5956-5958	to	_	
31-22	5958-5959	,	_	
31-23	5960-5961	“	_	
31-24	5961-5964	pay	_	
31-25	5965-5974	attention	_	
31-26	5975-5977	to	_	
31-27	5978-5981	all	_	
31-28	5982-5985	the	_	
31-29	5986-5993	somatic	_	
31-30	5994-5997	and	_	
31-31	5998-6007	affective	_	
31-32	6008-6015	signals	_	
31-33	6016-6019	and	_	
31-34	6020-6023	try	_	
31-35	6024-6026	to	_	
31-36	6027-6030	put	_	
31-37	6031-6035	them	_	
31-38	6036-6040	into	_	
31-39	6041-6046	words	_	
31-40	6046-6047	.	_	

#Text=What is the feeling like?
32-1	6048-6052	What	_	
32-2	6053-6055	is	_	
32-3	6056-6059	the	_	
32-4	6060-6067	feeling	_	
32-5	6068-6072	like	_	
32-6	6072-6073	?	_	

#Text=Where is it?”
33-1	6074-6079	Where	_	
33-2	6080-6082	is	_	
33-3	6083-6085	it	_	
33-4	6085-6086	?	_	
33-5	6086-6087	”	_	

#Text=(, pg. 51).
34-1	6088-6089	(	_	
34-2	6089-6090	,	_	
34-3	6091-6093	pg	_	
34-4	6093-6094	.	_	
34-5	6095-6097	51	_	
34-6	6097-6098	)	_	
34-7	6098-6099	.	_	

#Text=Impaired interoceptive awareness is a symptom of PTSD
#Text=If interoception is an important factor in SUD and recovery from SUD, then it is important to consider the implication for the significant subset of SUD individuals with co-morbid Post-Traumatic Stress Disorder (PTSD).
35-1	6100-6108	Impaired	_	
35-2	6109-6122	interoceptive	_	
35-3	6123-6132	awareness	_	
35-4	6133-6135	is	_	
35-5	6136-6137	a	_	
35-6	6138-6145	symptom	_	
35-7	6146-6148	of	_	
35-8	6149-6153	PTSD	_	
35-9	6154-6156	If	_	
35-10	6157-6170	interoception	_	
35-11	6171-6173	is	_	
35-12	6174-6176	an	_	
35-13	6177-6186	important	_	
35-14	6187-6193	factor	_	
35-15	6194-6196	in	_	
35-16	6197-6200	SUD	_	
35-17	6201-6204	and	_	
35-18	6205-6213	recovery	_	
35-19	6214-6218	from	_	
35-20	6219-6222	SUD	_	
35-21	6222-6223	,	_	
35-22	6224-6228	then	_	
35-23	6229-6231	it	_	
35-24	6232-6234	is	_	
35-25	6235-6244	important	_	
35-26	6245-6247	to	_	
35-27	6248-6256	consider	_	
35-28	6257-6260	the	_	
35-29	6261-6272	implication	_	
35-30	6273-6276	for	_	
35-31	6277-6280	the	_	
35-32	6281-6292	significant	_	
35-33	6293-6299	subset	_	
35-34	6300-6302	of	_	
35-35	6303-6306	SUD	_	
35-36	6307-6318	individuals	_	
35-37	6319-6323	with	_	
35-38	6324-6333	co-morbid	_	
35-39	6334-6348	Post-Traumatic	_	
35-40	6349-6355	Stress	_	
35-41	6356-6364	Disorder	_	
35-42	6365-6366	(	_	
35-43	6366-6370	PTSD	_	
35-44	6370-6371	)	_	
35-45	6371-6372	.	_	

#Text=Bodily attention appears to be relevant to the pathology of trauma-linked disorders, which includes intrusive memories and cognitions that may involve, or be triggered by interoceptive sensations and bodily awareness.
36-1	6373-6379	Bodily	_	
36-2	6380-6389	attention	_	
36-3	6390-6397	appears	_	
36-4	6398-6400	to	_	
36-5	6401-6403	be	_	
36-6	6404-6412	relevant	_	
36-7	6413-6415	to	_	
36-8	6416-6419	the	_	
36-9	6420-6429	pathology	_	
36-10	6430-6432	of	_	
36-11	6433-6446	trauma-linked	_	
36-12	6447-6456	disorders	_	
36-13	6456-6457	,	_	
36-14	6458-6463	which	_	
36-15	6464-6472	includes	_	
36-16	6473-6482	intrusive	_	
36-17	6483-6491	memories	_	
36-18	6492-6495	and	_	
36-19	6496-6506	cognitions	_	
36-20	6507-6511	that	_	
36-21	6512-6515	may	_	
36-22	6516-6523	involve	_	
36-23	6523-6524	,	_	
36-24	6525-6527	or	_	
36-25	6528-6530	be	_	
36-26	6531-6540	triggered	_	
36-27	6541-6543	by	_	
36-28	6544-6557	interoceptive	_	
36-29	6558-6568	sensations	_	
36-30	6569-6572	and	_	
36-31	6573-6579	bodily	_	
36-32	6580-6589	awareness	_	
36-33	6589-6590	.	_	

#Text=In line with these behavioral observations, PTSD and sexual trauma have previously been associated with altered brain metabolism in regions associated with interoceptive and somatosensory processing.
37-1	6591-6593	In	_	
37-2	6594-6598	line	_	
37-3	6599-6603	with	_	
37-4	6604-6609	these	_	
37-5	6610-6620	behavioral	_	
37-6	6621-6633	observations	_	
37-7	6633-6634	,	_	
37-8	6635-6639	PTSD	_	
37-9	6640-6643	and	_	
37-10	6644-6650	sexual	_	
37-11	6651-6657	trauma	_	
37-12	6658-6662	have	_	
37-13	6663-6673	previously	_	
37-14	6674-6678	been	_	
37-15	6679-6689	associated	_	
37-16	6690-6694	with	_	
37-17	6695-6702	altered	_	
37-18	6703-6708	brain	_	
37-19	6709-6719	metabolism	_	
37-20	6720-6722	in	_	
37-21	6723-6730	regions	_	
37-22	6731-6741	associated	_	
37-23	6742-6746	with	_	
37-24	6747-6760	interoceptive	_	
37-25	6761-6764	and	_	
37-26	6765-6778	somatosensory	_	
37-27	6779-6789	processing	_	
37-28	6789-6790	.	_	

#Text=Specifically, women with PTSD due to intimate partner violence have blunted subjective pain and pain-linked anterior insula responses that are inversely correlated with avoidant symptoms, and (primarily) female patients with dissociative PTSD show reduced functional connectivity of vestibular brainstem nuclei with a parieto-posterior insula network and the dorsolateral prefrontal cortex (DLFPC).
38-1	6791-6803	Specifically	_	
38-2	6803-6804	,	_	
38-3	6805-6810	women	_	
38-4	6811-6815	with	_	
38-5	6816-6820	PTSD	_	
38-6	6821-6824	due	_	
38-7	6825-6827	to	_	
38-8	6828-6836	intimate	_	
38-9	6837-6844	partner	_	
38-10	6845-6853	violence	_	
38-11	6854-6858	have	_	
38-12	6859-6866	blunted	_	
38-13	6867-6877	subjective	_	
38-14	6878-6882	pain	_	
38-15	6883-6886	and	_	
38-16	6887-6898	pain-linked	_	
38-17	6899-6907	anterior	_	
38-18	6908-6914	insula	_	
38-19	6915-6924	responses	_	
38-20	6925-6929	that	_	
38-21	6930-6933	are	_	
38-22	6934-6943	inversely	_	
38-23	6944-6954	correlated	_	
38-24	6955-6959	with	_	
38-25	6960-6968	avoidant	_	
38-26	6969-6977	symptoms	_	
38-27	6977-6978	,	_	
38-28	6979-6982	and	_	
38-29	6983-6984	(	_	
38-30	6984-6993	primarily	_	
38-31	6993-6994	)	_	
38-32	6995-7001	female	_	
38-33	7002-7010	patients	_	
38-34	7011-7015	with	_	
38-35	7016-7028	dissociative	_	
38-36	7029-7033	PTSD	_	
38-37	7034-7038	show	_	
38-38	7039-7046	reduced	_	
38-39	7047-7057	functional	_	
38-40	7058-7070	connectivity	_	
38-41	7071-7073	of	_	
38-42	7074-7084	vestibular	_	
38-43	7085-7094	brainstem	_	
38-44	7095-7101	nuclei	_	
38-45	7102-7106	with	_	
38-46	7107-7108	a	_	
38-47	7109-7126	parieto-posterior	_	
38-48	7127-7133	insula	_	
38-49	7134-7141	network	_	
38-50	7142-7145	and	_	
38-51	7146-7149	the	_	
38-52	7150-7162	dorsolateral	_	
38-53	7163-7173	prefrontal	_	
38-54	7174-7180	cortex	_	
38-55	7181-7182	(	_	
38-56	7182-7187	DLFPC	_	
38-57	7187-7188	)	_	
38-58	7188-7189	.	_	

#Text=Trauma and substance abuse comorbidity
#Text=Exposure to traumatic events are as high as 93% in some SUD samples.
39-1	7190-7196	Trauma	_	
39-2	7197-7200	and	_	
39-3	7201-7210	substance	_	
39-4	7211-7216	abuse	_	
39-5	7217-7228	comorbidity	_	
39-6	7229-7237	Exposure	_	
39-7	7238-7240	to	_	
39-8	7241-7250	traumatic	_	
39-9	7251-7257	events	_	
39-10	7258-7261	are	_	
39-11	7262-7264	as	_	
39-12	7265-7269	high	_	
39-13	7270-7272	as	_	
39-14	7273-7276	93%	_	
39-15	7277-7279	in	_	
39-16	7280-7284	some	_	
39-17	7285-7288	SUD	_	
39-18	7289-7296	samples	_	
39-19	7296-7297	.	_	

#Text=Among substance dependent groups, the lifetime prevalence of PTSD has been estimated to be between 26% and 52%, with current prevalence between 15% and 42%, depending on the sample.
40-1	7298-7303	Among	_	
40-2	7304-7313	substance	_	
40-3	7314-7323	dependent	_	
40-4	7324-7330	groups	_	
40-5	7330-7331	,	_	
40-6	7332-7335	the	_	
40-7	7336-7344	lifetime	_	
40-8	7345-7355	prevalence	_	
40-9	7356-7358	of	_	
40-10	7359-7363	PTSD	_	
40-11	7364-7367	has	_	
40-12	7368-7372	been	_	
40-13	7373-7382	estimated	_	
40-14	7383-7385	to	_	
40-15	7386-7388	be	_	
40-16	7389-7396	between	_	
40-17	7397-7400	26%	_	
40-18	7401-7404	and	_	
40-19	7405-7408	52%	_	
40-20	7408-7409	,	_	
40-21	7410-7414	with	_	
40-22	7415-7422	current	_	
40-23	7423-7433	prevalence	_	
40-24	7434-7441	between	_	
40-25	7442-7445	15%	_	
40-26	7446-7449	and	_	
40-27	7450-7453	42%	_	
40-28	7453-7454	,	_	
40-29	7455-7464	depending	_	
40-30	7465-7467	on	_	
40-31	7468-7471	the	_	
40-32	7472-7478	sample	_	
40-33	7478-7479	.	_	

#Text=Women with SUDs experience markedly higher rates of traumatic stress and victimization compared to men with SUDs, particularly for traumas relating to childhood and adulthood sexual and physical abuse.
41-1	7480-7485	Women	_	
41-2	7486-7490	with	_	
41-3	7491-7495	SUDs	_	
41-4	7496-7506	experience	_	
41-5	7507-7515	markedly	_	
41-6	7516-7522	higher	_	
41-7	7523-7528	rates	_	
41-8	7529-7531	of	_	
41-9	7532-7541	traumatic	_	
41-10	7542-7548	stress	_	
41-11	7549-7552	and	_	
41-12	7553-7566	victimization	_	
41-13	7567-7575	compared	_	
41-14	7576-7578	to	_	
41-15	7579-7582	men	_	
41-16	7583-7587	with	_	
41-17	7588-7592	SUDs	_	
41-18	7592-7593	,	_	
41-19	7594-7606	particularly	_	
41-20	7607-7610	for	_	
41-21	7611-7618	traumas	_	
41-22	7619-7627	relating	_	
41-23	7628-7630	to	_	
41-24	7631-7640	childhood	_	
41-25	7641-7644	and	_	
41-26	7645-7654	adulthood	_	
41-27	7655-7661	sexual	_	
41-28	7662-7665	and	_	
41-29	7666-7674	physical	_	
41-30	7675-7680	abuse	_	
41-31	7680-7681	.	_	

#Text=Women with SUDs may also experience higher rates of current and lifetime PTSD compared to men with SUDs.
42-1	7682-7687	Women	_	
42-2	7688-7692	with	_	
42-3	7693-7697	SUDs	_	
42-4	7698-7701	may	_	
42-5	7702-7706	also	_	
42-6	7707-7717	experience	_	
42-7	7718-7724	higher	_	
42-8	7725-7730	rates	_	
42-9	7731-7733	of	_	
42-10	7734-7741	current	_	
42-11	7742-7745	and	_	
42-12	7746-7754	lifetime	_	
42-13	7755-7759	PTSD	_	
42-14	7760-7768	compared	_	
42-15	7769-7771	to	_	
42-16	7772-7775	men	_	
42-17	7776-7780	with	_	
42-18	7781-7785	SUDs	_	
42-19	7785-7786	.	_	

#Text=PTSD symptoms exacerbate and are exacerbated by the presence of an SUD.
43-1	7787-7791	PTSD	_	
43-2	7792-7800	symptoms	_	
43-3	7801-7811	exacerbate	_	
43-4	7812-7815	and	_	
43-5	7816-7819	are	_	
43-6	7820-7831	exacerbated	_	
43-7	7832-7834	by	_	
43-8	7835-7838	the	_	
43-9	7839-7847	presence	_	
43-10	7848-7850	of	_	
43-11	7851-7853	an	_	
43-12	7854-7857	SUD	_	
43-13	7857-7858	.	_	

#Text=Individuals with co-occurring SUD and PTSD may face worse clinical outcomes, including greater psychosocial problems, need for services, more severe substance use, and higher rates of relapse than for individuals with SUD-only.
44-1	7859-7870	Individuals	_	
44-2	7871-7875	with	_	
44-3	7876-7888	co-occurring	_	
44-4	7889-7892	SUD	_	
44-5	7893-7896	and	_	
44-6	7897-7901	PTSD	_	
44-7	7902-7905	may	_	
44-8	7906-7910	face	_	
44-9	7911-7916	worse	_	
44-10	7917-7925	clinical	_	
44-11	7926-7934	outcomes	_	
44-12	7934-7935	,	_	
44-13	7936-7945	including	_	
44-14	7946-7953	greater	_	
44-15	7954-7966	psychosocial	_	
44-16	7967-7975	problems	_	
44-17	7975-7976	,	_	
44-18	7977-7981	need	_	
44-19	7982-7985	for	_	
44-20	7986-7994	services	_	
44-21	7994-7995	,	_	
44-22	7996-8000	more	_	
44-23	8001-8007	severe	_	
44-24	8008-8017	substance	_	
44-25	8018-8021	use	_	
44-26	8021-8022	,	_	
44-27	8023-8026	and	_	
44-28	8027-8033	higher	_	
44-29	8034-8039	rates	_	
44-30	8040-8042	of	_	
44-31	8043-8050	relapse	_	
44-32	8051-8055	than	_	
44-33	8056-8059	for	_	
44-34	8060-8071	individuals	_	
44-35	8072-8076	with	_	
44-36	8077-8085	SUD-only	_	
44-37	8085-8086	.	_	

#Text=Despite the established clinical relationship, trauma comorbidity in SUD is understudied in the neuroimaging literature.
45-1	8087-8094	Despite	_	
45-2	8095-8098	the	_	
45-3	8099-8110	established	_	
45-4	8111-8119	clinical	_	
45-5	8120-8132	relationship	_	
45-6	8132-8133	,	_	
45-7	8134-8140	trauma	_	
45-8	8141-8152	comorbidity	_	
45-9	8153-8155	in	_	
45-10	8156-8159	SUD	_	
45-11	8160-8162	is	_	
45-12	8163-8175	understudied	_	
45-13	8176-8178	in	_	
45-14	8179-8182	the	_	
45-15	8183-8195	neuroimaging	_	
45-16	8196-8206	literature	_	
45-17	8206-8207	.	_	

#Text=The few existing studies (notably:; and) highlight heightened limbic drug-cue reactivity and enhanced amygdala-striatal resting-state functional connectivity, respectively, in cocaine-dependent men with histories of trauma.
46-1	8208-8211	The	_	
46-2	8212-8215	few	_	
46-3	8216-8224	existing	_	
46-4	8225-8232	studies	_	
46-5	8233-8234	(	_	
46-6	8234-8241	notably	_	
46-7	8241-8242	:	_	
46-8	8242-8243	;	_	
46-9	8244-8247	and	_	
46-10	8247-8248	)	_	
46-11	8249-8258	highlight	_	
46-12	8259-8269	heightened	_	
46-13	8270-8276	limbic	_	
46-14	8277-8285	drug-cue	_	
46-15	8286-8296	reactivity	_	
46-16	8297-8300	and	_	
46-17	8301-8309	enhanced	_	
46-18	8310-8327	amygdala-striatal	_	
46-19	8328-8341	resting-state	_	
46-20	8342-8352	functional	_	
46-21	8353-8365	connectivity	_	
46-22	8365-8366	,	_	
46-23	8367-8379	respectively	_	
46-24	8379-8380	,	_	
46-25	8381-8383	in	_	
46-26	8384-8401	cocaine-dependent	_	
46-27	8402-8405	men	_	
46-28	8406-8410	with	_	
46-29	8411-8420	histories	_	
46-30	8421-8423	of	_	
46-31	8424-8430	trauma	_	
46-32	8430-8431	.	_	

#Text=These findings suggest that there may be distinctive correlates of traumatic stress and brain function among individuals with SUD.
47-1	8432-8437	These	_	
47-2	8438-8446	findings	_	
47-3	8447-8454	suggest	_	
47-4	8455-8459	that	_	
47-5	8460-8465	there	_	
47-6	8466-8469	may	_	
47-7	8470-8472	be	_	
47-8	8473-8484	distinctive	_	
47-9	8485-8495	correlates	_	
47-10	8496-8498	of	_	
47-11	8499-8508	traumatic	_	
47-12	8509-8515	stress	_	
47-13	8516-8519	and	_	
47-14	8520-8525	brain	_	
47-15	8526-8534	function	_	
47-16	8535-8540	among	_	
47-17	8541-8552	individuals	_	
47-18	8553-8557	with	_	
47-19	8558-8561	SUD	_	
47-20	8561-8562	.	_	

#Text=However, neither study included participants with PTSD diagnoses, a clinically relevant distinction, since exposure to trauma-categoric events in absence of post-traumatic stress symptoms may not have the same effect on brain function, nor the course and outcome of a SUD.
48-1	8563-8570	However	_	
48-2	8570-8571	,	_	
48-3	8572-8579	neither	_	
48-4	8580-8585	study	_	
48-5	8586-8594	included	_	
48-6	8595-8607	participants	_	
48-7	8608-8612	with	_	
48-8	8613-8617	PTSD	_	
48-9	8618-8627	diagnoses	_	
48-10	8627-8628	,	_	
48-11	8629-8630	a	_	
48-12	8631-8641	clinically	_	
48-13	8642-8650	relevant	_	
48-14	8651-8662	distinction	_	
48-15	8662-8663	,	_	
48-16	8664-8669	since	_	
48-17	8670-8678	exposure	_	
48-18	8679-8681	to	_	
48-19	8682-8698	trauma-categoric	_	
48-20	8699-8705	events	_	
48-21	8706-8708	in	_	
48-22	8709-8716	absence	_	
48-23	8717-8719	of	_	
48-24	8720-8734	post-traumatic	_	
48-25	8735-8741	stress	_	
48-26	8742-8750	symptoms	_	
48-27	8751-8754	may	_	
48-28	8755-8758	not	_	
48-29	8759-8763	have	_	
48-30	8764-8767	the	_	
48-31	8768-8772	same	_	
48-32	8773-8779	effect	_	
48-33	8780-8782	on	_	
48-34	8783-8788	brain	_	
48-35	8789-8797	function	_	
48-36	8797-8798	,	_	
48-37	8799-8802	nor	_	
48-38	8803-8806	the	_	
48-39	8807-8813	course	_	
48-40	8814-8817	and	_	
48-41	8818-8825	outcome	_	
48-42	8826-8828	of	_	
48-43	8829-8830	a	_	
48-44	8831-8834	SUD	_	
48-45	8834-8835	.	_	

#Text=It remains the case that PTSD has, to our knowledge, not yet been evaluated in a neuroimaging study of a substance-dependent population.
49-1	8836-8838	It	_	
49-2	8839-8846	remains	_	
49-3	8847-8850	the	_	
49-4	8851-8855	case	_	
49-5	8856-8860	that	_	
49-6	8861-8865	PTSD	_	
49-7	8866-8869	has	_	
49-8	8869-8870	,	_	
49-9	8871-8873	to	_	
49-10	8874-8877	our	_	
49-11	8878-8887	knowledge	_	
49-12	8887-8888	,	_	
49-13	8889-8892	not	_	
49-14	8893-8896	yet	_	
49-15	8897-8901	been	_	
49-16	8902-8911	evaluated	_	
49-17	8912-8914	in	_	
49-18	8915-8916	a	_	
49-19	8917-8929	neuroimaging	_	
49-20	8930-8935	study	_	
49-21	8936-8938	of	_	
49-22	8939-8940	a	_	
49-23	8941-8960	substance-dependent	_	
49-24	8961-8971	population	_	
49-25	8971-8972	.	_	

#Text=Given that women with SUDs experience markedly higher rates of trauma and PTSD relative to men with SUDs, especially due to interpersonal and domestic violence, there is a clear need to investigate neurobiological correlates in trauma-exposed, substance-dependent women with-and-without current PTSD diagnoses, as it may reveal functional differences with clinical implications.
50-1	8973-8978	Given	_	
50-2	8979-8983	that	_	
50-3	8984-8989	women	_	
50-4	8990-8994	with	_	
50-5	8995-8999	SUDs	_	
50-6	9000-9010	experience	_	
50-7	9011-9019	markedly	_	
50-8	9020-9026	higher	_	
50-9	9027-9032	rates	_	
50-10	9033-9035	of	_	
50-11	9036-9042	trauma	_	
50-12	9043-9046	and	_	
50-13	9047-9051	PTSD	_	
50-14	9052-9060	relative	_	
50-15	9061-9063	to	_	
50-16	9064-9067	men	_	
50-17	9068-9072	with	_	
50-18	9073-9077	SUDs	_	
50-19	9077-9078	,	_	
50-20	9079-9089	especially	_	
50-21	9090-9093	due	_	
50-22	9094-9096	to	_	
50-23	9097-9110	interpersonal	_	
50-24	9111-9114	and	_	
50-25	9115-9123	domestic	_	
50-26	9124-9132	violence	_	
50-27	9132-9133	,	_	
50-28	9134-9139	there	_	
50-29	9140-9142	is	_	
50-30	9143-9144	a	_	
50-31	9145-9150	clear	_	
50-32	9151-9155	need	_	
50-33	9156-9158	to	_	
50-34	9159-9170	investigate	_	
50-35	9171-9186	neurobiological	_	
50-36	9187-9197	correlates	_	
50-37	9198-9200	in	_	
50-38	9201-9215	trauma-exposed	_	
50-39	9215-9216	,	_	
50-40	9217-9236	substance-dependent	_	
50-41	9237-9242	women	_	
50-42	9243-9259	with-and-without	_	
50-43	9260-9267	current	_	
50-44	9268-9272	PTSD	_	
50-45	9273-9282	diagnoses	_	
50-46	9282-9283	,	_	
50-47	9284-9286	as	_	
50-48	9287-9289	it	_	
50-49	9290-9293	may	_	
50-50	9294-9300	reveal	_	
50-51	9301-9311	functional	_	
50-52	9312-9323	differences	_	
50-53	9324-9328	with	_	
50-54	9329-9337	clinical	_	
50-55	9338-9350	implications	_	
50-56	9350-9351	.	_	

#Text=The primary goal of the present report is to characterize deficits in interoceptive processing associated with PTSD comorbidity in a sample of women with SUD.
51-1	9352-9355	The	_	
51-2	9356-9363	primary	_	
51-3	9364-9368	goal	_	
51-4	9369-9371	of	_	
51-5	9372-9375	the	_	
51-6	9376-9383	present	_	
51-7	9384-9390	report	_	
51-8	9391-9393	is	_	
51-9	9394-9396	to	_	
51-10	9397-9409	characterize	_	
51-11	9410-9418	deficits	_	
51-12	9419-9421	in	_	
51-13	9422-9435	interoceptive	_	
51-14	9436-9446	processing	_	
51-15	9447-9457	associated	_	
51-16	9458-9462	with	_	
51-17	9463-9467	PTSD	_	
51-18	9468-9479	comorbidity	_	
51-19	9480-9482	in	_	
51-20	9483-9484	a	_	
51-21	9485-9491	sample	_	
51-22	9492-9494	of	_	
51-23	9495-9500	women	_	
51-24	9501-9505	with	_	
51-25	9506-9509	SUD	_	
51-26	9509-9510	.	_	

#Text=To do this, we capitalize on the robust “attentional spotlight” effect, by which brain network activity supporting interoception is enhanced when attention is explicitly directed at bodily sensations.
52-1	9511-9513	To	_	
52-2	9514-9516	do	_	
52-3	9517-9521	this	_	
52-4	9521-9522	,	_	
52-5	9523-9525	we	_	
52-6	9526-9536	capitalize	_	
52-7	9537-9539	on	_	
52-8	9540-9543	the	_	
52-9	9544-9550	robust	_	
52-10	9551-9552	“	_	
52-11	9552-9563	attentional	_	
52-12	9564-9573	spotlight	_	
52-13	9573-9574	”	_	
52-14	9575-9581	effect	_	
52-15	9581-9582	,	_	
52-16	9583-9585	by	_	
52-17	9586-9591	which	_	
52-18	9592-9597	brain	_	
52-19	9598-9605	network	_	
52-20	9606-9614	activity	_	
52-21	9615-9625	supporting	_	
52-22	9626-9639	interoception	_	
52-23	9640-9642	is	_	
52-24	9643-9651	enhanced	_	
52-25	9652-9656	when	_	
52-26	9657-9666	attention	_	
52-27	9667-9669	is	_	
52-28	9670-9680	explicitly	_	
52-29	9681-9689	directed	_	
52-30	9690-9692	at	_	
52-31	9693-9699	bodily	_	
52-32	9700-9710	sensations	_	
52-33	9710-9711	.	_	

#Text=This allows us to evaluate whether comorbid PTSD is associated with anomalous BOLD response during an interoceptive challenge (attention to bodily sensations of breathing) and to characterize the nature of any observed anomaly at the level of brain functional networks.
53-1	9712-9716	This	_	
53-2	9717-9723	allows	_	
53-3	9724-9726	us	_	
53-4	9727-9729	to	_	
53-5	9730-9738	evaluate	_	
53-6	9739-9746	whether	_	
53-7	9747-9755	comorbid	_	
53-8	9756-9760	PTSD	_	
53-9	9761-9763	is	_	
53-10	9764-9774	associated	_	
53-11	9775-9779	with	_	
53-12	9780-9789	anomalous	_	
53-13	9790-9794	BOLD	_	
53-14	9795-9803	response	_	
53-15	9804-9810	during	_	
53-16	9811-9813	an	_	
53-17	9814-9827	interoceptive	_	
53-18	9828-9837	challenge	_	
53-19	9838-9839	(	_	
53-20	9839-9848	attention	_	
53-21	9849-9851	to	_	
53-22	9852-9858	bodily	_	
53-23	9859-9869	sensations	_	
53-24	9870-9872	of	_	
53-25	9873-9882	breathing	_	
53-26	9882-9883	)	_	
53-27	9884-9887	and	_	
53-28	9888-9890	to	_	
53-29	9891-9903	characterize	_	
53-30	9904-9907	the	_	
53-31	9908-9914	nature	_	
53-32	9915-9917	of	_	
53-33	9918-9921	any	_	
53-34	9922-9930	observed	_	
53-35	9931-9938	anomaly	_	
53-36	9939-9941	at	_	
53-37	9942-9945	the	_	
53-38	9946-9951	level	_	
53-39	9952-9954	of	_	
53-40	9955-9960	brain	_	
53-41	9961-9971	functional	_	
53-42	9972-9980	networks	_	
53-43	9980-9981	.	_	

#Text=We study this issue in low socioeconomic-status (SES) women who recently completed detoxification and enrolled in a residential treatment program for SUDs.
54-1	9982-9984	We	_	
54-2	9985-9990	study	_	
54-3	9991-9995	this	_	
54-4	9996-10001	issue	_	
54-5	10002-10004	in	_	
54-6	10005-10008	low	_	
54-7	10009-10029	socioeconomic-status	_	
54-8	10030-10031	(	_	
54-9	10031-10034	SES	_	
54-10	10034-10035	)	_	
54-11	10036-10041	women	_	
54-12	10042-10045	who	_	
54-13	10046-10054	recently	_	
54-14	10055-10064	completed	_	
54-15	10065-10079	detoxification	_	
54-16	10080-10083	and	_	
54-17	10084-10092	enrolled	_	
54-18	10093-10095	in	_	
54-19	10096-10097	a	_	
54-20	10098-10109	residential	_	
54-21	10110-10119	treatment	_	
54-22	10120-10127	program	_	
54-23	10128-10131	for	_	
54-24	10132-10136	SUDs	_	
54-25	10136-10137	.	_	

#Text=FMRI data were acquired during the baseline period (pre-randomization) from a subset of patients participating in a clinical trial of Moment-by-Moment in Women's Recovery (MMWR).
55-1	10138-10142	FMRI	_	
55-2	10143-10147	data	_	
55-3	10148-10152	were	_	
55-4	10153-10161	acquired	_	
55-5	10162-10168	during	_	
55-6	10169-10172	the	_	
55-7	10173-10181	baseline	_	
55-8	10182-10188	period	_	
55-9	10189-10190	(	_	
55-10	10190-10207	pre-randomization	_	
55-11	10207-10208	)	_	
55-12	10209-10213	from	_	
55-13	10214-10215	a	_	
55-14	10216-10222	subset	_	
55-15	10223-10225	of	_	
55-16	10226-10234	patients	_	
55-17	10235-10248	participating	_	
55-18	10249-10251	in	_	
55-19	10252-10253	a	_	
55-20	10254-10262	clinical	_	
55-21	10263-10268	trial	_	
55-22	10269-10271	of	_	
55-23	10272-10288	Moment-by-Moment	_	
55-24	10289-10291	in	_	
55-25	10292-10299	Women's	_	
55-26	10300-10308	Recovery	_	
55-27	10309-10310	(	_	
55-28	10310-10314	MMWR	_	
55-29	10314-10315	)	_	
55-30	10315-10316	.	_	

#Text=MMWR is a trauma-informed, mindfulness-based adjunct intervention for low-income, ethnically and racially diverse women in residential treatment for SUDs.
56-1	10317-10321	MMWR	_	
56-2	10322-10324	is	_	
56-3	10325-10326	a	_	
56-4	10327-10342	trauma-informed	_	
56-5	10342-10343	,	_	
56-6	10344-10361	mindfulness-based	_	
56-7	10362-10369	adjunct	_	
56-8	10370-10382	intervention	_	
56-9	10383-10386	for	_	
56-10	10387-10397	low-income	_	
56-11	10397-10398	,	_	
56-12	10399-10409	ethnically	_	
56-13	10410-10413	and	_	
56-14	10414-10422	racially	_	
56-15	10423-10430	diverse	_	
56-16	10431-10436	women	_	
56-17	10437-10439	in	_	
56-18	10440-10451	residential	_	
56-19	10452-10461	treatment	_	
56-20	10462-10465	for	_	
56-21	10466-10470	SUDs	_	
56-22	10470-10471	.	_	

#Text=If interoception is indeed a critical factor in SUD and SUD treatment response, and if interoception is compromised among those with comorbid PTSD, then characterizing that compromise is an important step towards developing tailored treatment approaches for this subgroup.
57-1	10472-10474	If	_	
57-2	10475-10488	interoception	_	
57-3	10489-10491	is	_	
57-4	10492-10498	indeed	_	
57-5	10499-10500	a	_	
57-6	10501-10509	critical	_	
57-7	10510-10516	factor	_	
57-8	10517-10519	in	_	
57-9	10520-10523	SUD	_	
57-10	10524-10527	and	_	
57-11	10528-10531	SUD	_	
57-12	10532-10541	treatment	_	
57-13	10542-10550	response	_	
57-14	10550-10551	,	_	
57-15	10552-10555	and	_	
57-16	10556-10558	if	_	
57-17	10559-10572	interoception	_	
57-18	10573-10575	is	_	
57-19	10576-10587	compromised	_	
57-20	10588-10593	among	_	
57-21	10594-10599	those	_	
57-22	10600-10604	with	_	
57-23	10605-10613	comorbid	_	
57-24	10614-10618	PTSD	_	
57-25	10618-10619	,	_	
57-26	10620-10624	then	_	
57-27	10625-10639	characterizing	_	
57-28	10640-10644	that	_	
57-29	10645-10655	compromise	_	
57-30	10656-10658	is	_	
57-31	10659-10661	an	_	
57-32	10662-10671	important	_	
57-33	10672-10676	step	_	
57-34	10677-10684	towards	_	
57-35	10685-10695	developing	_	
57-36	10696-10704	tailored	_	
57-37	10705-10714	treatment	_	
57-38	10715-10725	approaches	_	
57-39	10726-10729	for	_	
57-40	10730-10734	this	_	
57-41	10735-10743	subgroup	_	
57-42	10743-10744	.	_	

#Text=We took a data-driven analytic approach, utilizing group independent components analysis and dual regression to identify task-modulated intrinsic functional networks that may distinguish female SUD patients with and without PTSD co-morbidity.
58-1	10745-10747	We	_	
58-2	10748-10752	took	_	
58-3	10753-10754	a	_	
58-4	10755-10766	data-driven	_	
58-5	10767-10775	analytic	_	
58-6	10776-10784	approach	_	
58-7	10784-10785	,	_	
58-8	10786-10795	utilizing	_	
58-9	10796-10801	group	_	
58-10	10802-10813	independent	_	
58-11	10814-10824	components	_	
58-12	10825-10833	analysis	_	
58-13	10834-10837	and	_	
58-14	10838-10842	dual	_	
58-15	10843-10853	regression	_	
58-16	10854-10856	to	_	
58-17	10857-10865	identify	_	
58-18	10866-10880	task-modulated	_	
58-19	10881-10890	intrinsic	_	
58-20	10891-10901	functional	_	
58-21	10902-10910	networks	_	
58-22	10911-10915	that	_	
58-23	10916-10919	may	_	
58-24	10920-10931	distinguish	_	
58-25	10932-10938	female	_	
58-26	10939-10942	SUD	_	
58-27	10943-10951	patients	_	
58-28	10952-10956	with	_	
58-29	10957-10960	and	_	
58-30	10961-10968	without	_	
58-31	10969-10973	PTSD	_	
58-32	10974-10986	co-morbidity	_	
58-33	10986-10987	.	_	

#Text=We hypothesized that PTSD comorbidity will be associated with reduced integration of the insula within networks associated with interoceptive attention.
59-1	10988-10990	We	_	
59-2	10991-11003	hypothesized	_	
59-3	11004-11008	that	_	
59-4	11009-11013	PTSD	_	
59-5	11014-11025	comorbidity	_	
59-6	11026-11030	will	_	
59-7	11031-11033	be	_	
59-8	11034-11044	associated	_	
59-9	11045-11049	with	_	
59-10	11050-11057	reduced	_	
59-11	11058-11069	integration	_	
59-12	11070-11072	of	_	
59-13	11073-11076	the	_	
59-14	11077-11083	insula	_	
59-15	11084-11090	within	_	
59-16	11091-11099	networks	_	
59-17	11100-11110	associated	_	
59-18	11111-11115	with	_	
59-19	11116-11129	interoceptive	_	
59-20	11130-11139	attention	_	
59-21	11139-11140	.	_	

#Text=Additionally, post-hoc correlational analyses of independent component networks that demonstrate significant spatial differences between the two groups were carried out to assess their association with lifetime exposure to sexual trauma across all participants.
60-1	11141-11153	Additionally	_	
60-2	11153-11154	,	_	
60-3	11155-11163	post-hoc	_	
60-4	11164-11177	correlational	_	
60-5	11178-11186	analyses	_	
60-6	11187-11189	of	_	
60-7	11190-11201	independent	_	
60-8	11202-11211	component	_	
60-9	11212-11220	networks	_	
60-10	11221-11225	that	_	
60-11	11226-11237	demonstrate	_	
60-12	11238-11249	significant	_	
60-13	11250-11257	spatial	_	
60-14	11258-11269	differences	_	
60-15	11270-11277	between	_	
60-16	11278-11281	the	_	
60-17	11282-11285	two	_	
60-18	11286-11292	groups	_	
60-19	11293-11297	were	_	
60-20	11298-11305	carried	_	
60-21	11306-11309	out	_	
60-22	11310-11312	to	_	
60-23	11313-11319	assess	_	
60-24	11320-11325	their	_	
60-25	11326-11337	association	_	
60-26	11338-11342	with	_	
60-27	11343-11351	lifetime	_	
60-28	11352-11360	exposure	_	
60-29	11361-11363	to	_	
60-30	11364-11370	sexual	_	
60-31	11371-11377	trauma	_	
60-32	11378-11384	across	_	
60-33	11385-11388	all	_	
60-34	11389-11401	participants	_	
60-35	11401-11402	.	_	

#Text=Methods
#Text=Participants
#Text=The full sample of participants were 48 ethnically-diverse, socio-economically disadvantaged female patients initiating women-only residential treatment for polysubstance use disorders (primarily moderate-to-severe methamphetamine and/or cocaine use disorders).
61-1	11403-11410	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
61-2	11411-11423	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-3	11424-11427	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-4	11428-11432	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-5	11433-11439	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-6	11440-11442	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-7	11443-11455	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-8	11456-11460	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-9	11461-11463	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-10	11464-11482	ethnically-diverse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-11	11482-11483	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-12	11484-11502	socio-economically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-13	11503-11516	disadvantaged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-14	11517-11523	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-15	11524-11532	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-16	11533-11543	initiating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-17	11544-11554	women-only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-18	11555-11566	residential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-19	11567-11576	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-20	11577-11580	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-21	11581-11594	polysubstance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[5]	
61-22	11595-11598	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[5]	
61-23	11599-11608	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[5]	
61-24	11609-11610	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-25	11610-11619	primarily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-26	11620-11638	moderate-to-severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-27	11639-11654	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-28	11655-11658	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-29	11658-11659	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-30	11659-11661	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-31	11662-11669	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-32	11670-11673	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-33	11674-11683	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-34	11683-11684	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
61-35	11684-11685	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Inclusion criteria for the study were as follows: female, between 18 and 50 years old, diagnosed with SUD, fluent in English, right-handed, and a current patient in the residential treatment program partnered with the parent study.
62-1	11686-11695	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-2	11696-11704	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-3	11705-11708	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-4	11709-11712	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-5	11713-11718	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-6	11719-11723	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-7	11724-11726	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-8	11727-11734	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-9	11734-11735	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-10	11736-11742	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-11	11742-11743	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-12	11744-11751	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-13	11752-11754	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-14	11755-11758	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-15	11759-11761	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-16	11761-11762	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-17	11762-11767	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-18	11768-11771	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-19	11771-11772	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-20	11773-11782	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-21	11783-11787	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-22	11788-11791	SUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-23	11791-11792	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-24	11793-11799	fluent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-25	11800-11802	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-26	11803-11810	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-27	11810-11811	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-28	11812-11824	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-29	11824-11825	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-30	11826-11829	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-31	11830-11831	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-32	11832-11839	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-33	11840-11847	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-34	11848-11850	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-35	11851-11854	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-36	11855-11866	residential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-37	11867-11876	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-38	11877-11884	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-39	11885-11894	partnered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-40	11895-11899	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-41	11900-11903	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-42	11904-11910	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-43	11911-11916	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
62-44	11916-11917	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Exclusion criteria included contraindications for fMRI: currently or possibly pregnant, using medical devices (cardiac pacemaker, implanted cardiac defibrillator, etc.), metal fragments including shrapnel or other nonremovable metal devices including dental braces or retainers, intrauterine device, history of head trauma resulting in loss of consciousness for >5 min, documented or subjectively reported claustrophobia, hair extensions or a wig connected by wire, permanent eyeliner, and BMI >36.
63-1	11918-11927	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-2	11928-11936	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-3	11937-11945	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-4	11946-11963	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-5	11964-11967	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-6	11968-11972	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]	
63-7	11972-11973	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-8	11974-11983	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-9	11984-11986	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-10	11987-11995	possibly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-11	11996-12004	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-12	12004-12005	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-13	12006-12011	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-14	12012-12019	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-15	12020-12027	devices	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-16	12028-12029	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-17	12029-12036	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-18	12037-12046	pacemaker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-19	12046-12047	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-20	12048-12057	implanted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-21	12058-12065	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-22	12066-12079	defibrillator	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-23	12079-12080	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-24	12081-12084	etc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-25	12084-12085	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-26	12085-12086	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-27	12086-12087	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-28	12088-12093	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-29	12094-12103	fragments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-30	12104-12113	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-31	12114-12122	shrapnel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-32	12123-12125	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-33	12126-12131	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-34	12132-12144	nonremovable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-35	12145-12150	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-36	12151-12158	devices	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-37	12159-12168	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-38	12169-12175	dental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-39	12176-12182	braces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-40	12183-12185	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-41	12186-12195	retainers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-42	12195-12196	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-43	12197-12209	intrauterine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-44	12210-12216	device	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-45	12216-12217	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-46	12218-12225	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-47	12226-12228	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-48	12229-12233	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-49	12234-12240	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-50	12241-12250	resulting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-51	12251-12253	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-52	12254-12258	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-53	12259-12261	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-54	12262-12275	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-55	12276-12279	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-56	12280-12281	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-57	12281-12282	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-58	12282-12283	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-59	12283-12286	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-60	12286-12287	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-61	12288-12298	documented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-62	12299-12301	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-63	12302-12314	subjectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-64	12315-12323	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-65	12324-12338	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-66	12338-12339	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-67	12340-12344	hair	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-68	12345-12355	extensions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-69	12356-12358	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-70	12359-12360	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-71	12361-12364	wig	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-72	12365-12374	connected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-73	12375-12377	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-74	12378-12382	wire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-75	12382-12383	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-76	12384-12393	permanent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-77	12394-12402	eyeliner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-78	12402-12403	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-79	12404-12407	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-80	12408-12411	BMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-81	12412-12413	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-82	12413-12415	36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
63-83	12415-12416	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Additionally, participants were excluded from the parent study if they had an untreated severe chronic mental health condition or untreated psychotic disorder based on clinical intake LR-DSM-IV or DSM-V or diagnostic assessment, or reported suicidality during the prior 30 days based on clinical intake assessment.
64-1	12417-12429	Additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-2	12429-12430	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-3	12431-12443	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-4	12444-12448	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-5	12449-12457	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-6	12458-12462	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-7	12463-12466	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-8	12467-12473	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-9	12474-12479	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-10	12480-12482	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-11	12483-12487	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-12	12488-12491	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-13	12492-12494	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-14	12495-12504	untreated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-15	12505-12511	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-16	12512-12519	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-17	12520-12526	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-18	12527-12533	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-19	12534-12543	condition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-20	12544-12546	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-21	12547-12556	untreated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-22	12557-12566	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-23	12567-12575	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-24	12576-12581	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-25	12582-12584	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-26	12585-12593	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-27	12594-12600	intake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-28	12601-12610	LR-DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-29	12611-12613	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-30	12614-12619	DSM-V	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-31	12620-12622	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-32	12623-12633	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-33	12634-12644	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-34	12644-12645	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-35	12646-12648	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-36	12649-12657	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-37	12658-12669	suicidality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-38	12670-12676	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-39	12677-12680	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-40	12681-12686	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-41	12687-12689	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-42	12689-12690	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-43	12690-12694	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-44	12695-12700	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-45	12701-12703	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-46	12704-12712	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-47	12713-12719	intake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-48	12720-12730	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-49	12730-12731	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Demographic and clinical characteristics of the study sample.
65-1	12732-12743	Demographic	_	
65-2	12744-12747	and	_	
65-3	12748-12756	clinical	_	
65-4	12757-12772	characteristics	_	
65-5	12773-12775	of	_	
65-6	12776-12779	the	_	
65-7	12780-12785	study	_	
65-8	12786-12792	sample	_	
65-9	12792-12793	.	_	

#Text=Table 1\t \t
#Text=\tAll participants\tSUD\tSUD + PTSD\tTest statistic\tP-value\t \tN\t43\t29\t14\t\t\t \tAge\t30.37 (7.7)\t29.2 (8.4)\t32.9 (5.6)\tt(41) = 1.5\t0.14\t \tEthnicity\t\t\t\tχ2(2) = 0.14\t0.93\t \t Hispanic/Latina\t65.1%\t65.5%\t64.3%\t\t\t \t Non-Hispanic Black\t16.3%\t17.24%\t14.3%\t\t\t \t Non-Hispanic White\t18.6%\t17.24%\t21.4%\t\t\t \tOther\t0%\t\t\t\t\t \tEducation\t\t\t\tχ2(2) = 3.6\t0.16\t \t Less than HS degree\t53.5%\t51.7%\t57.1%\t\t\t \t HS degree\t32.6%\t27.6%\t42.9%\t\t\t \t Some college\t13.9%\t20.7%\t0%\t\t\t \tASI drug use\t0.18 (0.15)\t0.17 (0.14)\t0.21 (0.18)\tt(41) = 0.74\t0.47\t \tASI alcohol use\t0.11 (0.17)\t0.095 (0.15)\t0.13 (0.2)\tt(41) = 0.62\t0.54\t \tBorderline diagnosis\t16.3%\t17.2%\t14.3%\tχ2(1) = 0.06\t0.81\t \tMood disorder diagnosis\t23.3%\t24.1%\t21.4%\tχ2(1) = 0.04\t0.84\t \tPsychoactive medication\t39.5%\t41.4%\t35,7%\tχ2(1) = 0.13\t0.72\t \t
#Text=ASI, Addiction Severity Index Drug and Alcohol use; HS, High School; values in first three columns refer to means with standard deviations in parentheses, otherwise percentages.
66-1	12794-12799	Table	_	
66-2	12800-12801	1	_	
66-3	12806-12809	All	_	
66-4	12810-12822	participants	_	
66-5	12823-12826	SUD	_	
66-6	12827-12830	SUD	_	
66-7	12830-12831	 	_	
66-8	12831-12832	+	_	
66-9	12832-12833	 	_	
66-10	12833-12837	PTSD	_	
66-11	12838-12842	Test	_	
66-12	12843-12852	statistic	_	
66-13	12853-12860	P-value	_	
66-14	12863-12864	N	_	
66-15	12865-12867	43	_	
66-16	12868-12870	29	_	
66-17	12871-12873	14	_	
66-18	12878-12881	Age	_	
66-19	12882-12887	30.37	_	
66-20	12888-12889	(	_	
66-21	12889-12892	7.7	_	
66-22	12892-12893	)	_	
66-23	12894-12898	29.2	_	
66-24	12899-12900	(	_	
66-25	12900-12903	8.4	_	
66-26	12903-12904	)	_	
66-27	12905-12909	32.9	_	
66-28	12910-12911	(	_	
66-29	12911-12914	5.6	_	
66-30	12914-12915	)	_	
66-31	12916-12917	t	_	
66-32	12917-12918	(	_	
66-33	12918-12920	41	_	
66-34	12920-12921	)	_	
66-35	12921-12922	 	_	
66-36	12922-12923	=	_	
66-37	12923-12924	 	_	
66-38	12924-12927	1.5	_	
66-39	12928-12932	0.14	_	
66-40	12935-12944	Ethnicity	_	
66-41	12948-12950	χ2	_	
66-42	12950-12951	(	_	
66-43	12951-12952	2	_	
66-44	12952-12953	)	_	
66-45	12953-12954	 	_	
66-46	12954-12955	=	_	
66-47	12955-12956	 	_	
66-48	12956-12960	0.14	_	
66-49	12961-12965	0.93	_	
66-50	12968-12969	 	_	
66-51	12969-12977	Hispanic	_	
66-52	12977-12978	/	_	
66-53	12978-12984	Latina	_	
66-54	12985-12990	65.1%	_	
66-55	12991-12996	65.5%	_	
66-56	12997-13002	64.3%	_	
66-57	13007-13008	 	_	
66-58	13008-13020	Non-Hispanic	_	
66-59	13021-13026	Black	_	
66-60	13027-13032	16.3%	_	
66-61	13033-13039	17.24%	_	
66-62	13040-13045	14.3%	_	
66-63	13050-13051	 	_	
66-64	13051-13063	Non-Hispanic	_	
66-65	13064-13069	White	_	
66-66	13070-13075	18.6%	_	
66-67	13076-13082	17.24%	_	
66-68	13083-13088	21.4%	_	
66-69	13093-13098	Other	_	
66-70	13099-13101	0%	_	
66-71	13108-13117	Education	_	
66-72	13121-13123	χ2	_	
66-73	13123-13124	(	_	
66-74	13124-13125	2	_	
66-75	13125-13126	)	_	
66-76	13126-13127	 	_	
66-77	13127-13128	=	_	
66-78	13128-13129	 	_	
66-79	13129-13132	3.6	_	
66-80	13133-13137	0.16	_	
66-81	13140-13141	 	_	
66-82	13141-13145	Less	_	
66-83	13146-13150	than	_	
66-84	13151-13153	HS	_	
66-85	13154-13160	degree	_	
66-86	13161-13166	53.5%	_	
66-87	13167-13172	51.7%	_	
66-88	13173-13178	57.1%	_	
66-89	13183-13184	 	_	
66-90	13184-13186	HS	_	
66-91	13187-13193	degree	_	
66-92	13194-13199	32.6%	_	
66-93	13200-13205	27.6%	_	
66-94	13206-13211	42.9%	_	
66-95	13216-13217	 	_	
66-96	13217-13221	Some	_	
66-97	13222-13229	college	_	
66-98	13230-13235	13.9%	_	
66-99	13236-13241	20.7%	_	
66-100	13242-13244	0%	_	
66-101	13249-13252	ASI	_	
66-102	13253-13257	drug	_	
66-103	13258-13261	use	_	
66-104	13262-13266	0.18	_	
66-105	13267-13268	(	_	
66-106	13268-13272	0.15	_	
66-107	13272-13273	)	_	
66-108	13274-13278	0.17	_	
66-109	13279-13280	(	_	
66-110	13280-13284	0.14	_	
66-111	13284-13285	)	_	
66-112	13286-13290	0.21	_	
66-113	13291-13292	(	_	
66-114	13292-13296	0.18	_	
66-115	13296-13297	)	_	
66-116	13298-13299	t	_	
66-117	13299-13300	(	_	
66-118	13300-13302	41	_	
66-119	13302-13303	)	_	
66-120	13303-13304	 	_	
66-121	13304-13305	=	_	
66-122	13305-13306	 	_	
66-123	13306-13310	0.74	_	
66-124	13311-13315	0.47	_	
66-125	13318-13321	ASI	_	
66-126	13322-13329	alcohol	_	
66-127	13330-13333	use	_	
66-128	13334-13338	0.11	_	
66-129	13339-13340	(	_	
66-130	13340-13344	0.17	_	
66-131	13344-13345	)	_	
66-132	13346-13351	0.095	_	
66-133	13352-13353	(	_	
66-134	13353-13357	0.15	_	
66-135	13357-13358	)	_	
66-136	13359-13363	0.13	_	
66-137	13364-13365	(	_	
66-138	13365-13368	0.2	_	
66-139	13368-13369	)	_	
66-140	13370-13371	t	_	
66-141	13371-13372	(	_	
66-142	13372-13374	41	_	
66-143	13374-13375	)	_	
66-144	13375-13376	 	_	
66-145	13376-13377	=	_	
66-146	13377-13378	 	_	
66-147	13378-13382	0.62	_	
66-148	13383-13387	0.54	_	
66-149	13390-13400	Borderline	_	
66-150	13401-13410	diagnosis	_	
66-151	13411-13416	16.3%	_	
66-152	13417-13422	17.2%	_	
66-153	13423-13428	14.3%	_	
66-154	13429-13431	χ2	_	
66-155	13431-13432	(	_	
66-156	13432-13433	1	_	
66-157	13433-13434	)	_	
66-158	13434-13435	 	_	
66-159	13435-13436	=	_	
66-160	13436-13437	 	_	
66-161	13437-13441	0.06	_	
66-162	13442-13446	0.81	_	
66-163	13449-13453	Mood	_	
66-164	13454-13462	disorder	_	
66-165	13463-13472	diagnosis	_	
66-166	13473-13478	23.3%	_	
66-167	13479-13484	24.1%	_	
66-168	13485-13490	21.4%	_	
66-169	13491-13493	χ2	_	
66-170	13493-13494	(	_	
66-171	13494-13495	1	_	
66-172	13495-13496	)	_	
66-173	13496-13497	 	_	
66-174	13497-13498	=	_	
66-175	13498-13499	 	_	
66-176	13499-13503	0.04	_	
66-177	13504-13508	0.84	_	
66-178	13511-13523	Psychoactive	_	
66-179	13524-13534	medication	_	
66-180	13535-13540	39.5%	_	
66-181	13541-13546	41.4%	_	
66-182	13547-13552	35,7%	_	
66-183	13553-13555	χ2	_	
66-184	13555-13556	(	_	
66-185	13556-13557	1	_	
66-186	13557-13558	)	_	
66-187	13558-13559	 	_	
66-188	13559-13560	=	_	
66-189	13560-13561	 	_	
66-190	13561-13565	0.13	_	
66-191	13566-13570	0.72	_	
66-192	13574-13577	ASI	_	
66-193	13577-13578	,	_	
66-194	13579-13588	Addiction	_	
66-195	13589-13597	Severity	_	
66-196	13598-13603	Index	_	
66-197	13604-13608	Drug	_	
66-198	13609-13612	and	_	
66-199	13613-13620	Alcohol	_	
66-200	13621-13624	use	_	
66-201	13624-13625	;	_	
66-202	13626-13628	HS	_	
66-203	13628-13629	,	_	
66-204	13630-13634	High	_	
66-205	13635-13641	School	_	
66-206	13641-13642	;	_	
66-207	13643-13649	values	_	
66-208	13650-13652	in	_	
66-209	13653-13658	first	_	
66-210	13659-13664	three	_	
66-211	13665-13672	columns	_	
66-212	13673-13678	refer	_	
66-213	13679-13681	to	_	
66-214	13682-13687	means	_	
66-215	13688-13692	with	_	
66-216	13693-13701	standard	_	
66-217	13702-13712	deviations	_	
66-218	13713-13715	in	_	
66-219	13716-13727	parentheses	_	
66-220	13727-13728	,	_	
66-221	13729-13738	otherwise	_	
66-222	13739-13750	percentages	_	
66-223	13750-13751	.	_	

#Text=Psychiatric diagnoses were based on LR-DSM-IV or DSM-V which were conducted by staff of the residential treatment program (the residential treatment program transitioned from the LR-DSM-IV to the DSM-V during the course of the clinical trial).
67-1	13752-13763	Psychiatric	_	
67-2	13764-13773	diagnoses	_	
67-3	13774-13778	were	_	
67-4	13779-13784	based	_	
67-5	13785-13787	on	_	
67-6	13788-13797	LR-DSM-IV	_	
67-7	13798-13800	or	_	
67-8	13801-13806	DSM-V	_	
67-9	13807-13812	which	_	
67-10	13813-13817	were	_	
67-11	13818-13827	conducted	_	
67-12	13828-13830	by	_	
67-13	13831-13836	staff	_	
67-14	13837-13839	of	_	
67-15	13840-13843	the	_	
67-16	13844-13855	residential	_	
67-17	13856-13865	treatment	_	
67-18	13866-13873	program	_	
67-19	13874-13875	(	_	
67-20	13875-13878	the	_	
67-21	13879-13890	residential	_	
67-22	13891-13900	treatment	_	
67-23	13901-13908	program	_	
67-24	13909-13921	transitioned	_	
67-25	13922-13926	from	_	
67-26	13927-13930	the	_	
67-27	13931-13940	LR-DSM-IV	_	
67-28	13941-13943	to	_	
67-29	13944-13947	the	_	
67-30	13948-13953	DSM-V	_	
67-31	13954-13960	during	_	
67-32	13961-13964	the	_	
67-33	13965-13971	course	_	
67-34	13972-13974	of	_	
67-35	13975-13978	the	_	
67-36	13979-13987	clinical	_	
67-37	13988-13993	trial	_	
67-38	13993-13994	)	_	
67-39	13994-13995	.	_	

#Text=Diagnoses were carried out by treatment center staff and confirmed by consensus meeting with the lead psychiatrist.
68-1	13996-14005	Diagnoses	_	
68-2	14006-14010	were	_	
68-3	14011-14018	carried	_	
68-4	14019-14022	out	_	
68-5	14023-14025	by	_	
68-6	14026-14035	treatment	_	
68-7	14036-14042	center	_	
68-8	14043-14048	staff	_	
68-9	14049-14052	and	_	
68-10	14053-14062	confirmed	_	
68-11	14063-14065	by	_	
68-12	14066-14075	consensus	_	
68-13	14076-14083	meeting	_	
68-14	14084-14088	with	_	
68-15	14089-14092	the	_	
68-16	14093-14097	lead	_	
68-17	14098-14110	psychiatrist	_	
68-18	14110-14111	.	_	

#Text=Although comorbid psychiatric diagnoses were not exclusionary for the parent study, for the present analysis we excluded individuals with the following diagnoses: schizophrenia, anxiety disorder other than PTSD, no history of stimulant use (the majority of patients had primarily diagnoses of stimulant use disorders or had polysubstance use histories that included stimulants).
69-1	14112-14120	Although	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-2	14121-14129	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-3	14130-14141	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-4	14142-14151	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-5	14152-14156	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-6	14157-14160	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-7	14161-14173	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-8	14174-14177	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-9	14178-14181	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-10	14182-14188	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-11	14189-14194	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-12	14194-14195	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-13	14196-14199	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-14	14200-14203	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-15	14204-14211	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-16	14212-14220	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-17	14221-14223	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-18	14224-14232	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-19	14233-14244	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-20	14245-14249	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-21	14250-14253	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-22	14254-14263	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-23	14264-14273	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-24	14273-14274	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-25	14275-14288	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-26	14288-14289	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-27	14290-14297	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-28	14298-14306	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-29	14307-14312	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-30	14313-14317	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-31	14318-14322	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-32	14322-14323	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-33	14324-14326	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-34	14327-14334	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-35	14335-14337	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-36	14338-14347	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-37	14348-14351	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-38	14352-14353	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-39	14353-14356	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-40	14357-14365	majority	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-41	14366-14368	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-42	14369-14377	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-43	14378-14381	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-44	14382-14391	primarily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-45	14392-14401	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-46	14402-14404	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-47	14405-14414	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-48	14415-14418	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-49	14419-14428	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-50	14429-14431	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-51	14432-14435	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-52	14436-14449	polysubstance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-53	14450-14453	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-54	14454-14463	histories	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-55	14464-14468	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-56	14469-14477	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-57	14478-14488	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-58	14488-14489	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
69-59	14489-14490	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Four participants were omitted based on these criteria.
70-1	14491-14495	Four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-2	14496-14508	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-3	14509-14513	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-4	14514-14521	omitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-5	14522-14527	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-6	14528-14530	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-7	14531-14536	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-8	14537-14545	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-9	14545-14546	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=A large proportion of participants for whom information was available were taking prescribed psychoactive medications (39.5%) and/or had mood disorders (23.3%), therefore we did not exclude participants on the basis of medication use or mood-disorder status.
71-1	14547-14548	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-2	14549-14554	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-3	14555-14565	proportion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-4	14566-14568	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-5	14569-14581	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-6	14582-14585	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-7	14586-14590	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-8	14591-14602	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-9	14603-14606	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-10	14607-14616	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-11	14617-14621	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-12	14622-14628	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-13	14629-14639	prescribed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-14	14640-14652	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-15	14653-14664	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-16	14665-14666	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-17	14666-14671	39.5%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-18	14671-14672	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-19	14673-14676	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-20	14676-14677	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-21	14677-14679	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-22	14680-14683	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-23	14684-14688	mood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-24	14689-14698	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-25	14699-14700	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-26	14700-14705	23.3%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-27	14705-14706	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-28	14706-14707	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-29	14708-14717	therefore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-30	14718-14720	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-31	14721-14724	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-32	14725-14728	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-33	14729-14736	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-34	14737-14749	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-35	14750-14752	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-36	14753-14756	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-37	14757-14762	basis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-38	14763-14765	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-39	14766-14776	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-40	14777-14780	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-41	14781-14783	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-42	14784-14797	mood-disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-43	14798-14804	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
71-44	14804-14805	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=One participant was removed from the study for the presence of non-removable dental work that the participant did not report during screening which caused signal dropout.
72-1	14806-14809	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-2	14810-14821	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-3	14822-14825	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-4	14826-14833	removed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-5	14834-14838	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-6	14839-14842	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-7	14843-14848	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-8	14849-14852	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-9	14853-14856	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-10	14857-14865	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-11	14866-14868	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-12	14869-14882	non-removable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-13	14883-14889	dental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-14	14890-14894	work	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-15	14895-14899	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-16	14900-14903	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-17	14904-14915	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-18	14916-14919	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-19	14920-14923	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-20	14924-14930	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-21	14931-14937	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-22	14938-14947	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-23	14948-14953	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-24	14954-14960	caused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-25	14961-14967	signal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-26	14968-14975	dropout	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
72-27	14975-14976	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=The 43 remaining participants were included in the study, 14 of whom had received a PTSD diagnosis.
73-1	14977-14980	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-2	14981-14983	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-3	14984-14993	remaining	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-4	14994-15006	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-5	15007-15011	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-6	15012-15020	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-7	15021-15023	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-8	15024-15027	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-9	15028-15033	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-10	15033-15034	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-11	15035-15037	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-12	15038-15040	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-13	15041-15045	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-14	15046-15049	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-15	15050-15058	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-16	15059-15060	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-17	15061-15065	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[15]	
73-18	15066-15075	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
73-19	15075-15076	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Each of the 43 participants contributed two runs of fMRI data, except for four subjects (two from the PTSD, two from the noPTSD group) who contributed one run due to excessive motion (>3 mm).
74-1	15077-15081	Each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-2	15082-15084	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-3	15085-15088	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-4	15089-15091	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-5	15092-15104	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-6	15105-15116	contributed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-7	15117-15120	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-8	15121-15125	runs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-9	15126-15128	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-10	15129-15133	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
74-11	15134-15138	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-12	15138-15139	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-13	15140-15146	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-14	15147-15150	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-15	15151-15155	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-16	15156-15164	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-17	15165-15166	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-18	15166-15169	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-19	15170-15174	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-20	15175-15178	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-21	15179-15183	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-22	15183-15184	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-23	15185-15188	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-24	15189-15193	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-25	15194-15197	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-26	15198-15204	noPTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-27	15205-15210	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-28	15210-15211	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-29	15212-15215	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-30	15216-15227	contributed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-31	15228-15231	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-32	15232-15235	run	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-33	15236-15239	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-34	15240-15242	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-35	15243-15252	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-36	15253-15259	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-37	15260-15261	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-38	15261-15262	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-39	15262-15263	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-40	15263-15264	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-41	15264-15266	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-42	15266-15267	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
74-43	15267-15268	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=See Table 1 for demographics and clinical characteristics.
75-1	15269-15272	See	_	
75-2	15273-15278	Table	_	
75-3	15279-15280	1	_	
75-4	15281-15284	for	_	
75-5	15285-15297	demographics	_	
75-6	15298-15301	and	_	
75-7	15302-15310	clinical	_	
75-8	15311-15326	characteristics	_	
75-9	15326-15327	.	_	

#Text=All study procedures were approved by the University of Southern California Institutional Review Board.
76-1	15328-15331	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-2	15332-15337	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-3	15338-15348	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-4	15349-15353	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-5	15354-15362	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-6	15363-15365	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-7	15366-15369	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-8	15370-15380	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-9	15381-15383	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-10	15384-15392	Southern	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-11	15393-15403	California	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-12	15404-15417	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-13	15418-15424	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-14	15425-15430	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
76-15	15430-15431	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Participants provided written informed consent and were compensated for their time.
77-1	15432-15444	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-2	15445-15453	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-3	15454-15461	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-4	15462-15470	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-5	15471-15478	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-6	15479-15482	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-7	15483-15487	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-8	15488-15499	compensated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-9	15500-15503	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-10	15504-15509	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-11	15510-15514	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
77-12	15514-15515	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Measures
#Text=Life stressors checklist – revised
#Text=The Life Stressor Checklist-Revised (LSC-R) is a measure of traumatic events and stressors that are particularly relevant to women's life experiences.
78-1	15516-15524	Measures	_	
78-2	15525-15529	Life	_	
78-3	15530-15539	stressors	_	
78-4	15540-15549	checklist	_	
78-5	15550-15551	–	_	
78-6	15552-15559	revised	_	
78-7	15560-15563	The	_	
78-8	15564-15568	Life	_	
78-9	15569-15577	Stressor	_	
78-10	15578-15595	Checklist-Revised	_	
78-11	15596-15597	(	_	
78-12	15597-15602	LSC-R	_	
78-13	15602-15603	)	_	
78-14	15604-15606	is	_	
78-15	15607-15608	a	_	
78-16	15609-15616	measure	_	
78-17	15617-15619	of	_	
78-18	15620-15629	traumatic	_	
78-19	15630-15636	events	_	
78-20	15637-15640	and	_	
78-21	15641-15650	stressors	_	
78-22	15651-15655	that	_	
78-23	15656-15659	are	_	
78-24	15660-15672	particularly	_	
78-25	15673-15681	relevant	_	
78-26	15682-15684	to	_	
78-27	15685-15692	women's	_	
78-28	15693-15697	life	_	
78-29	15698-15709	experiences	_	
78-30	15709-15710	.	_	

#Text=Its use has been validated in women with co-morbid substance abuse and mental disorders, with histories of interpersonal violence victimization.
79-1	15711-15714	Its	_	
79-2	15715-15718	use	_	
79-3	15719-15722	has	_	
79-4	15723-15727	been	_	
79-5	15728-15737	validated	_	
79-6	15738-15740	in	_	
79-7	15741-15746	women	_	
79-8	15747-15751	with	_	
79-9	15752-15761	co-morbid	_	
79-10	15762-15771	substance	_	
79-11	15772-15777	abuse	_	
79-12	15778-15781	and	_	
79-13	15782-15788	mental	_	
79-14	15789-15798	disorders	_	
79-15	15798-15799	,	_	
79-16	15800-15804	with	_	
79-17	15805-15814	histories	_	
79-18	15815-15817	of	_	
79-19	15818-15831	interpersonal	_	
79-20	15832-15840	violence	_	
79-21	15841-15854	victimization	_	
79-22	15854-15855	.	_	

#Text=LSC-R follows a yes/no response format with follow-up questions that characterize the life stage(s) at which events occurred and the degree to which the respondent is currently affected by the experience.
80-1	15856-15861	LSC-R	_	
80-2	15862-15869	follows	_	
80-3	15870-15871	a	_	
80-4	15872-15875	yes	_	
80-5	15875-15876	/	_	
80-6	15876-15878	no	_	
80-7	15879-15887	response	_	
80-8	15888-15894	format	_	
80-9	15895-15899	with	_	
80-10	15900-15909	follow-up	_	
80-11	15910-15919	questions	_	
80-12	15920-15924	that	_	
80-13	15925-15937	characterize	_	
80-14	15938-15941	the	_	
80-15	15942-15946	life	_	
80-16	15947-15952	stage	_	
80-17	15952-15953	(	_	
80-18	15953-15954	s	_	
80-19	15954-15955	)	_	
80-20	15956-15958	at	_	
80-21	15959-15964	which	_	
80-22	15965-15971	events	_	
80-23	15972-15980	occurred	_	
80-24	15981-15984	and	_	
80-25	15985-15988	the	_	
80-26	15989-15995	degree	_	
80-27	15996-15998	to	_	
80-28	15999-16004	which	_	
80-29	16005-16008	the	_	
80-30	16009-16019	respondent	_	
80-31	16020-16022	is	_	
80-32	16023-16032	currently	_	
80-33	16033-16041	affected	_	
80-34	16042-16044	by	_	
80-35	16045-16048	the	_	
80-36	16049-16059	experience	_	
80-37	16059-16060	.	_	

#Text=Events can be brief, single incidents or repeated traumas that may have occurred at any point in the lifespan (prior to age eighteen, adulthood, and within the last 8 months of the interview).
81-1	16061-16067	Events	_	
81-2	16068-16071	can	_	
81-3	16072-16074	be	_	
81-4	16075-16080	brief	_	
81-5	16080-16081	,	_	
81-6	16082-16088	single	_	
81-7	16089-16098	incidents	_	
81-8	16099-16101	or	_	
81-9	16102-16110	repeated	_	
81-10	16111-16118	traumas	_	
81-11	16119-16123	that	_	
81-12	16124-16127	may	_	
81-13	16128-16132	have	_	
81-14	16133-16141	occurred	_	
81-15	16142-16144	at	_	
81-16	16145-16148	any	_	
81-17	16149-16154	point	_	
81-18	16155-16157	in	_	
81-19	16158-16161	the	_	
81-20	16162-16170	lifespan	_	
81-21	16171-16172	(	_	
81-22	16172-16177	prior	_	
81-23	16178-16180	to	_	
81-24	16181-16184	age	_	
81-25	16185-16193	eighteen	_	
81-26	16193-16194	,	_	
81-27	16195-16204	adulthood	_	
81-28	16204-16205	,	_	
81-29	16206-16209	and	_	
81-30	16210-16216	within	_	
81-31	16217-16220	the	_	
81-32	16221-16225	last	_	
81-33	16226-16227	8	_	
81-34	16227-16228	 	_	
81-35	16228-16234	months	_	
81-36	16235-16237	of	_	
81-37	16238-16241	the	_	
81-38	16242-16251	interview	_	
81-39	16251-16252	)	_	
81-40	16252-16253	.	_	

#Text=For the present study, we use dichotomously scored responses (range: 0–30) reflecting events at any point during the lifespan.
82-1	16254-16257	For	_	
82-2	16258-16261	the	_	
82-3	16262-16269	present	_	
82-4	16270-16275	study	_	
82-5	16275-16276	,	_	
82-6	16277-16279	we	_	
82-7	16280-16283	use	_	
82-8	16284-16297	dichotomously	_	
82-9	16298-16304	scored	_	
82-10	16305-16314	responses	_	
82-11	16315-16316	(	_	
82-12	16316-16321	range	_	
82-13	16321-16322	:	_	
82-14	16323-16324	0	_	
82-15	16324-16325	–	_	
82-16	16325-16327	30	_	
82-17	16327-16328	)	_	
82-18	16329-16339	reflecting	_	
82-19	16340-16346	events	_	
82-20	16347-16349	at	_	
82-21	16350-16353	any	_	
82-22	16354-16359	point	_	
82-23	16360-16366	during	_	
82-24	16367-16370	the	_	
82-25	16371-16379	lifespan	_	
82-26	16379-16380	.	_	

#Text=Addiction severity index
#Text=Alcohol and substance use severity for the 30 days prior to treatment entry was assessed using the Addiction Severity Index (ASI:) and the Timeline Followback Interview (TLFB).
83-1	16381-16390	Addiction	_	
83-2	16391-16399	severity	_	
83-3	16400-16405	index	_	
83-4	16406-16413	Alcohol	_	
83-5	16414-16417	and	_	
83-6	16418-16427	substance	_	
83-7	16428-16431	use	_	
83-8	16432-16440	severity	_	
83-9	16441-16444	for	_	
83-10	16445-16448	the	_	
83-11	16449-16451	30	_	
83-12	16451-16452	 	_	
83-13	16452-16456	days	_	
83-14	16457-16462	prior	_	
83-15	16463-16465	to	_	
83-16	16466-16475	treatment	_	
83-17	16476-16481	entry	_	
83-18	16482-16485	was	_	
83-19	16486-16494	assessed	_	
83-20	16495-16500	using	_	
83-21	16501-16504	the	_	
83-22	16505-16514	Addiction	_	
83-23	16515-16523	Severity	_	
83-24	16524-16529	Index	_	
83-25	16530-16531	(	_	
83-26	16531-16534	ASI	_	
83-27	16534-16535	:	_	
83-28	16535-16536	)	_	
83-29	16537-16540	and	_	
83-30	16541-16544	the	_	
83-31	16545-16553	Timeline	_	
83-32	16554-16564	Followback	_	
83-33	16565-16574	Interview	_	
83-34	16575-16576	(	_	
83-35	16576-16580	TLFB	_	
83-36	16580-16581	)	_	
83-37	16581-16582	.	_	

#Text=Post-traumatic stress disorder (PTSD) symptoms scale
#Text=The PTSD Symptom Scale (PSS-I) is a semi-structured interview, which was used to obtain an overall severity score of PTSD symptoms according to DSM-IV, as well as separate severity scores for symptom subdomains: re-experiencing, avoidance, arousal.
84-1	16583-16597	Post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-2	16598-16604	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-3	16605-16613	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-4	16614-16615	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-5	16615-16619	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-6	16619-16620	)	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[19]	
84-7	16621-16629	symptoms	_	
84-8	16630-16635	scale	_	
84-9	16636-16639	The	_	
84-10	16640-16644	PTSD	_	
84-11	16645-16652	Symptom	_	
84-12	16653-16658	Scale	_	
84-13	16659-16660	(	_	
84-14	16660-16665	PSS-I	_	
84-15	16665-16666	)	_	
84-16	16667-16669	is	_	
84-17	16670-16671	a	_	
84-18	16672-16687	semi-structured	_	
84-19	16688-16697	interview	_	
84-20	16697-16698	,	_	
84-21	16699-16704	which	_	
84-22	16705-16708	was	_	
84-23	16709-16713	used	_	
84-24	16714-16716	to	_	
84-25	16717-16723	obtain	_	
84-26	16724-16726	an	_	
84-27	16727-16734	overall	_	
84-28	16735-16743	severity	_	
84-29	16744-16749	score	_	
84-30	16750-16752	of	_	
84-31	16753-16757	PTSD	_	
84-32	16758-16766	symptoms	_	
84-33	16767-16776	according	_	
84-34	16777-16779	to	_	
84-35	16780-16786	DSM-IV	_	
84-36	16786-16787	,	_	
84-37	16788-16790	as	_	
84-38	16791-16795	well	_	
84-39	16796-16798	as	_	
84-40	16799-16807	separate	_	
84-41	16808-16816	severity	_	
84-42	16817-16823	scores	_	
84-43	16824-16827	for	_	
84-44	16828-16835	symptom	_	
84-45	16836-16846	subdomains	_	
84-46	16846-16847	:	_	
84-47	16848-16863	re-experiencing	_	
84-48	16863-16864	,	_	
84-49	16865-16874	avoidance	_	
84-50	16874-16875	,	_	
84-51	16876-16883	arousal	_	
84-52	16883-16884	.	_	

#Text=Scores range from 0 to 34, with higher scores reflecting more severe symptomatology.
85-1	16885-16891	Scores	_	
85-2	16892-16897	range	_	
85-3	16898-16902	from	_	
85-4	16903-16904	0	_	
85-5	16905-16907	to	_	
85-6	16908-16910	34	_	
85-7	16910-16911	,	_	
85-8	16912-16916	with	_	
85-9	16917-16923	higher	_	
85-10	16924-16930	scores	_	
85-11	16931-16941	reflecting	_	
85-12	16942-16946	more	_	
85-13	16947-16953	severe	_	
85-14	16954-16968	symptomatology	_	
85-15	16968-16969	.	_	

#Text=The interoceptive-exteroceptive attention task
#Text=The Interoceptive-Exteroceptive Attention task (The IN-OUT task) was adapted from, which investigated BOLD changes in interoceptive attention in response to Mindfulness-Based Stress Reduction (MBSR) training.
86-1	16970-16973	The	_	
86-2	16974-17001	interoceptive-exteroceptive	_	
86-3	17002-17011	attention	_	
86-4	17012-17016	task	_	
86-5	17017-17020	The	_	
86-6	17021-17048	Interoceptive-Exteroceptive	_	
86-7	17049-17058	Attention	_	
86-8	17059-17063	task	_	
86-9	17064-17065	(	_	
86-10	17065-17068	The	_	
86-11	17069-17075	IN-OUT	_	
86-12	17076-17080	task	_	
86-13	17080-17081	)	_	
86-14	17082-17085	was	_	
86-15	17086-17093	adapted	_	
86-16	17094-17098	from	_	
86-17	17098-17099	,	_	
86-18	17100-17105	which	_	
86-19	17106-17118	investigated	_	
86-20	17119-17123	BOLD	_	
86-21	17124-17131	changes	_	
86-22	17132-17134	in	_	
86-23	17135-17148	interoceptive	_	
86-24	17149-17158	attention	_	
86-25	17159-17161	in	_	
86-26	17162-17170	response	_	
86-27	17171-17173	to	_	
86-28	17174-17191	Mindfulness-Based	_	
86-29	17192-17198	Stress	_	
86-30	17199-17208	Reduction	_	
86-31	17209-17210	(	_	
86-32	17210-17214	MBSR	_	
86-33	17214-17215	)	_	
86-34	17216-17224	training	_	
86-35	17224-17225	.	_	

#Text=The approach contrasts brain activity during attention to the sensations of breathing versus attention to an external target.
87-1	17226-17229	The	_	
87-2	17230-17238	approach	_	
87-3	17239-17248	contrasts	_	
87-4	17249-17254	brain	_	
87-5	17255-17263	activity	_	
87-6	17264-17270	during	_	
87-7	17271-17280	attention	_	
87-8	17281-17283	to	_	
87-9	17284-17287	the	_	
87-10	17288-17298	sensations	_	
87-11	17299-17301	of	_	
87-12	17302-17311	breathing	_	
87-13	17312-17318	versus	_	
87-14	17319-17328	attention	_	
87-15	17329-17331	to	_	
87-16	17332-17334	an	_	
87-17	17335-17343	external	_	
87-18	17344-17350	target	_	
87-19	17350-17351	.	_	

#Text=By contrasting internally and externally directed focus, this approach capitalizes on the “attentional spotlight” effect, whereby focus on a sensory quality amplifies the signal within brain regions associated with processing that sensory modality.
88-1	17352-17354	By	_	
88-2	17355-17366	contrasting	_	
88-3	17367-17377	internally	_	
88-4	17378-17381	and	_	
88-5	17382-17392	externally	_	
88-6	17393-17401	directed	_	
88-7	17402-17407	focus	_	
88-8	17407-17408	,	_	
88-9	17409-17413	this	_	
88-10	17414-17422	approach	_	
88-11	17423-17434	capitalizes	_	
88-12	17435-17437	on	_	
88-13	17438-17441	the	_	
88-14	17442-17443	“	_	
88-15	17443-17454	attentional	_	
88-16	17455-17464	spotlight	_	
88-17	17464-17465	”	_	
88-18	17466-17472	effect	_	
88-19	17472-17473	,	_	
88-20	17474-17481	whereby	_	
88-21	17482-17487	focus	_	
88-22	17488-17490	on	_	
88-23	17491-17492	a	_	
88-24	17493-17500	sensory	_	
88-25	17501-17508	quality	_	
88-26	17509-17518	amplifies	_	
88-27	17519-17522	the	_	
88-28	17523-17529	signal	_	
88-29	17530-17536	within	_	
88-30	17537-17542	brain	_	
88-31	17543-17550	regions	_	
88-32	17551-17561	associated	_	
88-33	17562-17566	with	_	
88-34	17567-17577	processing	_	
88-35	17578-17582	that	_	
88-36	17583-17590	sensory	_	
88-37	17591-17599	modality	_	
88-38	17599-17600	.	_	

#Text=Variations on this task have previously been used to isolate BOLD responses in regions associated with interoception in expert meditators, healthy individuals, as well as in clinical populations with depression and anorexia nervosa.
89-1	17601-17611	Variations	_	
89-2	17612-17614	on	_	
89-3	17615-17619	this	_	
89-4	17620-17624	task	_	
89-5	17625-17629	have	_	
89-6	17630-17640	previously	_	
89-7	17641-17645	been	_	
89-8	17646-17650	used	_	
89-9	17651-17653	to	_	
89-10	17654-17661	isolate	_	
89-11	17662-17666	BOLD	_	
89-12	17667-17676	responses	_	
89-13	17677-17679	in	_	
89-14	17680-17687	regions	_	
89-15	17688-17698	associated	_	
89-16	17699-17703	with	_	
89-17	17704-17717	interoception	_	
89-18	17718-17720	in	_	
89-19	17721-17727	expert	_	
89-20	17728-17738	meditators	_	
89-21	17738-17739	,	_	
89-22	17740-17747	healthy	_	
89-23	17748-17759	individuals	_	
89-24	17759-17760	,	_	
89-25	17761-17763	as	_	
89-26	17764-17768	well	_	
89-27	17769-17771	as	_	
89-28	17772-17774	in	_	
89-29	17775-17783	clinical	_	
89-30	17784-17795	populations	_	
89-31	17796-17800	with	_	
89-32	17801-17811	depression	_	
89-33	17812-17815	and	_	
89-34	17816-17824	anorexia	_	
89-35	17825-17832	nervosa	_	
89-36	17832-17833	.	_	

#Text=The magnitude of insula response during focused breathing tasks appears to track the quality of internal focus, which increases as a function of hours practiced in novices who participated in a mindfulness-based stress reduction (MBSR) program.
90-1	17834-17837	The	_	
90-2	17838-17847	magnitude	_	
90-3	17848-17850	of	_	
90-4	17851-17857	insula	_	
90-5	17858-17866	response	_	
90-6	17867-17873	during	_	
90-7	17874-17881	focused	_	
90-8	17882-17891	breathing	_	
90-9	17892-17897	tasks	_	
90-10	17898-17905	appears	_	
90-11	17906-17908	to	_	
90-12	17909-17914	track	_	
90-13	17915-17918	the	_	
90-14	17919-17926	quality	_	
90-15	17927-17929	of	_	
90-16	17930-17938	internal	_	
90-17	17939-17944	focus	_	
90-18	17944-17945	,	_	
90-19	17946-17951	which	_	
90-20	17952-17961	increases	_	
90-21	17962-17964	as	_	
90-22	17965-17966	a	_	
90-23	17967-17975	function	_	
90-24	17976-17978	of	_	
90-25	17979-17984	hours	_	
90-26	17985-17994	practiced	_	
90-27	17995-17997	in	_	
90-28	17998-18005	novices	_	
90-29	18006-18009	who	_	
90-30	18010-18022	participated	_	
90-31	18023-18025	in	_	
90-32	18026-18027	a	_	
90-33	18028-18045	mindfulness-based	_	
90-34	18046-18052	stress	_	
90-35	18053-18062	reduction	_	
90-36	18063-18064	(	_	
90-37	18064-18068	MBSR	_	
90-38	18068-18069	)	_	
90-39	18070-18077	program	_	
90-40	18077-18078	.	_	

#Text=During the IN-OUT task participants performed two experimental conditions involving sustained attentional targets: the interoceptive (IN) condition and the exteroceptive (OUT) condition.
91-1	18079-18085	During	_	
91-2	18086-18089	the	_	
91-3	18090-18096	IN-OUT	_	
91-4	18097-18101	task	_	
91-5	18102-18114	participants	_	
91-6	18115-18124	performed	_	
91-7	18125-18128	two	_	
91-8	18129-18141	experimental	_	
91-9	18142-18152	conditions	_	
91-10	18153-18162	involving	_	
91-11	18163-18172	sustained	_	
91-12	18173-18184	attentional	_	
91-13	18185-18192	targets	_	
91-14	18192-18193	:	_	
91-15	18194-18197	the	_	
91-16	18198-18211	interoceptive	_	
91-17	18212-18213	(	_	
91-18	18213-18215	IN	_	
91-19	18215-18216	)	_	
91-20	18217-18226	condition	_	
91-21	18227-18230	and	_	
91-22	18231-18234	the	_	
91-23	18235-18248	exteroceptive	_	
91-24	18249-18250	(	_	
91-25	18250-18253	OUT	_	
91-26	18253-18254	)	_	
91-27	18255-18264	condition	_	
91-28	18264-18265	.	_	

#Text=Participants completed two runs, each containing nine blocks.
92-1	18266-18278	Participants	_	
92-2	18279-18288	completed	_	
92-3	18289-18292	two	_	
92-4	18293-18297	runs	_	
92-5	18297-18298	,	_	
92-6	18299-18303	each	_	
92-7	18304-18314	containing	_	
92-8	18315-18319	nine	_	
92-9	18320-18326	blocks	_	
92-10	18326-18327	.	_	

#Text=The blocks were presented in pseudorandomized order- half of the runs contained five blocks of IN, and four blocks of OUT, while other blocks contained four blocks of IN and five blocks of OUT.
93-1	18328-18331	The	_	
93-2	18332-18338	blocks	_	
93-3	18339-18343	were	_	
93-4	18344-18353	presented	_	
93-5	18354-18356	in	_	
93-6	18357-18373	pseudorandomized	_	
93-7	18374-18379	order	_	
93-8	18379-18380	-	_	
93-9	18381-18385	half	_	
93-10	18386-18388	of	_	
93-11	18389-18392	the	_	
93-12	18393-18397	runs	_	
93-13	18398-18407	contained	_	
93-14	18408-18412	five	_	
93-15	18413-18419	blocks	_	
93-16	18420-18422	of	_	
93-17	18423-18425	IN	_	
93-18	18425-18426	,	_	
93-19	18427-18430	and	_	
93-20	18431-18435	four	_	
93-21	18436-18442	blocks	_	
93-22	18443-18445	of	_	
93-23	18446-18449	OUT	_	
93-24	18449-18450	,	_	
93-25	18451-18456	while	_	
93-26	18457-18462	other	_	
93-27	18463-18469	blocks	_	
93-28	18470-18479	contained	_	
93-29	18480-18484	four	_	
93-30	18485-18491	blocks	_	
93-31	18492-18494	of	_	
93-32	18495-18497	IN	_	
93-33	18498-18501	and	_	
93-34	18502-18506	five	_	
93-35	18507-18513	blocks	_	
93-36	18514-18516	of	_	
93-37	18517-18520	OUT	_	
93-38	18520-18521	.	_	

#Text=For the IN condition, subjects were instructed to attend to bodily sensations associated with their breathing cycle with the following instructions: “Please pay attention to the physical sensation of the breath wherever you feel it most strongly in the body.
94-1	18522-18525	For	_	
94-2	18526-18529	the	_	
94-3	18530-18532	IN	_	
94-4	18533-18542	condition	_	
94-5	18542-18543	,	_	
94-6	18544-18552	subjects	_	
94-7	18553-18557	were	_	
94-8	18558-18568	instructed	_	
94-9	18569-18571	to	_	
94-10	18572-18578	attend	_	
94-11	18579-18581	to	_	
94-12	18582-18588	bodily	_	
94-13	18589-18599	sensations	_	
94-14	18600-18610	associated	_	
94-15	18611-18615	with	_	
94-16	18616-18621	their	_	
94-17	18622-18631	breathing	_	
94-18	18632-18637	cycle	_	
94-19	18638-18642	with	_	
94-20	18643-18646	the	_	
94-21	18647-18656	following	_	
94-22	18657-18669	instructions	_	
94-23	18669-18670	:	_	
94-24	18671-18672	“	_	
94-25	18672-18678	Please	_	
94-26	18679-18682	pay	_	
94-27	18683-18692	attention	_	
94-28	18693-18695	to	_	
94-29	18696-18699	the	_	
94-30	18700-18708	physical	_	
94-31	18709-18718	sensation	_	
94-32	18719-18721	of	_	
94-33	18722-18725	the	_	
94-34	18726-18732	breath	_	
94-35	18733-18741	wherever	_	
94-36	18742-18745	you	_	
94-37	18746-18750	feel	_	
94-38	18751-18753	it	_	
94-39	18754-18758	most	_	
94-40	18759-18767	strongly	_	
94-41	18768-18770	in	_	
94-42	18771-18774	the	_	
94-43	18775-18779	body	_	
94-44	18779-18780	.	_	

#Text=Follow the natural and spontaneous movement of the breath, not trying to change it in any way.
95-1	18781-18787	Follow	_	
95-2	18788-18791	the	_	
95-3	18792-18799	natural	_	
95-4	18800-18803	and	_	
95-5	18804-18815	spontaneous	_	
95-6	18816-18824	movement	_	
95-7	18825-18827	of	_	
95-8	18828-18831	the	_	
95-9	18832-18838	breath	_	
95-10	18838-18839	,	_	
95-11	18840-18843	not	_	
95-12	18844-18850	trying	_	
95-13	18851-18853	to	_	
95-14	18854-18860	change	_	
95-15	18861-18863	it	_	
95-16	18864-18866	in	_	
95-17	18867-18870	any	_	
95-18	18871-18874	way	_	
95-19	18874-18875	.	_	

#Text=Just pay attention to it.
96-1	18876-18880	Just	_	
96-2	18881-18884	pay	_	
96-3	18885-18894	attention	_	
96-4	18895-18897	to	_	
96-5	18898-18900	it	_	
96-6	18900-18901	.	_	

#Text=If you find that your attention has wandered to something else, gently but firmly bring it back to the physical sensations of the breath in the body”.
97-1	18902-18904	If	_	
97-2	18905-18908	you	_	
97-3	18909-18913	find	_	
97-4	18914-18918	that	_	
97-5	18919-18923	your	_	
97-6	18924-18933	attention	_	
97-7	18934-18937	has	_	
97-8	18938-18946	wandered	_	
97-9	18947-18949	to	_	
97-10	18950-18959	something	_	
97-11	18960-18964	else	_	
97-12	18964-18965	,	_	
97-13	18966-18972	gently	_	
97-14	18973-18976	but	_	
97-15	18977-18983	firmly	_	
97-16	18984-18989	bring	_	
97-17	18990-18992	it	_	
97-18	18993-18997	back	_	
97-19	18998-19000	to	_	
97-20	19001-19004	the	_	
97-21	19005-19013	physical	_	
97-22	19014-19024	sensations	_	
97-23	19025-19027	of	_	
97-24	19028-19031	the	_	
97-25	19032-19038	breath	_	
97-26	19039-19041	in	_	
97-27	19042-19045	the	_	
97-28	19046-19050	body	_	
97-29	19050-19051	”	_	
97-30	19051-19052	.	_	

#Text=During the IN condition, an “O” appeared on the center of the screen for 36 s, on which subjects were instructed to fix their gaze while simultaneously attending to the sensations of their breathing cycle.
98-1	19053-19059	During	_	
98-2	19060-19063	the	_	
98-3	19064-19066	IN	_	
98-4	19067-19076	condition	_	
98-5	19076-19077	,	_	
98-6	19078-19080	an	_	
98-7	19081-19082	“	_	
98-8	19082-19083	O	_	
98-9	19083-19084	”	_	
98-10	19085-19093	appeared	_	
98-11	19094-19096	on	_	
98-12	19097-19100	the	_	
98-13	19101-19107	center	_	
98-14	19108-19110	of	_	
98-15	19111-19114	the	_	
98-16	19115-19121	screen	_	
98-17	19122-19125	for	_	
98-18	19126-19128	36	_	
98-19	19128-19129	 	_	
98-20	19129-19130	s	_	
98-21	19130-19131	,	_	
98-22	19132-19134	on	_	
98-23	19135-19140	which	_	
98-24	19141-19149	subjects	_	
98-25	19150-19154	were	_	
98-26	19155-19165	instructed	_	
98-27	19166-19168	to	_	
98-28	19169-19172	fix	_	
98-29	19173-19178	their	_	
98-30	19179-19183	gaze	_	
98-31	19184-19189	while	_	
98-32	19190-19204	simultaneously	_	
98-33	19205-19214	attending	_	
98-34	19215-19217	to	_	
98-35	19218-19221	the	_	
98-36	19222-19232	sensations	_	
98-37	19233-19235	of	_	
98-38	19236-19241	their	_	
98-39	19242-19251	breathing	_	
98-40	19252-19257	cycle	_	
98-41	19257-19258	.	_	

#Text=The OUT condition consisted of a “1-back” task, which we considered to be an attention control condition.
99-1	19259-19262	The	_	
99-2	19263-19266	OUT	_	
99-3	19267-19276	condition	_	
99-4	19277-19286	consisted	_	
99-5	19287-19289	of	_	
99-6	19290-19291	a	_	
99-7	19292-19293	“	_	
99-8	19293-19294	1	_	
99-9	19294-19295	-	_	
99-10	19295-19299	back	_	
99-11	19299-19300	”	_	
99-12	19301-19305	task	_	
99-13	19305-19306	,	_	
99-14	19307-19312	which	_	
99-15	19313-19315	we	_	
99-16	19316-19326	considered	_	
99-17	19327-19329	to	_	
99-18	19330-19332	be	_	
99-19	19333-19335	an	_	
99-20	19336-19345	attention	_	
99-21	19346-19353	control	_	
99-22	19354-19363	condition	_	
99-23	19363-19364	.	_	

#Text=During the OUT blocks, a letter from the set (A, B, C, D) was presented for 500 ms in a pseudorandom sequence.
100-1	19365-19371	During	_	
100-2	19372-19375	the	_	
100-3	19376-19379	OUT	_	
100-4	19380-19386	blocks	_	
100-5	19386-19387	,	_	
100-6	19388-19389	a	_	
100-7	19390-19396	letter	_	
100-8	19397-19401	from	_	
100-9	19402-19405	the	_	
100-10	19406-19409	set	_	
100-11	19410-19411	(	_	
100-12	19411-19412	A	_	
100-13	19412-19413	,	_	
100-14	19414-19415	B	_	
100-15	19415-19416	,	_	
100-16	19417-19418	C	_	
100-17	19418-19419	,	_	
100-18	19420-19421	D	_	
100-19	19421-19422	)	_	
100-20	19423-19426	was	_	
100-21	19427-19436	presented	_	
100-22	19437-19440	for	_	
100-23	19441-19444	500	_	
100-24	19444-19445	 	_	
100-25	19445-19447	ms	_	
100-26	19448-19450	in	_	
100-27	19451-19452	a	_	
100-28	19453-19465	pseudorandom	_	
100-29	19466-19474	sequence	_	
100-30	19474-19475	.	_	

#Text=A fixation cross was presented in between each letter for 900 ms.
101-1	19476-19477	A	_	
101-2	19478-19486	fixation	_	
101-3	19487-19492	cross	_	
101-4	19493-19496	was	_	
101-5	19497-19506	presented	_	
101-6	19507-19509	in	_	
101-7	19510-19517	between	_	
101-8	19518-19522	each	_	
101-9	19523-19529	letter	_	
101-10	19530-19533	for	_	
101-11	19534-19537	900	_	
101-12	19537-19538	 	_	
101-13	19538-19540	ms	_	
101-14	19540-19541	.	_	

#Text=When a letter repeated, the participant was instructed to press a key on the button box.
102-1	19542-19546	When	_	
102-2	19547-19548	a	_	
102-3	19549-19555	letter	_	
102-4	19556-19564	repeated	_	
102-5	19564-19565	,	_	
102-6	19566-19569	the	_	
102-7	19570-19581	participant	_	
102-8	19582-19585	was	_	
102-9	19586-19596	instructed	_	
102-10	19597-19599	to	_	
102-11	19600-19605	press	_	
102-12	19606-19607	a	_	
102-13	19608-19611	key	_	
102-14	19612-19614	on	_	
102-15	19615-19618	the	_	
102-16	19619-19625	button	_	
102-17	19626-19629	box	_	
102-18	19629-19630	.	_	

#Text=The OUT blocks lasted 38.7 s.
103-1	19631-19634	The	_	
103-2	19635-19638	OUT	_	
103-3	19639-19645	blocks	_	
103-4	19646-19652	lasted	_	
103-5	19653-19657	38.7	_	
103-6	19657-19658	 	_	
103-7	19658-19659	s	_	
103-8	19659-19660	.	_	

#Text=The sequence of letters presented, key presses, and response times were recorded for each OUT block.
104-1	19661-19664	The	_	
104-2	19665-19673	sequence	_	
104-3	19674-19676	of	_	
104-4	19677-19684	letters	_	
104-5	19685-19694	presented	_	
104-6	19694-19695	,	_	
104-7	19696-19699	key	_	
104-8	19700-19707	presses	_	
104-9	19707-19708	,	_	
104-10	19709-19712	and	_	
104-11	19713-19721	response	_	
104-12	19722-19727	times	_	
104-13	19728-19732	were	_	
104-14	19733-19741	recorded	_	
104-15	19742-19745	for	_	
104-16	19746-19750	each	_	
104-17	19751-19754	OUT	_	
104-18	19755-19760	block	_	
104-19	19760-19761	.	_	

#Text=Prior to each block, the subject was presented with an instruction screen for 10 s that cued them to the upcoming block.
#Text=fMRI acquisition and analysis
#Text=Imaging set-up
#Text=Images were acquired with a 3 T Siemens MAGNETON Prisma System, with a 20-channel head coil.
105-1	19762-19767	Prior	_	
105-2	19768-19770	to	_	
105-3	19771-19775	each	_	
105-4	19776-19781	block	_	
105-5	19781-19782	,	_	
105-6	19783-19786	the	_	
105-7	19787-19794	subject	_	
105-8	19795-19798	was	_	
105-9	19799-19808	presented	_	
105-10	19809-19813	with	_	
105-11	19814-19816	an	_	
105-12	19817-19828	instruction	_	
105-13	19829-19835	screen	_	
105-14	19836-19839	for	_	
105-15	19840-19842	10	_	
105-16	19842-19843	 	_	
105-17	19843-19844	s	_	
105-18	19845-19849	that	_	
105-19	19850-19854	cued	_	
105-20	19855-19859	them	_	
105-21	19860-19862	to	_	
105-22	19863-19866	the	_	
105-23	19867-19875	upcoming	_	
105-24	19876-19881	block	_	
105-25	19881-19882	.	_	
105-26	19883-19887	fMRI	_	
105-27	19888-19899	acquisition	_	
105-28	19900-19903	and	_	
105-29	19904-19912	analysis	_	
105-30	19913-19920	Imaging	_	
105-31	19921-19927	set-up	_	
105-32	19928-19934	Images	_	
105-33	19935-19939	were	_	
105-34	19940-19948	acquired	_	
105-35	19949-19953	with	_	
105-36	19954-19955	a	_	
105-37	19956-19957	3	_	
105-38	19957-19958	 	_	
105-39	19958-19959	T	_	
105-40	19960-19967	Siemens	_	
105-41	19968-19976	MAGNETON	_	
105-42	19977-19983	Prisma	_	
105-43	19984-19990	System	_	
105-44	19990-19991	,	_	
105-45	19992-19996	with	_	
105-46	19997-19998	a	_	
105-47	19999-20001	20	_	
105-48	20001-20002	-	_	
105-49	20002-20009	channel	_	
105-50	20010-20014	head	_	
105-51	20015-20019	coil	_	
105-52	20019-20020	.	_	

#Text=Functional images were obtained using a gradient echo, echo-planar, T2*-weighted pulse sequence (TR = 2000 ms, one shot per repetition, TE = 25 ms, flip angle = 90°, 64 × 64 in-plane resolution).
106-1	20021-20031	Functional	_	
106-2	20032-20038	images	_	
106-3	20039-20043	were	_	
106-4	20044-20052	obtained	_	
106-5	20053-20058	using	_	
106-6	20059-20060	a	_	
106-7	20061-20069	gradient	_	
106-8	20070-20074	echo	_	
106-9	20074-20075	,	_	
106-10	20076-20087	echo-planar	_	
106-11	20087-20088	,	_	
106-12	20089-20091	T2	_	
106-13	20091-20092	*	_	
106-14	20092-20093	-	_	
106-15	20093-20101	weighted	_	
106-16	20102-20107	pulse	_	
106-17	20108-20116	sequence	_	
106-18	20117-20118	(	_	
106-19	20118-20120	TR	_	
106-20	20120-20121	 	_	
106-21	20121-20122	=	_	
106-22	20122-20123	 	_	
106-23	20123-20127	2000	_	
106-24	20127-20128	 	_	
106-25	20128-20130	ms	_	
106-26	20130-20131	,	_	
106-27	20132-20135	one	_	
106-28	20136-20140	shot	_	
106-29	20141-20144	per	_	
106-30	20145-20155	repetition	_	
106-31	20155-20156	,	_	
106-32	20157-20159	TE	_	
106-33	20159-20160	 	_	
106-34	20160-20161	=	_	
106-35	20161-20162	 	_	
106-36	20162-20164	25	_	
106-37	20164-20165	 	_	
106-38	20165-20167	ms	_	
106-39	20167-20168	,	_	
106-40	20169-20173	flip	_	
106-41	20174-20179	angle	_	
106-42	20179-20180	 	_	
106-43	20180-20181	=	_	
106-44	20181-20182	 	_	
106-45	20182-20184	90	_	
106-46	20184-20185	°	_	
106-47	20185-20186	,	_	
106-48	20187-20189	64	_	
106-49	20189-20190	 	_	
106-50	20190-20191	×	_	
106-51	20191-20192	 	_	
106-52	20192-20194	64	_	
106-53	20195-20203	in-plane	_	
106-54	20204-20214	resolution	_	
106-55	20214-20215	)	_	
106-56	20215-20216	.	_	

#Text=Forty-one slices covering the entire brain were acquired with a voxel resolution of 3 cubic mm.
107-1	20217-20226	Forty-one	_	
107-2	20227-20233	slices	_	
107-3	20234-20242	covering	_	
107-4	20243-20246	the	_	
107-5	20247-20253	entire	_	
107-6	20254-20259	brain	_	
107-7	20260-20264	were	_	
107-8	20265-20273	acquired	_	
107-9	20274-20278	with	_	
107-10	20279-20280	a	_	
107-11	20281-20286	voxel	_	
107-12	20287-20297	resolution	_	
107-13	20298-20300	of	_	
107-14	20301-20302	3	_	
107-15	20303-20308	cubic	_	
107-16	20309-20311	mm	_	
107-17	20311-20312	.	_	

#Text=Structural T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) images were acquired with the following parameters: TR = 1950 ms, TE = 2.26 ms, TI = 900 ms, Flip Angle = 7°, matrix = 256 × 224, 1 mm isotropic resolution, 176 sagittal slices, acquisition time = 241 s.
108-1	20313-20323	Structural	_	
108-2	20324-20326	T1	_	
108-3	20326-20327	-	_	
108-4	20327-20335	weighted	_	
108-5	20336-20358	magnetization-prepared	_	
108-6	20359-20364	rapid	_	
108-7	20365-20373	gradient	_	
108-8	20374-20378	echo	_	
108-9	20379-20380	(	_	
108-10	20380-20386	MPRAGE	_	
108-11	20386-20387	)	_	
108-12	20388-20394	images	_	
108-13	20395-20399	were	_	
108-14	20400-20408	acquired	_	
108-15	20409-20413	with	_	
108-16	20414-20417	the	_	
108-17	20418-20427	following	_	
108-18	20428-20438	parameters	_	
108-19	20438-20439	:	_	
108-20	20440-20442	TR	_	
108-21	20442-20443	 	_	
108-22	20443-20444	=	_	
108-23	20444-20445	 	_	
108-24	20445-20449	1950	_	
108-25	20449-20450	 	_	
108-26	20450-20452	ms	_	
108-27	20452-20453	,	_	
108-28	20454-20456	TE	_	
108-29	20456-20457	 	_	
108-30	20457-20458	=	_	
108-31	20458-20459	 	_	
108-32	20459-20463	2.26	_	
108-33	20463-20464	 	_	
108-34	20464-20466	ms	_	
108-35	20466-20467	,	_	
108-36	20468-20470	TI	_	
108-37	20470-20471	 	_	
108-38	20471-20472	=	_	
108-39	20472-20473	 	_	
108-40	20473-20476	900	_	
108-41	20476-20477	 	_	
108-42	20477-20479	ms	_	
108-43	20479-20480	,	_	
108-44	20481-20485	Flip	_	
108-45	20486-20491	Angle	_	
108-46	20491-20492	 	_	
108-47	20492-20493	=	_	
108-48	20493-20494	 	_	
108-49	20494-20495	7	_	
108-50	20495-20496	°	_	
108-51	20496-20497	,	_	
108-52	20498-20504	matrix	_	
108-53	20504-20505	 	_	
108-54	20505-20506	=	_	
108-55	20506-20507	 	_	
108-56	20507-20510	256	_	
108-57	20510-20511	 	_	
108-58	20511-20512	×	_	
108-59	20512-20513	 	_	
108-60	20513-20516	224	_	
108-61	20516-20517	,	_	
108-62	20518-20519	1	_	
108-63	20519-20520	 	_	
108-64	20520-20522	mm	_	
108-65	20523-20532	isotropic	_	
108-66	20533-20543	resolution	_	
108-67	20543-20544	,	_	
108-68	20545-20548	176	_	
108-69	20549-20557	sagittal	_	
108-70	20558-20564	slices	_	
108-71	20564-20565	,	_	
108-72	20566-20577	acquisition	_	
108-73	20578-20582	time	_	
108-74	20582-20583	 	_	
108-75	20583-20584	=	_	
108-76	20584-20585	 	_	
108-77	20585-20588	241	_	
108-78	20588-20589	 	_	
108-79	20589-20590	s	_	
108-80	20590-20591	.	_	

#Text=Respiration and pulse oximetry were measured during scanning using Biopac MP150 hardware and MR-compatible respiratory stretch transducer and pulse oximeter (Nonin Medical, 8600FO).
109-1	20592-20603	Respiration	_	
109-2	20604-20607	and	_	
109-3	20608-20613	pulse	_	
109-4	20614-20622	oximetry	_	
109-5	20623-20627	were	_	
109-6	20628-20636	measured	_	
109-7	20637-20643	during	_	
109-8	20644-20652	scanning	_	
109-9	20653-20658	using	_	
109-10	20659-20665	Biopac	_	
109-11	20666-20671	MP150	_	
109-12	20672-20680	hardware	_	
109-13	20681-20684	and	_	
109-14	20685-20698	MR-compatible	_	
109-15	20699-20710	respiratory	_	
109-16	20711-20718	stretch	_	
109-17	20719-20729	transducer	_	
109-18	20730-20733	and	_	
109-19	20734-20739	pulse	_	
109-20	20740-20748	oximeter	_	
109-21	20749-20750	(	_	
109-22	20750-20755	Nonin	_	
109-23	20756-20763	Medical	_	
109-24	20763-20764	,	_	
109-25	20765-20771	8600FO	_	
109-26	20771-20772	)	_	
109-27	20772-20773	.	_	

#Text=Physiological data were sampled with a 1000 Hz sampling rate.
110-1	20774-20787	Physiological	_	
110-2	20788-20792	data	_	
110-3	20793-20797	were	_	
110-4	20798-20805	sampled	_	
110-5	20806-20810	with	_	
110-6	20811-20812	a	_	
110-7	20813-20817	1000	_	
110-8	20817-20818	 	_	
110-9	20818-20820	Hz	_	
110-10	20821-20829	sampling	_	
110-11	20830-20834	rate	_	
110-12	20834-20835	.	_	

#Text=The acquisition was synchronized to the scanner via a TTL pulse, and recorded in Biopac Acqknowledge software.
111-1	20836-20839	The	_	
111-2	20840-20851	acquisition	_	
111-3	20852-20855	was	_	
111-4	20856-20868	synchronized	_	
111-5	20869-20871	to	_	
111-6	20872-20875	the	_	
111-7	20876-20883	scanner	_	
111-8	20884-20887	via	_	
111-9	20888-20889	a	_	
111-10	20890-20893	TTL	_	
111-11	20894-20899	pulse	_	
111-12	20899-20900	,	_	
111-13	20901-20904	and	_	
111-14	20905-20913	recorded	_	
111-15	20914-20916	in	_	
111-16	20917-20923	Biopac	_	
111-17	20924-20936	Acqknowledge	_	
111-18	20937-20945	software	_	
111-19	20945-20946	.	_	

#Text=The IN-OUT Attention task was scripted using MATLAB and Psychtoolbox 3.
#Text=fMRI pre-processing
#Text=RETROICOR and respiratory and cardiac response functions (RVHRCOR) were applied to the functional volumes to reduce non-neuronal contributions of physiological noise.
112-1	20947-20950	The	_	
112-2	20951-20957	IN-OUT	_	
112-3	20958-20967	Attention	_	
112-4	20968-20972	task	_	
112-5	20973-20976	was	_	
112-6	20977-20985	scripted	_	
112-7	20986-20991	using	_	
112-8	20992-20998	MATLAB	_	
112-9	20999-21002	and	_	
112-10	21003-21015	Psychtoolbox	_	
112-11	21016-21017	3	_	
112-12	21017-21018	.	_	
112-13	21019-21023	fMRI	_	
112-14	21024-21038	pre-processing	_	
112-15	21039-21048	RETROICOR	_	
112-16	21049-21052	and	_	
112-17	21053-21064	respiratory	_	
112-18	21065-21068	and	_	
112-19	21069-21076	cardiac	_	
112-20	21077-21085	response	_	
112-21	21086-21095	functions	_	
112-22	21096-21097	(	_	
112-23	21097-21104	RVHRCOR	_	
112-24	21104-21105	)	_	
112-25	21106-21110	were	_	
112-26	21111-21118	applied	_	
112-27	21119-21121	to	_	
112-28	21122-21125	the	_	
112-29	21126-21136	functional	_	
112-30	21137-21144	volumes	_	
112-31	21145-21147	to	_	
112-32	21148-21154	reduce	_	
112-33	21155-21167	non-neuronal	_	
112-34	21168-21181	contributions	_	
112-35	21182-21184	of	_	
112-36	21185-21198	physiological	_	
112-37	21199-21204	noise	_	
112-38	21204-21205	.	_	

#Text=RETROICOR models periodic pulsatile noise in the BOLD time series associated with respiratory and cardiac cycles as a low-order Fourier phase expansion.
113-1	21206-21215	RETROICOR	_	
113-2	21216-21222	models	_	
113-3	21223-21231	periodic	_	
113-4	21232-21241	pulsatile	_	
113-5	21242-21247	noise	_	
113-6	21248-21250	in	_	
113-7	21251-21254	the	_	
113-8	21255-21259	BOLD	_	
113-9	21260-21264	time	_	
113-10	21265-21271	series	_	
113-11	21272-21282	associated	_	
113-12	21283-21287	with	_	
113-13	21288-21299	respiratory	_	
113-14	21300-21303	and	_	
113-15	21304-21311	cardiac	_	
113-16	21312-21318	cycles	_	
113-17	21319-21321	as	_	
113-18	21322-21323	a	_	
113-19	21324-21333	low-order	_	
113-20	21334-21341	Fourier	_	
113-21	21342-21347	phase	_	
113-22	21348-21357	expansion	_	
113-23	21357-21358	.	_	

#Text=RVHRCOR removes low-frequency cardiac and respiratory effects by convolving the respiratory and cardiac data with their respective response functions.
114-1	21359-21366	RVHRCOR	_	
114-2	21367-21374	removes	_	
114-3	21375-21388	low-frequency	_	
114-4	21389-21396	cardiac	_	
114-5	21397-21400	and	_	
114-6	21401-21412	respiratory	_	
114-7	21413-21420	effects	_	
114-8	21421-21423	by	_	
114-9	21424-21434	convolving	_	
114-10	21435-21438	the	_	
114-11	21439-21450	respiratory	_	
114-12	21451-21454	and	_	
114-13	21455-21462	cardiac	_	
114-14	21463-21467	data	_	
114-15	21468-21472	with	_	
114-16	21473-21478	their	_	
114-17	21479-21489	respective	_	
114-18	21490-21498	response	_	
114-19	21499-21508	functions	_	
114-20	21508-21509	.	_	

#Text=The convolved cardiac and respiratory waveforms are then used as regressors for each voxel's time series using least squares.
115-1	21510-21513	The	_	
115-2	21514-21523	convolved	_	
115-3	21524-21531	cardiac	_	
115-4	21532-21535	and	_	
115-5	21536-21547	respiratory	_	
115-6	21548-21557	waveforms	_	
115-7	21558-21561	are	_	
115-8	21562-21566	then	_	
115-9	21567-21571	used	_	
115-10	21572-21574	as	_	
115-11	21575-21585	regressors	_	
115-12	21586-21589	for	_	
115-13	21590-21594	each	_	
115-14	21595-21602	voxel's	_	
115-15	21603-21607	time	_	
115-16	21608-21614	series	_	
115-17	21615-21620	using	_	
115-18	21621-21626	least	_	
115-19	21627-21634	squares	_	
115-20	21634-21635	.	_	

#Text=RETROICOR (order = 4) and RVHRCOR were performed in MATLAB using code obtained from C.
116-1	21636-21645	RETROICOR	_	
116-2	21646-21647	(	_	
116-3	21647-21652	order	_	
116-4	21652-21653	 	_	
116-5	21653-21654	=	_	
116-6	21654-21655	 	_	
116-7	21655-21656	4	_	
116-8	21656-21657	)	_	
116-9	21658-21661	and	_	
116-10	21662-21669	RVHRCOR	_	
116-11	21670-21674	were	_	
116-12	21675-21684	performed	_	
116-13	21685-21687	in	_	
116-14	21688-21694	MATLAB	_	
116-15	21695-21700	using	_	
116-16	21701-21705	code	_	
116-17	21706-21714	obtained	_	
116-18	21715-21719	from	_	
116-19	21720-21721	C	_	
116-20	21721-21722	.	_	

#Text=Chang.
117-1	21723-21728	Chang	_	
117-2	21728-21729	.	_	

#Text=Subsequent pre-processing steps were carried out in FSL (FMRIB's Software Library; http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and included skull stripping with BET, motion correction (MCFLIRT), slice-timing correction, high-pass temporal filtering (90 s), and spatial smoothing using a 5 mm Gaussian FWHM filter.
118-1	21730-21740	Subsequent	_	
118-2	21741-21755	pre-processing	_	
118-3	21756-21761	steps	_	
118-4	21762-21766	were	_	
118-5	21767-21774	carried	_	
118-6	21775-21778	out	_	
118-7	21779-21781	in	_	
118-8	21782-21785	FSL	_	
118-9	21786-21787	(	_	
118-10	21787-21794	FMRIB's	_	
118-11	21795-21803	Software	_	
118-12	21804-21811	Library	_	
118-13	21811-21812	;	_	
118-14	21813-21817	http	_	
118-15	21817-21818	:	_	
118-16	21818-21819	/	_	
118-17	21819-21820	/	_	
118-18	21820-21838	fsl.fmrib.ox.ac.uk	_	
118-19	21838-21839	/	_	
118-20	21839-21842	fsl	_	
118-21	21842-21843	/	_	
118-22	21843-21850	fslwiki	_	
118-23	21850-21851	/	_	
118-24	21851-21852	)	_	
118-25	21853-21856	and	_	
118-26	21857-21865	included	_	
118-27	21866-21871	skull	_	
118-28	21872-21881	stripping	_	
118-29	21882-21886	with	_	
118-30	21887-21890	BET	_	
118-31	21890-21891	,	_	
118-32	21892-21898	motion	_	
118-33	21899-21909	correction	_	
118-34	21910-21911	(	_	
118-35	21911-21918	MCFLIRT	_	
118-36	21918-21919	)	_	
118-37	21919-21920	,	_	
118-38	21921-21933	slice-timing	_	
118-39	21934-21944	correction	_	
118-40	21944-21945	,	_	
118-41	21946-21955	high-pass	_	
118-42	21956-21964	temporal	_	
118-43	21965-21974	filtering	_	
118-44	21975-21976	(	_	
118-45	21976-21978	90	_	
118-46	21978-21979	 	_	
118-47	21979-21980	s	_	
118-48	21980-21981	)	_	
118-49	21981-21982	,	_	
118-50	21983-21986	and	_	
118-51	21987-21994	spatial	_	
118-52	21995-22004	smoothing	_	
118-53	22005-22010	using	_	
118-54	22011-22012	a	_	
118-55	22013-22014	5	_	
118-56	22014-22015	 	_	
118-57	22015-22017	mm	_	
118-58	22018-22026	Gaussian	_	
118-59	22027-22031	FWHM	_	
118-60	22032-22038	filter	_	
118-61	22038-22039	.	_	

#Text=Additional sources of movement and scanner noise were removed using FSL's MELODIC ICA for each individual run.
119-1	22040-22050	Additional	_	
119-2	22051-22058	sources	_	
119-3	22059-22061	of	_	
119-4	22062-22070	movement	_	
119-5	22071-22074	and	_	
119-6	22075-22082	scanner	_	
119-7	22083-22088	noise	_	
119-8	22089-22093	were	_	
119-9	22094-22101	removed	_	
119-10	22102-22107	using	_	
119-11	22108-22113	FSL's	_	
119-12	22114-22121	MELODIC	_	
119-13	22122-22125	ICA	_	
119-14	22126-22129	for	_	
119-15	22130-22134	each	_	
119-16	22135-22145	individual	_	
119-17	22146-22149	run	_	
119-18	22149-22150	.	_	

#Text=Subject-level ICA-based denoising substantially improves the reproducibility of group-ICA decompositions relative to both motion scrubbing and nuisance regression.
120-1	22151-22164	Subject-level	_	
120-2	22165-22174	ICA-based	_	
120-3	22175-22184	denoising	_	
120-4	22185-22198	substantially	_	
120-5	22199-22207	improves	_	
120-6	22208-22211	the	_	
120-7	22212-22227	reproducibility	_	
120-8	22228-22230	of	_	
120-9	22231-22240	group-ICA	_	
120-10	22241-22255	decompositions	_	
120-11	22256-22264	relative	_	
120-12	22265-22267	to	_	
120-13	22268-22272	both	_	
120-14	22273-22279	motion	_	
120-15	22280-22289	scrubbing	_	
120-16	22290-22293	and	_	
120-17	22294-22302	nuisance	_	
120-18	22303-22313	regression	_	
120-19	22313-22314	.	_	

#Text=Each component for each subject and run was manually inspected and labeled by an experimenter blind to participant diagnoses.
121-1	22315-22319	Each	_	
121-2	22320-22329	component	_	
121-3	22330-22333	for	_	
121-4	22334-22338	each	_	
121-5	22339-22346	subject	_	
121-6	22347-22350	and	_	
121-7	22351-22354	run	_	
121-8	22355-22358	was	_	
121-9	22359-22367	manually	_	
121-10	22368-22377	inspected	_	
121-11	22378-22381	and	_	
121-12	22382-22389	labeled	_	
121-13	22390-22392	by	_	
121-14	22393-22395	an	_	
121-15	22396-22408	experimenter	_	
121-16	22409-22414	blind	_	
121-17	22415-22417	to	_	
121-18	22418-22429	participant	_	
121-19	22430-22439	diagnoses	_	
121-20	22439-22440	.	_	

#Text=Components flagged as artifact were regressed from the functional volume.
122-1	22441-22451	Components	_	
122-2	22452-22459	flagged	_	
122-3	22460-22462	as	_	
122-4	22463-22471	artifact	_	
122-5	22472-22476	were	_	
122-6	22477-22486	regressed	_	
122-7	22487-22491	from	_	
122-8	22492-22495	the	_	
122-9	22496-22506	functional	_	
122-10	22507-22513	volume	_	
122-11	22513-22514	.	_	

#Text=The functional volumes were realigned to each participant's respective T1-weighted anatomical image, then normalized into standard space using 12°-of-freedom affine transformation and 2 mm resolution.
123-1	22515-22518	The	_	
123-2	22519-22529	functional	_	
123-3	22530-22537	volumes	_	
123-4	22538-22542	were	_	
123-5	22543-22552	realigned	_	
123-6	22553-22555	to	_	
123-7	22556-22560	each	_	
123-8	22561-22574	participant's	_	
123-9	22575-22585	respective	_	
123-10	22586-22588	T1	_	
123-11	22588-22589	-	_	
123-12	22589-22597	weighted	_	
123-13	22598-22608	anatomical	_	
123-14	22609-22614	image	_	
123-15	22614-22615	,	_	
123-16	22616-22620	then	_	
123-17	22621-22631	normalized	_	
123-18	22632-22636	into	_	
123-19	22637-22645	standard	_	
123-20	22646-22651	space	_	
123-21	22652-22657	using	_	
123-22	22658-22660	12	_	
123-23	22660-22661	°	_	
123-24	22661-22662	-	_	
123-25	22662-22672	of-freedom	_	
123-26	22673-22679	affine	_	
123-27	22680-22694	transformation	_	
123-28	22695-22698	and	_	
123-29	22699-22700	2	_	
123-30	22700-22701	 	_	
123-31	22701-22703	mm	_	
123-32	22704-22714	resolution	_	
123-33	22714-22715	.	_	

#Text=Group independent components analysis
#Text=To identify group-level intrinsic functional networks, we utilized the Multivariate Exploratory Linear Optimized Decomposition into Independent Components (MELODIC) algorithm in FSL.
124-1	22716-22721	Group	_	
124-2	22722-22733	independent	_	
124-3	22734-22744	components	_	
124-4	22745-22753	analysis	_	
124-5	22754-22756	To	_	
124-6	22757-22765	identify	_	
124-7	22766-22777	group-level	_	
124-8	22778-22787	intrinsic	_	
124-9	22788-22798	functional	_	
124-10	22799-22807	networks	_	
124-11	22807-22808	,	_	
124-12	22809-22811	we	_	
124-13	22812-22820	utilized	_	
124-14	22821-22824	the	_	
124-15	22825-22837	Multivariate	_	
124-16	22838-22849	Exploratory	_	
124-17	22850-22856	Linear	_	
124-18	22857-22866	Optimized	_	
124-19	22867-22880	Decomposition	_	
124-20	22881-22885	into	_	
124-21	22886-22897	Independent	_	
124-22	22898-22908	Components	_	
124-23	22909-22910	(	_	
124-24	22910-22917	MELODIC	_	
124-25	22917-22918	)	_	
124-26	22919-22928	algorithm	_	
124-27	22929-22931	in	_	
124-28	22932-22935	FSL	_	
124-29	22935-22936	.	_	

#Text=Independent components analysis separates underlying sources from a linearly mixed multivariate signal.
125-1	22937-22948	Independent	_	
125-2	22949-22959	components	_	
125-3	22960-22968	analysis	_	
125-4	22969-22978	separates	_	
125-5	22979-22989	underlying	_	
125-6	22990-22997	sources	_	
125-7	22998-23002	from	_	
125-8	23003-23004	a	_	
125-9	23005-23013	linearly	_	
125-10	23014-23019	mixed	_	
125-11	23020-23032	multivariate	_	
125-12	23033-23039	signal	_	
125-13	23039-23040	.	_	

#Text=Preprocessed fMRI data from each subject and run were temporally concatenated into a single 4D file (each subject provided two runs of data, less the four subjects who provided only one run, for a total of 82 runs) and submitted to MELODIC analysis, with variance normalization.
126-1	23041-23053	Preprocessed	_	
126-2	23054-23058	fMRI	_	
126-3	23059-23063	data	_	
126-4	23064-23068	from	_	
126-5	23069-23073	each	_	
126-6	23074-23081	subject	_	
126-7	23082-23085	and	_	
126-8	23086-23089	run	_	
126-9	23090-23094	were	_	
126-10	23095-23105	temporally	_	
126-11	23106-23118	concatenated	_	
126-12	23119-23123	into	_	
126-13	23124-23125	a	_	
126-14	23126-23132	single	_	
126-15	23133-23135	4D	_	
126-16	23136-23140	file	_	
126-17	23141-23142	(	_	
126-18	23142-23146	each	_	
126-19	23147-23154	subject	_	
126-20	23155-23163	provided	_	
126-21	23164-23167	two	_	
126-22	23168-23172	runs	_	
126-23	23173-23175	of	_	
126-24	23176-23180	data	_	
126-25	23180-23181	,	_	
126-26	23182-23186	less	_	
126-27	23187-23190	the	_	
126-28	23191-23195	four	_	
126-29	23196-23204	subjects	_	
126-30	23205-23208	who	_	
126-31	23209-23217	provided	_	
126-32	23218-23222	only	_	
126-33	23223-23226	one	_	
126-34	23227-23230	run	_	
126-35	23230-23231	,	_	
126-36	23232-23235	for	_	
126-37	23236-23237	a	_	
126-38	23238-23243	total	_	
126-39	23244-23246	of	_	
126-40	23247-23249	82	_	
126-41	23250-23254	runs	_	
126-42	23254-23255	)	_	
126-43	23256-23259	and	_	
126-44	23260-23269	submitted	_	
126-45	23270-23272	to	_	
126-46	23273-23280	MELODIC	_	
126-47	23281-23289	analysis	_	
126-48	23289-23290	,	_	
126-49	23291-23295	with	_	
126-50	23296-23304	variance	_	
126-51	23305-23318	normalization	_	
126-52	23318-23319	.	_	

#Text=Thus, the group ICA solution reflects the combined contributions of both the PTSD and noPTSD groups.
127-1	23320-23324	Thus	_	
127-2	23324-23325	,	_	
127-3	23326-23329	the	_	
127-4	23330-23335	group	_	
127-5	23336-23339	ICA	_	
127-6	23340-23348	solution	_	
127-7	23349-23357	reflects	_	
127-8	23358-23361	the	_	
127-9	23362-23370	combined	_	
127-10	23371-23384	contributions	_	
127-11	23385-23387	of	_	
127-12	23388-23392	both	_	
127-13	23393-23396	the	_	
127-14	23397-23401	PTSD	_	
127-15	23402-23405	and	_	
127-16	23406-23412	noPTSD	_	
127-17	23413-23419	groups	_	
127-18	23419-23420	.	_	

#Text=The dimensionality of the solution was constrained to 20 networks, a level of granularity commonly used to identify large-scale networks.
128-1	23421-23424	The	_	
128-2	23425-23439	dimensionality	_	
128-3	23440-23442	of	_	
128-4	23443-23446	the	_	
128-5	23447-23455	solution	_	
128-6	23456-23459	was	_	
128-7	23460-23471	constrained	_	
128-8	23472-23474	to	_	
128-9	23475-23477	20	_	
128-10	23478-23486	networks	_	
128-11	23486-23487	,	_	
128-12	23488-23489	a	_	
128-13	23490-23495	level	_	
128-14	23496-23498	of	_	
128-15	23499-23510	granularity	_	
128-16	23511-23519	commonly	_	
128-17	23520-23524	used	_	
128-18	23525-23527	to	_	
128-19	23528-23536	identify	_	
128-20	23537-23548	large-scale	_	
128-21	23549-23557	networks	_	
128-22	23557-23558	.	_	

#Text=Thereafter, the 20 group-level normalized networks were spatially cross-correlated against 20 network solution to determine their correspondence to a canonical set of intrinsic networks and artifacts.
129-1	23559-23569	Thereafter	_	
129-2	23569-23570	,	_	
129-3	23571-23574	the	_	
129-4	23575-23577	20	_	
129-5	23578-23589	group-level	_	
129-6	23590-23600	normalized	_	
129-7	23601-23609	networks	_	
129-8	23610-23614	were	_	
129-9	23615-23624	spatially	_	
129-10	23625-23641	cross-correlated	_	
129-11	23642-23649	against	_	
129-12	23650-23652	20	_	
129-13	23653-23660	network	_	
129-14	23661-23669	solution	_	
129-15	23670-23672	to	_	
129-16	23673-23682	determine	_	
129-17	23683-23688	their	_	
129-18	23689-23703	correspondence	_	
129-19	23704-23706	to	_	
129-20	23707-23708	a	_	
129-21	23709-23718	canonical	_	
129-22	23719-23722	set	_	
129-23	23723-23725	of	_	
129-24	23726-23735	intrinsic	_	
129-25	23736-23744	networks	_	
129-26	23745-23748	and	_	
129-27	23749-23758	artifacts	_	
129-28	23758-23759	.	_	

#Text=Dual regression to obtain subject-level networks
#Text=In the first stage of the dual regression, the unthresholded group-level networks are first regressed onto each participant's fMRI series to extract beta-weights that form a subject-specific time series for each component and functional run (the spatial regression).
130-1	23760-23764	Dual	_	
130-2	23765-23775	regression	_	
130-3	23776-23778	to	_	
130-4	23779-23785	obtain	_	
130-5	23786-23799	subject-level	_	
130-6	23800-23808	networks	_	
130-7	23809-23811	In	_	
130-8	23812-23815	the	_	
130-9	23816-23821	first	_	
130-10	23822-23827	stage	_	
130-11	23828-23830	of	_	
130-12	23831-23834	the	_	
130-13	23835-23839	dual	_	
130-14	23840-23850	regression	_	
130-15	23850-23851	,	_	
130-16	23852-23855	the	_	
130-17	23856-23869	unthresholded	_	
130-18	23870-23881	group-level	_	
130-19	23882-23890	networks	_	
130-20	23891-23894	are	_	
130-21	23895-23900	first	_	
130-22	23901-23910	regressed	_	
130-23	23911-23915	onto	_	
130-24	23916-23920	each	_	
130-25	23921-23934	participant's	_	
130-26	23935-23939	fMRI	_	
130-27	23940-23946	series	_	
130-28	23947-23949	to	_	
130-29	23950-23957	extract	_	
130-30	23958-23970	beta-weights	_	
130-31	23971-23975	that	_	
130-32	23976-23980	form	_	
130-33	23981-23982	a	_	
130-34	23983-23999	subject-specific	_	
130-35	24000-24004	time	_	
130-36	24005-24011	series	_	
130-37	24012-24015	for	_	
130-38	24016-24020	each	_	
130-39	24021-24030	component	_	
130-40	24031-24034	and	_	
130-41	24035-24045	functional	_	
130-42	24046-24049	run	_	
130-43	24050-24051	(	_	
130-44	24051-24054	the	_	
130-45	24055-24062	spatial	_	
130-46	24063-24073	regression	_	
130-47	24073-24074	)	_	
130-48	24074-24075	.	_	

#Text=Next, the variance-normalized time series for each component and run obtained from the first stage are used as predictor vectors for each participant's fMRI series to obtain a subject-specific component map (the temporal regression).
131-1	24076-24080	Next	_	
131-2	24080-24081	,	_	
131-3	24082-24085	the	_	
131-4	24086-24105	variance-normalized	_	
131-5	24106-24110	time	_	
131-6	24111-24117	series	_	
131-7	24118-24121	for	_	
131-8	24122-24126	each	_	
131-9	24127-24136	component	_	
131-10	24137-24140	and	_	
131-11	24141-24144	run	_	
131-12	24145-24153	obtained	_	
131-13	24154-24158	from	_	
131-14	24159-24162	the	_	
131-15	24163-24168	first	_	
131-16	24169-24174	stage	_	
131-17	24175-24178	are	_	
131-18	24179-24183	used	_	
131-19	24184-24186	as	_	
131-20	24187-24196	predictor	_	
131-21	24197-24204	vectors	_	
131-22	24205-24208	for	_	
131-23	24209-24213	each	_	
131-24	24214-24227	participant's	_	
131-25	24228-24232	fMRI	_	
131-26	24233-24239	series	_	
131-27	24240-24242	to	_	
131-28	24243-24249	obtain	_	
131-29	24250-24251	a	_	
131-30	24252-24268	subject-specific	_	
131-31	24269-24278	component	_	
131-32	24279-24282	map	_	
131-33	24283-24284	(	_	
131-34	24284-24287	the	_	
131-35	24288-24296	temporal	_	
131-36	24297-24307	regression	_	
131-37	24307-24308	)	_	
131-38	24308-24309	.	_	

#Text=These whole-brain spatial maps reflect each voxel's correlation with the group-level network; consequently, functional connectivity of a given network can manifest in any region of the brain, regardless of whether that region is typically associated with the canonical network.
132-1	24310-24315	These	_	
132-2	24316-24327	whole-brain	_	
132-3	24328-24335	spatial	_	
132-4	24336-24340	maps	_	
132-5	24341-24348	reflect	_	
132-6	24349-24353	each	_	
132-7	24354-24361	voxel's	_	
132-8	24362-24373	correlation	_	
132-9	24374-24378	with	_	
132-10	24379-24382	the	_	
132-11	24383-24394	group-level	_	
132-12	24395-24402	network	_	
132-13	24402-24403	;	_	
132-14	24404-24416	consequently	_	
132-15	24416-24417	,	_	
132-16	24418-24428	functional	_	
132-17	24429-24441	connectivity	_	
132-18	24442-24444	of	_	
132-19	24445-24446	a	_	
132-20	24447-24452	given	_	
132-21	24453-24460	network	_	
132-22	24461-24464	can	_	
132-23	24465-24473	manifest	_	
132-24	24474-24476	in	_	
132-25	24477-24480	any	_	
132-26	24481-24487	region	_	
132-27	24488-24490	of	_	
132-28	24491-24494	the	_	
132-29	24495-24500	brain	_	
132-30	24500-24501	,	_	
132-31	24502-24512	regardless	_	
132-32	24513-24515	of	_	
132-33	24516-24523	whether	_	
132-34	24524-24528	that	_	
132-35	24529-24535	region	_	
132-36	24536-24538	is	_	
132-37	24539-24548	typically	_	
132-38	24549-24559	associated	_	
132-39	24560-24564	with	_	
132-40	24565-24568	the	_	
132-41	24569-24578	canonical	_	
132-42	24579-24586	network	_	
132-43	24586-24587	.	_	

#Text=This approach allows identification of group differences in spatial connectivity of functional networks.
133-1	24588-24592	This	_	
133-2	24593-24601	approach	_	
133-3	24602-24608	allows	_	
133-4	24609-24623	identification	_	
133-5	24624-24626	of	_	
133-6	24627-24632	group	_	
133-7	24633-24644	differences	_	
133-8	24645-24647	in	_	
133-9	24648-24655	spatial	_	
133-10	24656-24668	connectivity	_	
133-11	24669-24671	of	_	
133-12	24672-24682	functional	_	
133-13	24683-24691	networks	_	
133-14	24691-24692	.	_	

#Text=We carried out dual regression on each group-level network individually, excluding: 1) the six networks deemed artifactual based on visual inspection and comparison with canonical networks and 2) the six networks that were not found to be significantly task-related (see Section 3.6 below).
134-1	24693-24695	We	_	
134-2	24696-24703	carried	_	
134-3	24704-24707	out	_	
134-4	24708-24712	dual	_	
134-5	24713-24723	regression	_	
134-6	24724-24726	on	_	
134-7	24727-24731	each	_	
134-8	24732-24743	group-level	_	
134-9	24744-24751	network	_	
134-10	24752-24764	individually	_	
134-11	24764-24765	,	_	
134-12	24766-24775	excluding	_	
134-13	24775-24776	:	_	
134-14	24777-24778	1	_	
134-15	24778-24779	)	_	
134-16	24780-24783	the	_	
134-17	24784-24787	six	_	
134-18	24788-24796	networks	_	
134-19	24797-24803	deemed	_	
134-20	24804-24815	artifactual	_	
134-21	24816-24821	based	_	
134-22	24822-24824	on	_	
134-23	24825-24831	visual	_	
134-24	24832-24842	inspection	_	
134-25	24843-24846	and	_	
134-26	24847-24857	comparison	_	
134-27	24858-24862	with	_	
134-28	24863-24872	canonical	_	
134-29	24873-24881	networks	_	
134-30	24882-24885	and	_	
134-31	24886-24887	2	_	
134-32	24887-24888	)	_	
134-33	24889-24892	the	_	
134-34	24893-24896	six	_	
134-35	24897-24905	networks	_	
134-36	24906-24910	that	_	
134-37	24911-24915	were	_	
134-38	24916-24919	not	_	
134-39	24920-24925	found	_	
134-40	24926-24928	to	_	
134-41	24929-24931	be	_	
134-42	24932-24945	significantly	_	
134-43	24946-24958	task-related	_	
134-44	24959-24960	(	_	
134-45	24960-24963	see	_	
134-46	24964-24971	Section	_	
134-47	24972-24975	3.6	_	
134-48	24976-24981	below	_	
134-49	24981-24982	)	_	
134-50	24982-24983	.	_	

#Text=Thus, we carried out eight separate dual regressions on the networks identified as significantly associated with IN and OUT conditions of the task.
135-1	24984-24988	Thus	_	
135-2	24988-24989	,	_	
135-3	24990-24992	we	_	
135-4	24993-25000	carried	_	
135-5	25001-25004	out	_	
135-6	25005-25010	eight	_	
135-7	25011-25019	separate	_	
135-8	25020-25024	dual	_	
135-9	25025-25036	regressions	_	
135-10	25037-25039	on	_	
135-11	25040-25043	the	_	
135-12	25044-25052	networks	_	
135-13	25053-25063	identified	_	
135-14	25064-25066	as	_	
135-15	25067-25080	significantly	_	
135-16	25081-25091	associated	_	
135-17	25092-25096	with	_	
135-18	25097-25099	IN	_	
135-19	25100-25103	and	_	
135-20	25104-25107	OUT	_	
135-21	25108-25118	conditions	_	
135-22	25119-25121	of	_	
135-23	25122-25125	the	_	
135-24	25126-25130	task	_	
135-25	25130-25131	.	_	

#Text=Each dual regression produced two spatial maps per subject (corresponding to the two runs, less the four exceptions who contributed one run of data).
136-1	25132-25136	Each	_	
136-2	25137-25141	dual	_	
136-3	25142-25152	regression	_	
136-4	25153-25161	produced	_	
136-5	25162-25165	two	_	
136-6	25166-25173	spatial	_	
136-7	25174-25178	maps	_	
136-8	25179-25182	per	_	
136-9	25183-25190	subject	_	
136-10	25191-25192	(	_	
136-11	25192-25205	corresponding	_	
136-12	25206-25208	to	_	
136-13	25209-25212	the	_	
136-14	25213-25216	two	_	
136-15	25217-25221	runs	_	
136-16	25221-25222	,	_	
136-17	25223-25227	less	_	
136-18	25228-25231	the	_	
136-19	25232-25236	four	_	
136-20	25237-25247	exceptions	_	
136-21	25248-25251	who	_	
136-22	25252-25263	contributed	_	
136-23	25264-25267	one	_	
136-24	25268-25271	run	_	
136-25	25272-25274	of	_	
136-26	25275-25279	data	_	
136-27	25279-25280	)	_	
136-28	25280-25281	.	_	

#Text=Each subject's Z-transformed maps were then averaged using the fslmaths to form a single 3D file for each component.
137-1	25282-25286	Each	_	
137-2	25287-25296	subject's	_	
137-3	25297-25310	Z-transformed	_	
137-4	25311-25315	maps	_	
137-5	25316-25320	were	_	
137-6	25321-25325	then	_	
137-7	25326-25334	averaged	_	
137-8	25335-25340	using	_	
137-9	25341-25344	the	_	
137-10	25345-25353	fslmaths	_	
137-11	25354-25356	to	_	
137-12	25357-25361	form	_	
137-13	25362-25363	a	_	
137-14	25364-25370	single	_	
137-15	25371-25373	3D	_	
137-16	25374-25378	file	_	
137-17	25379-25382	for	_	
137-18	25383-25387	each	_	
137-19	25388-25397	component	_	
137-20	25397-25398	.	_	

#Text=These averaged subject-specific spatial maps for a given component were then concatenated to form a 4D file, which served as the input for cross-subject statistics.
138-1	25399-25404	These	_	
138-2	25405-25413	averaged	_	
138-3	25414-25430	subject-specific	_	
138-4	25431-25438	spatial	_	
138-5	25439-25443	maps	_	
138-6	25444-25447	for	_	
138-7	25448-25449	a	_	
138-8	25450-25455	given	_	
138-9	25456-25465	component	_	
138-10	25466-25470	were	_	
138-11	25471-25475	then	_	
138-12	25476-25488	concatenated	_	
138-13	25489-25491	to	_	
138-14	25492-25496	form	_	
138-15	25497-25498	a	_	
138-16	25499-25501	4D	_	
138-17	25502-25506	file	_	
138-18	25506-25507	,	_	
138-19	25508-25513	which	_	
138-20	25514-25520	served	_	
138-21	25521-25523	as	_	
138-22	25524-25527	the	_	
138-23	25528-25533	input	_	
138-24	25534-25537	for	_	
138-25	25538-25551	cross-subject	_	
138-26	25552-25562	statistics	_	
138-27	25562-25563	.	_	

#Text=Identification of task-modulated networks
#Text=To identify task-modulated networks in ICA-analysis of task fMRI data, we regressed the run-specific activity time courses for each network against the run's respective task-design matrix using the fsl_glm utility.
139-1	25564-25578	Identification	_	
139-2	25579-25581	of	_	
139-3	25582-25596	task-modulated	_	
139-4	25597-25605	networks	_	
139-5	25606-25608	To	_	
139-6	25609-25617	identify	_	
139-7	25618-25632	task-modulated	_	
139-8	25633-25641	networks	_	
139-9	25642-25644	in	_	
139-10	25645-25657	ICA-analysis	_	
139-11	25658-25660	of	_	
139-12	25661-25665	task	_	
139-13	25666-25670	fMRI	_	
139-14	25671-25675	data	_	
139-15	25675-25676	,	_	
139-16	25677-25679	we	_	
139-17	25680-25689	regressed	_	
139-18	25690-25693	the	_	
139-19	25694-25706	run-specific	_	
139-20	25707-25715	activity	_	
139-21	25716-25720	time	_	
139-22	25721-25728	courses	_	
139-23	25729-25732	for	_	
139-24	25733-25737	each	_	
139-25	25738-25745	network	_	
139-26	25746-25753	against	_	
139-27	25754-25757	the	_	
139-28	25758-25763	run's	_	
139-29	25764-25774	respective	_	
139-30	25775-25786	task-design	_	
139-31	25787-25793	matrix	_	
139-32	25794-25799	using	_	
139-33	25800-25803	the	_	
139-34	25804-25811	fsl_glm	_	
139-35	25812-25819	utility	_	
139-36	25819-25820	.	_	

#Text=This approach essentially answers the question of whether a network is more active in one task condition, by allowing us to determine the fit between the network time-course and task design for each run.
140-1	25821-25825	This	_	
140-2	25826-25834	approach	_	
140-3	25835-25846	essentially	_	
140-4	25847-25854	answers	_	
140-5	25855-25858	the	_	
140-6	25859-25867	question	_	
140-7	25868-25870	of	_	
140-8	25871-25878	whether	_	
140-9	25879-25880	a	_	
140-10	25881-25888	network	_	
140-11	25889-25891	is	_	
140-12	25892-25896	more	_	
140-13	25897-25903	active	_	
140-14	25904-25906	in	_	
140-15	25907-25910	one	_	
140-16	25911-25915	task	_	
140-17	25916-25925	condition	_	
140-18	25925-25926	,	_	
140-19	25927-25929	by	_	
140-20	25930-25938	allowing	_	
140-21	25939-25941	us	_	
140-22	25942-25944	to	_	
140-23	25945-25954	determine	_	
140-24	25955-25958	the	_	
140-25	25959-25962	fit	_	
140-26	25963-25970	between	_	
140-27	25971-25974	the	_	
140-28	25975-25982	network	_	
140-29	25983-25994	time-course	_	
140-30	25995-25998	and	_	
140-31	25999-26003	task	_	
140-32	26004-26010	design	_	
140-33	26011-26014	for	_	
140-34	26015-26019	each	_	
140-35	26020-26023	run	_	
140-36	26023-26024	.	_	

#Text=After combining the beta estimates and variance from each regression using a fixed effects approach to obtain a single parameter estimate per subject and component, we could determine which components were relatively more active during IN blocks compared to OUT blocks and visa-versa using one-sample t-tests.
141-1	26025-26030	After	_	
141-2	26031-26040	combining	_	
141-3	26041-26044	the	_	
141-4	26045-26049	beta	_	
141-5	26050-26059	estimates	_	
141-6	26060-26063	and	_	
141-7	26064-26072	variance	_	
141-8	26073-26077	from	_	
141-9	26078-26082	each	_	
141-10	26083-26093	regression	_	
141-11	26094-26099	using	_	
141-12	26100-26101	a	_	
141-13	26102-26107	fixed	_	
141-14	26108-26115	effects	_	
141-15	26116-26124	approach	_	
141-16	26125-26127	to	_	
141-17	26128-26134	obtain	_	
141-18	26135-26136	a	_	
141-19	26137-26143	single	_	
141-20	26144-26153	parameter	_	
141-21	26154-26162	estimate	_	
141-22	26163-26166	per	_	
141-23	26167-26174	subject	_	
141-24	26175-26178	and	_	
141-25	26179-26188	component	_	
141-26	26188-26189	,	_	
141-27	26190-26192	we	_	
141-28	26193-26198	could	_	
141-29	26199-26208	determine	_	
141-30	26209-26214	which	_	
141-31	26215-26225	components	_	
141-32	26226-26230	were	_	
141-33	26231-26241	relatively	_	
141-34	26242-26246	more	_	
141-35	26247-26253	active	_	
141-36	26254-26260	during	_	
141-37	26261-26263	IN	_	
141-38	26264-26270	blocks	_	
141-39	26271-26279	compared	_	
141-40	26280-26282	to	_	
141-41	26283-26286	OUT	_	
141-42	26287-26293	blocks	_	
141-43	26294-26297	and	_	
141-44	26298-26308	visa-versa	_	
141-45	26309-26314	using	_	
141-46	26315-26325	one-sample	_	
141-47	26326-26333	t-tests	_	
141-48	26333-26334	.	_	

#Text=Since contrast estimates for the relative comparison of the two conditions (i.e.
142-1	26335-26340	Since	_	
142-2	26341-26349	contrast	_	
142-3	26350-26359	estimates	_	
142-4	26360-26363	for	_	
142-5	26364-26367	the	_	
142-6	26368-26376	relative	_	
142-7	26377-26387	comparison	_	
142-8	26388-26390	of	_	
142-9	26391-26394	the	_	
142-10	26395-26398	two	_	
142-11	26399-26409	conditions	_	
142-12	26410-26411	(	_	
142-13	26411-26414	i.e	_	
142-14	26414-26415	.	_	

#Text=OUT > IN, IN > OUT) differ only in sign, t-tests were set-up such that positive values indicated the degree to which the network was relatively more active during the IN condition, while negative values indicated the degree to which the network was relatively more active during the OUT condition.
143-1	26416-26419	OUT	_	
143-2	26420-26421	>	_	
143-3	26422-26424	IN	_	
143-4	26424-26425	,	_	
143-5	26426-26428	IN	_	
143-6	26429-26430	>	_	
143-7	26431-26434	OUT	_	
143-8	26434-26435	)	_	
143-9	26436-26442	differ	_	
143-10	26443-26447	only	_	
143-11	26448-26450	in	_	
143-12	26451-26455	sign	_	
143-13	26455-26456	,	_	
143-14	26457-26464	t-tests	_	
143-15	26465-26469	were	_	
143-16	26470-26476	set-up	_	
143-17	26477-26481	such	_	
143-18	26482-26486	that	_	
143-19	26487-26495	positive	_	
143-20	26496-26502	values	_	
143-21	26503-26512	indicated	_	
143-22	26513-26516	the	_	
143-23	26517-26523	degree	_	
143-24	26524-26526	to	_	
143-25	26527-26532	which	_	
143-26	26533-26536	the	_	
143-27	26537-26544	network	_	
143-28	26545-26548	was	_	
143-29	26549-26559	relatively	_	
143-30	26560-26564	more	_	
143-31	26565-26571	active	_	
143-32	26572-26578	during	_	
143-33	26579-26582	the	_	
143-34	26583-26585	IN	_	
143-35	26586-26595	condition	_	
143-36	26595-26596	,	_	
143-37	26597-26602	while	_	
143-38	26603-26611	negative	_	
143-39	26612-26618	values	_	
143-40	26619-26628	indicated	_	
143-41	26629-26632	the	_	
143-42	26633-26639	degree	_	
143-43	26640-26642	to	_	
143-44	26643-26648	which	_	
143-45	26649-26652	the	_	
143-46	26653-26660	network	_	
143-47	26661-26664	was	_	
143-48	26665-26675	relatively	_	
143-49	26676-26680	more	_	
143-50	26681-26687	active	_	
143-51	26688-26694	during	_	
143-52	26695-26698	the	_	
143-53	26699-26702	OUT	_	
143-54	26703-26712	condition	_	
143-55	26712-26713	.	_	

#Text=The p-values were further Bonferroni corrected, which limited the number of networks only to those that most strongly differentiated the two task conditions.
144-1	26714-26717	The	_	
144-2	26718-26726	p-values	_	
144-3	26727-26731	were	_	
144-4	26732-26739	further	_	
144-5	26740-26750	Bonferroni	_	
144-6	26751-26760	corrected	_	
144-7	26760-26761	,	_	
144-8	26762-26767	which	_	
144-9	26768-26775	limited	_	
144-10	26776-26779	the	_	
144-11	26780-26786	number	_	
144-12	26787-26789	of	_	
144-13	26790-26798	networks	_	
144-14	26799-26803	only	_	
144-15	26804-26806	to	_	
144-16	26807-26812	those	_	
144-17	26813-26817	that	_	
144-18	26818-26822	most	_	
144-19	26823-26831	strongly	_	
144-20	26832-26846	differentiated	_	
144-21	26847-26850	the	_	
144-22	26851-26854	two	_	
144-23	26855-26859	task	_	
144-24	26860-26870	conditions	_	
144-25	26870-26871	.	_	

#Text=Components which were significantly associated with the task were used to compare spatial differences in network functional connectivity across the PTSD and noPTSD groups.
145-1	26872-26882	Components	_	
145-2	26883-26888	which	_	
145-3	26889-26893	were	_	
145-4	26894-26907	significantly	_	
145-5	26908-26918	associated	_	
145-6	26919-26923	with	_	
145-7	26924-26927	the	_	
145-8	26928-26932	task	_	
145-9	26933-26937	were	_	
145-10	26938-26942	used	_	
145-11	26943-26945	to	_	
145-12	26946-26953	compare	_	
145-13	26954-26961	spatial	_	
145-14	26962-26973	differences	_	
145-15	26974-26976	in	_	
145-16	26977-26984	network	_	
145-17	26985-26995	functional	_	
145-18	26996-27008	connectivity	_	
145-19	27009-27015	across	_	
145-20	27016-27019	the	_	
145-21	27020-27024	PTSD	_	
145-22	27025-27028	and	_	
145-23	27029-27035	noPTSD	_	
145-24	27036-27042	groups	_	
145-25	27042-27043	.	_	

#Text=Functional connectivity of task-modulated networks
#Text=Group differences between noPTSD and PTSD were assessed for the networks that were determined to be significantly task-modulated, constrained to voxels within a binarized mask containing positive values.
146-1	27044-27054	Functional	_	
146-2	27055-27067	connectivity	_	
146-3	27068-27070	of	_	
146-4	27071-27085	task-modulated	_	
146-5	27086-27094	networks	_	
146-6	27095-27100	Group	_	
146-7	27101-27112	differences	_	
146-8	27113-27120	between	_	
146-9	27121-27127	noPTSD	_	
146-10	27128-27131	and	_	
146-11	27132-27136	PTSD	_	
146-12	27137-27141	were	_	
146-13	27142-27150	assessed	_	
146-14	27151-27154	for	_	
146-15	27155-27158	the	_	
146-16	27159-27167	networks	_	
146-17	27168-27172	that	_	
146-18	27173-27177	were	_	
146-19	27178-27188	determined	_	
146-20	27189-27191	to	_	
146-21	27192-27194	be	_	
146-22	27195-27208	significantly	_	
146-23	27209-27223	task-modulated	_	
146-24	27223-27224	,	_	
146-25	27225-27236	constrained	_	
146-26	27237-27239	to	_	
146-27	27240-27246	voxels	_	
146-28	27247-27253	within	_	
146-29	27254-27255	a	_	
146-30	27256-27265	binarized	_	
146-31	27266-27270	mask	_	
146-32	27271-27281	containing	_	
146-33	27282-27290	positive	_	
146-34	27291-27297	values	_	
146-35	27297-27298	.	_	

#Text=We used non-parametric Monte-Carlo based permutation testing with 10,000 permutations and alpha = 0.05.
147-1	27299-27301	We	_	
147-2	27302-27306	used	_	
147-3	27307-27321	non-parametric	_	
147-4	27322-27333	Monte-Carlo	_	
147-5	27334-27339	based	_	
147-6	27340-27351	permutation	_	
147-7	27352-27359	testing	_	
147-8	27360-27364	with	_	
147-9	27365-27371	10,000	_	
147-10	27372-27384	permutations	_	
147-11	27385-27388	and	_	
147-12	27389-27394	alpha	_	
147-13	27394-27395	 	_	
147-14	27395-27396	=	_	
147-15	27396-27397	 	_	
147-16	27397-27401	0.05	_	
147-17	27401-27402	.	_	

#Text=Clusters of activation were estimated using threshold-free cluster enhancement (TFCE) with a variance smoothing factor of 5 mm.
148-1	27403-27411	Clusters	_	
148-2	27412-27414	of	_	
148-3	27415-27425	activation	_	
148-4	27426-27430	were	_	
148-5	27431-27440	estimated	_	
148-6	27441-27446	using	_	
148-7	27447-27461	threshold-free	_	
148-8	27462-27469	cluster	_	
148-9	27470-27481	enhancement	_	
148-10	27482-27483	(	_	
148-11	27483-27487	TFCE	_	
148-12	27487-27488	)	_	
148-13	27489-27493	with	_	
148-14	27494-27495	a	_	
148-15	27496-27504	variance	_	
148-16	27505-27514	smoothing	_	
148-17	27515-27521	factor	_	
148-18	27522-27524	of	_	
148-19	27525-27526	5	_	
148-20	27526-27527	 	_	
148-21	27527-27529	mm	_	
148-22	27529-27530	.	_	

#Text=This procedure corrects for the family-wise error rate.
149-1	27531-27535	This	_	
149-2	27536-27545	procedure	_	
149-3	27546-27554	corrects	_	
149-4	27555-27558	for	_	
149-5	27559-27562	the	_	
149-6	27563-27574	family-wise	_	
149-7	27575-27580	error	_	
149-8	27581-27585	rate	_	
149-9	27585-27586	.	_	

#Text=Mean-centered age and ASI drug use severity scores were included as covariates of no-interest.
150-1	27587-27600	Mean-centered	_	
150-2	27601-27604	age	_	
150-3	27605-27608	and	_	
150-4	27609-27612	ASI	_	
150-5	27613-27617	drug	_	
150-6	27618-27621	use	_	
150-7	27622-27630	severity	_	
150-8	27631-27637	scores	_	
150-9	27638-27642	were	_	
150-10	27643-27651	included	_	
150-11	27652-27654	as	_	
150-12	27655-27665	covariates	_	
150-13	27666-27668	of	_	
150-14	27669-27680	no-interest	_	
150-15	27680-27681	.	_	

#Text=Statistical maps were rendered onto a standard MNI brain using MRIcroGL (http://www.mccauslandcenter.sc.edu/mricrogl/).
151-1	27682-27693	Statistical	_	
151-2	27694-27698	maps	_	
151-3	27699-27703	were	_	
151-4	27704-27712	rendered	_	
151-5	27713-27717	onto	_	
151-6	27718-27719	a	_	
151-7	27720-27728	standard	_	
151-8	27729-27732	MNI	_	
151-9	27733-27738	brain	_	
151-10	27739-27744	using	_	
151-11	27745-27753	MRIcroGL	_	
151-12	27754-27755	(	_	
151-13	27755-27759	http	_	
151-14	27759-27760	:	_	
151-15	27760-27761	/	_	
151-16	27761-27762	/	_	
151-17	27762-27789	www.mccauslandcenter.sc.edu	_	
151-18	27789-27790	/	_	
151-19	27790-27798	mricrogl	_	
151-20	27798-27799	/	_	
151-21	27799-27800	)	_	
151-22	27800-27801	.	_	

#Text=Probabilistic anatomical labels for cluster maxima were obtained from the Harvard-Oxford Cortical and Subcortical atlases, reported in standard MNI space.
152-1	27802-27815	Probabilistic	_	
152-2	27816-27826	anatomical	_	
152-3	27827-27833	labels	_	
152-4	27834-27837	for	_	
152-5	27838-27845	cluster	_	
152-6	27846-27852	maxima	_	
152-7	27853-27857	were	_	
152-8	27858-27866	obtained	_	
152-9	27867-27871	from	_	
152-10	27872-27875	the	_	
152-11	27876-27890	Harvard-Oxford	_	
152-12	27891-27899	Cortical	_	
152-13	27900-27903	and	_	
152-14	27904-27915	Subcortical	_	
152-15	27916-27923	atlases	_	
152-16	27923-27924	,	_	
152-17	27925-27933	reported	_	
152-18	27934-27936	in	_	
152-19	27937-27945	standard	_	
152-20	27946-27949	MNI	_	
152-21	27950-27955	space	_	
152-22	27955-27956	.	_	

#Text=Results
#Text=Demographic and clinical comparisons
#Text=Compared to those without a PTSD diagnosis, those with a PTSD diagnosis scored significantly higher on total PSS-I symptom severity (t(41) = 2.01, p = .025), and the subscales re-experiencing (t(41) = 2.0, p = .025) and avoidance severity (t(41) = 1.9, p = .032).
153-1	27957-27964	Results	_	
153-2	27965-27976	Demographic	_	
153-3	27977-27980	and	_	
153-4	27981-27989	clinical	_	
153-5	27990-28001	comparisons	_	
153-6	28002-28010	Compared	_	
153-7	28011-28013	to	_	
153-8	28014-28019	those	_	
153-9	28020-28027	without	_	
153-10	28028-28029	a	_	
153-11	28030-28034	PTSD	_	
153-12	28035-28044	diagnosis	_	
153-13	28044-28045	,	_	
153-14	28046-28051	those	_	
153-15	28052-28056	with	_	
153-16	28057-28058	a	_	
153-17	28059-28063	PTSD	_	
153-18	28064-28073	diagnosis	_	
153-19	28074-28080	scored	_	
153-20	28081-28094	significantly	_	
153-21	28095-28101	higher	_	
153-22	28102-28104	on	_	
153-23	28105-28110	total	_	
153-24	28111-28116	PSS-I	_	
153-25	28117-28124	symptom	_	
153-26	28125-28133	severity	_	
153-27	28134-28135	(	_	
153-28	28135-28136	t	_	
153-29	28136-28137	(	_	
153-30	28137-28139	41	_	
153-31	28139-28140	)	_	
153-32	28140-28141	 	_	
153-33	28141-28142	=	_	
153-34	28142-28143	 	_	
153-35	28143-28147	2.01	_	
153-36	28147-28148	,	_	
153-37	28149-28150	p	_	
153-38	28150-28151	 	_	
153-39	28151-28152	=	_	
153-40	28152-28153	 	_	
153-41	28153-28157	.025	_	
153-42	28157-28158	)	_	
153-43	28158-28159	,	_	
153-44	28160-28163	and	_	
153-45	28164-28167	the	_	
153-46	28168-28177	subscales	_	
153-47	28178-28193	re-experiencing	_	
153-48	28194-28195	(	_	
153-49	28195-28196	t	_	
153-50	28196-28197	(	_	
153-51	28197-28199	41	_	
153-52	28199-28200	)	_	
153-53	28200-28201	 	_	
153-54	28201-28202	=	_	
153-55	28202-28203	 	_	
153-56	28203-28206	2.0	_	
153-57	28206-28207	,	_	
153-58	28208-28209	p	_	
153-59	28209-28210	 	_	
153-60	28210-28211	=	_	
153-61	28211-28212	 	_	
153-62	28212-28216	.025	_	
153-63	28216-28217	)	_	
153-64	28218-28221	and	_	
153-65	28222-28231	avoidance	_	
153-66	28232-28240	severity	_	
153-67	28241-28242	(	_	
153-68	28242-28243	t	_	
153-69	28243-28244	(	_	
153-70	28244-28246	41	_	
153-71	28246-28247	)	_	
153-72	28247-28248	 	_	
153-73	28248-28249	=	_	
153-74	28249-28250	 	_	
153-75	28250-28253	1.9	_	
153-76	28253-28254	,	_	
153-77	28255-28256	p	_	
153-78	28256-28257	 	_	
153-79	28257-28258	=	_	
153-80	28258-28259	 	_	
153-81	28259-28263	.032	_	
153-82	28263-28264	)	_	
153-83	28264-28265	.	_	

#Text=However, compared to those with no PTSD diagnosis, those with a PTSD diagnosis did not exhibit higher scores on arousal symptoms (t(41) = 1.26, p = .108).
154-1	28266-28273	However	_	
154-2	28273-28274	,	_	
154-3	28275-28283	compared	_	
154-4	28284-28286	to	_	
154-5	28287-28292	those	_	
154-6	28293-28297	with	_	
154-7	28298-28300	no	_	
154-8	28301-28305	PTSD	_	
154-9	28306-28315	diagnosis	_	
154-10	28315-28316	,	_	
154-11	28317-28322	those	_	
154-12	28323-28327	with	_	
154-13	28328-28329	a	_	
154-14	28330-28334	PTSD	_	
154-15	28335-28344	diagnosis	_	
154-16	28345-28348	did	_	
154-17	28349-28352	not	_	
154-18	28353-28360	exhibit	_	
154-19	28361-28367	higher	_	
154-20	28368-28374	scores	_	
154-21	28375-28377	on	_	
154-22	28378-28385	arousal	_	
154-23	28386-28394	symptoms	_	
154-24	28395-28396	(	_	
154-25	28396-28397	t	_	
154-26	28397-28398	(	_	
154-27	28398-28400	41	_	
154-28	28400-28401	)	_	
154-29	28401-28402	 	_	
154-30	28402-28403	=	_	
154-31	28403-28404	 	_	
154-32	28404-28408	1.26	_	
154-33	28408-28409	,	_	
154-34	28410-28411	p	_	
154-35	28411-28412	 	_	
154-36	28412-28413	=	_	
154-37	28413-28414	 	_	
154-38	28414-28418	.108	_	
154-39	28418-28419	)	_	
154-40	28419-28420	.	_	

#Text=Apart from PTSD symptoms, the two groups did not differ on other clinical characteristics including current psychiatric medication use, other current co-occurring diagnoses, and ASI drug and alcohol use severity over the 30 days prior to intake.
155-1	28421-28426	Apart	_	
155-2	28427-28431	from	_	
155-3	28432-28436	PTSD	_	
155-4	28437-28445	symptoms	_	
155-5	28445-28446	,	_	
155-6	28447-28450	the	_	
155-7	28451-28454	two	_	
155-8	28455-28461	groups	_	
155-9	28462-28465	did	_	
155-10	28466-28469	not	_	
155-11	28470-28476	differ	_	
155-12	28477-28479	on	_	
155-13	28480-28485	other	_	
155-14	28486-28494	clinical	_	
155-15	28495-28510	characteristics	_	
155-16	28511-28520	including	_	
155-17	28521-28528	current	_	
155-18	28529-28540	psychiatric	_	
155-19	28541-28551	medication	_	
155-20	28552-28555	use	_	
155-21	28555-28556	,	_	
155-22	28557-28562	other	_	
155-23	28563-28570	current	_	
155-24	28571-28583	co-occurring	_	
155-25	28584-28593	diagnoses	_	
155-26	28593-28594	,	_	
155-27	28595-28598	and	_	
155-28	28599-28602	ASI	_	
155-29	28603-28607	drug	_	
155-30	28608-28611	and	_	
155-31	28612-28619	alcohol	_	
155-32	28620-28623	use	_	
155-33	28624-28632	severity	_	
155-34	28633-28637	over	_	
155-35	28638-28641	the	_	
155-36	28642-28644	30	_	
155-37	28644-28645	 	_	
155-38	28645-28649	days	_	
155-39	28650-28655	prior	_	
155-40	28656-28658	to	_	
155-41	28659-28665	intake	_	
155-42	28665-28666	.	_	

#Text=The PTSD group was slightly older on average (3.7 years), but the difference was not significant.
156-1	28667-28670	The	_	
156-2	28671-28675	PTSD	_	
156-3	28676-28681	group	_	
156-4	28682-28685	was	_	
156-5	28686-28694	slightly	_	
156-6	28695-28700	older	_	
156-7	28701-28703	on	_	
156-8	28704-28711	average	_	
156-9	28712-28713	(	_	
156-10	28713-28716	3.7	_	
156-11	28716-28717	 	_	
156-12	28717-28722	years	_	
156-13	28722-28723	)	_	
156-14	28723-28724	,	_	
156-15	28725-28728	but	_	
156-16	28729-28732	the	_	
156-17	28733-28743	difference	_	
156-18	28744-28747	was	_	
156-19	28748-28751	not	_	
156-20	28752-28763	significant	_	
156-21	28763-28764	.	_	

#Text=Groups also did not differ on educational achievement.
157-1	28765-28771	Groups	_	
157-2	28772-28776	also	_	
157-3	28777-28780	did	_	
157-4	28781-28784	not	_	
157-5	28785-28791	differ	_	
157-6	28792-28794	on	_	
157-7	28795-28806	educational	_	
157-8	28807-28818	achievement	_	
157-9	28818-28819	.	_	

#Text=Statistics for these comparisons are presented in Table 1.
158-1	28820-28830	Statistics	_	
158-2	28831-28834	for	_	
158-3	28835-28840	these	_	
158-4	28841-28852	comparisons	_	
158-5	28853-28856	are	_	
158-6	28857-28866	presented	_	
158-7	28867-28869	in	_	
158-8	28870-28875	Table	_	
158-9	28876-28877	1	_	
158-10	28877-28878	.	_	

#Text=Lifetime trauma exposure
#Text=Life stressors checklist revised (LSC-R)
#Text=Participants in the study experienced varying exposure to traumatic events during childhood and/or adulthood such as death or incarceration of close relatives, criminal justice and/or child welfare involvement, homelessness, and victimization through domestic violence, sexual/physical assaults, emotional abuse/neglect, and human trafficking.
159-1	28879-28887	Lifetime	_	
159-2	28888-28894	trauma	_	
159-3	28895-28903	exposure	_	
159-4	28904-28908	Life	_	
159-5	28909-28918	stressors	_	
159-6	28919-28928	checklist	_	
159-7	28929-28936	revised	_	
159-8	28937-28938	(	_	
159-9	28938-28943	LSC-R	_	
159-10	28943-28944	)	_	
159-11	28945-28957	Participants	_	
159-12	28958-28960	in	_	
159-13	28961-28964	the	_	
159-14	28965-28970	study	_	
159-15	28971-28982	experienced	_	
159-16	28983-28990	varying	_	
159-17	28991-28999	exposure	_	
159-18	29000-29002	to	_	
159-19	29003-29012	traumatic	_	
159-20	29013-29019	events	_	
159-21	29020-29026	during	_	
159-22	29027-29036	childhood	_	
159-23	29037-29040	and	_	
159-24	29040-29041	/	_	
159-25	29041-29043	or	_	
159-26	29044-29053	adulthood	_	
159-27	29054-29058	such	_	
159-28	29059-29061	as	_	
159-29	29062-29067	death	_	
159-30	29068-29070	or	_	
159-31	29071-29084	incarceration	_	
159-32	29085-29087	of	_	
159-33	29088-29093	close	_	
159-34	29094-29103	relatives	_	
159-35	29103-29104	,	_	
159-36	29105-29113	criminal	_	
159-37	29114-29121	justice	_	
159-38	29122-29125	and	_	
159-39	29125-29126	/	_	
159-40	29126-29128	or	_	
159-41	29129-29134	child	_	
159-42	29135-29142	welfare	_	
159-43	29143-29154	involvement	_	
159-44	29154-29155	,	_	
159-45	29156-29168	homelessness	_	
159-46	29168-29169	,	_	
159-47	29170-29173	and	_	
159-48	29174-29187	victimization	_	
159-49	29188-29195	through	_	
159-50	29196-29204	domestic	_	
159-51	29205-29213	violence	_	
159-52	29213-29214	,	_	
159-53	29215-29221	sexual	_	
159-54	29221-29222	/	_	
159-55	29222-29230	physical	_	
159-56	29231-29239	assaults	_	
159-57	29239-29240	,	_	
159-58	29241-29250	emotional	_	
159-59	29251-29256	abuse	_	
159-60	29256-29257	/	_	
159-61	29257-29264	neglect	_	
159-62	29264-29265	,	_	
159-63	29266-29269	and	_	
159-64	29270-29275	human	_	
159-65	29276-29287	trafficking	_	
159-66	29287-29288	.	_	

#Text=Across both groups, participants endorsed an average of 13.2 (SD: 5.5, range: 3–22) items from the LSC-R.
160-1	29289-29295	Across	_	
160-2	29296-29300	both	_	
160-3	29301-29307	groups	_	
160-4	29307-29308	,	_	
160-5	29309-29321	participants	_	
160-6	29322-29330	endorsed	_	
160-7	29331-29333	an	_	
160-8	29334-29341	average	_	
160-9	29342-29344	of	_	
160-10	29345-29349	13.2	_	
160-11	29350-29351	(	_	
160-12	29351-29353	SD	_	
160-13	29353-29354	:	_	
160-14	29355-29358	5.5	_	
160-15	29358-29359	,	_	
160-16	29360-29365	range	_	
160-17	29365-29366	:	_	
160-18	29367-29368	3	_	
160-19	29368-29369	–	_	
160-20	29369-29371	22	_	
160-21	29371-29372	)	_	
160-22	29373-29378	items	_	
160-23	29379-29383	from	_	
160-24	29384-29387	the	_	
160-25	29388-29393	LSC-R	_	
160-26	29393-29394	.	_	

#Text=The difference in total LSC-R between the groups was not significant (t(41) = 1.3, p = .19), indicating that within the sample, the number of stressors experienced was not strongly predictive of meeting PTSD criteria.
161-1	29395-29398	The	_	
161-2	29399-29409	difference	_	
161-3	29410-29412	in	_	
161-4	29413-29418	total	_	
161-5	29419-29424	LSC-R	_	
161-6	29425-29432	between	_	
161-7	29433-29436	the	_	
161-8	29437-29443	groups	_	
161-9	29444-29447	was	_	
161-10	29448-29451	not	_	
161-11	29452-29463	significant	_	
161-12	29464-29465	(	_	
161-13	29465-29466	t	_	
161-14	29466-29467	(	_	
161-15	29467-29469	41	_	
161-16	29469-29470	)	_	
161-17	29470-29471	 	_	
161-18	29471-29472	=	_	
161-19	29472-29473	 	_	
161-20	29473-29476	1.3	_	
161-21	29476-29477	,	_	
161-22	29478-29479	p	_	
161-23	29479-29480	 	_	
161-24	29480-29481	=	_	
161-25	29481-29482	 	_	
161-26	29482-29485	.19	_	
161-27	29485-29486	)	_	
161-28	29486-29487	,	_	
161-29	29488-29498	indicating	_	
161-30	29499-29503	that	_	
161-31	29504-29510	within	_	
161-32	29511-29514	the	_	
161-33	29515-29521	sample	_	
161-34	29521-29522	,	_	
161-35	29523-29526	the	_	
161-36	29527-29533	number	_	
161-37	29534-29536	of	_	
161-38	29537-29546	stressors	_	
161-39	29547-29558	experienced	_	
161-40	29559-29562	was	_	
161-41	29563-29566	not	_	
161-42	29567-29575	strongly	_	
161-43	29576-29586	predictive	_	
161-44	29587-29589	of	_	
161-45	29590-29597	meeting	_	
161-46	29598-29602	PTSD	_	
161-47	29603-29611	criteria	_	
161-48	29611-29612	.	_	

#Text=There was a positive correlation between age and the number of life stressors experienced (r(41) = 0.33, p = .03).
162-1	29613-29618	There	_	
162-2	29619-29622	was	_	
162-3	29623-29624	a	_	
162-4	29625-29633	positive	_	
162-5	29634-29645	correlation	_	
162-6	29646-29653	between	_	
162-7	29654-29657	age	_	
162-8	29658-29661	and	_	
162-9	29662-29665	the	_	
162-10	29666-29672	number	_	
162-11	29673-29675	of	_	
162-12	29676-29680	life	_	
162-13	29681-29690	stressors	_	
162-14	29691-29702	experienced	_	
162-15	29703-29704	(	_	
162-16	29704-29705	r	_	
162-17	29705-29706	(	_	
162-18	29706-29708	41	_	
162-19	29708-29709	)	_	
162-20	29709-29710	 	_	
162-21	29710-29711	=	_	
162-22	29711-29712	 	_	
162-23	29712-29716	0.33	_	
162-24	29716-29717	,	_	
162-25	29718-29719	p	_	
162-26	29719-29720	 	_	
162-27	29720-29721	=	_	
162-28	29721-29722	 	_	
162-29	29722-29725	.03	_	
162-30	29725-29726	)	_	
162-31	29726-29727	.	_	

#Text=The number of sexual trauma categories endorsed over the lifetime (yes/no: verbal sexual harassment, molestation, rape, and sex in exchange for goods or money qualified by the statement “when you did not want to”) accounted for 65.6% of the variance in total LSC-R item endorsement (r(41) = 0.81).
163-1	29728-29731	The	_	
163-2	29732-29738	number	_	
163-3	29739-29741	of	_	
163-4	29742-29748	sexual	_	
163-5	29749-29755	trauma	_	
163-6	29756-29766	categories	_	
163-7	29767-29775	endorsed	_	
163-8	29776-29780	over	_	
163-9	29781-29784	the	_	
163-10	29785-29793	lifetime	_	
163-11	29794-29795	(	_	
163-12	29795-29798	yes	_	
163-13	29798-29799	/	_	
163-14	29799-29801	no	_	
163-15	29801-29802	:	_	
163-16	29803-29809	verbal	_	
163-17	29810-29816	sexual	_	
163-18	29817-29827	harassment	_	
163-19	29827-29828	,	_	
163-20	29829-29840	molestation	_	
163-21	29840-29841	,	_	
163-22	29842-29846	rape	_	
163-23	29846-29847	,	_	
163-24	29848-29851	and	_	
163-25	29852-29855	sex	_	
163-26	29856-29858	in	_	
163-27	29859-29867	exchange	_	
163-28	29868-29871	for	_	
163-29	29872-29877	goods	_	
163-30	29878-29880	or	_	
163-31	29881-29886	money	_	
163-32	29887-29896	qualified	_	
163-33	29897-29899	by	_	
163-34	29900-29903	the	_	
163-35	29904-29913	statement	_	
163-36	29914-29915	“	_	
163-37	29915-29919	when	_	
163-38	29920-29923	you	_	
163-39	29924-29927	did	_	
163-40	29928-29931	not	_	
163-41	29932-29936	want	_	
163-42	29937-29939	to	_	
163-43	29939-29940	”	_	
163-44	29940-29941	)	_	
163-45	29942-29951	accounted	_	
163-46	29952-29955	for	_	
163-47	29956-29961	65.6%	_	
163-48	29962-29964	of	_	
163-49	29965-29968	the	_	
163-50	29969-29977	variance	_	
163-51	29978-29980	in	_	
163-52	29981-29986	total	_	
163-53	29987-29992	LSC-R	_	
163-54	29993-29997	item	_	
163-55	29998-30009	endorsement	_	
163-56	30010-30011	(	_	
163-57	30011-30012	r	_	
163-58	30012-30013	(	_	
163-59	30013-30015	41	_	
163-60	30015-30016	)	_	
163-61	30016-30017	 	_	
163-62	30017-30018	=	_	
163-63	30018-30019	 	_	
163-64	30019-30023	0.81	_	
163-65	30023-30024	)	_	
163-66	30024-30025	.	_	

#Text=The association between LSC-R total and Sexual Violence is comparable for both groups (PTSD: r(12) = 0.87; noPTSD: r(27) = 0.78).
164-1	30026-30029	The	_	
164-2	30030-30041	association	_	
164-3	30042-30049	between	_	
164-4	30050-30055	LSC-R	_	
164-5	30056-30061	total	_	
164-6	30062-30065	and	_	
164-7	30066-30072	Sexual	_	
164-8	30073-30081	Violence	_	
164-9	30082-30084	is	_	
164-10	30085-30095	comparable	_	
164-11	30096-30099	for	_	
164-12	30100-30104	both	_	
164-13	30105-30111	groups	_	
164-14	30112-30113	(	_	
164-15	30113-30117	PTSD	_	
164-16	30117-30118	:	_	
164-17	30119-30120	r	_	
164-18	30120-30121	(	_	
164-19	30121-30123	12	_	
164-20	30123-30124	)	_	
164-21	30124-30125	 	_	
164-22	30125-30126	=	_	
164-23	30126-30127	 	_	
164-24	30127-30131	0.87	_	
164-25	30131-30132	;	_	
164-26	30133-30139	noPTSD	_	
164-27	30139-30140	:	_	
164-28	30141-30142	r	_	
164-29	30142-30143	(	_	
164-30	30143-30145	27	_	
164-31	30145-30146	)	_	
164-32	30146-30147	 	_	
164-33	30147-30148	=	_	
164-34	30148-30149	 	_	
164-35	30149-30153	0.78	_	
164-36	30153-30154	)	_	
164-37	30154-30155	.	_	

#Text=Given that sexual abuse is particularly relevant to the development of psychiatric problems in women, including addiction, and has been linked to somatosensory gray matter and functional interoceptive deficits, lifetime exposure to Sexual Violence was carried forward as the variable of interest for post-hoc tests.
165-1	30156-30161	Given	_	
165-2	30162-30166	that	_	
165-3	30167-30173	sexual	_	
165-4	30174-30179	abuse	_	
165-5	30180-30182	is	_	
165-6	30183-30195	particularly	_	
165-7	30196-30204	relevant	_	
165-8	30205-30207	to	_	
165-9	30208-30211	the	_	
165-10	30212-30223	development	_	
165-11	30224-30226	of	_	
165-12	30227-30238	psychiatric	_	
165-13	30239-30247	problems	_	
165-14	30248-30250	in	_	
165-15	30251-30256	women	_	
165-16	30256-30257	,	_	
165-17	30258-30267	including	_	
165-18	30268-30277	addiction	_	
165-19	30277-30278	,	_	
165-20	30279-30282	and	_	
165-21	30283-30286	has	_	
165-22	30287-30291	been	_	
165-23	30292-30298	linked	_	
165-24	30299-30301	to	_	
165-25	30302-30315	somatosensory	_	
165-26	30316-30320	gray	_	
165-27	30321-30327	matter	_	
165-28	30328-30331	and	_	
165-29	30332-30342	functional	_	
165-30	30343-30356	interoceptive	_	
165-31	30357-30365	deficits	_	
165-32	30365-30366	,	_	
165-33	30367-30375	lifetime	_	
165-34	30376-30384	exposure	_	
165-35	30385-30387	to	_	
165-36	30388-30394	Sexual	_	
165-37	30395-30403	Violence	_	
165-38	30404-30407	was	_	
165-39	30408-30415	carried	_	
165-40	30416-30423	forward	_	
165-41	30424-30426	as	_	
165-42	30427-30430	the	_	
165-43	30431-30439	variable	_	
165-44	30440-30442	of	_	
165-45	30443-30451	interest	_	
165-46	30452-30455	for	_	
165-47	30456-30464	post-hoc	_	
165-48	30465-30470	tests	_	
165-49	30470-30471	.	_	

#Text=The two groups did not significantly differ in the number of endorsed Sexual Violence categories (t(41) = 1.5, p = .14).
166-1	30472-30475	The	_	
166-2	30476-30479	two	_	
166-3	30480-30486	groups	_	
166-4	30487-30490	did	_	
166-5	30491-30494	not	_	
166-6	30495-30508	significantly	_	
166-7	30509-30515	differ	_	
166-8	30516-30518	in	_	
166-9	30519-30522	the	_	
166-10	30523-30529	number	_	
166-11	30530-30532	of	_	
166-12	30533-30541	endorsed	_	
166-13	30542-30548	Sexual	_	
166-14	30549-30557	Violence	_	
166-15	30558-30568	categories	_	
166-16	30569-30570	(	_	
166-17	30570-30571	t	_	
166-18	30571-30572	(	_	
166-19	30572-30574	41	_	
166-20	30574-30575	)	_	
166-21	30575-30576	 	_	
166-22	30576-30577	=	_	
166-23	30577-30578	 	_	
166-24	30578-30581	1.5	_	
166-25	30581-30582	,	_	
166-26	30583-30584	p	_	
166-27	30584-30585	 	_	
166-28	30585-30586	=	_	
166-29	30586-30587	 	_	
166-30	30587-30590	.14	_	
166-31	30590-30591	)	_	
166-32	30591-30592	.	_	

#Text=Group independent components analysis and cross-correlation with a canonical resting state network template
#Text=The 20 ICs were spatially cross-correlated with Smith's 20 network solution (2009) to determine their correspondence with a set of canonical ICA templates and establish labels for the networks.
167-1	30593-30598	Group	_	
167-2	30599-30610	independent	_	
167-3	30611-30621	components	_	
167-4	30622-30630	analysis	_	
167-5	30631-30634	and	_	
167-6	30635-30652	cross-correlation	_	
167-7	30653-30657	with	_	
167-8	30658-30659	a	_	
167-9	30660-30669	canonical	_	
167-10	30670-30677	resting	_	
167-11	30678-30683	state	_	
167-12	30684-30691	network	_	
167-13	30692-30700	template	_	
167-14	30701-30704	The	_	
167-15	30705-30707	20	_	
167-16	30708-30711	ICs	_	
167-17	30712-30716	were	_	
167-18	30717-30726	spatially	_	
167-19	30727-30743	cross-correlated	_	
167-20	30744-30748	with	_	
167-21	30749-30756	Smith's	_	
167-22	30757-30759	20	_	
167-23	30760-30767	network	_	
167-24	30768-30776	solution	_	
167-25	30777-30778	(	_	
167-26	30778-30782	2009	_	
167-27	30782-30783	)	_	
167-28	30784-30786	to	_	
167-29	30787-30796	determine	_	
167-30	30797-30802	their	_	
167-31	30803-30817	correspondence	_	
167-32	30818-30822	with	_	
167-33	30823-30824	a	_	
167-34	30825-30828	set	_	
167-35	30829-30831	of	_	
167-36	30832-30841	canonical	_	
167-37	30842-30845	ICA	_	
167-38	30846-30855	templates	_	
167-39	30856-30859	and	_	
167-40	30860-30869	establish	_	
167-41	30870-30876	labels	_	
167-42	30877-30880	for	_	
167-43	30881-30884	the	_	
167-44	30885-30893	networks	_	
167-45	30893-30894	.	_	

#Text=Our ICA components demonstrated high correspondence to the templates: the primary (medial occipital; r = 0.80), secondary (occipital pole; r = 0.68) and tertiary (lateral occipital; r = 0.66) visual networks; the default mode (DMN; r = 0.50); a secondary DMN (DMN 2; r = 0.48); sensorimotor network (r = 0.66); bilateral auditory/insula network (r = 0.78); right-lateralized fronto-parietal network (r = 0.62); left-lateralized fronto-parietal network (r = 0.67); an executive/salience network (r = 0.48); an orbitofrontal network (OFC; r = 0.39); and a bilateral frontoparietal network (r = 0.59).
168-1	30895-30898	Our	_	
168-2	30899-30902	ICA	_	
168-3	30903-30913	components	_	
168-4	30914-30926	demonstrated	_	
168-5	30927-30931	high	_	
168-6	30932-30946	correspondence	_	
168-7	30947-30949	to	_	
168-8	30950-30953	the	_	
168-9	30954-30963	templates	_	
168-10	30963-30964	:	_	
168-11	30965-30968	the	_	
168-12	30969-30976	primary	_	
168-13	30977-30978	(	_	
168-14	30978-30984	medial	_	
168-15	30985-30994	occipital	_	
168-16	30994-30995	;	_	
168-17	30996-30997	r	_	
168-18	30997-30998	 	_	
168-19	30998-30999	=	_	
168-20	30999-31000	 	_	
168-21	31000-31004	0.80	_	
168-22	31004-31005	)	_	
168-23	31005-31006	,	_	
168-24	31007-31016	secondary	_	
168-25	31017-31018	(	_	
168-26	31018-31027	occipital	_	
168-27	31028-31032	pole	_	
168-28	31032-31033	;	_	
168-29	31034-31035	r	_	
168-30	31035-31036	 	_	
168-31	31036-31037	=	_	
168-32	31037-31038	 	_	
168-33	31038-31042	0.68	_	
168-34	31042-31043	)	_	
168-35	31044-31047	and	_	
168-36	31048-31056	tertiary	_	
168-37	31057-31058	(	_	
168-38	31058-31065	lateral	_	
168-39	31066-31075	occipital	_	
168-40	31075-31076	;	_	
168-41	31077-31078	r	_	
168-42	31078-31079	 	_	
168-43	31079-31080	=	_	
168-44	31080-31081	 	_	
168-45	31081-31085	0.66	_	
168-46	31085-31086	)	_	
168-47	31087-31093	visual	_	
168-48	31094-31102	networks	_	
168-49	31102-31103	;	_	
168-50	31104-31107	the	_	
168-51	31108-31115	default	_	
168-52	31116-31120	mode	_	
168-53	31121-31122	(	_	
168-54	31122-31125	DMN	_	
168-55	31125-31126	;	_	
168-56	31127-31128	r	_	
168-57	31128-31129	 	_	
168-58	31129-31130	=	_	
168-59	31130-31131	 	_	
168-60	31131-31135	0.50	_	
168-61	31135-31136	)	_	
168-62	31136-31137	;	_	
168-63	31138-31139	a	_	
168-64	31140-31149	secondary	_	
168-65	31150-31153	DMN	_	
168-66	31154-31155	(	_	
168-67	31155-31158	DMN	_	
168-68	31159-31160	2	_	
168-69	31160-31161	;	_	
168-70	31162-31163	r	_	
168-71	31163-31164	 	_	
168-72	31164-31165	=	_	
168-73	31165-31166	 	_	
168-74	31166-31170	0.48	_	
168-75	31170-31171	)	_	
168-76	31171-31172	;	_	
168-77	31173-31185	sensorimotor	_	
168-78	31186-31193	network	_	
168-79	31194-31195	(	_	
168-80	31195-31196	r	_	
168-81	31196-31197	 	_	
168-82	31197-31198	=	_	
168-83	31198-31199	 	_	
168-84	31199-31203	0.66	_	
168-85	31203-31204	)	_	
168-86	31204-31205	;	_	
168-87	31206-31215	bilateral	_	
168-88	31216-31224	auditory	_	
168-89	31224-31225	/	_	
168-90	31225-31231	insula	_	
168-91	31232-31239	network	_	
168-92	31240-31241	(	_	
168-93	31241-31242	r	_	
168-94	31242-31243	 	_	
168-95	31243-31244	=	_	
168-96	31244-31245	 	_	
168-97	31245-31249	0.78	_	
168-98	31249-31250	)	_	
168-99	31250-31251	;	_	
168-100	31252-31269	right-lateralized	_	
168-101	31270-31285	fronto-parietal	_	
168-102	31286-31293	network	_	
168-103	31294-31295	(	_	
168-104	31295-31296	r	_	
168-105	31296-31297	 	_	
168-106	31297-31298	=	_	
168-107	31298-31299	 	_	
168-108	31299-31303	0.62	_	
168-109	31303-31304	)	_	
168-110	31304-31305	;	_	
168-111	31306-31322	left-lateralized	_	
168-112	31323-31338	fronto-parietal	_	
168-113	31339-31346	network	_	
168-114	31347-31348	(	_	
168-115	31348-31349	r	_	
168-116	31349-31350	 	_	
168-117	31350-31351	=	_	
168-118	31351-31352	 	_	
168-119	31352-31356	0.67	_	
168-120	31356-31357	)	_	
168-121	31357-31358	;	_	
168-122	31359-31361	an	_	
168-123	31362-31371	executive	_	
168-124	31371-31372	/	_	
168-125	31372-31380	salience	_	
168-126	31381-31388	network	_	
168-127	31389-31390	(	_	
168-128	31390-31391	r	_	
168-129	31391-31392	 	_	
168-130	31392-31393	=	_	
168-131	31393-31394	 	_	
168-132	31394-31398	0.48	_	
168-133	31398-31399	)	_	
168-134	31399-31400	;	_	
168-135	31401-31403	an	_	
168-136	31404-31417	orbitofrontal	_	
168-137	31418-31425	network	_	
168-138	31426-31427	(	_	
168-139	31427-31430	OFC	_	
168-140	31430-31431	;	_	
168-141	31432-31433	r	_	
168-142	31433-31434	 	_	
168-143	31434-31435	=	_	
168-144	31435-31436	 	_	
168-145	31436-31440	0.39	_	
168-146	31440-31441	)	_	
168-147	31441-31442	;	_	
168-148	31443-31446	and	_	
168-149	31447-31448	a	_	
168-150	31449-31458	bilateral	_	
168-151	31459-31473	frontoparietal	_	
168-152	31474-31481	network	_	
168-153	31482-31483	(	_	
168-154	31483-31484	r	_	
168-155	31484-31485	 	_	
168-156	31485-31486	=	_	
168-157	31486-31487	 	_	
168-158	31487-31491	0.59	_	
168-159	31491-31492	)	_	
168-160	31492-31493	.	_	

#Text=There was an additional visual network in our solution that correlated with the secondary visual network (r = 0.46).
169-1	31494-31499	There	_	
169-2	31500-31503	was	_	
169-3	31504-31506	an	_	
169-4	31507-31517	additional	_	
169-5	31518-31524	visual	_	
169-6	31525-31532	network	_	
169-7	31533-31535	in	_	
169-8	31536-31539	our	_	
169-9	31540-31548	solution	_	
169-10	31549-31553	that	_	
169-11	31554-31564	correlated	_	
169-12	31565-31569	with	_	
169-13	31570-31573	the	_	
169-14	31574-31583	secondary	_	
169-15	31584-31590	visual	_	
169-16	31591-31598	network	_	
169-17	31599-31600	(	_	
169-18	31600-31601	r	_	
169-19	31601-31602	 	_	
169-20	31602-31603	=	_	
169-21	31603-31604	 	_	
169-22	31604-31608	0.46	_	
169-23	31608-31609	)	_	
169-24	31609-31610	.	_	

#Text=The orbitofrontal network was also correlated with the default mode network (r = 0.29).
170-1	31611-31614	The	_	
170-2	31615-31628	orbitofrontal	_	
170-3	31629-31636	network	_	
170-4	31637-31640	was	_	
170-5	31641-31645	also	_	
170-6	31646-31656	correlated	_	
170-7	31657-31661	with	_	
170-8	31662-31665	the	_	
170-9	31666-31673	default	_	
170-10	31674-31678	mode	_	
170-11	31679-31686	network	_	
170-12	31687-31688	(	_	
170-13	31688-31689	r	_	
170-14	31689-31690	 	_	
170-15	31690-31691	=	_	
170-16	31691-31692	 	_	
170-17	31692-31696	0.29	_	
170-18	31696-31697	)	_	
170-19	31697-31698	.	_	

#Text=We further identified a bilateral medial temporal network that did not have a clear correspondence to any brain networks in the Smith templates, with peak values located along the hippocampus and amygdala.
171-1	31699-31701	We	_	
171-2	31702-31709	further	_	
171-3	31710-31720	identified	_	
171-4	31721-31722	a	_	
171-5	31723-31732	bilateral	_	
171-6	31733-31739	medial	_	
171-7	31740-31748	temporal	_	
171-8	31749-31756	network	_	
171-9	31757-31761	that	_	
171-10	31762-31765	did	_	
171-11	31766-31769	not	_	
171-12	31770-31774	have	_	
171-13	31775-31776	a	_	
171-14	31777-31782	clear	_	
171-15	31783-31797	correspondence	_	
171-16	31798-31800	to	_	
171-17	31801-31804	any	_	
171-18	31805-31810	brain	_	
171-19	31811-31819	networks	_	
171-20	31820-31822	in	_	
171-21	31823-31826	the	_	
171-22	31827-31832	Smith	_	
171-23	31833-31842	templates	_	
171-24	31842-31843	,	_	
171-25	31844-31848	with	_	
171-26	31849-31853	peak	_	
171-27	31854-31860	values	_	
171-28	31861-31868	located	_	
171-29	31869-31874	along	_	
171-30	31875-31878	the	_	
171-31	31879-31890	hippocampus	_	
171-32	31891-31894	and	_	
171-33	31895-31903	amygdala	_	
171-34	31903-31904	.	_	

#Text=The remaining six networks were determined to be artifactual, containing noise relating white matter, ventricles, and head motion.
172-1	31905-31908	The	_	
172-2	31909-31918	remaining	_	
172-3	31919-31922	six	_	
172-4	31923-31931	networks	_	
172-5	31932-31936	were	_	
172-6	31937-31947	determined	_	
172-7	31948-31950	to	_	
172-8	31951-31953	be	_	
172-9	31954-31965	artifactual	_	
172-10	31965-31966	,	_	
172-11	31967-31977	containing	_	
172-12	31978-31983	noise	_	
172-13	31984-31992	relating	_	
172-14	31993-31998	white	_	
172-15	31999-32005	matter	_	
172-16	32005-32006	,	_	
172-17	32007-32017	ventricles	_	
172-18	32017-32018	,	_	
172-19	32019-32022	and	_	
172-20	32023-32027	head	_	
172-21	32028-32034	motion	_	
172-22	32034-32035	.	_	

#Text=Identification of task-modulated intrinsic networks
#Text=Group-level ICA networks that were significantly task-modulated.
173-1	32036-32050	Identification	_	
173-2	32051-32053	of	_	
173-3	32054-32068	task-modulated	_	
173-4	32069-32078	intrinsic	_	
173-5	32079-32087	networks	_	
173-6	32088-32099	Group-level	_	
173-7	32100-32103	ICA	_	
173-8	32104-32112	networks	_	
173-9	32113-32117	that	_	
173-10	32118-32122	were	_	
173-11	32123-32136	significantly	_	
173-12	32137-32151	task-modulated	_	
173-13	32151-32152	.	_	

#Text=Bar plots describe the beta weights for the fit between the subject level design matrix and their respective network time course.
174-1	32153-32156	Bar	_	
174-2	32157-32162	plots	_	
174-3	32163-32171	describe	_	
174-4	32172-32175	the	_	
174-5	32176-32180	beta	_	
174-6	32181-32188	weights	_	
174-7	32189-32192	for	_	
174-8	32193-32196	the	_	
174-9	32197-32200	fit	_	
174-10	32201-32208	between	_	
174-11	32209-32212	the	_	
174-12	32213-32220	subject	_	
174-13	32221-32226	level	_	
174-14	32227-32233	design	_	
174-15	32234-32240	matrix	_	
174-16	32241-32244	and	_	
174-17	32245-32250	their	_	
174-18	32251-32261	respective	_	
174-19	32262-32269	network	_	
174-20	32270-32274	time	_	
174-21	32275-32281	course	_	
174-22	32281-32282	.	_	

#Text=Negative values indicate the degree to which the network is more active during exteroceptive attention relative to interoceptive attention (OUT – IN), while positive values indicate the degree to which the network is more active during the interoceptive (IN) condition relative to the OUT condition (IN – OUT).
175-1	32283-32291	Negative	_	
175-2	32292-32298	values	_	
175-3	32299-32307	indicate	_	
175-4	32308-32311	the	_	
175-5	32312-32318	degree	_	
175-6	32319-32321	to	_	
175-7	32322-32327	which	_	
175-8	32328-32331	the	_	
175-9	32332-32339	network	_	
175-10	32340-32342	is	_	
175-11	32343-32347	more	_	
175-12	32348-32354	active	_	
175-13	32355-32361	during	_	
175-14	32362-32375	exteroceptive	_	
175-15	32376-32385	attention	_	
175-16	32386-32394	relative	_	
175-17	32395-32397	to	_	
175-18	32398-32411	interoceptive	_	
175-19	32412-32421	attention	_	
175-20	32422-32423	(	_	
175-21	32423-32426	OUT	_	
175-22	32427-32428	–	_	
175-23	32429-32431	IN	_	
175-24	32431-32432	)	_	
175-25	32432-32433	,	_	
175-26	32434-32439	while	_	
175-27	32440-32448	positive	_	
175-28	32449-32455	values	_	
175-29	32456-32464	indicate	_	
175-30	32465-32468	the	_	
175-31	32469-32475	degree	_	
175-32	32476-32478	to	_	
175-33	32479-32484	which	_	
175-34	32485-32488	the	_	
175-35	32489-32496	network	_	
175-36	32497-32499	is	_	
175-37	32500-32504	more	_	
175-38	32505-32511	active	_	
175-39	32512-32518	during	_	
175-40	32519-32522	the	_	
175-41	32523-32536	interoceptive	_	
175-42	32537-32538	(	_	
175-43	32538-32540	IN	_	
175-44	32540-32541	)	_	
175-45	32542-32551	condition	_	
175-46	32552-32560	relative	_	
175-47	32561-32563	to	_	
175-48	32564-32567	the	_	
175-49	32568-32571	OUT	_	
175-50	32572-32581	condition	_	
175-51	32582-32583	(	_	
175-52	32583-32585	IN	_	
175-53	32586-32587	–	_	
175-54	32588-32591	OUT	_	
175-55	32591-32592	)	_	
175-56	32592-32593	.	_	

#Text=DMN 1 = Default Mode network, DMN 2 = secondary Default mode network, ECN = Executive network, MTN = Medial temporal network, OFC = Orbitofrontal network, V1 = Medial occipital network, V3 = Lateral occipital network, V2 = Occipital pole network.
176-1	32594-32597	DMN	_	
176-2	32598-32599	1	_	
176-3	32599-32600	 	_	
176-4	32600-32601	=	_	
176-5	32601-32602	 	_	
176-6	32602-32609	Default	_	
176-7	32610-32614	Mode	_	
176-8	32615-32622	network	_	
176-9	32622-32623	,	_	
176-10	32624-32627	DMN	_	
176-11	32628-32629	2	_	
176-12	32629-32630	 	_	
176-13	32630-32631	=	_	
176-14	32631-32632	 	_	
176-15	32632-32641	secondary	_	
176-16	32642-32649	Default	_	
176-17	32650-32654	mode	_	
176-18	32655-32662	network	_	
176-19	32662-32663	,	_	
176-20	32664-32667	ECN	_	
176-21	32667-32668	 	_	
176-22	32668-32669	=	_	
176-23	32669-32670	 	_	
176-24	32670-32679	Executive	_	
176-25	32680-32687	network	_	
176-26	32687-32688	,	_	
176-27	32689-32692	MTN	_	
176-28	32692-32693	 	_	
176-29	32693-32694	=	_	
176-30	32694-32695	 	_	
176-31	32695-32701	Medial	_	
176-32	32702-32710	temporal	_	
176-33	32711-32718	network	_	
176-34	32718-32719	,	_	
176-35	32720-32723	OFC	_	
176-36	32723-32724	 	_	
176-37	32724-32725	=	_	
176-38	32725-32726	 	_	
176-39	32726-32739	Orbitofrontal	_	
176-40	32740-32747	network	_	
176-41	32747-32748	,	_	
176-42	32749-32751	V1	_	
176-43	32751-32752	 	_	
176-44	32752-32753	=	_	
176-45	32753-32754	 	_	
176-46	32754-32760	Medial	_	
176-47	32761-32770	occipital	_	
176-48	32771-32778	network	_	
176-49	32778-32779	,	_	
176-50	32780-32782	V3	_	
176-51	32782-32783	 	_	
176-52	32783-32784	=	_	
176-53	32784-32785	 	_	
176-54	32785-32792	Lateral	_	
176-55	32793-32802	occipital	_	
176-56	32803-32810	network	_	
176-57	32810-32811	,	_	
176-58	32812-32814	V2	_	
176-59	32814-32815	 	_	
176-60	32815-32816	=	_	
176-61	32816-32817	 	_	
176-62	32817-32826	Occipital	_	
176-63	32827-32831	pole	_	
176-64	32832-32839	network	_	
176-65	32839-32840	.	_	

#Text=Fig. 1
#Text=Of the 14 intrinsic brain networks labeled via template matching, eight satisfied the criterion for task relevance.
177-1	32841-32844	Fig	_	
177-2	32844-32845	.	_	
177-3	32846-32847	1	_	
177-4	32848-32850	Of	_	
177-5	32851-32854	the	_	
177-6	32855-32857	14	_	
177-7	32858-32867	intrinsic	_	
177-8	32868-32873	brain	_	
177-9	32874-32882	networks	_	
177-10	32883-32890	labeled	_	
177-11	32891-32894	via	_	
177-12	32895-32903	template	_	
177-13	32904-32912	matching	_	
177-14	32912-32913	,	_	
177-15	32914-32919	eight	_	
177-16	32920-32929	satisfied	_	
177-17	32930-32933	the	_	
177-18	32934-32943	criterion	_	
177-19	32944-32947	for	_	
177-20	32948-32952	task	_	
177-21	32953-32962	relevance	_	
177-22	32962-32963	.	_	

#Text=Specifically, these networks were significantly differentiated for IN relative to OUT blocks.
178-1	32964-32976	Specifically	_	
178-2	32976-32977	,	_	
178-3	32978-32983	these	_	
178-4	32984-32992	networks	_	
178-5	32993-32997	were	_	
178-6	32998-33011	significantly	_	
178-7	33012-33026	differentiated	_	
178-8	33027-33030	for	_	
178-9	33031-33033	IN	_	
178-10	33034-33042	relative	_	
178-11	33043-33045	to	_	
178-12	33046-33049	OUT	_	
178-13	33050-33056	blocks	_	
178-14	33056-33057	.	_	

#Text=Networks with significantly greater activation during IN relative to OUT blocks included: medial temporal (t(42) = 7.44, p < .00001), DMN (t(42) = 8.5, p < .00001), DMN 2 (t(42) = 4.1, p = .0002), OFC (t(42) = 3.75, p = .00054), and medial occipital (t(42) = 5.4, p < .00001).
179-1	33058-33066	Networks	_	
179-2	33067-33071	with	_	
179-3	33072-33085	significantly	_	
179-4	33086-33093	greater	_	
179-5	33094-33104	activation	_	
179-6	33105-33111	during	_	
179-7	33112-33114	IN	_	
179-8	33115-33123	relative	_	
179-9	33124-33126	to	_	
179-10	33127-33130	OUT	_	
179-11	33131-33137	blocks	_	
179-12	33138-33146	included	_	
179-13	33146-33147	:	_	
179-14	33148-33154	medial	_	
179-15	33155-33163	temporal	_	
179-16	33164-33165	(	_	
179-17	33165-33166	t	_	
179-18	33166-33167	(	_	
179-19	33167-33169	42	_	
179-20	33169-33170	)	_	
179-21	33170-33171	 	_	
179-22	33171-33172	=	_	
179-23	33172-33173	 	_	
179-24	33173-33177	7.44	_	
179-25	33177-33178	,	_	
179-26	33179-33180	p	_	
179-27	33180-33181	 	_	
179-28	33181-33182	<	_	
179-29	33182-33183	 	_	
179-30	33183-33189	.00001	_	
179-31	33189-33190	)	_	
179-32	33190-33191	,	_	
179-33	33192-33195	DMN	_	
179-34	33196-33197	(	_	
179-35	33197-33198	t	_	
179-36	33198-33199	(	_	
179-37	33199-33201	42	_	
179-38	33201-33202	)	_	
179-39	33202-33203	 	_	
179-40	33203-33204	=	_	
179-41	33204-33205	 	_	
179-42	33205-33208	8.5	_	
179-43	33208-33209	,	_	
179-44	33210-33211	p	_	
179-45	33211-33212	 	_	
179-46	33212-33213	<	_	
179-47	33213-33214	 	_	
179-48	33214-33220	.00001	_	
179-49	33220-33221	)	_	
179-50	33221-33222	,	_	
179-51	33223-33226	DMN	_	
179-52	33227-33228	2	_	
179-53	33229-33230	(	_	
179-54	33230-33231	t	_	
179-55	33231-33232	(	_	
179-56	33232-33234	42	_	
179-57	33234-33235	)	_	
179-58	33235-33236	 	_	
179-59	33236-33237	=	_	
179-60	33237-33238	 	_	
179-61	33238-33241	4.1	_	
179-62	33241-33242	,	_	
179-63	33243-33244	p	_	
179-64	33244-33245	 	_	
179-65	33245-33246	=	_	
179-66	33246-33247	 	_	
179-67	33247-33252	.0002	_	
179-68	33252-33253	)	_	
179-69	33253-33254	,	_	
179-70	33255-33258	OFC	_	
179-71	33259-33260	(	_	
179-72	33260-33261	t	_	
179-73	33261-33262	(	_	
179-74	33262-33264	42	_	
179-75	33264-33265	)	_	
179-76	33265-33266	 	_	
179-77	33266-33267	=	_	
179-78	33267-33268	 	_	
179-79	33268-33272	3.75	_	
179-80	33272-33273	,	_	
179-81	33274-33275	p	_	
179-82	33275-33276	 	_	
179-83	33276-33277	=	_	
179-84	33277-33278	 	_	
179-85	33278-33284	.00054	_	
179-86	33284-33285	)	_	
179-87	33285-33286	,	_	
179-88	33287-33290	and	_	
179-89	33291-33297	medial	_	
179-90	33298-33307	occipital	_	
179-91	33308-33309	(	_	
179-92	33309-33310	t	_	
179-93	33310-33311	(	_	
179-94	33311-33313	42	_	
179-95	33313-33314	)	_	
179-96	33314-33315	 	_	
179-97	33315-33316	=	_	
179-98	33316-33317	 	_	
179-99	33317-33320	5.4	_	
179-100	33320-33321	,	_	
179-101	33322-33323	p	_	
179-102	33323-33324	 	_	
179-103	33324-33325	<	_	
179-104	33325-33326	 	_	
179-105	33326-33332	.00001	_	
179-106	33332-33333	)	_	
179-107	33333-33334	.	_	

#Text=Networks with significantly greater activation during the OUT relative to IN blocks included: executive (t(42) = −13.5, p < .00001), occipital pole (t(42) = −5.7, p < .00001), and lateral occipital (t(42) = −6.0, p < .00001.
180-1	33335-33343	Networks	_	
180-2	33344-33348	with	_	
180-3	33349-33362	significantly	_	
180-4	33363-33370	greater	_	
180-5	33371-33381	activation	_	
180-6	33382-33388	during	_	
180-7	33389-33392	the	_	
180-8	33393-33396	OUT	_	
180-9	33397-33405	relative	_	
180-10	33406-33408	to	_	
180-11	33409-33411	IN	_	
180-12	33412-33418	blocks	_	
180-13	33419-33427	included	_	
180-14	33427-33428	:	_	
180-15	33429-33438	executive	_	
180-16	33439-33440	(	_	
180-17	33440-33441	t	_	
180-18	33441-33442	(	_	
180-19	33442-33444	42	_	
180-20	33444-33445	)	_	
180-21	33445-33446	 	_	
180-22	33446-33447	=	_	
180-23	33447-33448	 	_	
180-24	33448-33449	−	_	
180-25	33449-33453	13.5	_	
180-26	33453-33454	,	_	
180-27	33455-33456	p	_	
180-28	33456-33457	 	_	
180-29	33457-33458	<	_	
180-30	33458-33459	 	_	
180-31	33459-33465	.00001	_	
180-32	33465-33466	)	_	
180-33	33466-33467	,	_	
180-34	33468-33477	occipital	_	
180-35	33478-33482	pole	_	
180-36	33483-33484	(	_	
180-37	33484-33485	t	_	
180-38	33485-33486	(	_	
180-39	33486-33488	42	_	
180-40	33488-33489	)	_	
180-41	33489-33490	 	_	
180-42	33490-33491	=	_	
180-43	33491-33492	 	_	
180-44	33492-33493	−	_	
180-45	33493-33496	5.7	_	
180-46	33496-33497	,	_	
180-47	33498-33499	p	_	
180-48	33499-33500	 	_	
180-49	33500-33501	<	_	
180-50	33501-33502	 	_	
180-51	33502-33508	.00001	_	
180-52	33508-33509	)	_	
180-53	33509-33510	,	_	
180-54	33511-33514	and	_	
180-55	33515-33522	lateral	_	
180-56	33523-33532	occipital	_	
180-57	33533-33534	(	_	
180-58	33534-33535	t	_	
180-59	33535-33536	(	_	
180-60	33536-33538	42	_	
180-61	33538-33539	)	_	
180-62	33539-33540	 	_	
180-63	33540-33541	=	_	
180-64	33541-33542	 	_	
180-65	33542-33543	−	_	
180-66	33543-33546	6.0	_	
180-67	33546-33547	,	_	
180-68	33548-33549	p	_	
180-69	33549-33550	 	_	
180-70	33550-33551	<	_	
180-71	33551-33552	 	_	
180-72	33552-33558	.00001	_	
180-73	33558-33559	.	_	

#Text=Accordingly, spatial differences in network functional connectivity for PTSD and noPTSD groups were tested on these eight networks.
181-1	33560-33571	Accordingly	_	
181-2	33571-33572	,	_	
181-3	33573-33580	spatial	_	
181-4	33581-33592	differences	_	
181-5	33593-33595	in	_	
181-6	33596-33603	network	_	
181-7	33604-33614	functional	_	
181-8	33615-33627	connectivity	_	
181-9	33628-33631	for	_	
181-10	33632-33636	PTSD	_	
181-11	33637-33640	and	_	
181-12	33641-33647	noPTSD	_	
181-13	33648-33654	groups	_	
181-14	33655-33659	were	_	
181-15	33660-33666	tested	_	
181-16	33667-33669	on	_	
181-17	33670-33675	these	_	
181-18	33676-33681	eight	_	
181-19	33682-33690	networks	_	
181-20	33690-33691	.	_	

#Text=See Fig. 1.
182-1	33692-33695	See	_	
182-2	33696-33699	Fig	_	
182-3	33699-33700	.	_	
182-4	33701-33702	1	_	
182-5	33702-33703	.	_	

#Text=Spatial differences in network functional connectivity for PTSD versus noPTSD
#Text=To infer group differences in functional connectivity for the eight task-modulated networks, we conducted non-parametric voxel-wise regressions using randomise in FSL.
183-1	33704-33711	Spatial	_	
183-2	33712-33723	differences	_	
183-3	33724-33726	in	_	
183-4	33727-33734	network	_	
183-5	33735-33745	functional	_	
183-6	33746-33758	connectivity	_	
183-7	33759-33762	for	_	
183-8	33763-33767	PTSD	_	
183-9	33768-33774	versus	_	
183-10	33775-33781	noPTSD	_	
183-11	33782-33784	To	_	
183-12	33785-33790	infer	_	
183-13	33791-33796	group	_	
183-14	33797-33808	differences	_	
183-15	33809-33811	in	_	
183-16	33812-33822	functional	_	
183-17	33823-33835	connectivity	_	
183-18	33836-33839	for	_	
183-19	33840-33843	the	_	
183-20	33844-33849	eight	_	
183-21	33850-33864	task-modulated	_	
183-22	33865-33873	networks	_	
183-23	33873-33874	,	_	
183-24	33875-33877	we	_	
183-25	33878-33887	conducted	_	
183-26	33888-33902	non-parametric	_	
183-27	33903-33913	voxel-wise	_	
183-28	33914-33925	regressions	_	
183-29	33926-33931	using	_	
183-30	33932-33941	randomise	_	
183-31	33942-33944	in	_	
183-32	33945-33948	FSL	_	
183-33	33948-33949	.	_	

#Text=These tests included the one-tailed contrasts noPTSD > PTSD and PTSD > noPTSD for each network, controlling for recent drug use and age (demeaned across both groups) as covariates of no-interest.
184-1	33950-33955	These	_	
184-2	33956-33961	tests	_	
184-3	33962-33970	included	_	
184-4	33971-33974	the	_	
184-5	33975-33985	one-tailed	_	
184-6	33986-33995	contrasts	_	
184-7	33996-34002	noPTSD	_	
184-8	34003-34004	>	_	
184-9	34005-34009	PTSD	_	
184-10	34010-34013	and	_	
184-11	34014-34018	PTSD	_	
184-12	34019-34020	>	_	
184-13	34021-34027	noPTSD	_	
184-14	34028-34031	for	_	
184-15	34032-34036	each	_	
184-16	34037-34044	network	_	
184-17	34044-34045	,	_	
184-18	34046-34057	controlling	_	
184-19	34058-34061	for	_	
184-20	34062-34068	recent	_	
184-21	34069-34073	drug	_	
184-22	34074-34077	use	_	
184-23	34078-34081	and	_	
184-24	34082-34085	age	_	
184-25	34086-34087	(	_	
184-26	34087-34095	demeaned	_	
184-27	34096-34102	across	_	
184-28	34103-34107	both	_	
184-29	34108-34114	groups	_	
184-30	34114-34115	)	_	
184-31	34116-34118	as	_	
184-32	34119-34129	covariates	_	
184-33	34130-34132	of	_	
184-34	34133-34144	no-interest	_	
184-35	34144-34145	.	_	

#Text=Given that there were two contrasts performed on each network, a total of 16 tests were carried out.
185-1	34146-34151	Given	_	
185-2	34152-34156	that	_	
185-3	34157-34162	there	_	
185-4	34163-34167	were	_	
185-5	34168-34171	two	_	
185-6	34172-34181	contrasts	_	
185-7	34182-34191	performed	_	
185-8	34192-34194	on	_	
185-9	34195-34199	each	_	
185-10	34200-34207	network	_	
185-11	34207-34208	,	_	
185-12	34209-34210	a	_	
185-13	34211-34216	total	_	
185-14	34217-34219	of	_	
185-15	34220-34222	16	_	
185-16	34223-34228	tests	_	
185-17	34229-34233	were	_	
185-18	34234-34241	carried	_	
185-19	34242-34245	out	_	
185-20	34245-34246	.	_	

#Text=Accordingly, the TFCE-corrected p-values for cluster significance were further Bonferroni-corrected, with the alpha criterion for significance adjusted to 0.05/16 = 0.003125.
186-1	34247-34258	Accordingly	_	
186-2	34258-34259	,	_	
186-3	34260-34263	the	_	
186-4	34264-34278	TFCE-corrected	_	
186-5	34279-34287	p-values	_	
186-6	34288-34291	for	_	
186-7	34292-34299	cluster	_	
186-8	34300-34312	significance	_	
186-9	34313-34317	were	_	
186-10	34318-34325	further	_	
186-11	34326-34346	Bonferroni-corrected	_	
186-12	34346-34347	,	_	
186-13	34348-34352	with	_	
186-14	34353-34356	the	_	
186-15	34357-34362	alpha	_	
186-16	34363-34372	criterion	_	
186-17	34373-34376	for	_	
186-18	34377-34389	significance	_	
186-19	34390-34398	adjusted	_	
186-20	34399-34401	to	_	
186-21	34402-34406	0.05	_	
186-22	34406-34407	/	_	
186-23	34407-34409	16	_	
186-24	34409-34410	 	_	
186-25	34410-34411	=	_	
186-26	34411-34412	 	_	
186-27	34412-34420	0.003125	_	
186-28	34420-34421	.	_	

#Text=(A) Group-level OFC network from the MELODIC analysis.
187-1	34422-34423	(	_	
187-2	34423-34424	A	_	
187-3	34424-34425	)	_	
187-4	34426-34437	Group-level	_	
187-5	34438-34441	OFC	_	
187-6	34442-34449	network	_	
187-7	34450-34454	from	_	
187-8	34455-34458	the	_	
187-9	34459-34466	MELODIC	_	
187-10	34467-34475	analysis	_	
187-11	34475-34476	.	_	

#Text=(B) Group differences in functional integration of the OFC network.
188-1	34477-34478	(	_	
188-2	34478-34479	B	_	
188-3	34479-34480	)	_	
188-4	34481-34486	Group	_	
188-5	34487-34498	differences	_	
188-6	34499-34501	in	_	
188-7	34502-34512	functional	_	
188-8	34513-34524	integration	_	
188-9	34525-34527	of	_	
188-10	34528-34531	the	_	
188-11	34532-34535	OFC	_	
188-12	34536-34543	network	_	
188-13	34543-34544	.	_	

#Text=The group with PTSD exhibited reduced OFC network functional connectivity in multiple brain regions, including the bilateral mid-posterior insula, somatosensory cortex, precuneus, left middle and inferior frontal gryus, lateral occipital cortex/angular gyrus.
189-1	34545-34548	The	_	
189-2	34549-34554	group	_	
189-3	34555-34559	with	_	
189-4	34560-34564	PTSD	_	
189-5	34565-34574	exhibited	_	
189-6	34575-34582	reduced	_	
189-7	34583-34586	OFC	_	
189-8	34587-34594	network	_	
189-9	34595-34605	functional	_	
189-10	34606-34618	connectivity	_	
189-11	34619-34621	in	_	
189-12	34622-34630	multiple	_	
189-13	34631-34636	brain	_	
189-14	34637-34644	regions	_	
189-15	34644-34645	,	_	
189-16	34646-34655	including	_	
189-17	34656-34659	the	_	
189-18	34660-34669	bilateral	_	
189-19	34670-34683	mid-posterior	_	
189-20	34684-34690	insula	_	
189-21	34690-34691	,	_	
189-22	34692-34705	somatosensory	_	
189-23	34706-34712	cortex	_	
189-24	34712-34713	,	_	
189-25	34714-34723	precuneus	_	
189-26	34723-34724	,	_	
189-27	34725-34729	left	_	
189-28	34730-34736	middle	_	
189-29	34737-34740	and	_	
189-30	34741-34749	inferior	_	
189-31	34750-34757	frontal	_	
189-32	34758-34763	gryus	_	
189-33	34763-34764	,	_	
189-34	34765-34772	lateral	_	
189-35	34773-34782	occipital	_	
189-36	34783-34789	cortex	_	
189-37	34789-34790	/	_	
189-38	34790-34797	angular	_	
189-39	34798-34803	gyrus	_	
189-40	34803-34804	.	_	

#Text=Results displayed are TFCE and Bonferroni-corrected for multiple comparisons.
190-1	34805-34812	Results	_	
190-2	34813-34822	displayed	_	
190-3	34823-34826	are	_	
190-4	34827-34831	TFCE	_	
190-5	34832-34835	and	_	
190-6	34836-34856	Bonferroni-corrected	_	
190-7	34857-34860	for	_	
190-8	34861-34869	multiple	_	
190-9	34870-34881	comparisons	_	
190-10	34881-34882	.	_	

#Text=Fig. 2
#Text=MNI coordinates of cluster peaks.
191-1	34883-34886	Fig	_	
191-2	34886-34887	.	_	
191-3	34888-34889	2	_	
191-4	34890-34893	MNI	_	
191-5	34894-34905	coordinates	_	
191-6	34906-34908	of	_	
191-7	34909-34916	cluster	_	
191-8	34917-34922	peaks	_	
191-9	34922-34923	.	_	

#Text=Table 2\t \t
#Text=Peak Clusters noPTSD > PTSD\tHemisphere\tCluster Size (Voxels)\tx\ty\tz\t \tLateral occipital cortex, Angular gyrus, Lateral orbitofrontal, Inferior frontal gyrus, Middle frontal gyrus, Pre-central gyrus, Post-central gyrus\tL\t8891\t−54\t−68\t20\t \tCentral operculum, Post-central gyrus, Mid-posterior insula, Superior temporal gyrus, Posterior cingulate\tR\t3857\t62\t−12\t−8\t \tPrecuneus, Lingual gyrus\tL/R\t2773\t−14\t−52\t−2\t \tAngular gyrus, Lateral occipital cortex, Middle temporal gyrus\tR\t882\t60\t−58\t20\t \tMid-posterior insula\tL\t297\t−36\t−4\t0\t \tSupplementary motor cortex, Cingulate gyrus\tL/R\t124\t10\t−6\t46\t \tLateral orbitofrontal cortex\tR\t57\t46\t22\t−14\t \tFrontal pole\tL\t11\t−44\t52\t0\t \tAnterior cingulate\tL\t6\t−8\t−2\t42\t \t
#Text=All coordinates reported in MNI space.
192-1	34924-34929	Table	_	
192-2	34930-34931	2	_	
192-3	34935-34939	Peak	_	
192-4	34940-34948	Clusters	_	
192-5	34949-34955	noPTSD	_	
192-6	34955-34956	 	_	
192-7	34956-34957	>	_	
192-8	34957-34958	 	_	
192-9	34958-34962	PTSD	_	
192-10	34963-34973	Hemisphere	_	
192-11	34974-34981	Cluster	_	
192-12	34982-34986	Size	_	
192-13	34987-34988	(	_	
192-14	34988-34994	Voxels	_	
192-15	34994-34995	)	_	
192-16	34996-34997	x	_	
192-17	34998-34999	y	_	
192-18	35000-35001	z	_	
192-19	35004-35011	Lateral	_	
192-20	35012-35021	occipital	_	
192-21	35022-35028	cortex	_	
192-22	35028-35029	,	_	
192-23	35030-35037	Angular	_	
192-24	35038-35043	gyrus	_	
192-25	35043-35044	,	_	
192-26	35045-35052	Lateral	_	
192-27	35053-35066	orbitofrontal	_	
192-28	35066-35067	,	_	
192-29	35068-35076	Inferior	_	
192-30	35077-35084	frontal	_	
192-31	35085-35090	gyrus	_	
192-32	35090-35091	,	_	
192-33	35092-35098	Middle	_	
192-34	35099-35106	frontal	_	
192-35	35107-35112	gyrus	_	
192-36	35112-35113	,	_	
192-37	35114-35125	Pre-central	_	
192-38	35126-35131	gyrus	_	
192-39	35131-35132	,	_	
192-40	35133-35145	Post-central	_	
192-41	35146-35151	gyrus	_	
192-42	35152-35153	L	_	
192-43	35154-35158	8891	_	
192-44	35159-35160	−	_	
192-45	35160-35162	54	_	
192-46	35163-35164	−	_	
192-47	35164-35166	68	_	
192-48	35167-35169	20	_	
192-49	35172-35179	Central	_	
192-50	35180-35189	operculum	_	
192-51	35189-35190	,	_	
192-52	35191-35203	Post-central	_	
192-53	35204-35209	gyrus	_	
192-54	35209-35210	,	_	
192-55	35211-35224	Mid-posterior	_	
192-56	35225-35231	insula	_	
192-57	35231-35232	,	_	
192-58	35233-35241	Superior	_	
192-59	35242-35250	temporal	_	
192-60	35251-35256	gyrus	_	
192-61	35256-35257	,	_	
192-62	35258-35267	Posterior	_	
192-63	35268-35277	cingulate	_	
192-64	35278-35279	R	_	
192-65	35280-35284	3857	_	
192-66	35285-35287	62	_	
192-67	35288-35289	−	_	
192-68	35289-35291	12	_	
192-69	35292-35293	−	_	
192-70	35293-35294	8	_	
192-71	35297-35306	Precuneus	_	
192-72	35306-35307	,	_	
192-73	35308-35315	Lingual	_	
192-74	35316-35321	gyrus	_	
192-75	35322-35323	L	_	
192-76	35323-35324	/	_	
192-77	35324-35325	R	_	
192-78	35326-35330	2773	_	
192-79	35331-35332	−	_	
192-80	35332-35334	14	_	
192-81	35335-35336	−	_	
192-82	35336-35338	52	_	
192-83	35339-35340	−	_	
192-84	35340-35341	2	_	
192-85	35344-35351	Angular	_	
192-86	35352-35357	gyrus	_	
192-87	35357-35358	,	_	
192-88	35359-35366	Lateral	_	
192-89	35367-35376	occipital	_	
192-90	35377-35383	cortex	_	
192-91	35383-35384	,	_	
192-92	35385-35391	Middle	_	
192-93	35392-35400	temporal	_	
192-94	35401-35406	gyrus	_	
192-95	35407-35408	R	_	
192-96	35409-35412	882	_	
192-97	35413-35415	60	_	
192-98	35416-35417	−	_	
192-99	35417-35419	58	_	
192-100	35420-35422	20	_	
192-101	35425-35438	Mid-posterior	_	
192-102	35439-35445	insula	_	
192-103	35446-35447	L	_	
192-104	35448-35451	297	_	
192-105	35452-35453	−	_	
192-106	35453-35455	36	_	
192-107	35456-35457	−	_	
192-108	35457-35458	4	_	
192-109	35459-35460	0	_	
192-110	35463-35476	Supplementary	_	
192-111	35477-35482	motor	_	
192-112	35483-35489	cortex	_	
192-113	35489-35490	,	_	
192-114	35491-35500	Cingulate	_	
192-115	35501-35506	gyrus	_	
192-116	35507-35508	L	_	
192-117	35508-35509	/	_	
192-118	35509-35510	R	_	
192-119	35511-35514	124	_	
192-120	35515-35517	10	_	
192-121	35518-35519	−	_	
192-122	35519-35520	6	_	
192-123	35521-35523	46	_	
192-124	35526-35533	Lateral	_	
192-125	35534-35547	orbitofrontal	_	
192-126	35548-35554	cortex	_	
192-127	35555-35556	R	_	
192-128	35557-35559	57	_	
192-129	35560-35562	46	_	
192-130	35563-35565	22	_	
192-131	35566-35567	−	_	
192-132	35567-35569	14	_	
192-133	35572-35579	Frontal	_	
192-134	35580-35584	pole	_	
192-135	35585-35586	L	_	
192-136	35587-35589	11	_	
192-137	35590-35591	−	_	
192-138	35591-35593	44	_	
192-139	35594-35596	52	_	
192-140	35597-35598	0	_	
192-141	35601-35609	Anterior	_	
192-142	35610-35619	cingulate	_	
192-143	35620-35621	L	_	
192-144	35622-35623	6	_	
192-145	35624-35625	−	_	
192-146	35625-35626	8	_	
192-147	35627-35628	−	_	
192-148	35628-35629	2	_	
192-149	35630-35632	42	_	
192-150	35636-35639	All	_	
192-151	35640-35651	coordinates	_	
192-152	35652-35660	reported	_	
192-153	35661-35663	in	_	
192-154	35664-35667	MNI	_	
192-155	35668-35673	space	_	
192-156	35673-35674	.	_	

#Text=Peak cluster reported for a main cluster, but several maxima may be observed within a given cluster as large clusters were bridged by several voxels.
193-1	35675-35679	Peak	_	
193-2	35680-35687	cluster	_	
193-3	35688-35696	reported	_	
193-4	35697-35700	for	_	
193-5	35701-35702	a	_	
193-6	35703-35707	main	_	
193-7	35708-35715	cluster	_	
193-8	35715-35716	,	_	
193-9	35717-35720	but	_	
193-10	35721-35728	several	_	
193-11	35729-35735	maxima	_	
193-12	35736-35739	may	_	
193-13	35740-35742	be	_	
193-14	35743-35751	observed	_	
193-15	35752-35758	within	_	
193-16	35759-35760	a	_	
193-17	35761-35766	given	_	
193-18	35767-35774	cluster	_	
193-19	35775-35777	as	_	
193-20	35778-35783	large	_	
193-21	35784-35792	clusters	_	
193-22	35793-35797	were	_	
193-23	35798-35805	bridged	_	
193-24	35806-35808	by	_	
193-25	35809-35816	several	_	
193-26	35817-35823	voxels	_	
193-27	35823-35824	.	_	

#Text=Of the eight networks, only the orbitofrontal (OFC) network contained clusters that exceeded TFCE and Bonferroni-corrected thresholding for the test comparing spatial differences in functional connectivity for noPTSD > PTSD.
194-1	35825-35827	Of	_	
194-2	35828-35831	the	_	
194-3	35832-35837	eight	_	
194-4	35838-35846	networks	_	
194-5	35846-35847	,	_	
194-6	35848-35852	only	_	
194-7	35853-35856	the	_	
194-8	35857-35870	orbitofrontal	_	
194-9	35871-35872	(	_	
194-10	35872-35875	OFC	_	
194-11	35875-35876	)	_	
194-12	35877-35884	network	_	
194-13	35885-35894	contained	_	
194-14	35895-35903	clusters	_	
194-15	35904-35908	that	_	
194-16	35909-35917	exceeded	_	
194-17	35918-35922	TFCE	_	
194-18	35923-35926	and	_	
194-19	35927-35947	Bonferroni-corrected	_	
194-20	35948-35960	thresholding	_	
194-21	35961-35964	for	_	
194-22	35965-35968	the	_	
194-23	35969-35973	test	_	
194-24	35974-35983	comparing	_	
194-25	35984-35991	spatial	_	
194-26	35992-36003	differences	_	
194-27	36004-36006	in	_	
194-28	36007-36017	functional	_	
194-29	36018-36030	connectivity	_	
194-30	36031-36034	for	_	
194-31	36035-36041	noPTSD	_	
194-32	36042-36043	>	_	
194-33	36044-36048	PTSD	_	
194-34	36048-36049	.	_	

#Text=Differences in OFC functional connectivity were located in the bilateral insula, postcentral gyrus, precuneus, lateral OFC/frontal operculum, and left frontoparietal areas.
195-1	36050-36061	Differences	_	
195-2	36062-36064	in	_	
195-3	36065-36068	OFC	_	
195-4	36069-36079	functional	_	
195-5	36080-36092	connectivity	_	
195-6	36093-36097	were	_	
195-7	36098-36105	located	_	
195-8	36106-36108	in	_	
195-9	36109-36112	the	_	
195-10	36113-36122	bilateral	_	
195-11	36123-36129	insula	_	
195-12	36129-36130	,	_	
195-13	36131-36142	postcentral	_	
195-14	36143-36148	gyrus	_	
195-15	36148-36149	,	_	
195-16	36150-36159	precuneus	_	
195-17	36159-36160	,	_	
195-18	36161-36168	lateral	_	
195-19	36169-36172	OFC	_	
195-20	36172-36173	/	_	
195-21	36173-36180	frontal	_	
195-22	36181-36190	operculum	_	
195-23	36190-36191	,	_	
195-24	36192-36195	and	_	
195-25	36196-36200	left	_	
195-26	36201-36215	frontoparietal	_	
195-27	36216-36221	areas	_	
195-28	36221-36222	.	_	

#Text=The OFC network result is displayed at the Bonferroni-corrected threshold in Fig. 2.
196-1	36223-36226	The	_	
196-2	36227-36230	OFC	_	
196-3	36231-36238	network	_	
196-4	36239-36245	result	_	
196-5	36246-36248	is	_	
196-6	36249-36258	displayed	_	
196-7	36259-36261	at	_	
196-8	36262-36265	the	_	
196-9	36266-36286	Bonferroni-corrected	_	
196-10	36287-36296	threshold	_	
196-11	36297-36299	in	_	
196-12	36300-36303	Fig	_	
196-13	36303-36304	.	_	
196-14	36305-36306	2	_	
196-15	36306-36307	.	_	

#Text=MNI-coordinates for the peaks of clusters obtained from this analysis are reported in Table 2.
197-1	36308-36323	MNI-coordinates	_	
197-2	36324-36327	for	_	
197-3	36328-36331	the	_	
197-4	36332-36337	peaks	_	
197-5	36338-36340	of	_	
197-6	36341-36349	clusters	_	
197-7	36350-36358	obtained	_	
197-8	36359-36363	from	_	
197-9	36364-36368	this	_	
197-10	36369-36377	analysis	_	
197-11	36378-36381	are	_	
197-12	36382-36390	reported	_	
197-13	36391-36393	in	_	
197-14	36394-36399	Table	_	
197-15	36400-36401	2	_	
197-16	36401-36402	.	_	

#Text=The PTSD group did not display greater functional connectivity in any brain region for any of the eight networks.
198-1	36403-36406	The	_	
198-2	36407-36411	PTSD	_	
198-3	36412-36417	group	_	
198-4	36418-36421	did	_	
198-5	36422-36425	not	_	
198-6	36426-36433	display	_	
198-7	36434-36441	greater	_	
198-8	36442-36452	functional	_	
198-9	36453-36465	connectivity	_	
198-10	36466-36468	in	_	
198-11	36469-36472	any	_	
198-12	36473-36478	brain	_	
198-13	36479-36485	region	_	
198-14	36486-36489	for	_	
198-15	36490-36493	any	_	
198-16	36494-36496	of	_	
198-17	36497-36500	the	_	
198-18	36501-36506	eight	_	
198-19	36507-36515	networks	_	
198-20	36515-36516	.	_	

#Text=Mean OFC network strength associated with lifetime exposure to sexual trauma
#Text=Sexual Violence exposure and PTSD status are significantly negatively associated with mean OFC Network strength.
199-1	36517-36521	Mean	_	
199-2	36522-36525	OFC	_	
199-3	36526-36533	network	_	
199-4	36534-36542	strength	_	
199-5	36543-36553	associated	_	
199-6	36554-36558	with	_	
199-7	36559-36567	lifetime	_	
199-8	36568-36576	exposure	_	
199-9	36577-36579	to	_	
199-10	36580-36586	sexual	_	
199-11	36587-36593	trauma	_	
199-12	36594-36600	Sexual	_	
199-13	36601-36609	Violence	_	
199-14	36610-36618	exposure	_	
199-15	36619-36622	and	_	
199-16	36623-36627	PTSD	_	
199-17	36628-36634	status	_	
199-18	36635-36638	are	_	
199-19	36639-36652	significantly	_	
199-20	36653-36663	negatively	_	
199-21	36664-36674	associated	_	
199-22	36675-36679	with	_	
199-23	36680-36684	mean	_	
199-24	36685-36688	OFC	_	
199-25	36689-36696	Network	_	
199-26	36697-36705	strength	_	
199-27	36705-36706	.	_	

#Text=Scatterplot reflects the simple correlation between Sexual Violence and OFC Network for each group.
200-1	36707-36718	Scatterplot	_	
200-2	36719-36727	reflects	_	
200-3	36728-36731	the	_	
200-4	36732-36738	simple	_	
200-5	36739-36750	correlation	_	
200-6	36751-36758	between	_	
200-7	36759-36765	Sexual	_	
200-8	36766-36774	Violence	_	
200-9	36775-36778	and	_	
200-10	36779-36782	OFC	_	
200-11	36783-36790	Network	_	
200-12	36791-36794	for	_	
200-13	36795-36799	each	_	
200-14	36800-36805	group	_	
200-15	36805-36806	.	_	

#Text=Fig. 3
#Text=Given that the majority of participants (62.8%) had experienced at least one LSC-R sexual trauma category at some point in their life regardless of PTSD diagnosis, and that sexual trauma accounted for a large portion of variance in total LSC-R, independent post-hoc tests were carried out to identify whether the average strength of each participant's OFC network was associated with lifetime exposure to Sexual Violence above and beyond the effects of PTSD status.
201-1	36807-36810	Fig	_	
201-2	36810-36811	.	_	
201-3	36812-36813	3	_	
201-4	36814-36819	Given	_	
201-5	36820-36824	that	_	
201-6	36825-36828	the	_	
201-7	36829-36837	majority	_	
201-8	36838-36840	of	_	
201-9	36841-36853	participants	_	
201-10	36854-36855	(	_	
201-11	36855-36860	62.8%	_	
201-12	36860-36861	)	_	
201-13	36862-36865	had	_	
201-14	36866-36877	experienced	_	
201-15	36878-36880	at	_	
201-16	36881-36886	least	_	
201-17	36887-36890	one	_	
201-18	36891-36896	LSC-R	_	
201-19	36897-36903	sexual	_	
201-20	36904-36910	trauma	_	
201-21	36911-36919	category	_	
201-22	36920-36922	at	_	
201-23	36923-36927	some	_	
201-24	36928-36933	point	_	
201-25	36934-36936	in	_	
201-26	36937-36942	their	_	
201-27	36943-36947	life	_	
201-28	36948-36958	regardless	_	
201-29	36959-36961	of	_	
201-30	36962-36966	PTSD	_	
201-31	36967-36976	diagnosis	_	
201-32	36976-36977	,	_	
201-33	36978-36981	and	_	
201-34	36982-36986	that	_	
201-35	36987-36993	sexual	_	
201-36	36994-37000	trauma	_	
201-37	37001-37010	accounted	_	
201-38	37011-37014	for	_	
201-39	37015-37016	a	_	
201-40	37017-37022	large	_	
201-41	37023-37030	portion	_	
201-42	37031-37033	of	_	
201-43	37034-37042	variance	_	
201-44	37043-37045	in	_	
201-45	37046-37051	total	_	
201-46	37052-37057	LSC-R	_	
201-47	37057-37058	,	_	
201-48	37059-37070	independent	_	
201-49	37071-37079	post-hoc	_	
201-50	37080-37085	tests	_	
201-51	37086-37090	were	_	
201-52	37091-37098	carried	_	
201-53	37099-37102	out	_	
201-54	37103-37105	to	_	
201-55	37106-37114	identify	_	
201-56	37115-37122	whether	_	
201-57	37123-37126	the	_	
201-58	37127-37134	average	_	
201-59	37135-37143	strength	_	
201-60	37144-37146	of	_	
201-61	37147-37151	each	_	
201-62	37152-37165	participant's	_	
201-63	37166-37169	OFC	_	
201-64	37170-37177	network	_	
201-65	37178-37181	was	_	
201-66	37182-37192	associated	_	
201-67	37193-37197	with	_	
201-68	37198-37206	lifetime	_	
201-69	37207-37215	exposure	_	
201-70	37216-37218	to	_	
201-71	37219-37225	Sexual	_	
201-72	37226-37234	Violence	_	
201-73	37235-37240	above	_	
201-74	37241-37244	and	_	
201-75	37245-37251	beyond	_	
201-76	37252-37255	the	_	
201-77	37256-37263	effects	_	
201-78	37264-37266	of	_	
201-79	37267-37271	PTSD	_	
201-80	37272-37278	status	_	
201-81	37278-37279	.	_	

#Text=A multiple linear regression was calculated to predict the whole-brain average of the subject-level variance-normalized networks (masked for positive voxel-values), based on PTSD status (PTSD = 1, noPTSD = 0), Sexual Violence total, age, ASI drug and alcohol use.
202-1	37280-37281	A	_	
202-2	37282-37290	multiple	_	
202-3	37291-37297	linear	_	
202-4	37298-37308	regression	_	
202-5	37309-37312	was	_	
202-6	37313-37323	calculated	_	
202-7	37324-37326	to	_	
202-8	37327-37334	predict	_	
202-9	37335-37338	the	_	
202-10	37339-37350	whole-brain	_	
202-11	37351-37358	average	_	
202-12	37359-37361	of	_	
202-13	37362-37365	the	_	
202-14	37366-37379	subject-level	_	
202-15	37380-37399	variance-normalized	_	
202-16	37400-37408	networks	_	
202-17	37409-37410	(	_	
202-18	37410-37416	masked	_	
202-19	37417-37420	for	_	
202-20	37421-37429	positive	_	
202-21	37430-37442	voxel-values	_	
202-22	37442-37443	)	_	
202-23	37443-37444	,	_	
202-24	37445-37450	based	_	
202-25	37451-37453	on	_	
202-26	37454-37458	PTSD	_	
202-27	37459-37465	status	_	
202-28	37466-37467	(	_	
202-29	37467-37471	PTSD	_	
202-30	37471-37472	 	_	
202-31	37472-37473	=	_	
202-32	37473-37474	 	_	
202-33	37474-37475	1	_	
202-34	37475-37476	,	_	
202-35	37477-37483	noPTSD	_	
202-36	37483-37484	 	_	
202-37	37484-37485	=	_	
202-38	37485-37486	 	_	
202-39	37486-37487	0	_	
202-40	37487-37488	)	_	
202-41	37488-37489	,	_	
202-42	37490-37496	Sexual	_	
202-43	37497-37505	Violence	_	
202-44	37506-37511	total	_	
202-45	37511-37512	,	_	
202-46	37513-37516	age	_	
202-47	37516-37517	,	_	
202-48	37518-37521	ASI	_	
202-49	37522-37526	drug	_	
202-50	37527-37530	and	_	
202-51	37531-37538	alcohol	_	
202-52	37539-37542	use	_	
202-53	37542-37543	.	_	

#Text=For the OFC Network, a significant regression was found (F(5, 37) = 5.34, p = .00086, with adjusted-R2 = 0.34.
203-1	37544-37547	For	_	
203-2	37548-37551	the	_	
203-3	37552-37555	OFC	_	
203-4	37556-37563	Network	_	
203-5	37563-37564	,	_	
203-6	37565-37566	a	_	
203-7	37567-37578	significant	_	
203-8	37579-37589	regression	_	
203-9	37590-37593	was	_	
203-10	37594-37599	found	_	
203-11	37600-37601	(	_	
203-12	37601-37602	F	_	
203-13	37602-37603	(	_	
203-14	37603-37604	5	_	
203-15	37604-37605	,	_	
203-16	37606-37608	37	_	
203-17	37608-37609	)	_	
203-18	37609-37610	 	_	
203-19	37610-37611	=	_	
203-20	37611-37612	 	_	
203-21	37612-37616	5.34	_	
203-22	37616-37617	,	_	
203-23	37618-37619	p	_	
203-24	37619-37620	 	_	
203-25	37620-37621	=	_	
203-26	37621-37622	 	_	
203-27	37622-37628	.00086	_	
203-28	37628-37629	,	_	
203-29	37630-37634	with	_	
203-30	37635-37646	adjusted-R2	_	
203-31	37646-37647	 	_	
203-32	37647-37648	=	_	
203-33	37648-37649	 	_	
203-34	37649-37653	0.34	_	
203-35	37653-37654	.	_	

#Text=Age, alcohol and drug use were not significant predictors (β = −0.02, SE = 0.019, p = .26; β = 0.28, SE = 0.91, p = .76; β = 0.78, SE = 0.99, p = .43), whereas both PTSD and Sexual Violence independently explained significant variance: PTSD was associated with lower average OFC functional coherence (β = −0.92, SE = 0.30, p = .0039), consistent with the analysis of group differences in OFC network functional connectivity, while Sexual Violence accounted for additional variance (β = −0.24, SE = 0.095, p = .015), suggesting a cumulative effect of sexual traumas on the integrity of the OFC network across substance-dependent women both with and without PTSD (see Fig. 3).
204-1	37655-37658	Age	_	
204-2	37658-37659	,	_	
204-3	37660-37667	alcohol	_	
204-4	37668-37671	and	_	
204-5	37672-37676	drug	_	
204-6	37677-37680	use	_	
204-7	37681-37685	were	_	
204-8	37686-37689	not	_	
204-9	37690-37701	significant	_	
204-10	37702-37712	predictors	_	
204-11	37713-37714	(	_	
204-12	37714-37715	β	_	
204-13	37715-37716	 	_	
204-14	37716-37717	=	_	
204-15	37717-37718	 	_	
204-16	37718-37719	−	_	
204-17	37719-37723	0.02	_	
204-18	37723-37724	,	_	
204-19	37725-37727	SE	_	
204-20	37727-37728	 	_	
204-21	37728-37729	=	_	
204-22	37729-37730	 	_	
204-23	37730-37735	0.019	_	
204-24	37735-37736	,	_	
204-25	37737-37738	p	_	
204-26	37738-37739	 	_	
204-27	37739-37740	=	_	
204-28	37740-37741	 	_	
204-29	37741-37744	.26	_	
204-30	37744-37745	;	_	
204-31	37746-37747	β	_	
204-32	37747-37748	 	_	
204-33	37748-37749	=	_	
204-34	37749-37750	 	_	
204-35	37750-37754	0.28	_	
204-36	37754-37755	,	_	
204-37	37756-37758	SE	_	
204-38	37758-37759	 	_	
204-39	37759-37760	=	_	
204-40	37760-37761	 	_	
204-41	37761-37765	0.91	_	
204-42	37765-37766	,	_	
204-43	37767-37768	p	_	
204-44	37768-37769	 	_	
204-45	37769-37770	=	_	
204-46	37770-37771	 	_	
204-47	37771-37774	.76	_	
204-48	37774-37775	;	_	
204-49	37776-37777	β	_	
204-50	37777-37778	 	_	
204-51	37778-37779	=	_	
204-52	37779-37780	 	_	
204-53	37780-37784	0.78	_	
204-54	37784-37785	,	_	
204-55	37786-37788	SE	_	
204-56	37788-37789	 	_	
204-57	37789-37790	=	_	
204-58	37790-37791	 	_	
204-59	37791-37795	0.99	_	
204-60	37795-37796	,	_	
204-61	37797-37798	p	_	
204-62	37798-37799	 	_	
204-63	37799-37800	=	_	
204-64	37800-37801	 	_	
204-65	37801-37804	.43	_	
204-66	37804-37805	)	_	
204-67	37805-37806	,	_	
204-68	37807-37814	whereas	_	
204-69	37815-37819	both	_	
204-70	37820-37824	PTSD	_	
204-71	37825-37828	and	_	
204-72	37829-37835	Sexual	_	
204-73	37836-37844	Violence	_	
204-74	37845-37858	independently	_	
204-75	37859-37868	explained	_	
204-76	37869-37880	significant	_	
204-77	37881-37889	variance	_	
204-78	37889-37890	:	_	
204-79	37891-37895	PTSD	_	
204-80	37896-37899	was	_	
204-81	37900-37910	associated	_	
204-82	37911-37915	with	_	
204-83	37916-37921	lower	_	
204-84	37922-37929	average	_	
204-85	37930-37933	OFC	_	
204-86	37934-37944	functional	_	
204-87	37945-37954	coherence	_	
204-88	37955-37956	(	_	
204-89	37956-37957	β	_	
204-90	37957-37958	 	_	
204-91	37958-37959	=	_	
204-92	37959-37960	 	_	
204-93	37960-37961	−	_	
204-94	37961-37965	0.92	_	
204-95	37965-37966	,	_	
204-96	37967-37969	SE	_	
204-97	37969-37970	 	_	
204-98	37970-37971	=	_	
204-99	37971-37972	 	_	
204-100	37972-37976	0.30	_	
204-101	37976-37977	,	_	
204-102	37978-37979	p	_	
204-103	37979-37980	 	_	
204-104	37980-37981	=	_	
204-105	37981-37982	 	_	
204-106	37982-37987	.0039	_	
204-107	37987-37988	)	_	
204-108	37988-37989	,	_	
204-109	37990-38000	consistent	_	
204-110	38001-38005	with	_	
204-111	38006-38009	the	_	
204-112	38010-38018	analysis	_	
204-113	38019-38021	of	_	
204-114	38022-38027	group	_	
204-115	38028-38039	differences	_	
204-116	38040-38042	in	_	
204-117	38043-38046	OFC	_	
204-118	38047-38054	network	_	
204-119	38055-38065	functional	_	
204-120	38066-38078	connectivity	_	
204-121	38078-38079	,	_	
204-122	38080-38085	while	_	
204-123	38086-38092	Sexual	_	
204-124	38093-38101	Violence	_	
204-125	38102-38111	accounted	_	
204-126	38112-38115	for	_	
204-127	38116-38126	additional	_	
204-128	38127-38135	variance	_	
204-129	38136-38137	(	_	
204-130	38137-38138	β	_	
204-131	38138-38139	 	_	
204-132	38139-38140	=	_	
204-133	38140-38141	 	_	
204-134	38141-38142	−	_	
204-135	38142-38146	0.24	_	
204-136	38146-38147	,	_	
204-137	38148-38150	SE	_	
204-138	38150-38151	 	_	
204-139	38151-38152	=	_	
204-140	38152-38153	 	_	
204-141	38153-38158	0.095	_	
204-142	38158-38159	,	_	
204-143	38160-38161	p	_	
204-144	38161-38162	 	_	
204-145	38162-38163	=	_	
204-146	38163-38164	 	_	
204-147	38164-38168	.015	_	
204-148	38168-38169	)	_	
204-149	38169-38170	,	_	
204-150	38171-38181	suggesting	_	
204-151	38182-38183	a	_	
204-152	38184-38194	cumulative	_	
204-153	38195-38201	effect	_	
204-154	38202-38204	of	_	
204-155	38205-38211	sexual	_	
204-156	38212-38219	traumas	_	
204-157	38220-38222	on	_	
204-158	38223-38226	the	_	
204-159	38227-38236	integrity	_	
204-160	38237-38239	of	_	
204-161	38240-38243	the	_	
204-162	38244-38247	OFC	_	
204-163	38248-38255	network	_	
204-164	38256-38262	across	_	
204-165	38263-38282	substance-dependent	_	
204-166	38283-38288	women	_	
204-167	38289-38293	both	_	
204-168	38294-38298	with	_	
204-169	38299-38302	and	_	
204-170	38303-38310	without	_	
204-171	38311-38315	PTSD	_	
204-172	38316-38317	(	_	
204-173	38317-38320	see	_	
204-174	38321-38324	Fig	_	
204-175	38324-38325	.	_	
204-176	38326-38327	3	_	
204-177	38327-38328	)	_	
204-178	38328-38329	.	_	

#Text=The model intercept was also significant (β = 4.6, SE = .58, p = <.0001).
205-1	38330-38333	The	_	
205-2	38334-38339	model	_	
205-3	38340-38349	intercept	_	
205-4	38350-38353	was	_	
205-5	38354-38358	also	_	
205-6	38359-38370	significant	_	
205-7	38371-38372	(	_	
205-8	38372-38373	β	_	
205-9	38374-38375	=	_	
205-10	38376-38379	4.6	_	
205-11	38379-38380	,	_	
205-12	38381-38383	SE	_	
205-13	38384-38385	=	_	
205-14	38386-38389	.58	_	
205-15	38389-38390	,	_	
205-16	38391-38392	p	_	
205-17	38393-38394	=	_	
205-18	38395-38396	<	_	
205-19	38396-38401	.0001	_	
205-20	38401-38402	)	_	
205-21	38402-38403	.	_	

#Text=As a check on whether Sexual Violence accounts for similar variance as compared to total LSC-R score given the very high correlation between the variables (see Section 4.2.1), the same regression was run using total LSC-R score instead of Sexual Violence.
206-1	38404-38406	As	_	
206-2	38407-38408	a	_	
206-3	38409-38414	check	_	
206-4	38415-38417	on	_	
206-5	38418-38425	whether	_	
206-6	38426-38432	Sexual	_	
206-7	38433-38441	Violence	_	
206-8	38442-38450	accounts	_	
206-9	38451-38454	for	_	
206-10	38455-38462	similar	_	
206-11	38463-38471	variance	_	
206-12	38472-38474	as	_	
206-13	38475-38483	compared	_	
206-14	38484-38486	to	_	
206-15	38487-38492	total	_	
206-16	38493-38498	LSC-R	_	
206-17	38499-38504	score	_	
206-18	38505-38510	given	_	
206-19	38511-38514	the	_	
206-20	38515-38519	very	_	
206-21	38520-38524	high	_	
206-22	38525-38536	correlation	_	
206-23	38537-38544	between	_	
206-24	38545-38548	the	_	
206-25	38549-38558	variables	_	
206-26	38559-38560	(	_	
206-27	38560-38563	see	_	
206-28	38564-38571	Section	_	
206-29	38572-38577	4.2.1	_	
206-30	38577-38578	)	_	
206-31	38578-38579	,	_	
206-32	38580-38583	the	_	
206-33	38584-38588	same	_	
206-34	38589-38599	regression	_	
206-35	38600-38603	was	_	
206-36	38604-38607	run	_	
206-37	38608-38613	using	_	
206-38	38614-38619	total	_	
206-39	38620-38625	LSC-R	_	
206-40	38626-38631	score	_	
206-41	38632-38639	instead	_	
206-42	38640-38642	of	_	
206-43	38643-38649	Sexual	_	
206-44	38650-38658	Violence	_	
206-45	38658-38659	.	_	

#Text=In this model, LSC-R total was only a marginally significant predictor of OFC strength (β = −0.055, SE = 0.027, p = .052) whereas the estimates of the other predictors (PTSD, age, ASI drug and alcohol use) remained very similar.
207-1	38660-38662	In	_	
207-2	38663-38667	this	_	
207-3	38668-38673	model	_	
207-4	38673-38674	,	_	
207-5	38675-38680	LSC-R	_	
207-6	38681-38686	total	_	
207-7	38687-38690	was	_	
207-8	38691-38695	only	_	
207-9	38696-38697	a	_	
207-10	38698-38708	marginally	_	
207-11	38709-38720	significant	_	
207-12	38721-38730	predictor	_	
207-13	38731-38733	of	_	
207-14	38734-38737	OFC	_	
207-15	38738-38746	strength	_	
207-16	38747-38748	(	_	
207-17	38748-38749	β	_	
207-18	38749-38750	 	_	
207-19	38750-38751	=	_	
207-20	38751-38752	 	_	
207-21	38752-38753	−	_	
207-22	38753-38758	0.055	_	
207-23	38758-38759	,	_	
207-24	38760-38762	SE	_	
207-25	38762-38763	 	_	
207-26	38763-38764	=	_	
207-27	38764-38765	 	_	
207-28	38765-38770	0.027	_	
207-29	38770-38771	,	_	
207-30	38772-38773	p	_	
207-31	38773-38774	 	_	
207-32	38774-38775	=	_	
207-33	38775-38776	 	_	
207-34	38776-38780	.052	_	
207-35	38780-38781	)	_	
207-36	38782-38789	whereas	_	
207-37	38790-38793	the	_	
207-38	38794-38803	estimates	_	
207-39	38804-38806	of	_	
207-40	38807-38810	the	_	
207-41	38811-38816	other	_	
207-42	38817-38827	predictors	_	
207-43	38828-38829	(	_	
207-44	38829-38833	PTSD	_	
207-45	38833-38834	,	_	
207-46	38835-38838	age	_	
207-47	38838-38839	,	_	
207-48	38840-38843	ASI	_	
207-49	38844-38848	drug	_	
207-50	38849-38852	and	_	
207-51	38853-38860	alcohol	_	
207-52	38861-38864	use	_	
207-53	38864-38865	)	_	
207-54	38866-38874	remained	_	
207-55	38875-38879	very	_	
207-56	38880-38887	similar	_	
207-57	38887-38888	.	_	

#Text=Discussion
#Text=To our knowledge, this is the first study to investigate neural correlates of PTSD and traumatic stress in women diagnosed with SUD.
208-1	38889-38899	Discussion	_	
208-2	38900-38902	To	_	
208-3	38903-38906	our	_	
208-4	38907-38916	knowledge	_	
208-5	38916-38917	,	_	
208-6	38918-38922	this	_	
208-7	38923-38925	is	_	
208-8	38926-38929	the	_	
208-9	38930-38935	first	_	
208-10	38936-38941	study	_	
208-11	38942-38944	to	_	
208-12	38945-38956	investigate	_	
208-13	38957-38963	neural	_	
208-14	38964-38974	correlates	_	
208-15	38975-38977	of	_	
208-16	38978-38982	PTSD	_	
208-17	38983-38986	and	_	
208-18	38987-38996	traumatic	_	
208-19	38997-39003	stress	_	
208-20	39004-39006	in	_	
208-21	39007-39012	women	_	
208-22	39013-39022	diagnosed	_	
208-23	39023-39027	with	_	
208-24	39028-39031	SUD	_	
208-25	39031-39032	.	_	

#Text=To address the question of differences between trauma-exposed, substance-dependent women with and without current PTSD, we employed a data-driven approach.
209-1	39033-39035	To	_	
209-2	39036-39043	address	_	
209-3	39044-39047	the	_	
209-4	39048-39056	question	_	
209-5	39057-39059	of	_	
209-6	39060-39071	differences	_	
209-7	39072-39079	between	_	
209-8	39080-39094	trauma-exposed	_	
209-9	39094-39095	,	_	
209-10	39096-39115	substance-dependent	_	
209-11	39116-39121	women	_	
209-12	39122-39126	with	_	
209-13	39127-39130	and	_	
209-14	39131-39138	without	_	
209-15	39139-39146	current	_	
209-16	39147-39151	PTSD	_	
209-17	39151-39152	,	_	
209-18	39153-39155	we	_	
209-19	39156-39164	employed	_	
209-20	39165-39166	a	_	
209-21	39167-39178	data-driven	_	
209-22	39179-39187	approach	_	
209-23	39187-39188	.	_	

#Text=First, using independent components analysis and dual regression, we identified eight intrinsic functional networks that were significantly modulated by the interoceptive and exteroceptive task conditions.
210-1	39189-39194	First	_	
210-2	39194-39195	,	_	
210-3	39196-39201	using	_	
210-4	39202-39213	independent	_	
210-5	39214-39224	components	_	
210-6	39225-39233	analysis	_	
210-7	39234-39237	and	_	
210-8	39238-39242	dual	_	
210-9	39243-39253	regression	_	
210-10	39253-39254	,	_	
210-11	39255-39257	we	_	
210-12	39258-39268	identified	_	
210-13	39269-39274	eight	_	
210-14	39275-39284	intrinsic	_	
210-15	39285-39295	functional	_	
210-16	39296-39304	networks	_	
210-17	39305-39309	that	_	
210-18	39310-39314	were	_	
210-19	39315-39328	significantly	_	
210-20	39329-39338	modulated	_	
210-21	39339-39341	by	_	
210-22	39342-39345	the	_	
210-23	39346-39359	interoceptive	_	
210-24	39360-39363	and	_	
210-25	39364-39377	exteroceptive	_	
210-26	39378-39382	task	_	
210-27	39383-39393	conditions	_	
210-28	39393-39394	.	_	

#Text=These eight task-modulated networks were used to test network-level differences in functional connectivity for participants with comorbid PTSD and SUD compared to those with SUD-only.
211-1	39395-39400	These	_	
211-2	39401-39406	eight	_	
211-3	39407-39421	task-modulated	_	
211-4	39422-39430	networks	_	
211-5	39431-39435	were	_	
211-6	39436-39440	used	_	
211-7	39441-39443	to	_	
211-8	39444-39448	test	_	
211-9	39449-39462	network-level	_	
211-10	39463-39474	differences	_	
211-11	39475-39477	in	_	
211-12	39478-39488	functional	_	
211-13	39489-39501	connectivity	_	
211-14	39502-39505	for	_	
211-15	39506-39518	participants	_	
211-16	39519-39523	with	_	
211-17	39524-39532	comorbid	_	
211-18	39533-39537	PTSD	_	
211-19	39538-39541	and	_	
211-20	39542-39545	SUD	_	
211-21	39546-39554	compared	_	
211-22	39555-39557	to	_	
211-23	39558-39563	those	_	
211-24	39564-39568	with	_	
211-25	39569-39577	SUD-only	_	
211-26	39577-39578	.	_	

#Text=Only the OFC network significantly differentiated the PTSD and noPTSD groups.
212-1	39579-39583	Only	_	
212-2	39584-39587	the	_	
212-3	39588-39591	OFC	_	
212-4	39592-39599	network	_	
212-5	39600-39613	significantly	_	
212-6	39614-39628	differentiated	_	
212-7	39629-39632	the	_	
212-8	39633-39637	PTSD	_	
212-9	39638-39641	and	_	
212-10	39642-39648	noPTSD	_	
212-11	39649-39655	groups	_	
212-12	39655-39656	.	_	

#Text=Notably, we did not identify brain or performance differences (see Supplement) between PTSD and noPTSD for networks associated with exteroceptive task demands (the executive, lateral occipital, and occipital pole networks).
213-1	39657-39664	Notably	_	
213-2	39664-39665	,	_	
213-3	39666-39668	we	_	
213-4	39669-39672	did	_	
213-5	39673-39676	not	_	
213-6	39677-39685	identify	_	
213-7	39686-39691	brain	_	
213-8	39692-39694	or	_	
213-9	39695-39706	performance	_	
213-10	39707-39718	differences	_	
213-11	39719-39720	(	_	
213-12	39720-39723	see	_	
213-13	39724-39734	Supplement	_	
213-14	39734-39735	)	_	
213-15	39736-39743	between	_	
213-16	39744-39748	PTSD	_	
213-17	39749-39752	and	_	
213-18	39753-39759	noPTSD	_	
213-19	39760-39763	for	_	
213-20	39764-39772	networks	_	
213-21	39773-39783	associated	_	
213-22	39784-39788	with	_	
213-23	39789-39802	exteroceptive	_	
213-24	39803-39807	task	_	
213-25	39808-39815	demands	_	
213-26	39816-39817	(	_	
213-27	39817-39820	the	_	
213-28	39821-39830	executive	_	
213-29	39830-39831	,	_	
213-30	39832-39839	lateral	_	
213-31	39840-39849	occipital	_	
213-32	39849-39850	,	_	
213-33	39851-39854	and	_	
213-34	39855-39864	occipital	_	
213-35	39865-39869	pole	_	
213-36	39870-39878	networks	_	
213-37	39878-39879	)	_	
213-38	39879-39880	.	_	

#Text=Rather, group differences were found for the OFC network, whose time course was more active when participants were cued to attend to the sensations associated with their breathing cycle.
214-1	39881-39887	Rather	_	
214-2	39887-39888	,	_	
214-3	39889-39894	group	_	
214-4	39895-39906	differences	_	
214-5	39907-39911	were	_	
214-6	39912-39917	found	_	
214-7	39918-39921	for	_	
214-8	39922-39925	the	_	
214-9	39926-39929	OFC	_	
214-10	39930-39937	network	_	
214-11	39937-39938	,	_	
214-12	39939-39944	whose	_	
214-13	39945-39949	time	_	
214-14	39950-39956	course	_	
214-15	39957-39960	was	_	
214-16	39961-39965	more	_	
214-17	39966-39972	active	_	
214-18	39973-39977	when	_	
214-19	39978-39990	participants	_	
214-20	39991-39995	were	_	
214-21	39996-40000	cued	_	
214-22	40001-40003	to	_	
214-23	40004-40010	attend	_	
214-24	40011-40013	to	_	
214-25	40014-40017	the	_	
214-26	40018-40028	sensations	_	
214-27	40029-40039	associated	_	
214-28	40040-40044	with	_	
214-29	40045-40050	their	_	
214-30	40051-40060	breathing	_	
214-31	40061-40066	cycle	_	
214-32	40066-40067	.	_	

#Text=Hence, group differences were specific to a brain network involved in attentional modulation of viscerosensory processing.
215-1	40068-40073	Hence	_	
215-2	40073-40074	,	_	
215-3	40075-40080	group	_	
215-4	40081-40092	differences	_	
215-5	40093-40097	were	_	
215-6	40098-40106	specific	_	
215-7	40107-40109	to	_	
215-8	40110-40111	a	_	
215-9	40112-40117	brain	_	
215-10	40118-40125	network	_	
215-11	40126-40134	involved	_	
215-12	40135-40137	in	_	
215-13	40138-40149	attentional	_	
215-14	40150-40160	modulation	_	
215-15	40161-40163	of	_	
215-16	40164-40178	viscerosensory	_	
215-17	40179-40189	processing	_	
215-18	40189-40190	.	_	

#Text=The OFC is a functionally heterogeneous multimodal sensory-motor association region.
216-1	40191-40194	The	_	
216-2	40195-40198	OFC	_	
216-3	40199-40201	is	_	
216-4	40202-40203	a	_	
216-5	40204-40216	functionally	_	
216-6	40217-40230	heterogeneous	_	
216-7	40231-40241	multimodal	_	
216-8	40242-40255	sensory-motor	_	
216-9	40256-40267	association	_	
216-10	40268-40274	region	_	
216-11	40274-40275	.	_	

#Text=The lateral sector of the OFC is a convergence zone for sensory inputs from multiple modalities, including somatosensory and visceral afferents while the medial sector of the OFC provides outputs to brainstem visceromotor and hypothalamic structures.
217-1	40276-40279	The	_	
217-2	40280-40287	lateral	_	
217-3	40288-40294	sector	_	
217-4	40295-40297	of	_	
217-5	40298-40301	the	_	
217-6	40302-40305	OFC	_	
217-7	40306-40308	is	_	
217-8	40309-40310	a	_	
217-9	40311-40322	convergence	_	
217-10	40323-40327	zone	_	
217-11	40328-40331	for	_	
217-12	40332-40339	sensory	_	
217-13	40340-40346	inputs	_	
217-14	40347-40351	from	_	
217-15	40352-40360	multiple	_	
217-16	40361-40371	modalities	_	
217-17	40371-40372	,	_	
217-18	40373-40382	including	_	
217-19	40383-40396	somatosensory	_	
217-20	40397-40400	and	_	
217-21	40401-40409	visceral	_	
217-22	40410-40419	afferents	_	
217-23	40420-40425	while	_	
217-24	40426-40429	the	_	
217-25	40430-40436	medial	_	
217-26	40437-40443	sector	_	
217-27	40444-40446	of	_	
217-28	40447-40450	the	_	
217-29	40451-40454	OFC	_	
217-30	40455-40463	provides	_	
217-31	40464-40471	outputs	_	
217-32	40472-40474	to	_	
217-33	40475-40484	brainstem	_	
217-34	40485-40497	visceromotor	_	
217-35	40498-40501	and	_	
217-36	40502-40514	hypothalamic	_	
217-37	40515-40525	structures	_	
217-38	40525-40526	.	_	

#Text=In general, the OFC is functionally and anatomically coupled with the insula, striatum, lateral prefrontal cortices, and limbic structures.
218-1	40527-40529	In	_	
218-2	40530-40537	general	_	
218-3	40537-40538	,	_	
218-4	40539-40542	the	_	
218-5	40543-40546	OFC	_	
218-6	40547-40549	is	_	
218-7	40550-40562	functionally	_	
218-8	40563-40566	and	_	
218-9	40567-40579	anatomically	_	
218-10	40580-40587	coupled	_	
218-11	40588-40592	with	_	
218-12	40593-40596	the	_	
218-13	40597-40603	insula	_	
218-14	40603-40604	,	_	
218-15	40605-40613	striatum	_	
218-16	40613-40614	,	_	
218-17	40615-40622	lateral	_	
218-18	40623-40633	prefrontal	_	
218-19	40634-40642	cortices	_	
218-20	40642-40643	,	_	
218-21	40644-40647	and	_	
218-22	40648-40654	limbic	_	
218-23	40655-40665	structures	_	
218-24	40665-40666	.	_	

#Text=In relation to complex behaviors, the OFC is integral to functional states related to homeostasis and allostasis, such as mood and emotion, hypothalamic-pituitary-adrenal-axis (HPA) activity, reward, and decision-making.
219-1	40667-40669	In	_	
219-2	40670-40678	relation	_	
219-3	40679-40681	to	_	
219-4	40682-40689	complex	_	
219-5	40690-40699	behaviors	_	
219-6	40699-40700	,	_	
219-7	40701-40704	the	_	
219-8	40705-40708	OFC	_	
219-9	40709-40711	is	_	
219-10	40712-40720	integral	_	
219-11	40721-40723	to	_	
219-12	40724-40734	functional	_	
219-13	40735-40741	states	_	
219-14	40742-40749	related	_	
219-15	40750-40752	to	_	
219-16	40753-40764	homeostasis	_	
219-17	40765-40768	and	_	
219-18	40769-40779	allostasis	_	
219-19	40779-40780	,	_	
219-20	40781-40785	such	_	
219-21	40786-40788	as	_	
219-22	40789-40793	mood	_	
219-23	40794-40797	and	_	
219-24	40798-40805	emotion	_	
219-25	40805-40806	,	_	
219-26	40807-40842	hypothalamic-pituitary-adrenal-axis	_	
219-27	40843-40844	(	_	
219-28	40844-40847	HPA	_	
219-29	40847-40848	)	_	
219-30	40849-40857	activity	_	
219-31	40857-40858	,	_	
219-32	40859-40865	reward	_	
219-33	40865-40866	,	_	
219-34	40867-40870	and	_	
219-35	40871-40886	decision-making	_	
219-36	40886-40887	.	_	

#Text=Our observation of diminished OFC strength and functional connectivity in the PTSD group is highly consistent with many prior studies of post-traumatic stress in non-substance dependent individuals, who show reduced orbitofrontal or ventromedial prefrontal cortex (VMPFC) metabolism across a variety of task-demands, including trauma-related and trauma-unrelated task contexts.
220-1	40888-40891	Our	_	
220-2	40892-40903	observation	_	
220-3	40904-40906	of	_	
220-4	40907-40917	diminished	_	
220-5	40918-40921	OFC	_	
220-6	40922-40930	strength	_	
220-7	40931-40934	and	_	
220-8	40935-40945	functional	_	
220-9	40946-40958	connectivity	_	
220-10	40959-40961	in	_	
220-11	40962-40965	the	_	
220-12	40966-40970	PTSD	_	
220-13	40971-40976	group	_	
220-14	40977-40979	is	_	
220-15	40980-40986	highly	_	
220-16	40987-40997	consistent	_	
220-17	40998-41002	with	_	
220-18	41003-41007	many	_	
220-19	41008-41013	prior	_	
220-20	41014-41021	studies	_	
220-21	41022-41024	of	_	
220-22	41025-41039	post-traumatic	_	
220-23	41040-41046	stress	_	
220-24	41047-41049	in	_	
220-25	41050-41063	non-substance	_	
220-26	41064-41073	dependent	_	
220-27	41074-41085	individuals	_	
220-28	41085-41086	,	_	
220-29	41087-41090	who	_	
220-30	41091-41095	show	_	
220-31	41096-41103	reduced	_	
220-32	41104-41117	orbitofrontal	_	
220-33	41118-41120	or	_	
220-34	41121-41133	ventromedial	_	
220-35	41134-41144	prefrontal	_	
220-36	41145-41151	cortex	_	
220-37	41152-41153	(	_	
220-38	41153-41158	VMPFC	_	
220-39	41158-41159	)	_	
220-40	41160-41170	metabolism	_	
220-41	41171-41177	across	_	
220-42	41178-41179	a	_	
220-43	41180-41187	variety	_	
220-44	41188-41190	of	_	
220-45	41191-41203	task-demands	_	
220-46	41203-41204	,	_	
220-47	41205-41214	including	_	
220-48	41215-41229	trauma-related	_	
220-49	41230-41233	and	_	
220-50	41234-41250	trauma-unrelated	_	
220-51	41251-41255	task	_	
220-52	41256-41264	contexts	_	
220-53	41264-41265	.	_	

#Text=Confirming the association of PTSD with OFC/VMPFC function, a meta-analysis of 79 neuroimaging studies of PTSD also concluded that PTSD is associated with hypoactivity of ventromedial prefrontal regions, as well as of the inferior frontal gyrus.
221-1	41266-41276	Confirming	_	
221-2	41277-41280	the	_	
221-3	41281-41292	association	_	
221-4	41293-41295	of	_	
221-5	41296-41300	PTSD	_	
221-6	41301-41305	with	_	
221-7	41306-41309	OFC	_	
221-8	41309-41310	/	_	
221-9	41310-41315	VMPFC	_	
221-10	41316-41324	function	_	
221-11	41324-41325	,	_	
221-12	41326-41327	a	_	
221-13	41328-41341	meta-analysis	_	
221-14	41342-41344	of	_	
221-15	41345-41347	79	_	
221-16	41348-41360	neuroimaging	_	
221-17	41361-41368	studies	_	
221-18	41369-41371	of	_	
221-19	41372-41376	PTSD	_	
221-20	41377-41381	also	_	
221-21	41382-41391	concluded	_	
221-22	41392-41396	that	_	
221-23	41397-41401	PTSD	_	
221-24	41402-41404	is	_	
221-25	41405-41415	associated	_	
221-26	41416-41420	with	_	
221-27	41421-41433	hypoactivity	_	
221-28	41434-41436	of	_	
221-29	41437-41449	ventromedial	_	
221-30	41450-41460	prefrontal	_	
221-31	41461-41468	regions	_	
221-32	41468-41469	,	_	
221-33	41470-41472	as	_	
221-34	41473-41477	well	_	
221-35	41478-41480	as	_	
221-36	41481-41483	of	_	
221-37	41484-41487	the	_	
221-38	41488-41496	inferior	_	
221-39	41497-41504	frontal	_	
221-40	41505-41510	gyrus	_	
221-41	41510-41511	.	_	

#Text=The OFC is also a stress-sensitive cortical structure.
222-1	41512-41515	The	_	
222-2	41516-41519	OFC	_	
222-3	41520-41522	is	_	
222-4	41523-41527	also	_	
222-5	41528-41529	a	_	
222-6	41530-41546	stress-sensitive	_	
222-7	41547-41555	cortical	_	
222-8	41556-41565	structure	_	
222-9	41565-41566	.	_	

#Text=Pre-clinical research has established that chronic stress exposure leads to dendritic atrophy of the medial and orbital OFC, and altered activity of forebrain glucocorticoid receptors, which are involved in feedback regulation of the HPA-axis.
223-1	41567-41579	Pre-clinical	_	
223-2	41580-41588	research	_	
223-3	41589-41592	has	_	
223-4	41593-41604	established	_	
223-5	41605-41609	that	_	
223-6	41610-41617	chronic	_	
223-7	41618-41624	stress	_	
223-8	41625-41633	exposure	_	
223-9	41634-41639	leads	_	
223-10	41640-41642	to	_	
223-11	41643-41652	dendritic	_	
223-12	41653-41660	atrophy	_	
223-13	41661-41663	of	_	
223-14	41664-41667	the	_	
223-15	41668-41674	medial	_	
223-16	41675-41678	and	_	
223-17	41679-41686	orbital	_	
223-18	41687-41690	OFC	_	
223-19	41690-41691	,	_	
223-20	41692-41695	and	_	
223-21	41696-41703	altered	_	
223-22	41704-41712	activity	_	
223-23	41713-41715	of	_	
223-24	41716-41725	forebrain	_	
223-25	41726-41740	glucocorticoid	_	
223-26	41741-41750	receptors	_	
223-27	41750-41751	,	_	
223-28	41752-41757	which	_	
223-29	41758-41761	are	_	
223-30	41762-41770	involved	_	
223-31	41771-41773	in	_	
223-32	41774-41782	feedback	_	
223-33	41783-41793	regulation	_	
223-34	41794-41796	of	_	
223-35	41797-41800	the	_	
223-36	41801-41809	HPA-axis	_	
223-37	41809-41810	.	_	

#Text=It is repeatedly observed that adults and youth who experience childhood adversity have structural abnormalities of the OFC, expressed as reduced gray matter volumes.
224-1	41811-41813	It	_	
224-2	41814-41816	is	_	
224-3	41817-41827	repeatedly	_	
224-4	41828-41836	observed	_	
224-5	41837-41841	that	_	
224-6	41842-41848	adults	_	
224-7	41849-41852	and	_	
224-8	41853-41858	youth	_	
224-9	41859-41862	who	_	
224-10	41863-41873	experience	_	
224-11	41874-41883	childhood	_	
224-12	41884-41893	adversity	_	
224-13	41894-41898	have	_	
224-14	41899-41909	structural	_	
224-15	41910-41923	abnormalities	_	
224-16	41924-41926	of	_	
224-17	41927-41930	the	_	
224-18	41931-41934	OFC	_	
224-19	41934-41935	,	_	
224-20	41936-41945	expressed	_	
224-21	41946-41948	as	_	
224-22	41949-41956	reduced	_	
224-23	41957-41961	gray	_	
224-24	41962-41968	matter	_	
224-25	41969-41976	volumes	_	
224-26	41976-41977	.	_	

#Text=It is possible that depressed metabolism and volume of the OFC is a consequence of early experiences, which generate a vulnerability for the development of PTSD in response to traumas.
225-1	41978-41980	It	_	
225-2	41981-41983	is	_	
225-3	41984-41992	possible	_	
225-4	41993-41997	that	_	
225-5	41998-42007	depressed	_	
225-6	42008-42018	metabolism	_	
225-7	42019-42022	and	_	
225-8	42023-42029	volume	_	
225-9	42030-42032	of	_	
225-10	42033-42036	the	_	
225-11	42037-42040	OFC	_	
225-12	42041-42043	is	_	
225-13	42044-42045	a	_	
225-14	42046-42057	consequence	_	
225-15	42058-42060	of	_	
225-16	42061-42066	early	_	
225-17	42067-42078	experiences	_	
225-18	42078-42079	,	_	
225-19	42080-42085	which	_	
225-20	42086-42094	generate	_	
225-21	42095-42096	a	_	
225-22	42097-42110	vulnerability	_	
225-23	42111-42114	for	_	
225-24	42115-42118	the	_	
225-25	42119-42130	development	_	
225-26	42131-42133	of	_	
225-27	42134-42138	PTSD	_	
225-28	42139-42141	in	_	
225-29	42142-42150	response	_	
225-30	42151-42153	to	_	
225-31	42154-42161	traumas	_	
225-32	42161-42162	.	_	

#Text=Alternatively, OFC atrophy and hypometabolism could also reflect the neurobiological consequences of traumatic stress and PTSD itself.
226-1	42163-42176	Alternatively	_	
226-2	42176-42177	,	_	
226-3	42178-42181	OFC	_	
226-4	42182-42189	atrophy	_	
226-5	42190-42193	and	_	
226-6	42194-42208	hypometabolism	_	
226-7	42209-42214	could	_	
226-8	42215-42219	also	_	
226-9	42220-42227	reflect	_	
226-10	42228-42231	the	_	
226-11	42232-42247	neurobiological	_	
226-12	42248-42260	consequences	_	
226-13	42261-42263	of	_	
226-14	42264-42273	traumatic	_	
226-15	42274-42280	stress	_	
226-16	42281-42284	and	_	
226-17	42285-42289	PTSD	_	
226-18	42290-42296	itself	_	
226-19	42296-42297	.	_	

#Text=Suggestively, report that maltreated youth with PTSD have decreased VMPFC gray matter volume relative both to maltreated youth without PTSD and non-maltreated controls.
227-1	42298-42310	Suggestively	_	
227-2	42310-42311	,	_	
227-3	42312-42318	report	_	
227-4	42319-42323	that	_	
227-5	42324-42334	maltreated	_	
227-6	42335-42340	youth	_	
227-7	42341-42345	with	_	
227-8	42346-42350	PTSD	_	
227-9	42351-42355	have	_	
227-10	42356-42365	decreased	_	
227-11	42366-42371	VMPFC	_	
227-12	42372-42376	gray	_	
227-13	42377-42383	matter	_	
227-14	42384-42390	volume	_	
227-15	42391-42399	relative	_	
227-16	42400-42404	both	_	
227-17	42405-42407	to	_	
227-18	42408-42418	maltreated	_	
227-19	42419-42424	youth	_	
227-20	42425-42432	without	_	
227-21	42433-42437	PTSD	_	
227-22	42438-42441	and	_	
227-23	42442-42456	non-maltreated	_	
227-24	42457-42465	controls	_	
227-25	42465-42466	.	_	

#Text=More directly, Dahlgren and colleagues reported a twin study indicating that diminished medial prefrontal function is an acquired (rather than pre-existing) feature of PTSD.
228-1	42467-42471	More	_	
228-2	42472-42480	directly	_	
228-3	42480-42481	,	_	
228-4	42482-42490	Dahlgren	_	
228-5	42491-42494	and	_	
228-6	42495-42505	colleagues	_	
228-7	42506-42514	reported	_	
228-8	42515-42516	a	_	
228-9	42517-42521	twin	_	
228-10	42522-42527	study	_	
228-11	42528-42538	indicating	_	
228-12	42539-42543	that	_	
228-13	42544-42554	diminished	_	
228-14	42555-42561	medial	_	
228-15	42562-42572	prefrontal	_	
228-16	42573-42581	function	_	
228-17	42582-42584	is	_	
228-18	42585-42587	an	_	
228-19	42588-42596	acquired	_	
228-20	42597-42598	(	_	
228-21	42598-42604	rather	_	
228-22	42605-42609	than	_	
228-23	42610-42622	pre-existing	_	
228-24	42622-42623	)	_	
228-25	42624-42631	feature	_	
228-26	42632-42634	of	_	
228-27	42635-42639	PTSD	_	
228-28	42639-42640	.	_	

#Text=Our data also suggest that diminished OFC network strength is predictive of current PTSD.
229-1	42641-42644	Our	_	
229-2	42645-42649	data	_	
229-3	42650-42654	also	_	
229-4	42655-42662	suggest	_	
229-5	42663-42667	that	_	
229-6	42668-42678	diminished	_	
229-7	42679-42682	OFC	_	
229-8	42683-42690	network	_	
229-9	42691-42699	strength	_	
229-10	42700-42702	is	_	
229-11	42703-42713	predictive	_	
229-12	42714-42716	of	_	
229-13	42717-42724	current	_	
229-14	42725-42729	PTSD	_	
229-15	42729-42730	.	_	

#Text=We further observed that the strength of the OFC network for each subject was negatively associated with the severity of sexual trauma history across all participants, over-and-above the contribution of PTSD status alone.
230-1	42731-42733	We	_	
230-2	42734-42741	further	_	
230-3	42742-42750	observed	_	
230-4	42751-42755	that	_	
230-5	42756-42759	the	_	
230-6	42760-42768	strength	_	
230-7	42769-42771	of	_	
230-8	42772-42775	the	_	
230-9	42776-42779	OFC	_	
230-10	42780-42787	network	_	
230-11	42788-42791	for	_	
230-12	42792-42796	each	_	
230-13	42797-42804	subject	_	
230-14	42805-42808	was	_	
230-15	42809-42819	negatively	_	
230-16	42820-42830	associated	_	
230-17	42831-42835	with	_	
230-18	42836-42839	the	_	
230-19	42840-42848	severity	_	
230-20	42849-42851	of	_	
230-21	42852-42858	sexual	_	
230-22	42859-42865	trauma	_	
230-23	42866-42873	history	_	
230-24	42874-42880	across	_	
230-25	42881-42884	all	_	
230-26	42885-42897	participants	_	
230-27	42897-42898	,	_	
230-28	42899-42913	over-and-above	_	
230-29	42914-42917	the	_	
230-30	42918-42930	contribution	_	
230-31	42931-42933	of	_	
230-32	42934-42938	PTSD	_	
230-33	42939-42945	status	_	
230-34	42946-42951	alone	_	
230-35	42951-42952	.	_	

#Text=These results suggest that functional integrity of the OFC network is also sensitive to the cumulative effects of exposure to sexual trauma in women with SUD.
231-1	42953-42958	These	_	
231-2	42959-42966	results	_	
231-3	42967-42974	suggest	_	
231-4	42975-42979	that	_	
231-5	42980-42990	functional	_	
231-6	42991-43000	integrity	_	
231-7	43001-43003	of	_	
231-8	43004-43007	the	_	
231-9	43008-43011	OFC	_	
231-10	43012-43019	network	_	
231-11	43020-43022	is	_	
231-12	43023-43027	also	_	
231-13	43028-43037	sensitive	_	
231-14	43038-43040	to	_	
231-15	43041-43044	the	_	
231-16	43045-43055	cumulative	_	
231-17	43056-43063	effects	_	
231-18	43064-43066	of	_	
231-19	43067-43075	exposure	_	
231-20	43076-43078	to	_	
231-21	43079-43085	sexual	_	
231-22	43086-43092	trauma	_	
231-23	43093-43095	in	_	
231-24	43096-43101	women	_	
231-25	43102-43106	with	_	
231-26	43107-43110	SUD	_	
231-27	43110-43111	.	_	

#Text=The spatial differences in orbitofrontal network connectivity manifested in a set of brain regions associated with interoception, somatosensation, bodily self-consciousness, and cognitive control.
232-1	43112-43115	The	_	
232-2	43116-43123	spatial	_	
232-3	43124-43135	differences	_	
232-4	43136-43138	in	_	
232-5	43139-43152	orbitofrontal	_	
232-6	43153-43160	network	_	
232-7	43161-43173	connectivity	_	
232-8	43174-43184	manifested	_	
232-9	43185-43187	in	_	
232-10	43188-43189	a	_	
232-11	43190-43193	set	_	
232-12	43194-43196	of	_	
232-13	43197-43202	brain	_	
232-14	43203-43210	regions	_	
232-15	43211-43221	associated	_	
232-16	43222-43226	with	_	
232-17	43227-43240	interoception	_	
232-18	43240-43241	,	_	
232-19	43242-43257	somatosensation	_	
232-20	43257-43258	,	_	
232-21	43259-43265	bodily	_	
232-22	43266-43284	self-consciousness	_	
232-23	43284-43285	,	_	
232-24	43286-43289	and	_	
232-25	43290-43299	cognitive	_	
232-26	43300-43307	control	_	
232-27	43307-43308	.	_	

#Text=Concerning visceral and somatic sensation, the PTSD group demonstrated reduced bilateral mid-posterior insula and somatosensory cortex functional connectivity with the OFC network, which may suggest weaker interoceptive and somatic representations of the body and viscera during breath awareness.
233-1	43309-43319	Concerning	_	
233-2	43320-43328	visceral	_	
233-3	43329-43332	and	_	
233-4	43333-43340	somatic	_	
233-5	43341-43350	sensation	_	
233-6	43350-43351	,	_	
233-7	43352-43355	the	_	
233-8	43356-43360	PTSD	_	
233-9	43361-43366	group	_	
233-10	43367-43379	demonstrated	_	
233-11	43380-43387	reduced	_	
233-12	43388-43397	bilateral	_	
233-13	43398-43411	mid-posterior	_	
233-14	43412-43418	insula	_	
233-15	43419-43422	and	_	
233-16	43423-43436	somatosensory	_	
233-17	43437-43443	cortex	_	
233-18	43444-43454	functional	_	
233-19	43455-43467	connectivity	_	
233-20	43468-43472	with	_	
233-21	43473-43476	the	_	
233-22	43477-43480	OFC	_	
233-23	43481-43488	network	_	
233-24	43488-43489	,	_	
233-25	43490-43495	which	_	
233-26	43496-43499	may	_	
233-27	43500-43507	suggest	_	
233-28	43508-43514	weaker	_	
233-29	43515-43528	interoceptive	_	
233-30	43529-43532	and	_	
233-31	43533-43540	somatic	_	
233-32	43541-43556	representations	_	
233-33	43557-43559	of	_	
233-34	43560-43563	the	_	
233-35	43564-43568	body	_	
233-36	43569-43572	and	_	
233-37	43573-43580	viscera	_	
233-38	43581-43587	during	_	
233-39	43588-43594	breath	_	
233-40	43595-43604	awareness	_	
233-41	43604-43605	.	_	

#Text=The mid-posterior insula is the terminus of major vagal and spinothalamic lamina I pathways that convey homeostatic and viscerosensory information to the cortex.
234-1	43606-43609	The	_	
234-2	43610-43623	mid-posterior	_	
234-3	43624-43630	insula	_	
234-4	43631-43633	is	_	
234-5	43634-43637	the	_	
234-6	43638-43646	terminus	_	
234-7	43647-43649	of	_	
234-8	43650-43655	major	_	
234-9	43656-43661	vagal	_	
234-10	43662-43665	and	_	
234-11	43666-43679	spinothalamic	_	
234-12	43680-43686	lamina	_	
234-13	43687-43688	I	_	
234-14	43689-43697	pathways	_	
234-15	43698-43702	that	_	
234-16	43703-43709	convey	_	
234-17	43710-43721	homeostatic	_	
234-18	43722-43725	and	_	
234-19	43726-43740	viscerosensory	_	
234-20	43741-43752	information	_	
234-21	43753-43755	to	_	
234-22	43756-43759	the	_	
234-23	43760-43766	cortex	_	
234-24	43766-43767	.	_	

#Text=Activity in this region is responsive to homeostatic states and interoceptive manipulations.
235-1	43768-43776	Activity	_	
235-2	43777-43779	in	_	
235-3	43780-43784	this	_	
235-4	43785-43791	region	_	
235-5	43792-43794	is	_	
235-6	43795-43805	responsive	_	
235-7	43806-43808	to	_	
235-8	43809-43820	homeostatic	_	
235-9	43821-43827	states	_	
235-10	43828-43831	and	_	
235-11	43832-43845	interoceptive	_	
235-12	43846-43859	manipulations	_	
235-13	43859-43860	.	_	

#Text=According to one model, interoceptive information is propagated along a posterior-anterior axis in the insula, eventually reaching the orbitofrontal cortices, whereby visceral status can affect mood as well as goal-directed behaviors, including drug seeking.
236-1	43861-43870	According	_	
236-2	43871-43873	to	_	
236-3	43874-43877	one	_	
236-4	43878-43883	model	_	
236-5	43883-43884	,	_	
236-6	43885-43898	interoceptive	_	
236-7	43899-43910	information	_	
236-8	43911-43913	is	_	
236-9	43914-43924	propagated	_	
236-10	43925-43930	along	_	
236-11	43931-43932	a	_	
236-12	43933-43951	posterior-anterior	_	
236-13	43952-43956	axis	_	
236-14	43957-43959	in	_	
236-15	43960-43963	the	_	
236-16	43964-43970	insula	_	
236-17	43970-43971	,	_	
236-18	43972-43982	eventually	_	
236-19	43983-43991	reaching	_	
236-20	43992-43995	the	_	
236-21	43996-44009	orbitofrontal	_	
236-22	44010-44018	cortices	_	
236-23	44018-44019	,	_	
236-24	44020-44027	whereby	_	
236-25	44028-44036	visceral	_	
236-26	44037-44043	status	_	
236-27	44044-44047	can	_	
236-28	44048-44054	affect	_	
236-29	44055-44059	mood	_	
236-30	44060-44062	as	_	
236-31	44063-44067	well	_	
236-32	44068-44070	as	_	
236-33	44071-44084	goal-directed	_	
236-34	44085-44094	behaviors	_	
236-35	44094-44095	,	_	
236-36	44096-44105	including	_	
236-37	44106-44110	drug	_	
236-38	44111-44118	seeking	_	
236-39	44118-44119	.	_	

#Text=Mindful or attentive breathing exercises can be seen as an interoceptive manipulation.
237-1	44120-44127	Mindful	_	
237-2	44128-44130	or	_	
237-3	44131-44140	attentive	_	
237-4	44141-44150	breathing	_	
237-5	44151-44160	exercises	_	
237-6	44161-44164	can	_	
237-7	44165-44167	be	_	
237-8	44168-44172	seen	_	
237-9	44173-44175	as	_	
237-10	44176-44178	an	_	
237-11	44179-44192	interoceptive	_	
237-12	44193-44205	manipulation	_	
237-13	44205-44206	.	_	

#Text=Brief interventions that employ attention to breathing are known to transiently decrease subjective states of distress in both clinical and healthy populations.
238-1	44207-44212	Brief	_	
238-2	44213-44226	interventions	_	
238-3	44227-44231	that	_	
238-4	44232-44238	employ	_	
238-5	44239-44248	attention	_	
238-6	44249-44251	to	_	
238-7	44252-44261	breathing	_	
238-8	44262-44265	are	_	
238-9	44266-44271	known	_	
238-10	44272-44274	to	_	
238-11	44275-44286	transiently	_	
238-12	44287-44295	decrease	_	
238-13	44296-44306	subjective	_	
238-14	44307-44313	states	_	
238-15	44314-44316	of	_	
238-16	44317-44325	distress	_	
238-17	44326-44328	in	_	
238-18	44329-44333	both	_	
238-19	44334-44342	clinical	_	
238-20	44343-44346	and	_	
238-21	44347-44354	healthy	_	
238-22	44355-44366	populations	_	
238-23	44366-44367	.	_	

#Text=In an fMRI paradigm, attention to breathing also downregulates amygdala responses and increases prefrontal activity during emotional picture viewing, which suggests a potential brain mechanism through which mindfulness practices may support emotion regulation.
239-1	44368-44370	In	_	
239-2	44371-44373	an	_	
239-3	44374-44378	fMRI	_	
239-4	44379-44387	paradigm	_	
239-5	44387-44388	,	_	
239-6	44389-44398	attention	_	
239-7	44399-44401	to	_	
239-8	44402-44411	breathing	_	
239-9	44412-44416	also	_	
239-10	44417-44430	downregulates	_	
239-11	44431-44439	amygdala	_	
239-12	44440-44449	responses	_	
239-13	44450-44453	and	_	
239-14	44454-44463	increases	_	
239-15	44464-44474	prefrontal	_	
239-16	44475-44483	activity	_	
239-17	44484-44490	during	_	
239-18	44491-44500	emotional	_	
239-19	44501-44508	picture	_	
239-20	44509-44516	viewing	_	
239-21	44516-44517	,	_	
239-22	44518-44523	which	_	
239-23	44524-44532	suggests	_	
239-24	44533-44534	a	_	
239-25	44535-44544	potential	_	
239-26	44545-44550	brain	_	
239-27	44551-44560	mechanism	_	
239-28	44561-44568	through	_	
239-29	44569-44574	which	_	
239-30	44575-44586	mindfulness	_	
239-31	44587-44596	practices	_	
239-32	44597-44600	may	_	
239-33	44601-44608	support	_	
239-34	44609-44616	emotion	_	
239-35	44617-44627	regulation	_	
239-36	44627-44628	.	_	

#Text=Activation of lateral prefrontal regions are also observed in fMRI studies of focused-meditation.
240-1	44629-44639	Activation	_	
240-2	44640-44642	of	_	
240-3	44643-44650	lateral	_	
240-4	44651-44661	prefrontal	_	
240-5	44662-44669	regions	_	
240-6	44670-44673	are	_	
240-7	44674-44678	also	_	
240-8	44679-44687	observed	_	
240-9	44688-44690	in	_	
240-10	44691-44695	fMRI	_	
240-11	44696-44703	studies	_	
240-12	44704-44706	of	_	
240-13	44707-44725	focused-meditation	_	
240-14	44725-44726	.	_	

#Text=In particular, reported that greater dorsolateral prefrontal activity was associated with periods of greater self-reported focus during such exercises, whereas it diminished during periods of mind-wandering and “awareness of” mindbwandering.
241-1	44727-44729	In	_	
241-2	44730-44740	particular	_	
241-3	44740-44741	,	_	
241-4	44742-44750	reported	_	
241-5	44751-44755	that	_	
241-6	44756-44763	greater	_	
241-7	44764-44776	dorsolateral	_	
241-8	44777-44787	prefrontal	_	
241-9	44788-44796	activity	_	
241-10	44797-44800	was	_	
241-11	44801-44811	associated	_	
241-12	44812-44816	with	_	
241-13	44817-44824	periods	_	
241-14	44825-44827	of	_	
241-15	44828-44835	greater	_	
241-16	44836-44849	self-reported	_	
241-17	44850-44855	focus	_	
241-18	44856-44862	during	_	
241-19	44863-44867	such	_	
241-20	44868-44877	exercises	_	
241-21	44877-44878	,	_	
241-22	44879-44886	whereas	_	
241-23	44887-44889	it	_	
241-24	44890-44900	diminished	_	
241-25	44901-44907	during	_	
241-26	44908-44915	periods	_	
241-27	44916-44918	of	_	
241-28	44919-44933	mind-wandering	_	
241-29	44934-44937	and	_	
241-30	44938-44939	“	_	
241-31	44939-44948	awareness	_	
241-32	44949-44951	of	_	
241-33	44951-44952	”	_	
241-34	44953-44967	mindbwandering	_	
241-35	44967-44968	.	_	

#Text=These reports suggest that cognitive control is required to sustain attention on body sensations and inhibit mind-wandering.
242-1	44969-44974	These	_	
242-2	44975-44982	reports	_	
242-3	44983-44990	suggest	_	
242-4	44991-44995	that	_	
242-5	44996-45005	cognitive	_	
242-6	45006-45013	control	_	
242-7	45014-45016	is	_	
242-8	45017-45025	required	_	
242-9	45026-45028	to	_	
242-10	45029-45036	sustain	_	
242-11	45037-45046	attention	_	
242-12	45047-45049	on	_	
242-13	45050-45054	body	_	
242-14	45055-45065	sensations	_	
242-15	45066-45069	and	_	
242-16	45070-45077	inhibit	_	
242-17	45078-45092	mind-wandering	_	
242-18	45092-45093	.	_	

#Text=In our study we observed reduced OFC functional connectivity with the dorsal and ventrolateral prefrontal regions in the PTSD group relative to the noPTSD group.
243-1	45094-45096	In	_	
243-2	45097-45100	our	_	
243-3	45101-45106	study	_	
243-4	45107-45109	we	_	
243-5	45110-45118	observed	_	
243-6	45119-45126	reduced	_	
243-7	45127-45130	OFC	_	
243-8	45131-45141	functional	_	
243-9	45142-45154	connectivity	_	
243-10	45155-45159	with	_	
243-11	45160-45163	the	_	
243-12	45164-45170	dorsal	_	
243-13	45171-45174	and	_	
243-14	45175-45188	ventrolateral	_	
243-15	45189-45199	prefrontal	_	
243-16	45200-45207	regions	_	
243-17	45208-45210	in	_	
243-18	45211-45214	the	_	
243-19	45215-45219	PTSD	_	
243-20	45220-45225	group	_	
243-21	45226-45234	relative	_	
243-22	45235-45237	to	_	
243-23	45238-45241	the	_	
243-24	45242-45248	noPTSD	_	
243-25	45249-45254	group	_	
243-26	45254-45255	.	_	

#Text=Furthermore, it is reported that in women with PTSD, low executive functioning is related to greater intrusive thought persistence and cognitive avoidance strategies.
244-1	45256-45267	Furthermore	_	
244-2	45267-45268	,	_	
244-3	45269-45271	it	_	
244-4	45272-45274	is	_	
244-5	45275-45283	reported	_	
244-6	45284-45288	that	_	
244-7	45289-45291	in	_	
244-8	45292-45297	women	_	
244-9	45298-45302	with	_	
244-10	45303-45307	PTSD	_	
244-11	45307-45308	,	_	
244-12	45309-45312	low	_	
244-13	45313-45322	executive	_	
244-14	45323-45334	functioning	_	
244-15	45335-45337	is	_	
244-16	45338-45345	related	_	
244-17	45346-45348	to	_	
244-18	45349-45356	greater	_	
244-19	45357-45366	intrusive	_	
244-20	45367-45374	thought	_	
244-21	45375-45386	persistence	_	
244-22	45387-45390	and	_	
244-23	45391-45400	cognitive	_	
244-24	45401-45410	avoidance	_	
244-25	45411-45421	strategies	_	
244-26	45421-45422	.	_	

#Text=Initially, women with SUD-PTSD comorbidity may have more difficulties engaging the interoceptive and attentional resources that may support emotional regulation in the context of mindfulness practices, which could be relevant to understanding the efficacy of mindfulness-based interventions for this sub-population.
245-1	45423-45432	Initially	_	
245-2	45432-45433	,	_	
245-3	45434-45439	women	_	
245-4	45440-45444	with	_	
245-5	45445-45453	SUD-PTSD	_	
245-6	45454-45465	comorbidity	_	
245-7	45466-45469	may	_	
245-8	45470-45474	have	_	
245-9	45475-45479	more	_	
245-10	45480-45492	difficulties	_	
245-11	45493-45501	engaging	_	
245-12	45502-45505	the	_	
245-13	45506-45519	interoceptive	_	
245-14	45520-45523	and	_	
245-15	45524-45535	attentional	_	
245-16	45536-45545	resources	_	
245-17	45546-45550	that	_	
245-18	45551-45554	may	_	
245-19	45555-45562	support	_	
245-20	45563-45572	emotional	_	
245-21	45573-45583	regulation	_	
245-22	45584-45586	in	_	
245-23	45587-45590	the	_	
245-24	45591-45598	context	_	
245-25	45599-45601	of	_	
245-26	45602-45613	mindfulness	_	
245-27	45614-45623	practices	_	
245-28	45623-45624	,	_	
245-29	45625-45630	which	_	
245-30	45631-45636	could	_	
245-31	45637-45639	be	_	
245-32	45640-45648	relevant	_	
245-33	45649-45651	to	_	
245-34	45652-45665	understanding	_	
245-35	45666-45669	the	_	
245-36	45670-45678	efficacy	_	
245-37	45679-45681	of	_	
245-38	45682-45699	mindfulness-based	_	
245-39	45700-45713	interventions	_	
245-40	45714-45717	for	_	
245-41	45718-45722	this	_	
245-42	45723-45737	sub-population	_	
245-43	45737-45738	.	_	

#Text=In addition to the insula, in the PTSD group we also observed reduced OFC functional connectivity with the angular gyrus/temporal-parietal junction (TPJ) and lateral occipital cortex (in particular, an area consistent with the extrastriate body area).
246-1	45739-45741	In	_	
246-2	45742-45750	addition	_	
246-3	45751-45753	to	_	
246-4	45754-45757	the	_	
246-5	45758-45764	insula	_	
246-6	45764-45765	,	_	
246-7	45766-45768	in	_	
246-8	45769-45772	the	_	
246-9	45773-45777	PTSD	_	
246-10	45778-45783	group	_	
246-11	45784-45786	we	_	
246-12	45787-45791	also	_	
246-13	45792-45800	observed	_	
246-14	45801-45808	reduced	_	
246-15	45809-45812	OFC	_	
246-16	45813-45823	functional	_	
246-17	45824-45836	connectivity	_	
246-18	45837-45841	with	_	
246-19	45842-45845	the	_	
246-20	45846-45853	angular	_	
246-21	45854-45859	gyrus	_	
246-22	45859-45860	/	_	
246-23	45860-45877	temporal-parietal	_	
246-24	45878-45886	junction	_	
246-25	45887-45888	(	_	
246-26	45888-45891	TPJ	_	
246-27	45891-45892	)	_	
246-28	45893-45896	and	_	
246-29	45897-45904	lateral	_	
246-30	45905-45914	occipital	_	
246-31	45915-45921	cortex	_	
246-32	45922-45923	(	_	
246-33	45923-45925	in	_	
246-34	45926-45936	particular	_	
246-35	45936-45937	,	_	
246-36	45938-45940	an	_	
246-37	45941-45945	area	_	
246-38	45946-45956	consistent	_	
246-39	45957-45961	with	_	
246-40	45962-45965	the	_	
246-41	45966-45978	extrastriate	_	
246-42	45979-45983	body	_	
246-43	45984-45988	area	_	
246-44	45988-45989	)	_	
246-45	45989-45990	.	_	

#Text=These areas are involved in sensorimotor integration of vestibular, interoceptive, proprioceptive, motor, and visual inputs that support the sense of body ownership, agency, first-person perspective and localization in space.
247-1	45991-45996	These	_	
247-2	45997-46002	areas	_	
247-3	46003-46006	are	_	
247-4	46007-46015	involved	_	
247-5	46016-46018	in	_	
247-6	46019-46031	sensorimotor	_	
247-7	46032-46043	integration	_	
247-8	46044-46046	of	_	
247-9	46047-46057	vestibular	_	
247-10	46057-46058	,	_	
247-11	46059-46072	interoceptive	_	
247-12	46072-46073	,	_	
247-13	46074-46088	proprioceptive	_	
247-14	46088-46089	,	_	
247-15	46090-46095	motor	_	
247-16	46095-46096	,	_	
247-17	46097-46100	and	_	
247-18	46101-46107	visual	_	
247-19	46108-46114	inputs	_	
247-20	46115-46119	that	_	
247-21	46120-46127	support	_	
247-22	46128-46131	the	_	
247-23	46132-46137	sense	_	
247-24	46138-46140	of	_	
247-25	46141-46145	body	_	
247-26	46146-46155	ownership	_	
247-27	46155-46156	,	_	
247-28	46157-46163	agency	_	
247-29	46163-46164	,	_	
247-30	46165-46177	first-person	_	
247-31	46178-46189	perspective	_	
247-32	46190-46193	and	_	
247-33	46194-46206	localization	_	
247-34	46207-46209	in	_	
247-35	46210-46215	space	_	
247-36	46215-46216	.	_	

#Text=Associative pairing of self to a visual symbol also activates these regions relative to associative pairing of visual symbols to non-self objects, and lesions of the extrastriate and temporo-parietal cortices can produce disorders of bodily self-consciousness, and these regions appear to be relevant to dissociative PTSD.
248-1	46217-46228	Associative	_	
248-2	46229-46236	pairing	_	
248-3	46237-46239	of	_	
248-4	46240-46244	self	_	
248-5	46245-46247	to	_	
248-6	46248-46249	a	_	
248-7	46250-46256	visual	_	
248-8	46257-46263	symbol	_	
248-9	46264-46268	also	_	
248-10	46269-46278	activates	_	
248-11	46279-46284	these	_	
248-12	46285-46292	regions	_	
248-13	46293-46301	relative	_	
248-14	46302-46304	to	_	
248-15	46305-46316	associative	_	
248-16	46317-46324	pairing	_	
248-17	46325-46327	of	_	
248-18	46328-46334	visual	_	
248-19	46335-46342	symbols	_	
248-20	46343-46345	to	_	
248-21	46346-46354	non-self	_	
248-22	46355-46362	objects	_	
248-23	46362-46363	,	_	
248-24	46364-46367	and	_	
248-25	46368-46375	lesions	_	
248-26	46376-46378	of	_	
248-27	46379-46382	the	_	
248-28	46383-46395	extrastriate	_	
248-29	46396-46399	and	_	
248-30	46400-46416	temporo-parietal	_	
248-31	46417-46425	cortices	_	
248-32	46426-46429	can	_	
248-33	46430-46437	produce	_	
248-34	46438-46447	disorders	_	
248-35	46448-46450	of	_	
248-36	46451-46457	bodily	_	
248-37	46458-46476	self-consciousness	_	
248-38	46476-46477	,	_	
248-39	46478-46481	and	_	
248-40	46482-46487	these	_	
248-41	46488-46495	regions	_	
248-42	46496-46502	appear	_	
248-43	46503-46505	to	_	
248-44	46506-46508	be	_	
248-45	46509-46517	relevant	_	
248-46	46518-46520	to	_	
248-47	46521-46533	dissociative	_	
248-48	46534-46538	PTSD	_	
248-49	46538-46539	.	_	

#Text=TPJ activations have also been observed during breath awareness paradigms.
249-1	46540-46543	TPJ	_	
249-2	46544-46555	activations	_	
249-3	46556-46560	have	_	
249-4	46561-46565	also	_	
249-5	46566-46570	been	_	
249-6	46571-46579	observed	_	
249-7	46580-46586	during	_	
249-8	46587-46593	breath	_	
249-9	46594-46603	awareness	_	
249-10	46604-46613	paradigms	_	
249-11	46613-46614	.	_	

#Text=Observed differences in functional connectivity of these regions with the OFC network during interoceptive attention is particularly interesting given that reduced medial OFC metabolism has previously been associated with dissociative symptoms in PTSD.
250-1	46615-46623	Observed	_	
250-2	46624-46635	differences	_	
250-3	46636-46638	in	_	
250-4	46639-46649	functional	_	
250-5	46650-46662	connectivity	_	
250-6	46663-46665	of	_	
250-7	46666-46671	these	_	
250-8	46672-46679	regions	_	
250-9	46680-46684	with	_	
250-10	46685-46688	the	_	
250-11	46689-46692	OFC	_	
250-12	46693-46700	network	_	
250-13	46701-46707	during	_	
250-14	46708-46721	interoceptive	_	
250-15	46722-46731	attention	_	
250-16	46732-46734	is	_	
250-17	46735-46747	particularly	_	
250-18	46748-46759	interesting	_	
250-19	46760-46765	given	_	
250-20	46766-46770	that	_	
250-21	46771-46778	reduced	_	
250-22	46779-46785	medial	_	
250-23	46786-46789	OFC	_	
250-24	46790-46800	metabolism	_	
250-25	46801-46804	has	_	
250-26	46805-46815	previously	_	
250-27	46816-46820	been	_	
250-28	46821-46831	associated	_	
250-29	46832-46836	with	_	
250-30	46837-46849	dissociative	_	
250-31	46850-46858	symptoms	_	
250-32	46859-46861	in	_	
250-33	46862-46866	PTSD	_	
250-34	46866-46867	.	_	

#Text=Stress regulation, interoceptive exposure and mindfulness for relapse prevention
#Text=Stress increases the likelihood of relapse in individuals with histories of addiction, an effect which may be more pronounced in females with SUDs.
251-1	46868-46874	Stress	_	
251-2	46875-46885	regulation	_	
251-3	46885-46886	,	_	
251-4	46887-46900	interoceptive	_	
251-5	46901-46909	exposure	_	
251-6	46910-46913	and	_	
251-7	46914-46925	mindfulness	_	
251-8	46926-46929	for	_	
251-9	46930-46937	relapse	_	
251-10	46938-46948	prevention	_	
251-11	46949-46955	Stress	_	
251-12	46956-46965	increases	_	
251-13	46966-46969	the	_	
251-14	46970-46980	likelihood	_	
251-15	46981-46983	of	_	
251-16	46984-46991	relapse	_	
251-17	46992-46994	in	_	
251-18	46995-47006	individuals	_	
251-19	47007-47011	with	_	
251-20	47012-47021	histories	_	
251-21	47022-47024	of	_	
251-22	47025-47034	addiction	_	
251-23	47034-47035	,	_	
251-24	47036-47038	an	_	
251-25	47039-47045	effect	_	
251-26	47046-47051	which	_	
251-27	47052-47055	may	_	
251-28	47056-47058	be	_	
251-29	47059-47063	more	_	
251-30	47064-47074	pronounced	_	
251-31	47075-47077	in	_	
251-32	47078-47085	females	_	
251-33	47086-47090	with	_	
251-34	47091-47095	SUDs	_	
251-35	47095-47096	.	_	

#Text=In the context of traumatic stress, drug use may serve as an avoidance or numbing strategy in response to aversive interoceptive and emotional states.
252-1	47097-47099	In	_	
252-2	47100-47103	the	_	
252-3	47104-47111	context	_	
252-4	47112-47114	of	_	
252-5	47115-47124	traumatic	_	
252-6	47125-47131	stress	_	
252-7	47131-47132	,	_	
252-8	47133-47137	drug	_	
252-9	47138-47141	use	_	
252-10	47142-47145	may	_	
252-11	47146-47151	serve	_	
252-12	47152-47154	as	_	
252-13	47155-47157	an	_	
252-14	47158-47167	avoidance	_	
252-15	47168-47170	or	_	
252-16	47171-47178	numbing	_	
252-17	47179-47187	strategy	_	
252-18	47188-47190	in	_	
252-19	47191-47199	response	_	
252-20	47200-47202	to	_	
252-21	47203-47211	aversive	_	
252-22	47212-47225	interoceptive	_	
252-23	47226-47229	and	_	
252-24	47230-47239	emotional	_	
252-25	47240-47246	states	_	
252-26	47246-47247	.	_	

#Text=Use-withdrawal-relapse cycles contribute to dysregulation of HPA, sympathetic-adrenal medullary (SAM) and immune response systems which may worsen traumatic stress symptoms.
253-1	47248-47270	Use-withdrawal-relapse	_	
253-2	47271-47277	cycles	_	
253-3	47278-47288	contribute	_	
253-4	47289-47291	to	_	
253-5	47292-47305	dysregulation	_	
253-6	47306-47308	of	_	
253-7	47309-47312	HPA	_	
253-8	47312-47313	,	_	
253-9	47314-47333	sympathetic-adrenal	_	
253-10	47334-47343	medullary	_	
253-11	47344-47345	(	_	
253-12	47345-47348	SAM	_	
253-13	47348-47349	)	_	
253-14	47350-47353	and	_	
253-15	47354-47360	immune	_	
253-16	47361-47369	response	_	
253-17	47370-47377	systems	_	
253-18	47378-47383	which	_	
253-19	47384-47387	may	_	
253-20	47388-47394	worsen	_	
253-21	47395-47404	traumatic	_	
253-22	47405-47411	stress	_	
253-23	47412-47420	symptoms	_	
253-24	47420-47421	.	_	

#Text=Mindfulness treatments tailored to women with comorbid substance abuse and traumatic stress may be especially suited for addressing dysregulated stress responses that can precipitate relapse.
254-1	47422-47433	Mindfulness	_	
254-2	47434-47444	treatments	_	
254-3	47445-47453	tailored	_	
254-4	47454-47456	to	_	
254-5	47457-47462	women	_	
254-6	47463-47467	with	_	
254-7	47468-47476	comorbid	_	
254-8	47477-47486	substance	_	
254-9	47487-47492	abuse	_	
254-10	47493-47496	and	_	
254-11	47497-47506	traumatic	_	
254-12	47507-47513	stress	_	
254-13	47514-47517	may	_	
254-14	47518-47520	be	_	
254-15	47521-47531	especially	_	
254-16	47532-47538	suited	_	
254-17	47539-47542	for	_	
254-18	47543-47553	addressing	_	
254-19	47554-47566	dysregulated	_	
254-20	47567-47573	stress	_	
254-21	47574-47583	responses	_	
254-22	47584-47588	that	_	
254-23	47589-47592	can	_	
254-24	47593-47604	precipitate	_	
254-25	47605-47612	relapse	_	
254-26	47612-47613	.	_	

#Text=Specifically, certain mindfulness exercises such as focused breathing and the body scan may act as a form of interoceptive exposure therapy, as well as serve to re-integrate an embodied sense of self, and down-regulate stress-reactivity.
255-1	47614-47626	Specifically	_	
255-2	47626-47627	,	_	
255-3	47628-47635	certain	_	
255-4	47636-47647	mindfulness	_	
255-5	47648-47657	exercises	_	
255-6	47658-47662	such	_	
255-7	47663-47665	as	_	
255-8	47666-47673	focused	_	
255-9	47674-47683	breathing	_	
255-10	47684-47687	and	_	
255-11	47688-47691	the	_	
255-12	47692-47696	body	_	
255-13	47697-47701	scan	_	
255-14	47702-47705	may	_	
255-15	47706-47709	act	_	
255-16	47710-47712	as	_	
255-17	47713-47714	a	_	
255-18	47715-47719	form	_	
255-19	47720-47722	of	_	
255-20	47723-47736	interoceptive	_	
255-21	47737-47745	exposure	_	
255-22	47746-47753	therapy	_	
255-23	47753-47754	,	_	
255-24	47755-47757	as	_	
255-25	47758-47762	well	_	
255-26	47763-47765	as	_	
255-27	47766-47771	serve	_	
255-28	47772-47774	to	_	
255-29	47775-47787	re-integrate	_	
255-30	47788-47790	an	_	
255-31	47791-47799	embodied	_	
255-32	47800-47805	sense	_	
255-33	47806-47808	of	_	
255-34	47809-47813	self	_	
255-35	47813-47814	,	_	
255-36	47815-47818	and	_	
255-37	47819-47832	down-regulate	_	
255-38	47833-47850	stress-reactivity	_	
255-39	47850-47851	.	_	

#Text=In healthy individuals, mindfulness training has been found to strengthen white matter connectivity between insula and the prefrontal cortex, including the OFC.
256-1	47852-47854	In	_	
256-2	47855-47862	healthy	_	
256-3	47863-47874	individuals	_	
256-4	47874-47875	,	_	
256-5	47876-47887	mindfulness	_	
256-6	47888-47896	training	_	
256-7	47897-47900	has	_	
256-8	47901-47905	been	_	
256-9	47906-47911	found	_	
256-10	47912-47914	to	_	
256-11	47915-47925	strengthen	_	
256-12	47926-47931	white	_	
256-13	47932-47938	matter	_	
256-14	47939-47951	connectivity	_	
256-15	47952-47959	between	_	
256-16	47960-47966	insula	_	
256-17	47967-47970	and	_	
256-18	47971-47974	the	_	
256-19	47975-47985	prefrontal	_	
256-20	47986-47992	cortex	_	
256-21	47992-47993	,	_	
256-22	47994-48003	including	_	
256-23	48004-48007	the	_	
256-24	48008-48011	OFC	_	
256-25	48011-48012	.	_	

#Text=Moreover, part of mindfulness training consists of developing a metacognitive stance towards aversive physiological states, thoughts, and emotions, which may reduce dissociation and conditioned behaviors, including drug seeking, in response to interoceptive or psychological stressors.
257-1	48013-48021	Moreover	_	
257-2	48021-48022	,	_	
257-3	48023-48027	part	_	
257-4	48028-48030	of	_	
257-5	48031-48042	mindfulness	_	
257-6	48043-48051	training	_	
257-7	48052-48060	consists	_	
257-8	48061-48063	of	_	
257-9	48064-48074	developing	_	
257-10	48075-48076	a	_	
257-11	48077-48090	metacognitive	_	
257-12	48091-48097	stance	_	
257-13	48098-48105	towards	_	
257-14	48106-48114	aversive	_	
257-15	48115-48128	physiological	_	
257-16	48129-48135	states	_	
257-17	48135-48136	,	_	
257-18	48137-48145	thoughts	_	
257-19	48145-48146	,	_	
257-20	48147-48150	and	_	
257-21	48151-48159	emotions	_	
257-22	48159-48160	,	_	
257-23	48161-48166	which	_	
257-24	48167-48170	may	_	
257-25	48171-48177	reduce	_	
257-26	48178-48190	dissociation	_	
257-27	48191-48194	and	_	
257-28	48195-48206	conditioned	_	
257-29	48207-48216	behaviors	_	
257-30	48216-48217	,	_	
257-31	48218-48227	including	_	
257-32	48228-48232	drug	_	
257-33	48233-48240	seeking	_	
257-34	48240-48241	,	_	
257-35	48242-48244	in	_	
257-36	48245-48253	response	_	
257-37	48254-48256	to	_	
257-38	48257-48270	interoceptive	_	
257-39	48271-48273	or	_	
257-40	48274-48287	psychological	_	
257-41	48288-48297	stressors	_	
257-42	48297-48298	.	_	

#Text=Limitations and future directions
#Text=First, our sample size is modest for group comparisons.
258-1	48299-48310	Limitations	_	
258-2	48311-48314	and	_	
258-3	48315-48321	future	_	
258-4	48322-48332	directions	_	
258-5	48333-48338	First	_	
258-6	48338-48339	,	_	
258-7	48340-48343	our	_	
258-8	48344-48350	sample	_	
258-9	48351-48355	size	_	
258-10	48356-48358	is	_	
258-11	48359-48365	modest	_	
258-12	48366-48369	for	_	
258-13	48370-48375	group	_	
258-14	48376-48387	comparisons	_	
258-15	48387-48388	.	_	

#Text=However, we employed nonparametric permutation methods for inference of group differences, a statistically strict method which has been shown to generate minimal levels of false positives relative to parametric methods of inference, and we applied Bonferroni correction on the tests performed, further reducing the potential for false positives.
259-1	48389-48396	However	_	
259-2	48396-48397	,	_	
259-3	48398-48400	we	_	
259-4	48401-48409	employed	_	
259-5	48410-48423	nonparametric	_	
259-6	48424-48435	permutation	_	
259-7	48436-48443	methods	_	
259-8	48444-48447	for	_	
259-9	48448-48457	inference	_	
259-10	48458-48460	of	_	
259-11	48461-48466	group	_	
259-12	48467-48478	differences	_	
259-13	48478-48479	,	_	
259-14	48480-48481	a	_	
259-15	48482-48495	statistically	_	
259-16	48496-48502	strict	_	
259-17	48503-48509	method	_	
259-18	48510-48515	which	_	
259-19	48516-48519	has	_	
259-20	48520-48524	been	_	
259-21	48525-48530	shown	_	
259-22	48531-48533	to	_	
259-23	48534-48542	generate	_	
259-24	48543-48550	minimal	_	
259-25	48551-48557	levels	_	
259-26	48558-48560	of	_	
259-27	48561-48566	false	_	
259-28	48567-48576	positives	_	
259-29	48577-48585	relative	_	
259-30	48586-48588	to	_	
259-31	48589-48599	parametric	_	
259-32	48600-48607	methods	_	
259-33	48608-48610	of	_	
259-34	48611-48620	inference	_	
259-35	48620-48621	,	_	
259-36	48622-48625	and	_	
259-37	48626-48628	we	_	
259-38	48629-48636	applied	_	
259-39	48637-48647	Bonferroni	_	
259-40	48648-48658	correction	_	
259-41	48659-48661	on	_	
259-42	48662-48665	the	_	
259-43	48666-48671	tests	_	
259-44	48672-48681	performed	_	
259-45	48681-48682	,	_	
259-46	48683-48690	further	_	
259-47	48691-48699	reducing	_	
259-48	48700-48703	the	_	
259-49	48704-48713	potential	_	
259-50	48714-48717	for	_	
259-51	48718-48723	false	_	
259-52	48724-48733	positives	_	
259-53	48733-48734	.	_	

#Text=Moreover, the observation of depressed OFC network function and connectivity is highly consistent with prior studies.
260-1	48735-48743	Moreover	_	
260-2	48743-48744	,	_	
260-3	48745-48748	the	_	
260-4	48749-48760	observation	_	
260-5	48761-48763	of	_	
260-6	48764-48773	depressed	_	
260-7	48774-48777	OFC	_	
260-8	48778-48785	network	_	
260-9	48786-48794	function	_	
260-10	48795-48798	and	_	
260-11	48799-48811	connectivity	_	
260-12	48812-48814	is	_	
260-13	48815-48821	highly	_	
260-14	48822-48832	consistent	_	
260-15	48833-48837	with	_	
260-16	48838-48843	prior	_	
260-17	48844-48851	studies	_	
260-18	48851-48852	.	_	

#Text=Nevertheless, the risk of Type 1 error related to “file-drawer problems” is heightened when sample sizes are small, as is the case in the present study, and so the results presented here should not be taken as definitive.
261-1	48853-48865	Nevertheless	_	
261-2	48865-48866	,	_	
261-3	48867-48870	the	_	
261-4	48871-48875	risk	_	
261-5	48876-48878	of	_	
261-6	48879-48883	Type	_	
261-7	48884-48885	1	_	
261-8	48886-48891	error	_	
261-9	48892-48899	related	_	
261-10	48900-48902	to	_	
261-11	48903-48904	“	_	
261-12	48904-48915	file-drawer	_	
261-13	48916-48924	problems	_	
261-14	48924-48925	”	_	
261-15	48926-48928	is	_	
261-16	48929-48939	heightened	_	
261-17	48940-48944	when	_	
261-18	48945-48951	sample	_	
261-19	48952-48957	sizes	_	
261-20	48958-48961	are	_	
261-21	48962-48967	small	_	
261-22	48967-48968	,	_	
261-23	48969-48971	as	_	
261-24	48972-48974	is	_	
261-25	48975-48978	the	_	
261-26	48979-48983	case	_	
261-27	48984-48986	in	_	
261-28	48987-48990	the	_	
261-29	48991-48998	present	_	
261-30	48999-49004	study	_	
261-31	49004-49005	,	_	
261-32	49006-49009	and	_	
261-33	49010-49012	so	_	
261-34	49013-49016	the	_	
261-35	49017-49024	results	_	
261-36	49025-49034	presented	_	
261-37	49035-49039	here	_	
261-38	49040-49046	should	_	
261-39	49047-49050	not	_	
261-40	49051-49053	be	_	
261-41	49054-49059	taken	_	
261-42	49060-49062	as	_	
261-43	49063-49073	definitive	_	
261-44	49073-49074	.	_	

#Text=Second, this study was cross-sectional, therefore the design does not allow us to distinguish whether group differences in brain metabolism are antecedent (and perhaps causal contributors) to the development of PTSD or whether these differences are related to the sequelae of PTSD (or the sequelae of PTSD in the context of addiction).
262-1	49075-49081	Second	_	
262-2	49081-49082	,	_	
262-3	49083-49087	this	_	
262-4	49088-49093	study	_	
262-5	49094-49097	was	_	
262-6	49098-49113	cross-sectional	_	
262-7	49113-49114	,	_	
262-8	49115-49124	therefore	_	
262-9	49125-49128	the	_	
262-10	49129-49135	design	_	
262-11	49136-49140	does	_	
262-12	49141-49144	not	_	
262-13	49145-49150	allow	_	
262-14	49151-49153	us	_	
262-15	49154-49156	to	_	
262-16	49157-49168	distinguish	_	
262-17	49169-49176	whether	_	
262-18	49177-49182	group	_	
262-19	49183-49194	differences	_	
262-20	49195-49197	in	_	
262-21	49198-49203	brain	_	
262-22	49204-49214	metabolism	_	
262-23	49215-49218	are	_	
262-24	49219-49229	antecedent	_	
262-25	49230-49231	(	_	
262-26	49231-49234	and	_	
262-27	49235-49242	perhaps	_	
262-28	49243-49249	causal	_	
262-29	49250-49262	contributors	_	
262-30	49262-49263	)	_	
262-31	49264-49266	to	_	
262-32	49267-49270	the	_	
262-33	49271-49282	development	_	
262-34	49283-49285	of	_	
262-35	49286-49290	PTSD	_	
262-36	49291-49293	or	_	
262-37	49294-49301	whether	_	
262-38	49302-49307	these	_	
262-39	49308-49319	differences	_	
262-40	49320-49323	are	_	
262-41	49324-49331	related	_	
262-42	49332-49334	to	_	
262-43	49335-49338	the	_	
262-44	49339-49347	sequelae	_	
262-45	49348-49350	of	_	
262-46	49351-49355	PTSD	_	
262-47	49356-49357	(	_	
262-48	49357-49359	or	_	
262-49	49360-49363	the	_	
262-50	49364-49372	sequelae	_	
262-51	49373-49375	of	_	
262-52	49376-49380	PTSD	_	
262-53	49381-49383	in	_	
262-54	49384-49387	the	_	
262-55	49388-49395	context	_	
262-56	49396-49398	of	_	
262-57	49399-49408	addiction	_	
262-58	49408-49409	)	_	
262-59	49409-49410	.	_	

#Text=Although psychoactive medication use was similar across the two groups, the potential influence of these medications could not be ruled out.
263-1	49411-49419	Although	_	
263-2	49420-49432	psychoactive	_	
263-3	49433-49443	medication	_	
263-4	49444-49447	use	_	
263-5	49448-49451	was	_	
263-6	49452-49459	similar	_	
263-7	49460-49466	across	_	
263-8	49467-49470	the	_	
263-9	49471-49474	two	_	
263-10	49475-49481	groups	_	
263-11	49481-49482	,	_	
263-12	49483-49486	the	_	
263-13	49487-49496	potential	_	
263-14	49497-49506	influence	_	
263-15	49507-49509	of	_	
263-16	49510-49515	these	_	
263-17	49516-49527	medications	_	
263-18	49528-49533	could	_	
263-19	49534-49537	not	_	
263-20	49538-49540	be	_	
263-21	49541-49546	ruled	_	
263-22	49547-49550	out	_	
263-23	49550-49551	.	_	

#Text=We were also not able to exclude subjects on the basis of psychiatric comorbidities apart from PTSD.
264-1	49552-49554	We	_	
264-2	49555-49559	were	_	
264-3	49560-49564	also	_	
264-4	49565-49568	not	_	
264-5	49569-49573	able	_	
264-6	49574-49576	to	_	
264-7	49577-49584	exclude	_	
264-8	49585-49593	subjects	_	
264-9	49594-49596	on	_	
264-10	49597-49600	the	_	
264-11	49601-49606	basis	_	
264-12	49607-49609	of	_	
264-13	49610-49621	psychiatric	_	
264-14	49622-49635	comorbidities	_	
264-15	49636-49641	apart	_	
264-16	49642-49646	from	_	
264-17	49647-49651	PTSD	_	
264-18	49651-49652	.	_	

#Text=However, comorbidity in SUD is common, and in the present study the rates of mood and borderline disorders were similar between PTSD and noPTSD groups, thus these data may be more representative of female SUD populations, thereby supporting the generalizability of the findings.
265-1	49653-49660	However	_	
265-2	49660-49661	,	_	
265-3	49662-49673	comorbidity	_	
265-4	49674-49676	in	_	
265-5	49677-49680	SUD	_	
265-6	49681-49683	is	_	
265-7	49684-49690	common	_	
265-8	49690-49691	,	_	
265-9	49692-49695	and	_	
265-10	49696-49698	in	_	
265-11	49699-49702	the	_	
265-12	49703-49710	present	_	
265-13	49711-49716	study	_	
265-14	49717-49720	the	_	
265-15	49721-49726	rates	_	
265-16	49727-49729	of	_	
265-17	49730-49734	mood	_	
265-18	49735-49738	and	_	
265-19	49739-49749	borderline	_	
265-20	49750-49759	disorders	_	
265-21	49760-49764	were	_	
265-22	49765-49772	similar	_	
265-23	49773-49780	between	_	
265-24	49781-49785	PTSD	_	
265-25	49786-49789	and	_	
265-26	49790-49796	noPTSD	_	
265-27	49797-49803	groups	_	
265-28	49803-49804	,	_	
265-29	49805-49809	thus	_	
265-30	49810-49815	these	_	
265-31	49816-49820	data	_	
265-32	49821-49824	may	_	
265-33	49825-49827	be	_	
265-34	49828-49832	more	_	
265-35	49833-49847	representative	_	
265-36	49848-49850	of	_	
265-37	49851-49857	female	_	
265-38	49858-49861	SUD	_	
265-39	49862-49873	populations	_	
265-40	49873-49874	,	_	
265-41	49875-49882	thereby	_	
265-42	49883-49893	supporting	_	
265-43	49894-49897	the	_	
265-44	49898-49914	generalizability	_	
265-45	49915-49917	of	_	
265-46	49918-49921	the	_	
265-47	49922-49930	findings	_	
265-48	49930-49931	.	_	

#Text=Nevertheless, it is not entirely clear how substance use may have interacted with the present findings (i.e. limiting its generalizability to PTSD specifically).
266-1	49932-49944	Nevertheless	_	
266-2	49944-49945	,	_	
266-3	49946-49948	it	_	
266-4	49949-49951	is	_	
266-5	49952-49955	not	_	
266-6	49956-49964	entirely	_	
266-7	49965-49970	clear	_	
266-8	49971-49974	how	_	
266-9	49975-49984	substance	_	
266-10	49985-49988	use	_	
266-11	49989-49992	may	_	
266-12	49993-49997	have	_	
266-13	49998-50008	interacted	_	
266-14	50009-50013	with	_	
266-15	50014-50017	the	_	
266-16	50018-50025	present	_	
266-17	50026-50034	findings	_	
266-18	50035-50036	(	_	
266-19	50036-50039	i.e	_	
266-20	50039-50040	.	_	
266-21	50041-50049	limiting	_	
266-22	50050-50053	its	_	
266-23	50054-50070	generalizability	_	
266-24	50071-50073	to	_	
266-25	50074-50078	PTSD	_	
266-26	50079-50091	specifically	_	
266-27	50091-50092	)	_	
266-28	50092-50093	.	_	

#Text=OFC gray matter and functional impairments have also been noted in substance abuse disorders.
267-1	50094-50097	OFC	_	
267-2	50098-50102	gray	_	
267-3	50103-50109	matter	_	
267-4	50110-50113	and	_	
267-5	50114-50124	functional	_	
267-6	50125-50136	impairments	_	
267-7	50137-50141	have	_	
267-8	50142-50146	also	_	
267-9	50147-50151	been	_	
267-10	50152-50157	noted	_	
267-11	50158-50160	in	_	
267-12	50161-50170	substance	_	
267-13	50171-50176	abuse	_	
267-14	50177-50186	disorders	_	
267-15	50186-50187	.	_	

#Text=Similarly, interoceptive processing deficits have also been observed in substance dependent individuals without PTSD.
268-1	50188-50197	Similarly	_	
268-2	50197-50198	,	_	
268-3	50199-50212	interoceptive	_	
268-4	50213-50223	processing	_	
268-5	50224-50232	deficits	_	
268-6	50233-50237	have	_	
268-7	50238-50242	also	_	
268-8	50243-50247	been	_	
268-9	50248-50256	observed	_	
268-10	50257-50259	in	_	
268-11	50260-50269	substance	_	
268-12	50270-50279	dependent	_	
268-13	50280-50291	individuals	_	
268-14	50292-50299	without	_	
268-15	50300-50304	PTSD	_	
268-16	50304-50305	.	_	

#Text=Consequently, it is not clear whether PTSD results in primary deficits in processing somato-visceral information relative to SUD, or whether this relative difference might be a consequence of a supraordinate factor such as attentional difficulties (although there were no performance differences in the exteroceptive task [see Supplement]).
269-1	50306-50318	Consequently	_	
269-2	50318-50319	,	_	
269-3	50320-50322	it	_	
269-4	50323-50325	is	_	
269-5	50326-50329	not	_	
269-6	50330-50335	clear	_	
269-7	50336-50343	whether	_	
269-8	50344-50348	PTSD	_	
269-9	50349-50356	results	_	
269-10	50357-50359	in	_	
269-11	50360-50367	primary	_	
269-12	50368-50376	deficits	_	
269-13	50377-50379	in	_	
269-14	50380-50390	processing	_	
269-15	50391-50406	somato-visceral	_	
269-16	50407-50418	information	_	
269-17	50419-50427	relative	_	
269-18	50428-50430	to	_	
269-19	50431-50434	SUD	_	
269-20	50434-50435	,	_	
269-21	50436-50438	or	_	
269-22	50439-50446	whether	_	
269-23	50447-50451	this	_	
269-24	50452-50460	relative	_	
269-25	50461-50471	difference	_	
269-26	50472-50477	might	_	
269-27	50478-50480	be	_	
269-28	50481-50482	a	_	
269-29	50483-50494	consequence	_	
269-30	50495-50497	of	_	
269-31	50498-50499	a	_	
269-32	50500-50513	supraordinate	_	
269-33	50514-50520	factor	_	
269-34	50521-50525	such	_	
269-35	50526-50528	as	_	
269-36	50529-50540	attentional	_	
269-37	50541-50553	difficulties	_	
269-38	50554-50555	(	_	
269-39	50555-50563	although	_	
269-40	50564-50569	there	_	
269-41	50570-50574	were	_	
269-42	50575-50577	no	_	
269-43	50578-50589	performance	_	
269-44	50590-50601	differences	_	
269-45	50602-50604	in	_	
269-46	50605-50608	the	_	
269-47	50609-50622	exteroceptive	_	
269-48	50623-50627	task	_	
269-49	50628-50629	[	_	
269-50	50629-50632	see	_	
269-51	50633-50643	Supplement	_	
269-52	50643-50644	]	_	
269-53	50644-50645	)	_	
269-54	50645-50646	.	_	

#Text=However, since we did not have a measure of performance difficulty for the two task conditions, we also cannot be certain whether perceived difficulty played a role.
270-1	50647-50654	However	_	
270-2	50654-50655	,	_	
270-3	50656-50661	since	_	
270-4	50662-50664	we	_	
270-5	50665-50668	did	_	
270-6	50669-50672	not	_	
270-7	50673-50677	have	_	
270-8	50678-50679	a	_	
270-9	50680-50687	measure	_	
270-10	50688-50690	of	_	
270-11	50691-50702	performance	_	
270-12	50703-50713	difficulty	_	
270-13	50714-50717	for	_	
270-14	50718-50721	the	_	
270-15	50722-50725	two	_	
270-16	50726-50730	task	_	
270-17	50731-50741	conditions	_	
270-18	50741-50742	,	_	
270-19	50743-50745	we	_	
270-20	50746-50750	also	_	
270-21	50751-50757	cannot	_	
270-22	50758-50760	be	_	
270-23	50761-50768	certain	_	
270-24	50769-50776	whether	_	
270-25	50777-50786	perceived	_	
270-26	50787-50797	difficulty	_	
270-27	50798-50804	played	_	
270-28	50805-50806	a	_	
270-29	50807-50811	role	_	
270-30	50811-50812	.	_	

#Text=Behavioral measures of interoception should be incorporated in future studies, or, alternatively, could utilize assessments of interoceptive function that do not necessarily impose attentional or cognitive demands (e.g. pharmacological challenges).
271-1	50813-50823	Behavioral	_	
271-2	50824-50832	measures	_	
271-3	50833-50835	of	_	
271-4	50836-50849	interoception	_	
271-5	50850-50856	should	_	
271-6	50857-50859	be	_	
271-7	50860-50872	incorporated	_	
271-8	50873-50875	in	_	
271-9	50876-50882	future	_	
271-10	50883-50890	studies	_	
271-11	50890-50891	,	_	
271-12	50892-50894	or	_	
271-13	50894-50895	,	_	
271-14	50896-50909	alternatively	_	
271-15	50909-50910	,	_	
271-16	50911-50916	could	_	
271-17	50917-50924	utilize	_	
271-18	50925-50936	assessments	_	
271-19	50937-50939	of	_	
271-20	50940-50953	interoceptive	_	
271-21	50954-50962	function	_	
271-22	50963-50967	that	_	
271-23	50968-50970	do	_	
271-24	50971-50974	not	_	
271-25	50975-50986	necessarily	_	
271-26	50987-50993	impose	_	
271-27	50994-51005	attentional	_	
271-28	51006-51008	or	_	
271-29	51009-51018	cognitive	_	
271-30	51019-51026	demands	_	
271-31	51027-51028	(	_	
271-32	51028-51031	e.g	_	
271-33	51031-51032	.	_	
271-34	51033-51048	pharmacological	_	
271-35	51049-51059	challenges	_	
271-36	51059-51060	)	_	
271-37	51060-51061	.	_	

#Text=To address these interpretive ambiguities, future studies could incorporate demographically matched, non-substance abusing comparison groups with-and-without trauma/PTSD to identify associations of the OFC and interoceptive networks that are uniquely related to substance abuse versus those related to PTSD, and potential interactions between the disorders.
272-1	51062-51064	To	_	
272-2	51065-51072	address	_	
272-3	51073-51078	these	_	
272-4	51079-51091	interpretive	_	
272-5	51092-51103	ambiguities	_	
272-6	51103-51104	,	_	
272-7	51105-51111	future	_	
272-8	51112-51119	studies	_	
272-9	51120-51125	could	_	
272-10	51126-51137	incorporate	_	
272-11	51138-51153	demographically	_	
272-12	51154-51161	matched	_	
272-13	51161-51162	,	_	
272-14	51163-51176	non-substance	_	
272-15	51177-51184	abusing	_	
272-16	51185-51195	comparison	_	
272-17	51196-51202	groups	_	
272-18	51203-51219	with-and-without	_	
272-19	51220-51226	trauma	_	
272-20	51226-51227	/	_	
272-21	51227-51231	PTSD	_	
272-22	51232-51234	to	_	
272-23	51235-51243	identify	_	
272-24	51244-51256	associations	_	
272-25	51257-51259	of	_	
272-26	51260-51263	the	_	
272-27	51264-51267	OFC	_	
272-28	51268-51271	and	_	
272-29	51272-51285	interoceptive	_	
272-30	51286-51294	networks	_	
272-31	51295-51299	that	_	
272-32	51300-51303	are	_	
272-33	51304-51312	uniquely	_	
272-34	51313-51320	related	_	
272-35	51321-51323	to	_	
272-36	51324-51333	substance	_	
272-37	51334-51339	abuse	_	
272-38	51340-51346	versus	_	
272-39	51347-51352	those	_	
272-40	51353-51360	related	_	
272-41	51361-51363	to	_	
272-42	51364-51368	PTSD	_	
272-43	51368-51369	,	_	
272-44	51370-51373	and	_	
272-45	51374-51383	potential	_	
272-46	51384-51396	interactions	_	
272-47	51397-51404	between	_	
272-48	51405-51408	the	_	
272-49	51409-51418	disorders	_	
272-50	51418-51419	.	_	

#Text=Lastly, in the current study we only assessed participants at a single time-point, soon after admission to SUD treatment, thus we do not know how interoceptive, somatosensory and orbitofrontal function may change with treatment.
273-1	51420-51426	Lastly	_	
273-2	51426-51427	,	_	
273-3	51428-51430	in	_	
273-4	51431-51434	the	_	
273-5	51435-51442	current	_	
273-6	51443-51448	study	_	
273-7	51449-51451	we	_	
273-8	51452-51456	only	_	
273-9	51457-51465	assessed	_	
273-10	51466-51478	participants	_	
273-11	51479-51481	at	_	
273-12	51482-51483	a	_	
273-13	51484-51490	single	_	
273-14	51491-51501	time-point	_	
273-15	51501-51502	,	_	
273-16	51503-51507	soon	_	
273-17	51508-51513	after	_	
273-18	51514-51523	admission	_	
273-19	51524-51526	to	_	
273-20	51527-51530	SUD	_	
273-21	51531-51540	treatment	_	
273-22	51540-51541	,	_	
273-23	51542-51546	thus	_	
273-24	51547-51549	we	_	
273-25	51550-51552	do	_	
273-26	51553-51556	not	_	
273-27	51557-51561	know	_	
273-28	51562-51565	how	_	
273-29	51566-51579	interoceptive	_	
273-30	51579-51580	,	_	
273-31	51581-51594	somatosensory	_	
273-32	51595-51598	and	_	
273-33	51599-51612	orbitofrontal	_	
273-34	51613-51621	function	_	
273-35	51622-51625	may	_	
273-36	51626-51632	change	_	
273-37	51633-51637	with	_	
273-38	51638-51647	treatment	_	
273-39	51647-51648	.	_	

#Text=However, we have identified that insula and orbitofrontal metabolism, as well as functional connectivity between these regions may be useful neurobiological marker of clinical response for women with PTSD and substance abuse disorders.
274-1	51649-51656	However	_	
274-2	51656-51657	,	_	
274-3	51658-51660	we	_	
274-4	51661-51665	have	_	
274-5	51666-51676	identified	_	
274-6	51677-51681	that	_	
274-7	51682-51688	insula	_	
274-8	51689-51692	and	_	
274-9	51693-51706	orbitofrontal	_	
274-10	51707-51717	metabolism	_	
274-11	51717-51718	,	_	
274-12	51719-51721	as	_	
274-13	51722-51726	well	_	
274-14	51727-51729	as	_	
274-15	51730-51740	functional	_	
274-16	51741-51753	connectivity	_	
274-17	51754-51761	between	_	
274-18	51762-51767	these	_	
274-19	51768-51775	regions	_	
274-20	51776-51779	may	_	
274-21	51780-51782	be	_	
274-22	51783-51789	useful	_	
274-23	51790-51805	neurobiological	_	
274-24	51806-51812	marker	_	
274-25	51813-51815	of	_	
274-26	51816-51824	clinical	_	
274-27	51825-51833	response	_	
274-28	51834-51837	for	_	
274-29	51838-51843	women	_	
274-30	51844-51848	with	_	
274-31	51849-51853	PTSD	_	
274-32	51854-51857	and	_	
274-33	51858-51867	substance	_	
274-34	51868-51873	abuse	_	
274-35	51874-51883	disorders	_	
274-36	51883-51884	.	_	

#Text=Conclusion
#Text=Interoception is increasingly recognized as a construct relevant to the symptomatology of mental health conditions, including substance abuse and anxiety disorders.
275-1	51885-51895	Conclusion	_	
275-2	51896-51909	Interoception	_	
275-3	51910-51912	is	_	
275-4	51913-51925	increasingly	_	
275-5	51926-51936	recognized	_	
275-6	51937-51939	as	_	
275-7	51940-51941	a	_	
275-8	51942-51951	construct	_	
275-9	51952-51960	relevant	_	
275-10	51961-51963	to	_	
275-11	51964-51967	the	_	
275-12	51968-51982	symptomatology	_	
275-13	51983-51985	of	_	
275-14	51986-51992	mental	_	
275-15	51993-51999	health	_	
275-16	52000-52010	conditions	_	
275-17	52010-52011	,	_	
275-18	52012-52021	including	_	
275-19	52022-52031	substance	_	
275-20	52032-52037	abuse	_	
275-21	52038-52041	and	_	
275-22	52042-52049	anxiety	_	
275-23	52050-52059	disorders	_	
275-24	52059-52060	.	_	

#Text=As the first neuroimaging study to examine SUD and PTSD comorbidity in women with varying degrees of exposure to traumatic stressors, we provide a novel brain network-level account of interoceptive differences within this sub-population.
276-1	52061-52063	As	_	
276-2	52064-52067	the	_	
276-3	52068-52073	first	_	
276-4	52074-52086	neuroimaging	_	
276-5	52087-52092	study	_	
276-6	52093-52095	to	_	
276-7	52096-52103	examine	_	
276-8	52104-52107	SUD	_	
276-9	52108-52111	and	_	
276-10	52112-52116	PTSD	_	
276-11	52117-52128	comorbidity	_	
276-12	52129-52131	in	_	
276-13	52132-52137	women	_	
276-14	52138-52142	with	_	
276-15	52143-52150	varying	_	
276-16	52151-52158	degrees	_	
276-17	52159-52161	of	_	
276-18	52162-52170	exposure	_	
276-19	52171-52173	to	_	
276-20	52174-52183	traumatic	_	
276-21	52184-52193	stressors	_	
276-22	52193-52194	,	_	
276-23	52195-52197	we	_	
276-24	52198-52205	provide	_	
276-25	52206-52207	a	_	
276-26	52208-52213	novel	_	
276-27	52214-52219	brain	_	
276-28	52220-52233	network-level	_	
276-29	52234-52241	account	_	
276-30	52242-52244	of	_	
276-31	52245-52258	interoceptive	_	
276-32	52259-52270	differences	_	
276-33	52271-52277	within	_	
276-34	52278-52282	this	_	
276-35	52283-52297	sub-population	_	
276-36	52297-52298	.	_	

#Text=Specifically, in the PTSD subgroup we observed reduced functional connectivity of an orbitofrontal network with the insula, somatosensory and cognitive control regions during an interoceptive task during which participants attended to sensations of breathing.
277-1	52299-52311	Specifically	_	
277-2	52311-52312	,	_	
277-3	52313-52315	in	_	
277-4	52316-52319	the	_	
277-5	52320-52324	PTSD	_	
277-6	52325-52333	subgroup	_	
277-7	52334-52336	we	_	
277-8	52337-52345	observed	_	
277-9	52346-52353	reduced	_	
277-10	52354-52364	functional	_	
277-11	52365-52377	connectivity	_	
277-12	52378-52380	of	_	
277-13	52381-52383	an	_	
277-14	52384-52397	orbitofrontal	_	
277-15	52398-52405	network	_	
277-16	52406-52410	with	_	
277-17	52411-52414	the	_	
277-18	52415-52421	insula	_	
277-19	52421-52422	,	_	
277-20	52423-52436	somatosensory	_	
277-21	52437-52440	and	_	
277-22	52441-52450	cognitive	_	
277-23	52451-52458	control	_	
277-24	52459-52466	regions	_	
277-25	52467-52473	during	_	
277-26	52474-52476	an	_	
277-27	52477-52490	interoceptive	_	
277-28	52491-52495	task	_	
277-29	52496-52502	during	_	
277-30	52503-52508	which	_	
277-31	52509-52521	participants	_	
277-32	52522-52530	attended	_	
277-33	52531-52533	to	_	
277-34	52534-52544	sensations	_	
277-35	52545-52547	of	_	
277-36	52548-52557	breathing	_	
277-37	52557-52558	.	_	

#Text=Group differences in network functional connectivity were specific to task-modulated networks associated with interoception, and not those associated with exteroception.
278-1	52559-52564	Group	_	
278-2	52565-52576	differences	_	
278-3	52577-52579	in	_	
278-4	52580-52587	network	_	
278-5	52588-52598	functional	_	
278-6	52599-52611	connectivity	_	
278-7	52612-52616	were	_	
278-8	52617-52625	specific	_	
278-9	52626-52628	to	_	
278-10	52629-52643	task-modulated	_	
278-11	52644-52652	networks	_	
278-12	52653-52663	associated	_	
278-13	52664-52668	with	_	
278-14	52669-52682	interoception	_	
278-15	52682-52683	,	_	
278-16	52684-52687	and	_	
278-17	52688-52691	not	_	
278-18	52692-52697	those	_	
278-19	52698-52708	associated	_	
278-20	52709-52713	with	_	
278-21	52714-52727	exteroception	_	
278-22	52727-52728	.	_	

#Text=Post-hoc correlational analyses further identified a cumulative association between sexual trauma exposure and OFC network strength during interoception, independently from PTSD status.
279-1	52729-52737	Post-hoc	_	
279-2	52738-52751	correlational	_	
279-3	52752-52760	analyses	_	
279-4	52761-52768	further	_	
279-5	52769-52779	identified	_	
279-6	52780-52781	a	_	
279-7	52782-52792	cumulative	_	
279-8	52793-52804	association	_	
279-9	52805-52812	between	_	
279-10	52813-52819	sexual	_	
279-11	52820-52826	trauma	_	
279-12	52827-52835	exposure	_	
279-13	52836-52839	and	_	
279-14	52840-52843	OFC	_	
279-15	52844-52851	network	_	
279-16	52852-52860	strength	_	
279-17	52861-52867	during	_	
279-18	52868-52881	interoception	_	
279-19	52881-52882	,	_	
279-20	52883-52896	independently	_	
279-21	52897-52901	from	_	
279-22	52902-52906	PTSD	_	
279-23	52907-52913	status	_	
279-24	52913-52914	.	_	

#Text=Traumatic stress-dependent differences in the orbitofrontal cortices may be relevant to the clinical responses to interventions for women with substance use disorders.
280-1	52915-52924	Traumatic	_	
280-2	52925-52941	stress-dependent	_	
280-3	52942-52953	differences	_	
280-4	52954-52956	in	_	
280-5	52957-52960	the	_	
280-6	52961-52974	orbitofrontal	_	
280-7	52975-52983	cortices	_	
280-8	52984-52987	may	_	
280-9	52988-52990	be	_	
280-10	52991-52999	relevant	_	
280-11	53000-53002	to	_	
280-12	53003-53006	the	_	
280-13	53007-53015	clinical	_	
280-14	53016-53025	responses	_	
280-15	53026-53028	to	_	
280-16	53029-53042	interventions	_	
280-17	53043-53046	for	_	
280-18	53047-53052	women	_	
280-19	53053-53057	with	_	
280-20	53058-53067	substance	_	
280-21	53068-53071	use	_	
280-22	53072-53081	disorders	_	
280-23	53081-53082	.	_	

#Text=Declaration of Competing Interest
#Text=All authors declare that there are no conflicts of interest.
281-1	53083-53094	Declaration	_	
281-2	53095-53097	of	_	
281-3	53098-53107	Competing	_	
281-4	53108-53116	Interest	_	
281-5	53117-53120	All	_	
281-6	53121-53128	authors	_	
281-7	53129-53136	declare	_	
281-8	53137-53141	that	_	
281-9	53142-53147	there	_	
281-10	53148-53151	are	_	
281-11	53152-53154	no	_	
281-12	53155-53164	conflicts	_	
281-13	53165-53167	of	_	
281-14	53168-53176	interest	_	
281-15	53176-53177	.	_	

#Text=References
#Text=Moment-by-moment in Women's recovery: randomized controlled trial protocol to test the efficacy of a mindfulness-based intervention on treatment retention and relapse prevention among women in residential treatment for substance use disorder
#Text=Feasibility, acceptability, and preliminary outcomes of a mindfulness-based relapse prevention intervention for culturally-diverse, low-income women in substance use disorder treatment
#Text=Autoscopic phenomena: case report and review of literature
#Text=Stress signalling pathways that impair prefrontal cortex structure and function
#Text=Major depressive disorder is associated with abnormal interoceptive activity and functional connectivity in the insula
#Text=How the brain wants what the body needs: the neural basis of positive alliesthesia
#Text=The somatic marker hypothesis: A neural theory of economic decision
#Text=Emotion, decision making and the orbitofrontal cortex
#Text=Probabilistic independent component analysis for functional magnetic resonance imaging
#Text=Group comparison of resting-state fMRI data using multi-subject ICA and dual regression
#Text=The respiration response function: the temporal dynamics of fMRI signal fluctuations related to changes in respiration
#Text=Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders
#Text=Multisensory brain mechanisms of bodily self-consciousness
#Text=Accounting for intrusive thoughts in PTSD: contributions of cognitive control and deliberate regulation strategies
#Text=Standardized mirror confrontation: body-related emotions, cognitions and level of dissociation in patients with posttraumatic stress disorder after childhood sexual abuse
#Text=The role of mindfulness as approach-based coping in the PTSD-substance abuse cycle
#Text=Mindfulness-based treatments for posttraumatic stress disorder : a review of the treatment literature and neurobiological evidence
#Text=Anxiety-associated locomotor activation and adrenal responsiveness
#Text=A physical correlate of the ‘spotlight’ of visual attention
#Text=Neural correlates of attentional expertise in long-term meditation practitioners
#Text=Alexithymia: a general deficit of interoception
#Text=fMRI of thermal pain: effects of stimulus laterality and attention
#Text=Breathing practices for treatment of psychiatric and stress-related medical conditions
#Text=Violence perpetration and childhood abuse among men and women in substance abuse treatment
#Text=
#Text=Influence of heart rate on the BOLD signal: the cardiac response function
#Text=The role of affective dysregulation in drug addiction
#Text=Increased functional coupling between the left fronto-parietal network and anterior insula predicts steeper delay discounting in smokers
#Text=How do you feel?
282-1	53178-53188	References	_	
282-2	53189-53205	Moment-by-moment	_	
282-3	53206-53208	in	_	
282-4	53209-53216	Women's	_	
282-5	53217-53225	recovery	_	
282-6	53225-53226	:	_	
282-7	53227-53237	randomized	_	
282-8	53238-53248	controlled	_	
282-9	53249-53254	trial	_	
282-10	53255-53263	protocol	_	
282-11	53264-53266	to	_	
282-12	53267-53271	test	_	
282-13	53272-53275	the	_	
282-14	53276-53284	efficacy	_	
282-15	53285-53287	of	_	
282-16	53288-53289	a	_	
282-17	53290-53307	mindfulness-based	_	
282-18	53308-53320	intervention	_	
282-19	53321-53323	on	_	
282-20	53324-53333	treatment	_	
282-21	53334-53343	retention	_	
282-22	53344-53347	and	_	
282-23	53348-53355	relapse	_	
282-24	53356-53366	prevention	_	
282-25	53367-53372	among	_	
282-26	53373-53378	women	_	
282-27	53379-53381	in	_	
282-28	53382-53393	residential	_	
282-29	53394-53403	treatment	_	
282-30	53404-53407	for	_	
282-31	53408-53417	substance	_	
282-32	53418-53421	use	_	
282-33	53422-53430	disorder	_	
282-34	53431-53442	Feasibility	_	
282-35	53442-53443	,	_	
282-36	53444-53457	acceptability	_	
282-37	53457-53458	,	_	
282-38	53459-53462	and	_	
282-39	53463-53474	preliminary	_	
282-40	53475-53483	outcomes	_	
282-41	53484-53486	of	_	
282-42	53487-53488	a	_	
282-43	53489-53506	mindfulness-based	_	
282-44	53507-53514	relapse	_	
282-45	53515-53525	prevention	_	
282-46	53526-53538	intervention	_	
282-47	53539-53542	for	_	
282-48	53543-53561	culturally-diverse	_	
282-49	53561-53562	,	_	
282-50	53563-53573	low-income	_	
282-51	53574-53579	women	_	
282-52	53580-53582	in	_	
282-53	53583-53592	substance	_	
282-54	53593-53596	use	_	
282-55	53597-53605	disorder	_	
282-56	53606-53615	treatment	_	
282-57	53616-53626	Autoscopic	_	
282-58	53627-53636	phenomena	_	
282-59	53636-53637	:	_	
282-60	53638-53642	case	_	
282-61	53643-53649	report	_	
282-62	53650-53653	and	_	
282-63	53654-53660	review	_	
282-64	53661-53663	of	_	
282-65	53664-53674	literature	_	
282-66	53675-53681	Stress	_	
282-67	53682-53692	signalling	_	
282-68	53693-53701	pathways	_	
282-69	53702-53706	that	_	
282-70	53707-53713	impair	_	
282-71	53714-53724	prefrontal	_	
282-72	53725-53731	cortex	_	
282-73	53732-53741	structure	_	
282-74	53742-53745	and	_	
282-75	53746-53754	function	_	
282-76	53755-53760	Major	_	
282-77	53761-53771	depressive	_	
282-78	53772-53780	disorder	_	
282-79	53781-53783	is	_	
282-80	53784-53794	associated	_	
282-81	53795-53799	with	_	
282-82	53800-53808	abnormal	_	
282-83	53809-53822	interoceptive	_	
282-84	53823-53831	activity	_	
282-85	53832-53835	and	_	
282-86	53836-53846	functional	_	
282-87	53847-53859	connectivity	_	
282-88	53860-53862	in	_	
282-89	53863-53866	the	_	
282-90	53867-53873	insula	_	
282-91	53874-53877	How	_	
282-92	53878-53881	the	_	
282-93	53882-53887	brain	_	
282-94	53888-53893	wants	_	
282-95	53894-53898	what	_	
282-96	53899-53902	the	_	
282-97	53903-53907	body	_	
282-98	53908-53913	needs	_	
282-99	53913-53914	:	_	
282-100	53915-53918	the	_	
282-101	53919-53925	neural	_	
282-102	53926-53931	basis	_	
282-103	53932-53934	of	_	
282-104	53935-53943	positive	_	
282-105	53944-53956	alliesthesia	_	
282-106	53957-53960	The	_	
282-107	53961-53968	somatic	_	
282-108	53969-53975	marker	_	
282-109	53976-53986	hypothesis	_	
282-110	53986-53987	:	_	
282-111	53988-53989	A	_	
282-112	53990-53996	neural	_	
282-113	53997-54003	theory	_	
282-114	54004-54006	of	_	
282-115	54007-54015	economic	_	
282-116	54016-54024	decision	_	
282-117	54025-54032	Emotion	_	
282-118	54032-54033	,	_	
282-119	54034-54042	decision	_	
282-120	54043-54049	making	_	
282-121	54050-54053	and	_	
282-122	54054-54057	the	_	
282-123	54058-54071	orbitofrontal	_	
282-124	54072-54078	cortex	_	
282-125	54079-54092	Probabilistic	_	
282-126	54093-54104	independent	_	
282-127	54105-54114	component	_	
282-128	54115-54123	analysis	_	
282-129	54124-54127	for	_	
282-130	54128-54138	functional	_	
282-131	54139-54147	magnetic	_	
282-132	54148-54157	resonance	_	
282-133	54158-54165	imaging	_	
282-134	54166-54171	Group	_	
282-135	54172-54182	comparison	_	
282-136	54183-54185	of	_	
282-137	54186-54199	resting-state	_	
282-138	54200-54204	fMRI	_	
282-139	54205-54209	data	_	
282-140	54210-54215	using	_	
282-141	54216-54229	multi-subject	_	
282-142	54230-54233	ICA	_	
282-143	54234-54237	and	_	
282-144	54238-54242	dual	_	
282-145	54243-54253	regression	_	
282-146	54254-54257	The	_	
282-147	54258-54269	respiration	_	
282-148	54270-54278	response	_	
282-149	54279-54287	function	_	
282-150	54287-54288	:	_	
282-151	54289-54292	the	_	
282-152	54293-54301	temporal	_	
282-153	54302-54310	dynamics	_	
282-154	54311-54313	of	_	
282-155	54314-54318	fMRI	_	
282-156	54319-54325	signal	_	
282-157	54326-54338	fluctuations	_	
282-158	54339-54346	related	_	
282-159	54347-54349	to	_	
282-160	54350-54357	changes	_	
282-161	54358-54360	in	_	
282-162	54361-54372	respiration	_	
282-163	54373-54380	Alcohol	_	
282-164	54380-54381	,	_	
282-165	54382-54388	stress	_	
282-166	54388-54389	,	_	
282-167	54390-54393	and	_	
282-168	54394-54409	glucocorticoids	_	
282-169	54409-54410	:	_	
282-170	54411-54415	from	_	
282-171	54416-54420	risk	_	
282-172	54421-54423	to	_	
282-173	54424-54434	dependence	_	
282-174	54435-54438	and	_	
282-175	54439-54446	relapse	_	
282-176	54447-54449	in	_	
282-177	54450-54457	alcohol	_	
282-178	54458-54461	use	_	
282-179	54462-54471	disorders	_	
282-180	54472-54484	Multisensory	_	
282-181	54485-54490	brain	_	
282-182	54491-54501	mechanisms	_	
282-183	54502-54504	of	_	
282-184	54505-54511	bodily	_	
282-185	54512-54530	self-consciousness	_	
282-186	54531-54541	Accounting	_	
282-187	54542-54545	for	_	
282-188	54546-54555	intrusive	_	
282-189	54556-54564	thoughts	_	
282-190	54565-54567	in	_	
282-191	54568-54572	PTSD	_	
282-192	54572-54573	:	_	
282-193	54574-54587	contributions	_	
282-194	54588-54590	of	_	
282-195	54591-54600	cognitive	_	
282-196	54601-54608	control	_	
282-197	54609-54612	and	_	
282-198	54613-54623	deliberate	_	
282-199	54624-54634	regulation	_	
282-200	54635-54645	strategies	_	
282-201	54646-54658	Standardized	_	
282-202	54659-54665	mirror	_	
282-203	54666-54679	confrontation	_	
282-204	54679-54680	:	_	
282-205	54681-54693	body-related	_	
282-206	54694-54702	emotions	_	
282-207	54702-54703	,	_	
282-208	54704-54714	cognitions	_	
282-209	54715-54718	and	_	
282-210	54719-54724	level	_	
282-211	54725-54727	of	_	
282-212	54728-54740	dissociation	_	
282-213	54741-54743	in	_	
282-214	54744-54752	patients	_	
282-215	54753-54757	with	_	
282-216	54758-54771	posttraumatic	_	
282-217	54772-54778	stress	_	
282-218	54779-54787	disorder	_	
282-219	54788-54793	after	_	
282-220	54794-54803	childhood	_	
282-221	54804-54810	sexual	_	
282-222	54811-54816	abuse	_	
282-223	54817-54820	The	_	
282-224	54821-54825	role	_	
282-225	54826-54828	of	_	
282-226	54829-54840	mindfulness	_	
282-227	54841-54843	as	_	
282-228	54844-54858	approach-based	_	
282-229	54859-54865	coping	_	
282-230	54866-54868	in	_	
282-231	54869-54872	the	_	
282-232	54873-54887	PTSD-substance	_	
282-233	54888-54893	abuse	_	
282-234	54894-54899	cycle	_	
282-235	54900-54917	Mindfulness-based	_	
282-236	54918-54928	treatments	_	
282-237	54929-54932	for	_	
282-238	54933-54946	posttraumatic	_	
282-239	54947-54953	stress	_	
282-240	54954-54962	disorder	_	
282-241	54963-54964	:	_	
282-242	54965-54966	a	_	
282-243	54967-54973	review	_	
282-244	54974-54976	of	_	
282-245	54977-54980	the	_	
282-246	54981-54990	treatment	_	
282-247	54991-55001	literature	_	
282-248	55002-55005	and	_	
282-249	55006-55021	neurobiological	_	
282-250	55022-55030	evidence	_	
282-251	55031-55049	Anxiety-associated	_	
282-252	55050-55059	locomotor	_	
282-253	55060-55070	activation	_	
282-254	55071-55074	and	_	
282-255	55075-55082	adrenal	_	
282-256	55083-55097	responsiveness	_	
282-257	55098-55099	A	_	
282-258	55100-55108	physical	_	
282-259	55109-55118	correlate	_	
282-260	55119-55121	of	_	
282-261	55122-55125	the	_	
282-262	55126-55127	‘	_	
282-263	55127-55136	spotlight	_	
282-264	55136-55137	’	_	
282-265	55138-55140	of	_	
282-266	55141-55147	visual	_	
282-267	55148-55157	attention	_	
282-268	55158-55164	Neural	_	
282-269	55165-55175	correlates	_	
282-270	55176-55178	of	_	
282-271	55179-55190	attentional	_	
282-272	55191-55200	expertise	_	
282-273	55201-55203	in	_	
282-274	55204-55213	long-term	_	
282-275	55214-55224	meditation	_	
282-276	55225-55238	practitioners	_	
282-277	55239-55250	Alexithymia	_	
282-278	55250-55251	:	_	
282-279	55252-55253	a	_	
282-280	55254-55261	general	_	
282-281	55262-55269	deficit	_	
282-282	55270-55272	of	_	
282-283	55273-55286	interoception	_	
282-284	55287-55291	fMRI	_	
282-285	55292-55294	of	_	
282-286	55295-55302	thermal	_	
282-287	55303-55307	pain	_	
282-288	55307-55308	:	_	
282-289	55309-55316	effects	_	
282-290	55317-55319	of	_	
282-291	55320-55328	stimulus	_	
282-292	55329-55339	laterality	_	
282-293	55340-55343	and	_	
282-294	55344-55353	attention	_	
282-295	55354-55363	Breathing	_	
282-296	55364-55373	practices	_	
282-297	55374-55377	for	_	
282-298	55378-55387	treatment	_	
282-299	55388-55390	of	_	
282-300	55391-55402	psychiatric	_	
282-301	55403-55406	and	_	
282-302	55407-55421	stress-related	_	
282-303	55422-55429	medical	_	
282-304	55430-55440	conditions	_	
282-305	55441-55449	Violence	_	
282-306	55450-55462	perpetration	_	
282-307	55463-55466	and	_	
282-308	55467-55476	childhood	_	
282-309	55477-55482	abuse	_	
282-310	55483-55488	among	_	
282-311	55489-55492	men	_	
282-312	55493-55496	and	_	
282-313	55497-55502	women	_	
282-314	55503-55505	in	_	
282-315	55506-55515	substance	_	
282-316	55516-55521	abuse	_	
282-317	55522-55531	treatment	_	
282-318	55533-55542	Influence	_	
282-319	55543-55545	of	_	
282-320	55546-55551	heart	_	
282-321	55552-55556	rate	_	
282-322	55557-55559	on	_	
282-323	55560-55563	the	_	
282-324	55564-55568	BOLD	_	
282-325	55569-55575	signal	_	
282-326	55575-55576	:	_	
282-327	55577-55580	the	_	
282-328	55581-55588	cardiac	_	
282-329	55589-55597	response	_	
282-330	55598-55606	function	_	
282-331	55607-55610	The	_	
282-332	55611-55615	role	_	
282-333	55616-55618	of	_	
282-334	55619-55628	affective	_	
282-335	55629-55642	dysregulation	_	
282-336	55643-55645	in	_	
282-337	55646-55650	drug	_	
282-338	55651-55660	addiction	_	
282-339	55661-55670	Increased	_	
282-340	55671-55681	functional	_	
282-341	55682-55690	coupling	_	
282-342	55691-55698	between	_	
282-343	55699-55702	the	_	
282-344	55703-55707	left	_	
282-345	55708-55723	fronto-parietal	_	
282-346	55724-55731	network	_	
282-347	55732-55735	and	_	
282-348	55736-55744	anterior	_	
282-349	55745-55751	insula	_	
282-350	55752-55760	predicts	_	
282-351	55761-55768	steeper	_	
282-352	55769-55774	delay	_	
282-353	55775-55786	discounting	_	
282-354	55787-55789	in	_	
282-355	55790-55797	smokers	_	
282-356	55798-55801	How	_	
282-357	55802-55804	do	_	
282-358	55805-55808	you	_	
282-359	55809-55813	feel	_	
282-360	55813-55814	?	_	

#Text=Interoception: the sense of the physiological condition of the body
#Text=Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired characteristic of PTSD
#Text=History of sexual, emotional or physical abuse and psychiatric comorbidity in substance-dependent patients
#Text=Neural correlates of focused attention during a brief mindfulness induction
#Text=Mindful attention to breath regulates emotions via increased amygdala-prefrontal cortex connectivity
#Text=Multimethod alexithymia assessment in adolescents and young adults with a cannabis use disorder
#Text=Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Attentional modulation of primary interoceptive and exteroceptive cortices
#Text=Mindfulness meditation training alters cortical representations of interoceptive attention
#Text=Psychological, Physical, and Sexual Abuse in Addicted Patients Who Undergo Treatment
#Text=Interoceptive predictions in the brain
#Text=Anterior cingulate activity to salient stimuli is modulated by autonomic arousal in posttraumatic stress disorder
#Text=Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics
#Text=Reliability and validity of a brief instrument for assessing post-traumatic stress disorder
#Text=Unseen scars: cocaine patients with prior trauma evidence heightened resting state functional connectivity (RSFC) between the amygdala and limbic-striatal regions
#Text=Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR
#Text=Dysfunction of the prefrontal cortex in addiction : neuroimaging findings and clinical implications
#Text=The neurocircuitry of impaired insight in drug addiction
#Text=Early stress is associated with alterations in the orbitofrontal cortex: A tensor-based morphometry investigation of brain structure and behavioral risk
#Text=Sensory overload and imbalance: resting-state vestibular connectivity in PTSD and its dissociative subtype
#Text=Neural origins of human sickness in interoceptive responses to inflammation
#Text=Quantitative magnetization transfer imaging as a biomarker for effects of systemic inflammation on the brain
#Text=Neuroimaging of child abuse: a critical review
#Text=Mind wandering and attention during focused meditation: A fine-grained temporal analysis of fluctuating cognitive states
#Text=How the heart speaks to the brain: neural activity during cardiorespiratory interoceptive stimulation
#Text=Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies
#Text=Decreased cortical representation of genital somatosensory field after childhood sexual abuse
#Text=Neural regulation of the stress response: glucocorticoid feedback mechanisms
#Text=Neural correlates of attention bias in posttraumatic stress disorder
#Text=Distinct illusory own-body perceptions caused by damage to posterior insula and extrastriate cortex
#Text=Do treatment improvements in PTSD severity affect substance use outcomes?
283-1	55815-55828	Interoception	_	
283-2	55828-55829	:	_	
283-3	55830-55833	the	_	
283-4	55834-55839	sense	_	
283-5	55840-55842	of	_	
283-6	55843-55846	the	_	
283-7	55847-55860	physiological	_	
283-8	55861-55870	condition	_	
283-9	55871-55873	of	_	
283-10	55874-55877	the	_	
283-11	55878-55882	body	_	
283-12	55883-55893	Diminished	_	
283-13	55894-55900	medial	_	
283-14	55901-55911	prefrontal	_	
283-15	55912-55918	cortex	_	
283-16	55919-55929	activation	_	
283-17	55930-55936	during	_	
283-18	55937-55940	the	_	
283-19	55941-55953	recollection	_	
283-20	55954-55956	of	_	
283-21	55957-55966	stressful	_	
283-22	55967-55973	events	_	
283-23	55974-55976	is	_	
283-24	55977-55979	an	_	
283-25	55980-55988	acquired	_	
283-26	55989-56003	characteristic	_	
283-27	56004-56006	of	_	
283-28	56007-56011	PTSD	_	
283-29	56012-56019	History	_	
283-30	56020-56022	of	_	
283-31	56023-56029	sexual	_	
283-32	56029-56030	,	_	
283-33	56031-56040	emotional	_	
283-34	56041-56043	or	_	
283-35	56044-56052	physical	_	
283-36	56053-56058	abuse	_	
283-37	56059-56062	and	_	
283-38	56063-56074	psychiatric	_	
283-39	56075-56086	comorbidity	_	
283-40	56087-56089	in	_	
283-41	56090-56109	substance-dependent	_	
283-42	56110-56118	patients	_	
283-43	56119-56125	Neural	_	
283-44	56126-56136	correlates	_	
283-45	56137-56139	of	_	
283-46	56140-56147	focused	_	
283-47	56148-56157	attention	_	
283-48	56158-56164	during	_	
283-49	56165-56166	a	_	
283-50	56167-56172	brief	_	
283-51	56173-56184	mindfulness	_	
283-52	56185-56194	induction	_	
283-53	56195-56202	Mindful	_	
283-54	56203-56212	attention	_	
283-55	56213-56215	to	_	
283-56	56216-56222	breath	_	
283-57	56223-56232	regulates	_	
283-58	56233-56241	emotions	_	
283-59	56242-56245	via	_	
283-60	56246-56255	increased	_	
283-61	56256-56275	amygdala-prefrontal	_	
283-62	56276-56282	cortex	_	
283-63	56283-56295	connectivity	_	
283-64	56296-56307	Multimethod	_	
283-65	56308-56319	alexithymia	_	
283-66	56320-56330	assessment	_	
283-67	56331-56333	in	_	
283-68	56334-56345	adolescents	_	
283-69	56346-56349	and	_	
283-70	56350-56355	young	_	
283-71	56356-56362	adults	_	
283-72	56363-56367	with	_	
283-73	56368-56369	a	_	
283-74	56370-56378	cannabis	_	
283-75	56379-56382	use	_	
283-76	56383-56391	disorder	_	
283-77	56392-56399	Cluster	_	
283-78	56400-56407	failure	_	
283-79	56407-56408	:	_	
283-80	56409-56412	Why	_	
283-81	56413-56417	fMRI	_	
283-82	56418-56428	inferences	_	
283-83	56429-56432	for	_	
283-84	56433-56440	spatial	_	
283-85	56441-56447	extent	_	
283-86	56448-56452	have	_	
283-87	56453-56461	inflated	_	
283-88	56462-56476	false-positive	_	
283-89	56477-56482	rates	_	
283-90	56483-56494	Attentional	_	
283-91	56495-56505	modulation	_	
283-92	56506-56508	of	_	
283-93	56509-56516	primary	_	
283-94	56517-56530	interoceptive	_	
283-95	56531-56534	and	_	
283-96	56535-56548	exteroceptive	_	
283-97	56549-56557	cortices	_	
283-98	56558-56569	Mindfulness	_	
283-99	56570-56580	meditation	_	
283-100	56581-56589	training	_	
283-101	56590-56596	alters	_	
283-102	56597-56605	cortical	_	
283-103	56606-56621	representations	_	
283-104	56622-56624	of	_	
283-105	56625-56638	interoceptive	_	
283-106	56639-56648	attention	_	
283-107	56649-56662	Psychological	_	
283-108	56662-56663	,	_	
283-109	56664-56672	Physical	_	
283-110	56672-56673	,	_	
283-111	56674-56677	and	_	
283-112	56678-56684	Sexual	_	
283-113	56685-56690	Abuse	_	
283-114	56691-56693	in	_	
283-115	56694-56702	Addicted	_	
283-116	56703-56711	Patients	_	
283-117	56712-56715	Who	_	
283-118	56716-56723	Undergo	_	
283-119	56724-56733	Treatment	_	
283-120	56734-56747	Interoceptive	_	
283-121	56748-56759	predictions	_	
283-122	56760-56762	in	_	
283-123	56763-56766	the	_	
283-124	56767-56772	brain	_	
283-125	56773-56781	Anterior	_	
283-126	56782-56791	cingulate	_	
283-127	56792-56800	activity	_	
283-128	56801-56803	to	_	
283-129	56804-56811	salient	_	
283-130	56812-56819	stimuli	_	
283-131	56820-56822	is	_	
283-132	56823-56832	modulated	_	
283-133	56833-56835	by	_	
283-134	56836-56845	autonomic	_	
283-135	56846-56853	arousal	_	
283-136	56854-56856	in	_	
283-137	56857-56870	posttraumatic	_	
283-138	56871-56877	stress	_	
283-139	56878-56886	disorder	_	
283-140	56887-56897	Randomized	_	
283-141	56898-56903	trial	_	
283-142	56904-56906	of	_	
283-143	56907-56916	prolonged	_	
283-144	56917-56925	exposure	_	
283-145	56926-56929	for	_	
283-146	56930-56943	posttraumatic	_	
283-147	56944-56950	stress	_	
283-148	56951-56959	disorder	_	
283-149	56960-56964	with	_	
283-150	56965-56968	and	_	
283-151	56969-56976	without	_	
283-152	56977-56986	cognitive	_	
283-153	56987-57000	restructuring	_	
283-154	57000-57001	:	_	
283-155	57002-57009	outcome	_	
283-156	57010-57012	at	_	
283-157	57013-57021	academic	_	
283-158	57022-57025	and	_	
283-159	57026-57035	community	_	
283-160	57036-57043	clinics	_	
283-161	57044-57055	Reliability	_	
283-162	57056-57059	and	_	
283-163	57060-57068	validity	_	
283-164	57069-57071	of	_	
283-165	57072-57073	a	_	
283-166	57074-57079	brief	_	
283-167	57080-57090	instrument	_	
283-168	57091-57094	for	_	
283-169	57095-57104	assessing	_	
283-170	57105-57119	post-traumatic	_	
283-171	57120-57126	stress	_	
283-172	57127-57135	disorder	_	
283-173	57136-57142	Unseen	_	
283-174	57143-57148	scars	_	
283-175	57148-57149	:	_	
283-176	57150-57157	cocaine	_	
283-177	57158-57166	patients	_	
283-178	57167-57171	with	_	
283-179	57172-57177	prior	_	
283-180	57178-57184	trauma	_	
283-181	57185-57193	evidence	_	
283-182	57194-57204	heightened	_	
283-183	57205-57212	resting	_	
283-184	57213-57218	state	_	
283-185	57219-57229	functional	_	
283-186	57230-57242	connectivity	_	
283-187	57243-57244	(	_	
283-188	57244-57248	RSFC	_	
283-189	57248-57249	)	_	
283-190	57250-57257	between	_	
283-191	57258-57261	the	_	
283-192	57262-57270	amygdala	_	
283-193	57271-57274	and	_	
283-194	57275-57290	limbic-striatal	_	
283-195	57291-57298	regions	_	
283-196	57299-57310	Image-based	_	
283-197	57311-57317	method	_	
283-198	57318-57321	for	_	
283-199	57322-57335	retrospective	_	
283-200	57336-57346	correction	_	
283-201	57347-57349	of	_	
283-202	57350-57363	physiological	_	
283-203	57364-57370	motion	_	
283-204	57371-57378	effects	_	
283-205	57379-57381	in	_	
283-206	57382-57386	fMRI	_	
283-207	57386-57387	:	_	
283-208	57388-57397	RETROICOR	_	
283-209	57398-57409	Dysfunction	_	
283-210	57410-57412	of	_	
283-211	57413-57416	the	_	
283-212	57417-57427	prefrontal	_	
283-213	57428-57434	cortex	_	
283-214	57435-57437	in	_	
283-215	57438-57447	addiction	_	
283-216	57448-57449	:	_	
283-217	57450-57462	neuroimaging	_	
283-218	57463-57471	findings	_	
283-219	57472-57475	and	_	
283-220	57476-57484	clinical	_	
283-221	57485-57497	implications	_	
283-222	57498-57501	The	_	
283-223	57502-57516	neurocircuitry	_	
283-224	57517-57519	of	_	
283-225	57520-57528	impaired	_	
283-226	57529-57536	insight	_	
283-227	57537-57539	in	_	
283-228	57540-57544	drug	_	
283-229	57545-57554	addiction	_	
283-230	57555-57560	Early	_	
283-231	57561-57567	stress	_	
283-232	57568-57570	is	_	
283-233	57571-57581	associated	_	
283-234	57582-57586	with	_	
283-235	57587-57598	alterations	_	
283-236	57599-57601	in	_	
283-237	57602-57605	the	_	
283-238	57606-57619	orbitofrontal	_	
283-239	57620-57626	cortex	_	
283-240	57626-57627	:	_	
283-241	57628-57629	A	_	
283-242	57630-57642	tensor-based	_	
283-243	57643-57654	morphometry	_	
283-244	57655-57668	investigation	_	
283-245	57669-57671	of	_	
283-246	57672-57677	brain	_	
283-247	57678-57687	structure	_	
283-248	57688-57691	and	_	
283-249	57692-57702	behavioral	_	
283-250	57703-57707	risk	_	
283-251	57708-57715	Sensory	_	
283-252	57716-57724	overload	_	
283-253	57725-57728	and	_	
283-254	57729-57738	imbalance	_	
283-255	57738-57739	:	_	
283-256	57740-57753	resting-state	_	
283-257	57754-57764	vestibular	_	
283-258	57765-57777	connectivity	_	
283-259	57778-57780	in	_	
283-260	57781-57785	PTSD	_	
283-261	57786-57789	and	_	
283-262	57790-57793	its	_	
283-263	57794-57806	dissociative	_	
283-264	57807-57814	subtype	_	
283-265	57815-57821	Neural	_	
283-266	57822-57829	origins	_	
283-267	57830-57832	of	_	
283-268	57833-57838	human	_	
283-269	57839-57847	sickness	_	
283-270	57848-57850	in	_	
283-271	57851-57864	interoceptive	_	
283-272	57865-57874	responses	_	
283-273	57875-57877	to	_	
283-274	57878-57890	inflammation	_	
283-275	57891-57903	Quantitative	_	
283-276	57904-57917	magnetization	_	
283-277	57918-57926	transfer	_	
283-278	57927-57934	imaging	_	
283-279	57935-57937	as	_	
283-280	57938-57939	a	_	
283-281	57940-57949	biomarker	_	
283-282	57950-57953	for	_	
283-283	57954-57961	effects	_	
283-284	57962-57964	of	_	
283-285	57965-57973	systemic	_	
283-286	57974-57986	inflammation	_	
283-287	57987-57989	on	_	
283-288	57990-57993	the	_	
283-289	57994-57999	brain	_	
283-290	58000-58012	Neuroimaging	_	
283-291	58013-58015	of	_	
283-292	58016-58021	child	_	
283-293	58022-58027	abuse	_	
283-294	58027-58028	:	_	
283-295	58029-58030	a	_	
283-296	58031-58039	critical	_	
283-297	58040-58046	review	_	
283-298	58047-58051	Mind	_	
283-299	58052-58061	wandering	_	
283-300	58062-58065	and	_	
283-301	58066-58075	attention	_	
283-302	58076-58082	during	_	
283-303	58083-58090	focused	_	
283-304	58091-58101	meditation	_	
283-305	58101-58102	:	_	
283-306	58103-58104	A	_	
283-307	58105-58117	fine-grained	_	
283-308	58118-58126	temporal	_	
283-309	58127-58135	analysis	_	
283-310	58136-58138	of	_	
283-311	58139-58150	fluctuating	_	
283-312	58151-58160	cognitive	_	
283-313	58161-58167	states	_	
283-314	58168-58171	How	_	
283-315	58172-58175	the	_	
283-316	58176-58181	heart	_	
283-317	58182-58188	speaks	_	
283-318	58189-58191	to	_	
283-319	58192-58195	the	_	
283-320	58196-58201	brain	_	
283-321	58201-58202	:	_	
283-322	58203-58209	neural	_	
283-323	58210-58218	activity	_	
283-324	58219-58225	during	_	
283-325	58226-58243	cardiorespiratory	_	
283-326	58244-58257	interoceptive	_	
283-327	58258-58269	stimulation	_	
283-328	58270-58277	Emotion	_	
283-329	58278-58281	and	_	
283-330	58282-58291	cognition	_	
283-331	58292-58304	interactions	_	
283-332	58305-58307	in	_	
283-333	58308-58312	PTSD	_	
283-334	58312-58313	:	_	
283-335	58314-58315	a	_	
283-336	58316-58322	review	_	
283-337	58323-58325	of	_	
283-338	58326-58340	neurocognitive	_	
283-339	58341-58344	and	_	
283-340	58345-58357	neuroimaging	_	
283-341	58358-58365	studies	_	
283-342	58366-58375	Decreased	_	
283-343	58376-58384	cortical	_	
283-344	58385-58399	representation	_	
283-345	58400-58402	of	_	
283-346	58403-58410	genital	_	
283-347	58411-58424	somatosensory	_	
283-348	58425-58430	field	_	
283-349	58431-58436	after	_	
283-350	58437-58446	childhood	_	
283-351	58447-58453	sexual	_	
283-352	58454-58459	abuse	_	
283-353	58460-58466	Neural	_	
283-354	58467-58477	regulation	_	
283-355	58478-58480	of	_	
283-356	58481-58484	the	_	
283-357	58485-58491	stress	_	
283-358	58492-58500	response	_	
283-359	58500-58501	:	_	
283-360	58502-58516	glucocorticoid	_	
283-361	58517-58525	feedback	_	
283-362	58526-58536	mechanisms	_	
283-363	58537-58543	Neural	_	
283-364	58544-58554	correlates	_	
283-365	58555-58557	of	_	
283-366	58558-58567	attention	_	
283-367	58568-58572	bias	_	
283-368	58573-58575	in	_	
283-369	58576-58589	posttraumatic	_	
283-370	58590-58596	stress	_	
283-371	58597-58605	disorder	_	
283-372	58606-58614	Distinct	_	
283-373	58615-58623	illusory	_	
283-374	58624-58632	own-body	_	
283-375	58633-58644	perceptions	_	
283-376	58645-58651	caused	_	
283-377	58652-58654	by	_	
283-378	58655-58661	damage	_	
283-379	58662-58664	to	_	
283-380	58665-58674	posterior	_	
283-381	58675-58681	insula	_	
283-382	58682-58685	and	_	
283-383	58686-58698	extrastriate	_	
283-384	58699-58705	cortex	_	
283-385	58706-58708	Do	_	
283-386	58709-58718	treatment	_	
283-387	58719-58731	improvements	_	
283-388	58732-58734	in	_	
283-389	58735-58739	PTSD	_	
283-390	58740-58748	severity	_	
283-391	58749-58755	affect	_	
283-392	58756-58765	substance	_	
283-393	58766-58769	use	_	
283-394	58770-58778	outcomes	_	
283-395	58778-58779	?	_	

#Text=A secondary analysis from a randomized clinical trial in NIDA's clinical trials network
#Text=Acquired alexithymia following damage to the anterior insula
#Text=Differential engagement of anterior cingulate and adjacent medial frontal cortex in adept meditators and non-meditators
#Text=Identity-specific coding of future rewards in the human orbitofrontal cortex
#Text=Severity of childhood trauma is predictive of cocaine relapse outcomes in women but not men
#Text=Substance use disorders in patients with posttraumatic stress disorder : A review of the literature
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Attention to touch modulates activity in both primary and secondary somatosensory areas
#Text=One-session mindfulness meditation: A randomized controlled study of effects on cognition and mood
#Text=A randomized controlled trial on cognitive restructuring and imagery modification to reduce the feeling of being contaminated in adult survivors of childhood sexual abuse suffering from posttraumatic stress disorder
#Text=Childhood sexual abuse and adult psychiatric and substance use disorders in women
#Text=Altered insula activity during visceral interoception in weight-restored patients with anorexia nervosa
#Text=Influence of visceral interoceptive experience on the brain's response to food images in anorexia nervosa
#Text=Interoception and mental health: a roadmap
#Text=A prospective study of sex differences in the lifetime risk of posttraumatic stress disorder among abused and neglected children grown up
#Text=Immunosuppression induced by a conditioned stimulus associated with cocaine self-administration
#Text=Interoceptive awareness changes the posterior insula functional connectivity profile
#Text=Neurobiological correlates of physical self-concept and self-identification with avatars in addicted players of massively multiplayer online role-playing games (MMORPGs)
#Text=Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting
#Text=Is alexithymia a negative factor for maintaining abstinence?
284-1	58780-58781	A	_	
284-2	58782-58791	secondary	_	
284-3	58792-58800	analysis	_	
284-4	58801-58805	from	_	
284-5	58806-58807	a	_	
284-6	58808-58818	randomized	_	
284-7	58819-58827	clinical	_	
284-8	58828-58833	trial	_	
284-9	58834-58836	in	_	
284-10	58837-58843	NIDA's	_	
284-11	58844-58852	clinical	_	
284-12	58853-58859	trials	_	
284-13	58860-58867	network	_	
284-14	58868-58876	Acquired	_	
284-15	58877-58888	alexithymia	_	
284-16	58889-58898	following	_	
284-17	58899-58905	damage	_	
284-18	58906-58908	to	_	
284-19	58909-58912	the	_	
284-20	58913-58921	anterior	_	
284-21	58922-58928	insula	_	
284-22	58929-58941	Differential	_	
284-23	58942-58952	engagement	_	
284-24	58953-58955	of	_	
284-25	58956-58964	anterior	_	
284-26	58965-58974	cingulate	_	
284-27	58975-58978	and	_	
284-28	58979-58987	adjacent	_	
284-29	58988-58994	medial	_	
284-30	58995-59002	frontal	_	
284-31	59003-59009	cortex	_	
284-32	59010-59012	in	_	
284-33	59013-59018	adept	_	
284-34	59019-59029	meditators	_	
284-35	59030-59033	and	_	
284-36	59034-59048	non-meditators	_	
284-37	59049-59066	Identity-specific	_	
284-38	59067-59073	coding	_	
284-39	59074-59076	of	_	
284-40	59077-59083	future	_	
284-41	59084-59091	rewards	_	
284-42	59092-59094	in	_	
284-43	59095-59098	the	_	
284-44	59099-59104	human	_	
284-45	59105-59118	orbitofrontal	_	
284-46	59119-59125	cortex	_	
284-47	59126-59134	Severity	_	
284-48	59135-59137	of	_	
284-49	59138-59147	childhood	_	
284-50	59148-59154	trauma	_	
284-51	59155-59157	is	_	
284-52	59158-59168	predictive	_	
284-53	59169-59171	of	_	
284-54	59172-59179	cocaine	_	
284-55	59180-59187	relapse	_	
284-56	59188-59196	outcomes	_	
284-57	59197-59199	in	_	
284-58	59200-59205	women	_	
284-59	59206-59209	but	_	
284-60	59210-59213	not	_	
284-61	59214-59217	men	_	
284-62	59218-59227	Substance	_	
284-63	59228-59231	use	_	
284-64	59232-59241	disorders	_	
284-65	59242-59244	in	_	
284-66	59245-59253	patients	_	
284-67	59254-59258	with	_	
284-68	59259-59272	posttraumatic	_	
284-69	59273-59279	stress	_	
284-70	59280-59288	disorder	_	
284-71	59289-59290	:	_	
284-72	59291-59292	A	_	
284-73	59293-59299	review	_	
284-74	59300-59302	of	_	
284-75	59303-59306	the	_	
284-76	59307-59317	literature	_	
284-77	59318-59326	Improved	_	
284-78	59327-59339	optimization	_	
284-79	59340-59343	for	_	
284-80	59344-59347	the	_	
284-81	59348-59354	robust	_	
284-82	59355-59358	and	_	
284-83	59359-59367	accurate	_	
284-84	59368-59374	linear	_	
284-85	59375-59387	registration	_	
284-86	59388-59391	and	_	
284-87	59392-59398	motion	_	
284-88	59399-59409	correction	_	
284-89	59410-59412	of	_	
284-90	59413-59418	brain	_	
284-91	59419-59425	images	_	
284-92	59426-59435	Attention	_	
284-93	59436-59438	to	_	
284-94	59439-59444	touch	_	
284-95	59445-59454	modulates	_	
284-96	59455-59463	activity	_	
284-97	59464-59466	in	_	
284-98	59467-59471	both	_	
284-99	59472-59479	primary	_	
284-100	59480-59483	and	_	
284-101	59484-59493	secondary	_	
284-102	59494-59507	somatosensory	_	
284-103	59508-59513	areas	_	
284-104	59514-59525	One-session	_	
284-105	59526-59537	mindfulness	_	
284-106	59538-59548	meditation	_	
284-107	59548-59549	:	_	
284-108	59550-59551	A	_	
284-109	59552-59562	randomized	_	
284-110	59563-59573	controlled	_	
284-111	59574-59579	study	_	
284-112	59580-59582	of	_	
284-113	59583-59590	effects	_	
284-114	59591-59593	on	_	
284-115	59594-59603	cognition	_	
284-116	59604-59607	and	_	
284-117	59608-59612	mood	_	
284-118	59613-59614	A	_	
284-119	59615-59625	randomized	_	
284-120	59626-59636	controlled	_	
284-121	59637-59642	trial	_	
284-122	59643-59645	on	_	
284-123	59646-59655	cognitive	_	
284-124	59656-59669	restructuring	_	
284-125	59670-59673	and	_	
284-126	59674-59681	imagery	_	
284-127	59682-59694	modification	_	
284-128	59695-59697	to	_	
284-129	59698-59704	reduce	_	
284-130	59705-59708	the	_	
284-131	59709-59716	feeling	_	
284-132	59717-59719	of	_	
284-133	59720-59725	being	_	
284-134	59726-59738	contaminated	_	
284-135	59739-59741	in	_	
284-136	59742-59747	adult	_	
284-137	59748-59757	survivors	_	
284-138	59758-59760	of	_	
284-139	59761-59770	childhood	_	
284-140	59771-59777	sexual	_	
284-141	59778-59783	abuse	_	
284-142	59784-59793	suffering	_	
284-143	59794-59798	from	_	
284-144	59799-59812	posttraumatic	_	
284-145	59813-59819	stress	_	
284-146	59820-59828	disorder	_	
284-147	59829-59838	Childhood	_	
284-148	59839-59845	sexual	_	
284-149	59846-59851	abuse	_	
284-150	59852-59855	and	_	
284-151	59856-59861	adult	_	
284-152	59862-59873	psychiatric	_	
284-153	59874-59877	and	_	
284-154	59878-59887	substance	_	
284-155	59888-59891	use	_	
284-156	59892-59901	disorders	_	
284-157	59902-59904	in	_	
284-158	59905-59910	women	_	
284-159	59911-59918	Altered	_	
284-160	59919-59925	insula	_	
284-161	59926-59934	activity	_	
284-162	59935-59941	during	_	
284-163	59942-59950	visceral	_	
284-164	59951-59964	interoception	_	
284-165	59965-59967	in	_	
284-166	59968-59983	weight-restored	_	
284-167	59984-59992	patients	_	
284-168	59993-59997	with	_	
284-169	59998-60006	anorexia	_	
284-170	60007-60014	nervosa	_	
284-171	60015-60024	Influence	_	
284-172	60025-60027	of	_	
284-173	60028-60036	visceral	_	
284-174	60037-60050	interoceptive	_	
284-175	60051-60061	experience	_	
284-176	60062-60064	on	_	
284-177	60065-60068	the	_	
284-178	60069-60076	brain's	_	
284-179	60077-60085	response	_	
284-180	60086-60088	to	_	
284-181	60089-60093	food	_	
284-182	60094-60100	images	_	
284-183	60101-60103	in	_	
284-184	60104-60112	anorexia	_	
284-185	60113-60120	nervosa	_	
284-186	60121-60134	Interoception	_	
284-187	60135-60138	and	_	
284-188	60139-60145	mental	_	
284-189	60146-60152	health	_	
284-190	60152-60153	:	_	
284-191	60154-60155	a	_	
284-192	60156-60163	roadmap	_	
284-193	60164-60165	A	_	
284-194	60166-60177	prospective	_	
284-195	60178-60183	study	_	
284-196	60184-60186	of	_	
284-197	60187-60190	sex	_	
284-198	60191-60202	differences	_	
284-199	60203-60205	in	_	
284-200	60206-60209	the	_	
284-201	60210-60218	lifetime	_	
284-202	60219-60223	risk	_	
284-203	60224-60226	of	_	
284-204	60227-60240	posttraumatic	_	
284-205	60241-60247	stress	_	
284-206	60248-60256	disorder	_	
284-207	60257-60262	among	_	
284-208	60263-60269	abused	_	
284-209	60270-60273	and	_	
284-210	60274-60283	neglected	_	
284-211	60284-60292	children	_	
284-212	60293-60298	grown	_	
284-213	60299-60301	up	_	
284-214	60302-60319	Immunosuppression	_	
284-215	60320-60327	induced	_	
284-216	60328-60330	by	_	
284-217	60331-60332	a	_	
284-218	60333-60344	conditioned	_	
284-219	60345-60353	stimulus	_	
284-220	60354-60364	associated	_	
284-221	60365-60369	with	_	
284-222	60370-60377	cocaine	_	
284-223	60378-60397	self-administration	_	
284-224	60398-60411	Interoceptive	_	
284-225	60412-60421	awareness	_	
284-226	60422-60429	changes	_	
284-227	60430-60433	the	_	
284-228	60434-60443	posterior	_	
284-229	60444-60450	insula	_	
284-230	60451-60461	functional	_	
284-231	60462-60474	connectivity	_	
284-232	60475-60482	profile	_	
284-233	60483-60498	Neurobiological	_	
284-234	60499-60509	correlates	_	
284-235	60510-60512	of	_	
284-236	60513-60521	physical	_	
284-237	60522-60534	self-concept	_	
284-238	60535-60538	and	_	
284-239	60539-60558	self-identification	_	
284-240	60559-60563	with	_	
284-241	60564-60571	avatars	_	
284-242	60572-60574	in	_	
284-243	60575-60583	addicted	_	
284-244	60584-60591	players	_	
284-245	60592-60594	of	_	
284-246	60595-60604	massively	_	
284-247	60605-60616	multiplayer	_	
284-248	60617-60623	online	_	
284-249	60624-60636	role-playing	_	
284-250	60637-60642	games	_	
284-251	60643-60644	(	_	
284-252	60644-60651	MMORPGs	_	
284-253	60651-60652	)	_	
284-254	60653-60667	Stress-induced	_	
284-255	60668-60679	alterations	_	
284-256	60680-60682	in	_	
284-257	60683-60693	prefrontal	_	
284-258	60694-60702	cortical	_	
284-259	60703-60712	dendritic	_	
284-260	60713-60723	morphology	_	
284-261	60724-60731	predict	_	
284-262	60732-60741	selective	_	
284-263	60742-60753	impairments	_	
284-264	60754-60756	in	_	
284-265	60757-60767	perceptual	_	
284-266	60768-60779	attentional	_	
284-267	60780-60792	set-shifting	_	
284-268	60793-60795	Is	_	
284-269	60796-60807	alexithymia	_	
284-270	60808-60809	a	_	
284-271	60810-60818	negative	_	
284-272	60819-60825	factor	_	
284-273	60826-60829	for	_	
284-274	60830-60841	maintaining	_	
284-275	60842-60852	abstinence	_	
284-276	60852-60853	?	_	

#Text=A follow-up study
#Text=Correspondence of the brain; functional architecture during activation and rest
#Text=Yohimbine administration and cue-reactivity in cocaine-dependent individuals
#Text=Methamphetamine dependent individuals show attenuated brain response to pleasant interoceptive stimuli
#Text=The assessment of trauma history in women with co-occurring substance abuse and mental disorders and a history of interpersonal violence
#Text=The fifth edition of the addiction severity index
#Text=Posttraumatic stress disorder : A metabolic disorder in disguise ?
285-1	60854-60855	A	_	
285-2	60856-60865	follow-up	_	
285-3	60866-60871	study	_	
285-4	60872-60886	Correspondence	_	
285-5	60887-60889	of	_	
285-6	60890-60893	the	_	
285-7	60894-60899	brain	_	
285-8	60899-60900	;	_	
285-9	60901-60911	functional	_	
285-10	60912-60924	architecture	_	
285-11	60925-60931	during	_	
285-12	60932-60942	activation	_	
285-13	60943-60946	and	_	
285-14	60947-60951	rest	_	
285-15	60952-60961	Yohimbine	_	
285-16	60962-60976	administration	_	
285-17	60977-60980	and	_	
285-18	60981-60995	cue-reactivity	_	
285-19	60996-60998	in	_	
285-20	60999-61016	cocaine-dependent	_	
285-21	61017-61028	individuals	_	
285-22	61029-61044	Methamphetamine	_	
285-23	61045-61054	dependent	_	
285-24	61055-61066	individuals	_	
285-25	61067-61071	show	_	
285-26	61072-61082	attenuated	_	
285-27	61083-61088	brain	_	
285-28	61089-61097	response	_	
285-29	61098-61100	to	_	
285-30	61101-61109	pleasant	_	
285-31	61110-61123	interoceptive	_	
285-32	61124-61131	stimuli	_	
285-33	61132-61135	The	_	
285-34	61136-61146	assessment	_	
285-35	61147-61149	of	_	
285-36	61150-61156	trauma	_	
285-37	61157-61164	history	_	
285-38	61165-61167	in	_	
285-39	61168-61173	women	_	
285-40	61174-61178	with	_	
285-41	61179-61191	co-occurring	_	
285-42	61192-61201	substance	_	
285-43	61202-61207	abuse	_	
285-44	61208-61211	and	_	
285-45	61212-61218	mental	_	
285-46	61219-61228	disorders	_	
285-47	61229-61232	and	_	
285-48	61233-61234	a	_	
285-49	61235-61242	history	_	
285-50	61243-61245	of	_	
285-51	61246-61259	interpersonal	_	
285-52	61260-61268	violence	_	
285-53	61269-61272	The	_	
285-54	61273-61278	fifth	_	
285-55	61279-61286	edition	_	
285-56	61287-61289	of	_	
285-57	61290-61293	the	_	
285-58	61294-61303	addiction	_	
285-59	61304-61312	severity	_	
285-60	61313-61318	index	_	
285-61	61319-61332	Posttraumatic	_	
285-62	61333-61339	stress	_	
285-63	61340-61348	disorder	_	
285-64	61349-61350	:	_	
285-65	61351-61352	A	_	
285-66	61353-61362	metabolic	_	
285-67	61363-61371	disorder	_	
285-68	61372-61374	in	_	
285-69	61375-61383	disguise	_	
285-70	61384-61385	?	_	

#Text=Amygdala, Hippocampus, and ventral medial prefrontal cortex volumes differ in maltreated youth with and without chronic posttraumatic stress disorder
#Text=Violence-related PTSD and neural activation when seeing emotionally charged male-female interactions
#Text=The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making
#Text=The effect of 5 minutes of mindful breathing to the perception of distress and physiological responses in palliative care cancer patients: A randomized controlled study
#Text=Using dual regression to investigate network shape and amplitude in functional connectivity analyses
#Text=The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans
#Text=Course and treatment of patients with both substance use and posttraumatic stress disorders
#Text=Precipitants of first substance use in recently abstinent substance use disorder patients with PTSD
#Text=The somatic marker hypothesis: revisiting the role of the ‘body-loop’ in decision-making
#Text=Dissociation reduction in body therapy during sexual abuse recovery
#Text=Evaluation of ICA-AROMA and alternative strategies for motion artifact removal in resting state fMRI
#Text=Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues
#Text=Trauma and post-traumatic stress disorder in a drug treatment community service
#Text=Reliability of the timeline followback for cocaine, cannabis, and cigarette use
#Text=Convergence of sensory systems in the orbitofrontal cortex in primates and brain design for emotion
#Text=Physical and sexual abuse history and addiction treatment outcomes
#Text=Altered processing of contextual information during fear extinction in PTSD: an fMRI study
#Text=Childhood trauma and dissociation in patients with alcohol dependence, drug dependence, or both-A multi-center study
#Text=Neural correlates of heart-focused interoception: A functional magnetic resonance imaging meta-analysis
#Text=Mindfulness training induces structural connectome changes in insula networks
#Text=Dynamic influences on smoking relapse process
#Text=Glucocorticoid receptor mRNA and protein isoform alterations in the orbitofrontal cortex in schizophrenia and bipolar disorder
#Text=Chronic stress, drug use, and vulnerability to addiction
#Text=Fast robust automated brain extraction
#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference
#Text=“I Don't like being that hyperaware of my body”: women survivors of sexual violence and their experience of exercise
#Text=Neural dysregulation in posttraumatic stress disorder: evidence for disrupted equilibrium between salience and default mode brain networks
#Text=You are the danger: attenuated insula response in methamphetamine users during aversive interoceptive decision-making
#Text=Neural correlates of altered pain response in women with posttraumatic stress disorder from intimate partner violence
#Text=Reduced connectivity between the left fusiform body area and the extrastriate body area in anorexia nervosa is associated with body image distortion
#Text=Self as object : emerging trends in self research
#Text=Medial orbitofrontal cortex gray matter is reduced in
#Text=Brain and cognition increases in the right dorsolateral prefrontal cortex and decreases the rostral prefrontal cortex activation after-8 weeks of focused attention based mindfulness meditation
#Text=Distinct intrinsic network connectivity patterns of post-traumatic stress disorder symptom clusters
#Text=Functional network topology associated with posttraumatic stress disorder in veterans
#Text=The role of interoception in addiction: A critical review
#Text=Co-occurring posttraumatic stress and substance use: emerging research on correlates, mechanisms, and treatments - introduction to the special issue
#Text=Response inhibition and fronto-striatal-thalamic circuit dysfunction in cocaine addiction
#Text=Permutation inference for the general linear model
#Text=
#Text=Meta-analytic connectivity modeling reveals differential functional connectivity of the medial and lateral orbitofrontal cortex
#Text=Anhedonia and individual differences in orbitofrontal cortex sulcogyral morphology
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2019.101973.
286-1	61386-61394	Amygdala	_	
286-2	61394-61395	,	_	
286-3	61396-61407	Hippocampus	_	
286-4	61407-61408	,	_	
286-5	61409-61412	and	_	
286-6	61413-61420	ventral	_	
286-7	61421-61427	medial	_	
286-8	61428-61438	prefrontal	_	
286-9	61439-61445	cortex	_	
286-10	61446-61453	volumes	_	
286-11	61454-61460	differ	_	
286-12	61461-61463	in	_	
286-13	61464-61474	maltreated	_	
286-14	61475-61480	youth	_	
286-15	61481-61485	with	_	
286-16	61486-61489	and	_	
286-17	61490-61497	without	_	
286-18	61498-61505	chronic	_	
286-19	61506-61519	posttraumatic	_	
286-20	61520-61526	stress	_	
286-21	61527-61535	disorder	_	
286-22	61536-61552	Violence-related	_	
286-23	61553-61557	PTSD	_	
286-24	61558-61561	and	_	
286-25	61562-61568	neural	_	
286-26	61569-61579	activation	_	
286-27	61580-61584	when	_	
286-28	61585-61591	seeing	_	
286-29	61592-61603	emotionally	_	
286-30	61604-61611	charged	_	
286-31	61612-61623	male-female	_	
286-32	61624-61636	interactions	_	
286-33	61637-61640	The	_	
286-34	61641-61647	insula	_	
286-35	61648-61651	and	_	
286-36	61652-61656	drug	_	
286-37	61657-61666	addiction	_	
286-38	61666-61667	:	_	
286-39	61668-61670	an	_	
286-40	61671-61684	interoceptive	_	
286-41	61685-61689	view	_	
286-42	61690-61692	of	_	
286-43	61693-61701	pleasure	_	
286-44	61701-61702	,	_	
286-45	61703-61708	urges	_	
286-46	61708-61709	,	_	
286-47	61710-61713	and	_	
286-48	61714-61729	decision-making	_	
286-49	61730-61733	The	_	
286-50	61734-61740	effect	_	
286-51	61741-61743	of	_	
286-52	61744-61745	5	_	
286-53	61746-61753	minutes	_	
286-54	61754-61756	of	_	
286-55	61757-61764	mindful	_	
286-56	61765-61774	breathing	_	
286-57	61775-61777	to	_	
286-58	61778-61781	the	_	
286-59	61782-61792	perception	_	
286-60	61793-61795	of	_	
286-61	61796-61804	distress	_	
286-62	61805-61808	and	_	
286-63	61809-61822	physiological	_	
286-64	61823-61832	responses	_	
286-65	61833-61835	in	_	
286-66	61836-61846	palliative	_	
286-67	61847-61851	care	_	
286-68	61852-61858	cancer	_	
286-69	61859-61867	patients	_	
286-70	61867-61868	:	_	
286-71	61869-61870	A	_	
286-72	61871-61881	randomized	_	
286-73	61882-61892	controlled	_	
286-74	61893-61898	study	_	
286-75	61899-61904	Using	_	
286-76	61905-61909	dual	_	
286-77	61910-61920	regression	_	
286-78	61921-61923	to	_	
286-79	61924-61935	investigate	_	
286-80	61936-61943	network	_	
286-81	61944-61949	shape	_	
286-82	61950-61953	and	_	
286-83	61954-61963	amplitude	_	
286-84	61964-61966	in	_	
286-85	61967-61977	functional	_	
286-86	61978-61990	connectivity	_	
286-87	61991-61999	analyses	_	
286-88	62000-62003	The	_	
286-89	62004-62016	organization	_	
286-90	62017-62019	of	_	
286-91	62020-62028	networks	_	
286-92	62029-62035	within	_	
286-93	62036-62039	the	_	
286-94	62040-62047	orbital	_	
286-95	62048-62051	and	_	
286-96	62052-62058	medial	_	
286-97	62059-62069	prefrontal	_	
286-98	62070-62076	cortex	_	
286-99	62077-62079	of	_	
286-100	62080-62084	rats	_	
286-101	62084-62085	,	_	
286-102	62086-62093	monkeys	_	
286-103	62094-62097	and	_	
286-104	62098-62104	humans	_	
286-105	62105-62111	Course	_	
286-106	62112-62115	and	_	
286-107	62116-62125	treatment	_	
286-108	62126-62128	of	_	
286-109	62129-62137	patients	_	
286-110	62138-62142	with	_	
286-111	62143-62147	both	_	
286-112	62148-62157	substance	_	
286-113	62158-62161	use	_	
286-114	62162-62165	and	_	
286-115	62166-62179	posttraumatic	_	
286-116	62180-62186	stress	_	
286-117	62187-62196	disorders	_	
286-118	62197-62209	Precipitants	_	
286-119	62210-62212	of	_	
286-120	62213-62218	first	_	
286-121	62219-62228	substance	_	
286-122	62229-62232	use	_	
286-123	62233-62235	in	_	
286-124	62236-62244	recently	_	
286-125	62245-62254	abstinent	_	
286-126	62255-62264	substance	_	
286-127	62265-62268	use	_	
286-128	62269-62277	disorder	_	
286-129	62278-62286	patients	_	
286-130	62287-62291	with	_	
286-131	62292-62296	PTSD	_	
286-132	62297-62300	The	_	
286-133	62301-62308	somatic	_	
286-134	62309-62315	marker	_	
286-135	62316-62326	hypothesis	_	
286-136	62326-62327	:	_	
286-137	62328-62338	revisiting	_	
286-138	62339-62342	the	_	
286-139	62343-62347	role	_	
286-140	62348-62350	of	_	
286-141	62351-62354	the	_	
286-142	62355-62356	‘	_	
286-143	62356-62365	body-loop	_	
286-144	62365-62366	’	_	
286-145	62367-62369	in	_	
286-146	62370-62385	decision-making	_	
286-147	62386-62398	Dissociation	_	
286-148	62399-62408	reduction	_	
286-149	62409-62411	in	_	
286-150	62412-62416	body	_	
286-151	62417-62424	therapy	_	
286-152	62425-62431	during	_	
286-153	62432-62438	sexual	_	
286-154	62439-62444	abuse	_	
286-155	62445-62453	recovery	_	
286-156	62454-62464	Evaluation	_	
286-157	62465-62467	of	_	
286-158	62468-62477	ICA-AROMA	_	
286-159	62478-62481	and	_	
286-160	62482-62493	alternative	_	
286-161	62494-62504	strategies	_	
286-162	62505-62508	for	_	
286-163	62509-62515	motion	_	
286-164	62516-62524	artifact	_	
286-165	62525-62532	removal	_	
286-166	62533-62535	in	_	
286-167	62536-62543	resting	_	
286-168	62544-62549	state	_	
286-169	62550-62554	fMRI	_	
286-170	62555-62564	Emotional	_	
286-171	62564-62565	,	_	
286-172	62566-62574	physical	_	
286-173	62575-62578	and	_	
286-174	62579-62585	sexual	_	
286-175	62586-62591	abuse	_	
286-176	62592-62595	are	_	
286-177	62596-62606	associated	_	
286-178	62607-62611	with	_	
286-179	62612-62613	a	_	
286-180	62614-62624	heightened	_	
286-181	62625-62631	limbic	_	
286-182	62632-62640	response	_	
286-183	62641-62643	to	_	
286-184	62644-62651	cocaine	_	
286-185	62652-62656	cues	_	
286-186	62657-62663	Trauma	_	
286-187	62664-62667	and	_	
286-188	62668-62682	post-traumatic	_	
286-189	62683-62689	stress	_	
286-190	62690-62698	disorder	_	
286-191	62699-62701	in	_	
286-192	62702-62703	a	_	
286-193	62704-62708	drug	_	
286-194	62709-62718	treatment	_	
286-195	62719-62728	community	_	
286-196	62729-62736	service	_	
286-197	62737-62748	Reliability	_	
286-198	62749-62751	of	_	
286-199	62752-62755	the	_	
286-200	62756-62764	timeline	_	
286-201	62765-62775	followback	_	
286-202	62776-62779	for	_	
286-203	62780-62787	cocaine	_	
286-204	62787-62788	,	_	
286-205	62789-62797	cannabis	_	
286-206	62797-62798	,	_	
286-207	62799-62802	and	_	
286-208	62803-62812	cigarette	_	
286-209	62813-62816	use	_	
286-210	62817-62828	Convergence	_	
286-211	62829-62831	of	_	
286-212	62832-62839	sensory	_	
286-213	62840-62847	systems	_	
286-214	62848-62850	in	_	
286-215	62851-62854	the	_	
286-216	62855-62868	orbitofrontal	_	
286-217	62869-62875	cortex	_	
286-218	62876-62878	in	_	
286-219	62879-62887	primates	_	
286-220	62888-62891	and	_	
286-221	62892-62897	brain	_	
286-222	62898-62904	design	_	
286-223	62905-62908	for	_	
286-224	62909-62916	emotion	_	
286-225	62917-62925	Physical	_	
286-226	62926-62929	and	_	
286-227	62930-62936	sexual	_	
286-228	62937-62942	abuse	_	
286-229	62943-62950	history	_	
286-230	62951-62954	and	_	
286-231	62955-62964	addiction	_	
286-232	62965-62974	treatment	_	
286-233	62975-62983	outcomes	_	
286-234	62984-62991	Altered	_	
286-235	62992-63002	processing	_	
286-236	63003-63005	of	_	
286-237	63006-63016	contextual	_	
286-238	63017-63028	information	_	
286-239	63029-63035	during	_	
286-240	63036-63040	fear	_	
286-241	63041-63051	extinction	_	
286-242	63052-63054	in	_	
286-243	63055-63059	PTSD	_	
286-244	63059-63060	:	_	
286-245	63061-63063	an	_	
286-246	63064-63068	fMRI	_	
286-247	63069-63074	study	_	
286-248	63075-63084	Childhood	_	
286-249	63085-63091	trauma	_	
286-250	63092-63095	and	_	
286-251	63096-63108	dissociation	_	
286-252	63109-63111	in	_	
286-253	63112-63120	patients	_	
286-254	63121-63125	with	_	
286-255	63126-63133	alcohol	_	
286-256	63134-63144	dependence	_	
286-257	63144-63145	,	_	
286-258	63146-63150	drug	_	
286-259	63151-63161	dependence	_	
286-260	63161-63162	,	_	
286-261	63163-63165	or	_	
286-262	63166-63172	both-A	_	
286-263	63173-63185	multi-center	_	
286-264	63186-63191	study	_	
286-265	63192-63198	Neural	_	
286-266	63199-63209	correlates	_	
286-267	63210-63212	of	_	
286-268	63213-63226	heart-focused	_	
286-269	63227-63240	interoception	_	
286-270	63240-63241	:	_	
286-271	63242-63243	A	_	
286-272	63244-63254	functional	_	
286-273	63255-63263	magnetic	_	
286-274	63264-63273	resonance	_	
286-275	63274-63281	imaging	_	
286-276	63282-63295	meta-analysis	_	
286-277	63296-63307	Mindfulness	_	
286-278	63308-63316	training	_	
286-279	63317-63324	induces	_	
286-280	63325-63335	structural	_	
286-281	63336-63346	connectome	_	
286-282	63347-63354	changes	_	
286-283	63355-63357	in	_	
286-284	63358-63364	insula	_	
286-285	63365-63373	networks	_	
286-286	63374-63381	Dynamic	_	
286-287	63382-63392	influences	_	
286-288	63393-63395	on	_	
286-289	63396-63403	smoking	_	
286-290	63404-63411	relapse	_	
286-291	63412-63419	process	_	
286-292	63420-63434	Glucocorticoid	_	
286-293	63435-63443	receptor	_	
286-294	63444-63448	mRNA	_	
286-295	63449-63452	and	_	
286-296	63453-63460	protein	_	
286-297	63461-63468	isoform	_	
286-298	63469-63480	alterations	_	
286-299	63481-63483	in	_	
286-300	63484-63487	the	_	
286-301	63488-63501	orbitofrontal	_	
286-302	63502-63508	cortex	_	
286-303	63509-63511	in	_	
286-304	63512-63525	schizophrenia	_	
286-305	63526-63529	and	_	
286-306	63530-63537	bipolar	_	
286-307	63538-63546	disorder	_	
286-308	63547-63554	Chronic	_	
286-309	63555-63561	stress	_	
286-310	63561-63562	,	_	
286-311	63563-63567	drug	_	
286-312	63568-63571	use	_	
286-313	63571-63572	,	_	
286-314	63573-63576	and	_	
286-315	63577-63590	vulnerability	_	
286-316	63591-63593	to	_	
286-317	63594-63603	addiction	_	
286-318	63604-63608	Fast	_	
286-319	63609-63615	robust	_	
286-320	63616-63625	automated	_	
286-321	63626-63631	brain	_	
286-322	63632-63642	extraction	_	
286-323	63643-63657	Threshold-free	_	
286-324	63658-63665	cluster	_	
286-325	63666-63677	enhancement	_	
286-326	63677-63678	:	_	
286-327	63679-63689	addressing	_	
286-328	63690-63698	problems	_	
286-329	63699-63701	of	_	
286-330	63702-63711	smoothing	_	
286-331	63711-63712	,	_	
286-332	63713-63722	threshold	_	
286-333	63723-63733	dependence	_	
286-334	63734-63737	and	_	
286-335	63738-63750	localisation	_	
286-336	63751-63753	in	_	
286-337	63754-63761	cluster	_	
286-338	63762-63771	inference	_	
286-339	63772-63773	“	_	
286-340	63773-63774	I	_	
286-341	63775-63780	Don't	_	
286-342	63781-63785	like	_	
286-343	63786-63791	being	_	
286-344	63792-63796	that	_	
286-345	63797-63807	hyperaware	_	
286-346	63808-63810	of	_	
286-347	63811-63813	my	_	
286-348	63814-63818	body	_	
286-349	63818-63819	”	_	
286-350	63819-63820	:	_	
286-351	63821-63826	women	_	
286-352	63827-63836	survivors	_	
286-353	63837-63839	of	_	
286-354	63840-63846	sexual	_	
286-355	63847-63855	violence	_	
286-356	63856-63859	and	_	
286-357	63860-63865	their	_	
286-358	63866-63876	experience	_	
286-359	63877-63879	of	_	
286-360	63880-63888	exercise	_	
286-361	63889-63895	Neural	_	
286-362	63896-63909	dysregulation	_	
286-363	63910-63912	in	_	
286-364	63913-63926	posttraumatic	_	
286-365	63927-63933	stress	_	
286-366	63934-63942	disorder	_	
286-367	63942-63943	:	_	
286-368	63944-63952	evidence	_	
286-369	63953-63956	for	_	
286-370	63957-63966	disrupted	_	
286-371	63967-63978	equilibrium	_	
286-372	63979-63986	between	_	
286-373	63987-63995	salience	_	
286-374	63996-63999	and	_	
286-375	64000-64007	default	_	
286-376	64008-64012	mode	_	
286-377	64013-64018	brain	_	
286-378	64019-64027	networks	_	
286-379	64028-64031	You	_	
286-380	64032-64035	are	_	
286-381	64036-64039	the	_	
286-382	64040-64046	danger	_	
286-383	64046-64047	:	_	
286-384	64048-64058	attenuated	_	
286-385	64059-64065	insula	_	
286-386	64066-64074	response	_	
286-387	64075-64077	in	_	
286-388	64078-64093	methamphetamine	_	
286-389	64094-64099	users	_	
286-390	64100-64106	during	_	
286-391	64107-64115	aversive	_	
286-392	64116-64129	interoceptive	_	
286-393	64130-64145	decision-making	_	
286-394	64146-64152	Neural	_	
286-395	64153-64163	correlates	_	
286-396	64164-64166	of	_	
286-397	64167-64174	altered	_	
286-398	64175-64179	pain	_	
286-399	64180-64188	response	_	
286-400	64189-64191	in	_	
286-401	64192-64197	women	_	
286-402	64198-64202	with	_	
286-403	64203-64216	posttraumatic	_	
286-404	64217-64223	stress	_	
286-405	64224-64232	disorder	_	
286-406	64233-64237	from	_	
286-407	64238-64246	intimate	_	
286-408	64247-64254	partner	_	
286-409	64255-64263	violence	_	
286-410	64264-64271	Reduced	_	
286-411	64272-64284	connectivity	_	
286-412	64285-64292	between	_	
286-413	64293-64296	the	_	
286-414	64297-64301	left	_	
286-415	64302-64310	fusiform	_	
286-416	64311-64315	body	_	
286-417	64316-64320	area	_	
286-418	64321-64324	and	_	
286-419	64325-64328	the	_	
286-420	64329-64341	extrastriate	_	
286-421	64342-64346	body	_	
286-422	64347-64351	area	_	
286-423	64352-64354	in	_	
286-424	64355-64363	anorexia	_	
286-425	64364-64371	nervosa	_	
286-426	64372-64374	is	_	
286-427	64375-64385	associated	_	
286-428	64386-64390	with	_	
286-429	64391-64395	body	_	
286-430	64396-64401	image	_	
286-431	64402-64412	distortion	_	
286-432	64413-64417	Self	_	
286-433	64418-64420	as	_	
286-434	64421-64427	object	_	
286-435	64428-64429	:	_	
286-436	64430-64438	emerging	_	
286-437	64439-64445	trends	_	
286-438	64446-64448	in	_	
286-439	64449-64453	self	_	
286-440	64454-64462	research	_	
286-441	64463-64469	Medial	_	
286-442	64470-64483	orbitofrontal	_	
286-443	64484-64490	cortex	_	
286-444	64491-64495	gray	_	
286-445	64496-64502	matter	_	
286-446	64503-64505	is	_	
286-447	64506-64513	reduced	_	
286-448	64514-64516	in	_	
286-449	64517-64522	Brain	_	
286-450	64523-64526	and	_	
286-451	64527-64536	cognition	_	
286-452	64537-64546	increases	_	
286-453	64547-64549	in	_	
286-454	64550-64553	the	_	
286-455	64554-64559	right	_	
286-456	64560-64572	dorsolateral	_	
286-457	64573-64583	prefrontal	_	
286-458	64584-64590	cortex	_	
286-459	64591-64594	and	_	
286-460	64595-64604	decreases	_	
286-461	64605-64608	the	_	
286-462	64609-64616	rostral	_	
286-463	64617-64627	prefrontal	_	
286-464	64628-64634	cortex	_	
286-465	64635-64645	activation	_	
286-466	64646-64651	after	_	
286-467	64651-64652	-	_	
286-468	64652-64653	8	_	
286-469	64654-64659	weeks	_	
286-470	64660-64662	of	_	
286-471	64663-64670	focused	_	
286-472	64671-64680	attention	_	
286-473	64681-64686	based	_	
286-474	64687-64698	mindfulness	_	
286-475	64699-64709	meditation	_	
286-476	64710-64718	Distinct	_	
286-477	64719-64728	intrinsic	_	
286-478	64729-64736	network	_	
286-479	64737-64749	connectivity	_	
286-480	64750-64758	patterns	_	
286-481	64759-64761	of	_	
286-482	64762-64776	post-traumatic	_	
286-483	64777-64783	stress	_	
286-484	64784-64792	disorder	_	
286-485	64793-64800	symptom	_	
286-486	64801-64809	clusters	_	
286-487	64810-64820	Functional	_	
286-488	64821-64828	network	_	
286-489	64829-64837	topology	_	
286-490	64838-64848	associated	_	
286-491	64849-64853	with	_	
286-492	64854-64867	posttraumatic	_	
286-493	64868-64874	stress	_	
286-494	64875-64883	disorder	_	
286-495	64884-64886	in	_	
286-496	64887-64895	veterans	_	
286-497	64896-64899	The	_	
286-498	64900-64904	role	_	
286-499	64905-64907	of	_	
286-500	64908-64921	interoception	_	
286-501	64922-64924	in	_	
286-502	64925-64934	addiction	_	
286-503	64934-64935	:	_	
286-504	64936-64937	A	_	
286-505	64938-64946	critical	_	
286-506	64947-64953	review	_	
286-507	64954-64966	Co-occurring	_	
286-508	64967-64980	posttraumatic	_	
286-509	64981-64987	stress	_	
286-510	64988-64991	and	_	
286-511	64992-65001	substance	_	
286-512	65002-65005	use	_	
286-513	65005-65006	:	_	
286-514	65007-65015	emerging	_	
286-515	65016-65024	research	_	
286-516	65025-65027	on	_	
286-517	65028-65038	correlates	_	
286-518	65038-65039	,	_	
286-519	65040-65050	mechanisms	_	
286-520	65050-65051	,	_	
286-521	65052-65055	and	_	
286-522	65056-65066	treatments	_	
286-523	65067-65068	-	_	
286-524	65069-65081	introduction	_	
286-525	65082-65084	to	_	
286-526	65085-65088	the	_	
286-527	65089-65096	special	_	
286-528	65097-65102	issue	_	
286-529	65103-65111	Response	_	
286-530	65112-65122	inhibition	_	
286-531	65123-65126	and	_	
286-532	65127-65151	fronto-striatal-thalamic	_	
286-533	65152-65159	circuit	_	
286-534	65160-65171	dysfunction	_	
286-535	65172-65174	in	_	
286-536	65175-65182	cocaine	_	
286-537	65183-65192	addiction	_	
286-538	65193-65204	Permutation	_	
286-539	65205-65214	inference	_	
286-540	65215-65218	for	_	
286-541	65219-65222	the	_	
286-542	65223-65230	general	_	
286-543	65231-65237	linear	_	
286-544	65238-65243	model	_	
286-545	65245-65258	Meta-analytic	_	
286-546	65259-65271	connectivity	_	
286-547	65272-65280	modeling	_	
286-548	65281-65288	reveals	_	
286-549	65289-65301	differential	_	
286-550	65302-65312	functional	_	
286-551	65313-65325	connectivity	_	
286-552	65326-65328	of	_	
286-553	65329-65332	the	_	
286-554	65333-65339	medial	_	
286-555	65340-65343	and	_	
286-556	65344-65351	lateral	_	
286-557	65352-65365	orbitofrontal	_	
286-558	65366-65372	cortex	_	
286-559	65373-65382	Anhedonia	_	
286-560	65383-65386	and	_	
286-561	65387-65397	individual	_	
286-562	65398-65409	differences	_	
286-563	65410-65412	in	_	
286-564	65413-65426	orbitofrontal	_	
286-565	65427-65433	cortex	_	
286-566	65434-65444	sulcogyral	_	
286-567	65445-65455	morphology	_	
286-568	65456-65469	Supplementary	_	
286-569	65470-65474	data	_	
286-570	65475-65488	Supplementary	_	
286-571	65489-65493	data	_	
286-572	65494-65496	to	_	
286-573	65497-65501	this	_	
286-574	65502-65509	article	_	
286-575	65510-65513	can	_	
286-576	65514-65516	be	_	
286-577	65517-65522	found	_	
286-578	65523-65529	online	_	
286-579	65530-65532	at	_	
286-580	65533-65538	https	_	
286-581	65538-65539	:	_	
286-582	65539-65540	/	_	
286-583	65540-65541	/	_	
286-584	65541-65548	doi.org	_	
286-585	65548-65549	/	_	
286-586	65549-65556	10.1016	_	
286-587	65556-65557	/	_	
286-588	65557-65563	j.nicl	_	
286-589	65563-65575	.2019.101973	_	
286-590	65575-65576	.	_	
